{
 "cells": [
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Import 100 articles abstract from pubmed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import csv\n",
    "import pandas as pd\n",
    "from Bio import Entrez\n",
    "from Bio import Medline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CSV file created: pubmed_abstracts.csv\n",
      "[{'PMID': '37031410', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230409', 'IS': '1110-4902 (Print)', 'VI': '30', 'IP': '2', 'DP': '2023 Apr', 'TI': 'Serum metabolomic profiles and semaphorin-3A as biomarkers of diabetic retinopathy progression.', 'PG': '83-98', 'AB': 'Diabetic retinopathy (DR) is a typical microvascular complication of diabetes mellitus (DM) and it remains one of the leading causes of vision loss worldwide. Studies postulated that a distinct metabolic signature of DR exists and can be resolved from that of diabetes alone. Serum Semaphorin3A (Sema3A) levels have also been found to be correlated with the phenotypes of diabetic retinopathy. We aimed to analyze and identify serum metabolites and serum Sema3A levels that could be useful biomarkers of DR progression. This cross-sectional study included 45 type 2 diabetes (T2D) patients. Diabetic patients were divided into three groups based on the status of their complications: non-DR (NDR, n=15), non-proliferative DR (NPDR, n=15), and proliferative DR (PDR, n=15) groups. Serum metabolomic profiles of these patients were determined by using high-performance liquid chromatography-mass spectrometry (HPLC-MS), and serum Sema3A levels measured by ELISA. Metabolomics analysis revealed a set of metabolites that were altered in the serum of PDR patients as compared with NPDR and NDR groups. Among these metabolites total asymmetric dimethylarginine (ADMA) and Kynurenine were potential predictors of PDR patients. Significantly higher serum levels of Sema3A in PDR patients as compared with NPDR and NDR groups (p < 0.001), their serum levels were positively correlated with the central macular thickness (r= 0.952, p < 0.001) and negatively correlated with the superficial macular density (r=-0.952, p < 0.001). In conclusion, the metabolite signatures identified in this study and serum Sema3A levels could be proposed as biomarkers for DR development and progression in T2D patients. However, Sema3A was superior to metabolomics in the prediction of the severity of DR.', 'CI': ['Copyright(c) by the Egyptian Association of Immunologists.'], 'FAU': ['Mokhtar, Entsar R', 'Mahmoud, Doaa A', 'Ebrahim, Gamil E', 'Al Anany, Mona G', 'Seliem, Nora', 'Hassan, Marwa M'], 'AU': ['Mokhtar ER', 'Mahmoud DA', 'Ebrahim GE', 'Al Anany MG', 'Seliem N', 'Hassan MM'], 'AD': ['Department of Clinical Pathology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.', 'Department of Ophthalmology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.', 'Department of Chemistry of Flavor and Aroma, National Research Center, Dokki, Cairo, Egypt.', 'Department of Physiology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.', 'Department of Medical Biochemistry, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.', 'Department of Internal Medicine, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'PL': 'Egypt', 'TA': 'Egypt J Immunol', 'JT': 'The Egyptian journal of immunology', 'JID': '9816016', 'SB': 'IM', 'EDAT': '2023/04/10 06:00', 'MHDA': '2023/04/10 06:00', 'CRDT': ['2023/04/09 11:26'], 'PHST': ['2023/04/09 11:26 [entrez]', '2023/04/10 06:00 [pubmed]', '2023/04/10 06:00 [medline]'], 'PST': 'ppublish', 'SO': 'Egypt J Immunol. 2023 Apr;30(2):83-98.'}, {'PMID': '37030494', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230408', 'IS': '1879-1891 (Electronic) 0002-9394 (Linking)', 'DP': '2023 Apr 6', 'TI': 'Benefits of a laser chorioretinal anastomosis plus ranibizumab vs ranibizumab alone for central retinal vein occlusion: 4-year results.', 'LID': 'S0002-9394(23)00150-2 [pii] 10.1016/j.ajo.2023.03.034 [doi]', 'AB': 'PURPOSE: Evaluate what clinical gains can be achieved over conventional treatment with ranibizumab alone for central retinal vein occlusion (CRVO) when causal pathology is additionally successfully addressed with a laser-induced chorio-retinal anastomosis (L-CRA). DESIGN: 2-year extension of prospective, randomized, controlled clinical trial. METHODS: 58 patients with macular edema secondary to CRVO randomized 1:1 to receive either an L-CRA (29) or sham procedure (29) at baseline and then monthly intravitreal ranibizumab 0.5mg Outcomes (best corrected visual acuity (BCVA), central subfield thickness (CST), injection requirements) were monitored in the monthly pro re nata (PRN) ranibizumab phase from months 7-48. RESULTS: Injection requirements for those with a functioning L-CRA (24 of 29) during the monthly PRN period from 7-24 months, were mean (95% confidence interval [CI]) of 2.18 [1.57, 2.78] injections compared to 7.07 [6.08, 8.06] (p<0.0001) for control (ranibizumab alone). These decreased further over the next 2 years to 0.29 (0.14, 0.61) compared to 2.20 (1.68, 2.88) (p<0.001) for the third year and 0.25 (0.11, 0.56) and 1.84 (1.34, 2.54) for the fourth year (p<0.001). Mean BCVA was statistically different at all follow-up time points from month 7 through to month 48 for the group with the functioning L-CRA compared to the control monotherapy group. This improved to 14.06 letters at month 48 (p=0.009). There was no difference in CST between any of the groups over the 48 months of follow-up. CONCLUSION: For CRVO patients, addressing causal pathology in addition to conventional therapy, improves BCVA and reduces injection requirements.', 'CI': ['Copyright (c) 2023. Published by Elsevier Inc.'], 'FAU': ['McAllister, Ian L', 'Smithies, Lynne A', 'Chen, Fred K', 'Mackey, David A', 'Sanfilippo, Paul G'], 'AU': ['McAllister IL', 'Smithies LA', 'Chen FK', 'Mackey DA', 'Sanfilippo PG'], 'AD': ['Centre for Ophthalmology and Visual Science, (Lions Eye Institute), the University of Western Australia, Perth, Australia. Electronic address: ianmcallister@lei.org.au.', 'Centre for Ophthalmology and Visual Science, (Lions Eye Institute), the University of Western Australia, Perth, Australia.', 'Centre for Ophthalmology and Visual Science, (Lions Eye Institute), the University of Western Australia, Perth, Australia.', 'Centre for Ophthalmology and Visual Science, (Lions Eye Institute), the University of Western Australia, Perth, Australia.', 'Centre for Ophthalmology and Visual Science, (Lions Eye Institute), the University of Western Australia, Perth, Australia; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia. +61893810870.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230406', 'PL': 'United States', 'TA': 'Am J Ophthalmol', 'JT': 'American journal of ophthalmology', 'JID': '0370500', 'SB': 'IM', 'EDAT': '2023/04/09 06:00', 'MHDA': '2023/04/09 06:00', 'CRDT': ['2023/04/08 19:27'], 'PHST': ['2022/09/05 00:00 [received]', '2023/03/25 00:00 [revised]', '2023/03/27 00:00 [accepted]', '2023/04/08 19:27 [entrez]', '2023/04/09 06:00 [pubmed]', '2023/04/09 06:00 [medline]'], 'AID': ['S0002-9394(23)00150-2 [pii]', '10.1016/j.ajo.2023.03.034 [doi]'], 'PST': 'aheadofprint', 'SO': 'Am J Ophthalmol. 2023 Apr 6:S0002-9394(23)00150-2. doi: 10.1016/j.ajo.2023.03.034.'}, {'PMID': '37030454', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230408', 'IS': '1549-4713 (Electronic) 0161-6420 (Linking)', 'DP': '2023 Apr 6', 'TI': '14-Year Outcome of Angle-Closure Prevention with Laser Iridotomy in the Zhongshan Angle Closure Prevention Study: Extended Follow-Up of a Randomized Controlled Trial.', 'LID': 'S0161-6420(23)00201-4 [pii] 10.1016/j.ophtha.2023.03.024 [doi]', 'AB': 'PURPOSE: This study aimed to evaluate the efficacy of laser peripheral iridotomy (LPI) prophylaxis for primary angle closure suspects (PACS) after 14 years and to identify risk factors for the conversion from PACS to primary angle closure (PAC). DESIGN: An extended follow-up of Zhongshan Angle Closure Prevention (ZAP) study. PARTICIPANTS: A total of 889 Chinese patients aged 50 to 70 years with bilateral PACS. METHODS: Each patient received LPI in one randomly selected eye, with the fellow untreated eye serving as a control. Since the risk of glaucoma was low and acute angle closure (AAC) only occurred in rare cases, the follow-up was extended to 14 years despite substantial benefits of LPI reported after the 6-year visit. MAIN OUTCOME MEASURES: The primary outcome was incidence of PAC, a composite endpoint including peripheral anterior synechiae (PAS), intraocular pressure (IOP) > 24 mmHg, or AAC. RESULTS: During the 14 years, 390 LPI-treated eyes and 388 control eyes were lost to the follow-up. A total of 33 LPI-treated eyes and 105 control eyes reached primary endpoints (P <0.01). Within them, twelve eyes developed AAC or primary angle closure glaucoma (AAC: five control eyes and one LPI-treated eye; PACG: four control eyes and two LPI-treated eyes). The hazard ratio for progression to PAC was 0.31 (95% confidence interval, 0.21-0.46) in LPI-treated eyes compared with control eyes. At the 14-year visit, LPI-treated eyes had severer nuclear cataract, higher IOP, larger angle width and limbal anterior chamber depth (LACD) than control eyes. Higher IOP, shallower LACD, and central anterior chamber depth (CACD) were associated with an increased risk of developing endpoints in control eyes. In the treated group, eyes with higher IOP, shallower LACD, or less IOP elevation after dark room-prone provocative tests (DRPPT) were more likely to develop PAC after LPI. CONCLUSIONS: Despite a two-third decrease in PAC incidence after LPI, the cumulative risk of PAC was relatively low in the community-based PACS population over 14 years. Apart from IOP, IOP elevation after DRPPT, CACD, and LACD, more risk factors are needed to achieve precise prediction of PAC occurrence and guide clinical practice.', 'CI': ['Copyright (c) 2023. Published by Elsevier Inc.'], 'FAU': ['Yuan, Yixiong', 'Wang, Wei', 'Xiong, Ruilin', 'Zhang, Jian', 'Li, Cong', 'Yang, Shaopeng', 'Friedman, David S', 'Foster, Paul J', 'He, Mingguang'], 'AU': ['Yuan Y', 'Wang W', 'Xiong R', 'Zhang J', 'Li C', 'Yang S', 'Friedman DS', 'Foster PJ', 'He M'], 'AD': ['State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China. Electronic address: wangwei@gzzoc.com.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Harvard Medical School, Boston, MA, USA.', 'National Biomedical Research Centre for Ophthalmology, UCL Institute of Ophthalmology and Moorfields Eye Hospital, London, England.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230406', 'PL': 'United States', 'TA': 'Ophthalmology', 'JT': 'Ophthalmology', 'JID': '7802443', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['extended follow-up', 'laser peripheral iridotomy', 'primary angle closure'], 'EDAT': '2023/04/09 06:00', 'MHDA': '2023/04/09 06:00', 'CRDT': ['2023/04/08 19:27'], 'PHST': ['2022/12/22 00:00 [received]', '2023/03/21 00:00 [revised]', '2023/03/31 00:00 [accepted]', '2023/04/08 19:27 [entrez]', '2023/04/09 06:00 [pubmed]', '2023/04/09 06:00 [medline]'], 'AID': ['S0161-6420(23)00201-4 [pii]', '10.1016/j.ophtha.2023.03.024 [doi]'], 'PST': 'aheadofprint', 'SO': 'Ophthalmology. 2023 Apr 6:S0161-6420(23)00201-4. doi: 10.1016/j.ophtha.2023.03.024.'}, {'PMID': '37029360', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230407', 'IS': '1471-2415 (Electronic) 1471-2415 (Linking)', 'VI': '23', 'IP': '1', 'DP': '2023 Apr 7', 'TI': 'Clinical efficacy of a new surgical technique of oral mucosal epithelial transplantation for severe ocular surface disorders.', 'PG': '145', 'LID': '10.1186/s12886-023-02879-4 [doi] 145', 'AB': 'BACKGROUND: Severe ocular surface disorders are one of the major blinding diseases, and a paucity of original tissue obscures successful reconstruction. We developed a new surgical technique of direct oral mucosal epithelial transplantation (OMET) to reconstruct severely damaged ocular surfaces in 2011. This study elaborates on the clinical efficacy of OMET. METHODS: A retrospective review of patients with severe ocular surface disorders who underwent OMET from 2011 to 2021 at the Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine was conducted. Patients who were followed up for at least 3 months postoperatively and had sufficient pre or postoperative records were included. Surgical efficacy was evaluated by comparing the best-corrected visual acuity (BCVA), corneal transparency, neovascularization grade, and symblepharon grade. Additionally, postoperative ocular surface impression cytology was used to study the morphology of the newborn epithelial cells. RESULTS: Forty-eight patients (49 eyes; mean age: 42.55 +/- 12.40 years, range:12-66 years) were enrolled in the study. The etiology included chemical burns (30 eyes), thermal burns (16 eyes), explosive injuries (1 eye), Stevens-Johnson syndrome (1 eye), and multiple pterygiums (1 eye). The mean follow-up period was 25.97 +/- 22.99 months. Postoperatively, 29 eyes (59.18%) showed improved corneal transparency, 26 eyes (53.06%) had improved BCVA, 47 eyes (95.92%) had a stable epithelium until the final follow-up, 44 eyes (89.80%) had a reduced neovascularization grade. Of the 20 eyes with preoperative symblepharon, 15 (75%) were completely resolved, and five (25%) were partially resolved. Impression cytological studies showed no postoperative conjunctival invasion onto the corneal surface. CONCLUSIONS: OMET is a safe and effective surgical technique for reconstruction in severe ocular surface disorder by maintaining a stable epithelium and reducing the neovascularization and symblepharon grade.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Zhu, Yuan-Fang', 'Qiu, Wen-Ya', 'Xu, Ye-Sheng', 'Yao, Yu-Feng'], 'AU': ['Zhu YF', 'Qiu WY', 'Xu YS', 'Yao YF'], 'AD': ['Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.', 'Key Laboratory for Corneal Diseases Research of Zhejiang Province, NO. 3 East QingChun Rd, Hangzhou, Zhejiang, China.', 'Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.', 'Key Laboratory for Corneal Diseases Research of Zhejiang Province, NO. 3 East QingChun Rd, Hangzhou, Zhejiang, China.', 'Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.', 'Key Laboratory for Corneal Diseases Research of Zhejiang Province, NO. 3 East QingChun Rd, Hangzhou, Zhejiang, China.', 'Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. yaoyf@zju.edu.cn.', 'Key Laboratory for Corneal Diseases Research of Zhejiang Province, NO. 3 East QingChun Rd, Hangzhou, Zhejiang, China. yaoyf@zju.edu.cn.'], 'LA': ['eng'], 'GR': ['2021KY-723, 2019ZD040 and WKJ-ZJ-1905/the Health Commission of Zhejiang Province/', '2021KY-723, 2019ZD040 and WKJ-ZJ-1905/the Health Commission of Zhejiang Province/', '2021KY-723, 2019ZD040 and WKJ-ZJ-1905/the Health Commission of Zhejiang Province/', '2021KY-723, 2019ZD040 and WKJ-ZJ-1905/the Health Commission of Zhejiang Province/', 'LGF21H120004/the Science and Technology Department of Zhejiang province/', 'LGF21H120004/the Science and Technology Department of Zhejiang province/', 'U20A20387/the National Natural Science Foundation of China/', 'U20A20387/the National Natural Science Foundation of China/'], 'PT': ['Journal Article'], 'DEP': '20230407', 'PL': 'England', 'TA': 'BMC Ophthalmol', 'JT': 'BMC ophthalmology', 'JID': '100967802', 'SB': 'IM', 'PMC': 'PMC10080810', 'OTO': ['NOTNLM'], 'OT': ['Limbal stem cell deficiency', 'Ocular surface disorder', 'Oral mucosal epithelia', 'Symblepharon'], 'COIS': ['The authors declare that they have no competing interests.'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 23:34'], 'PHST': ['2022/11/06 00:00 [received]', '2023/03/22 00:00 [accepted]', '2023/04/07 23:34 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['10.1186/s12886-023-02879-4 [pii]', '2879 [pii]', '10.1186/s12886-023-02879-4 [doi]'], 'PST': 'epublish', 'SO': 'BMC Ophthalmol. 2023 Apr 7;23(1):145. doi: 10.1186/s12886-023-02879-4.'}, {'PMID': '37029348', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230409', 'IS': '1689-1392 (Electronic) 1425-8153 (Print) 1425-8153 (Linking)', 'VI': '28', 'IP': '1', 'DP': '2023 Apr 7', 'TI': 'Can precancerous stem cells be risk markers for malignant transformation in the oral mucosa?', 'PG': '30', 'LID': '10.1186/s11658-023-00441-0 [doi] 30', 'AB': 'Accurate assessment of the carcinogenic potential of oral mucosal diseases can significantly reduce the prevalence of oral cancer. We speculate that precancerous stem cells (pCSCs) arise during the evolution of carcinomas based on long-term experimental findings, published literature, and the cancer stem cell (CSC) theory, wherein pCSCs exist in precancerous lesions and have characteristics of both CSCs and normal stem cells. This apparently contradictory feature may be the foundation of the reversible transformation of precancerous lesions. Predicting malignant transformation in potentially malignant oral illnesses would allow for focused treatment, prognosis, and secondary prevention. Currently available clinical assays for chromosomal instability and DNA aneuploidy have several deficiencies. We hope that our study will increase attention to pCSC research and lead to the development of novel strategies for the prevention and treatment of oral cancer by identifying pCSC markers.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Wang, Shan', 'Ying, Liu', 'Yu, Shu-Yi', 'Bai, Jie', 'Hao, Chunbo'], 'AU': ['Wang S', 'Ying L', 'Yu SY', 'Bai J', 'Hao C'], 'AD': [\"Department of Oral Pathology, School of Stomatology, Hainan Medical University, Haikou, 571199, People's Republic of China. birchtree20032003@126.com.\", \"Department of Stomatology, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570216, People's Republic of China. birchtree20032003@126.com.\", \"College of Pharmacy, Hainan Medical University, Haikou, 571199, People's Republic of China.\", \"Pharmacy Department, First Affiliated Hospital of Jiamusi University, Jiamusi, 154003, People's Republic of China.\", \"Department of Ophthalmology, the Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, 322000, People's Republic of China. 8020234@zju.edu.cn.\", \"Department of Stomatology, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, 570100, People's Republic of China. haochunbonuli@sina.com.\"], 'LA': ['eng'], 'PT': ['Letter'], 'DEP': '20230407', 'PL': 'England', 'TA': 'Cell Mol Biol Lett', 'JT': 'Cellular & molecular biology letters', 'JID': '9607427', 'SB': 'IM', 'PMC': 'PMC10080963', 'OTO': ['NOTNLM'], 'OT': ['Cancer stem cells', 'Dysplasia', 'Malignant transformation', 'Oral cancer', 'Precancerous stem cells'], 'COIS': ['The authors declare that they have no competing interests.'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 23:33'], 'PHST': ['2022/10/24 00:00 [received]', '2023/03/20 00:00 [accepted]', '2023/04/07 23:33 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['10.1186/s11658-023-00441-0 [pii]', '441 [pii]', '10.1186/s11658-023-00441-0 [doi]'], 'PST': 'epublish', 'SO': 'Cell Mol Biol Lett. 2023 Apr 7;28(1):30. doi: 10.1186/s11658-023-00441-0.'}, {'PMID': '37029212', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230407', 'IS': '1573-2630 (Electronic) 0165-5701 (Linking)', 'DP': '2023 Apr 7', 'TI': 'Is the clinical course of non-arteritic ischemic optic neuropathy associated with oxidative damage and the dynamics of the antioxidant response?', 'LID': '10.1007/s10792-023-02699-x [doi]', 'AB': \"PURPOSE: Oxidative stress is known to be a decisive factor in the wide etiopathogenesis of optic neuropathy. This study aimed to comprehensively evaluate the interaction of optic neuropathy's clinical course with systemic oxidative damage and antioxidant response dynamics in a large series. METHODS: This case-controlled clinical study included 33 non-arteritic anterior ischemic optic neuropathy (NAION) patients and 32 healthy individuals. Extensive systemic oxidation profiles were statistically compared between the two groups, and correlations between the clinical and biochemical data in the study group were analyzed. RESULTS: Vitamin E and malondialdehyde (MDA) levels were significantly higher in the study group. Significant correlations were observed in the analyses between clinical findings and oxidative stress parameters. Correlations between vitamin E and intraocular pressure (IOP), between B(12) and cup-to-disk ratio (c/d), between antioxidant glutathione and superoxide dismutase (SOD) enzyme systems, and between uric acid (UA) and age were found to be very significant. As significant correlations were found in either clinical and biochemical data or in oxidative stress parameters, correlations between vitamin E and cholesterol, MDA were found to be very significant. CONCLUSIONS: This study not only supplies significant information regarding oxidative damage and antioxidant response in NAION, but also points out the specific interactions of neuromodulators, like vitamin E, in intracellular signaling pathways and regulation mechanisms. A better reading of these connections may help improve diagnosis, follow-ups and treatment criteria and strategies.\", 'CI': ['(c) 2023. The Author(s), under exclusive licence to Springer Nature B.V.'], 'FAU': ['Engin, Kaya Nusret', 'Harmanci Karagulle, Duygu', 'Durmaz Engin, Ceren', 'Kant, Melis', 'Yaman, Aylin', 'Akis, Merve', 'Ozel Yildiz, Sevda', 'Islekel, Huray', 'Guner Akdogan, Gul', 'Soylev Bajin, Meltem'], 'AU': ['Engin KN', 'Harmanci Karagulle D', 'Durmaz Engin C', 'Kant M', 'Yaman A', 'Akis M', 'Ozel Yildiz S', 'Islekel H', 'Guner Akdogan G', 'Soylev Bajin M'], 'AUID': ['ORCID: 0000-0001-6842-1897'], 'AD': ['Department of Ophthalmology, Umraniyemraniye Education and Research Hospital, Saglik University, Elmalikent Mh. Umraniye, 34764, Istanbul, Turkey. kayanengin@hotmail.com.', 'Graduate School of Health Science, Department of Molecular Genetics, Dokuz Eylul University, Izmir, Turkey.', 'Faculty of Medicine, Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey.', 'Faculty of Medicine, Department of Biochemistry, Dokuz Eylul University, Izmir, Turkey.', 'Faculty of Medicine, Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey.', 'Faculty of Medicine, Department of Biochemistry, Dokuz Eylul University, Izmir, Turkey.', 'Istanbul Faculty of Medicine, Department of Biostatistics, Istanbul University, Istanbul, Turkey.', 'Graduate School of Health Science, Department of Molecular Genetics, Dokuz Eylul University, Izmir, Turkey.', 'Faculty of Medicine, Department of Biochemistry, Dokuz Eylul University, Izmir, Turkey.', 'Department of Medical Biochemistry, School of Medicine, Izmir University of Economics, Izmir, Turkey.', 'Faculty of Medicine, Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey.'], 'LA': ['eng'], 'GR': ['2016.KB.SAG.062/Dokuz Eylul Universitesi/'], 'PT': ['Journal Article'], 'DEP': '20230407', 'PL': 'Netherlands', 'TA': 'Int Ophthalmol', 'JT': 'International ophthalmology', 'JID': '7904294', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': [\"8-hydroxy-2'-deoxyguanosine\", 'Non-arteritic anterior ischemic optic neuropathy', 'Oxidative', 'Stress', 'Vitamin B12', 'Vitamin E'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 23:21'], 'PHST': ['2021/12/06 00:00 [received]', '2023/03/24 00:00 [accepted]', '2023/04/07 23:21 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['10.1007/s10792-023-02699-x [pii]', '10.1007/s10792-023-02699-x [doi]'], 'PST': 'aheadofprint', 'SO': 'Int Ophthalmol. 2023 Apr 7. doi: 10.1007/s10792-023-02699-x.'}, {'PMID': '37029145', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230407', 'IS': '2045-2322 (Electronic) 2045-2322 (Linking)', 'VI': '13', 'IP': '1', 'DP': '2023 Apr 7', 'TI': 'Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.', 'PG': '5700', 'LID': '10.1038/s41598-023-31726-1 [doi] 5700', 'AB': 'This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and safety of preservative-free and preserved brimonidine tartrate 0.15% in open-angle glaucoma and ocular hypertension. Sixty eyes of 60 patients with intraocular pressure (IOP) >/= 15 mmHg diagnosed with open-angle glaucoma or ocular hypertension were randomized to preserved (n = 31) and preservative-free (n = 29) brimonidine groups. The enrolled eyes received brimonidine monotherapy three times daily. Main outcome measures were corneal/conjunctival staining score, ocular surface disease index, patient satisfaction score, drug tolerance, and drug adherence rate 12 weeks post first administration. Secondary outcome measurements included visual acuity, IOP, drug tolerance, tear-film break-up time, hemodynamic changes including blood pressure and heart rates, and ocular adverse events. After 12 weeks, both preserved and preservative-free groups showed similar IOP reduction, corneal and conjunctival staining scores, drug tolerance, and adherence rates. The preservative-free group showed significantly better tear-film break-up time and higher patient satisfaction regarding drug use and management. Systolic and diastolic blood pressure reductions during the 12 weeks were significantly lower in the preserved group than in the preservative-free group. Preservative-free brimonidine tartrate showed comparable efficacy and safety, better corneal tear film stability, and patient satisfaction than preserved brimonidine.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Kim, Ko Eun', 'Lee, Chang Kyu', 'Shin, Jonghoon', 'Kim, Yuri', 'Rho, Seungsoo'], 'AU': ['Kim KE', 'Lee CK', 'Shin J', 'Kim Y', 'Rho S'], 'AD': ['Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.', 'Department of Ophthalmology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.', 'Department of Ophthalmology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.', 'Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.', 'Department of Ophthalmology, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13496, Republic of Korea.', 'Department of Ophthalmology, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13496, Republic of Korea. harryrho@gmail.com.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230407', 'PL': 'England', 'TA': 'Sci Rep', 'JT': 'Scientific reports', 'JID': '101563288', 'SB': 'IM', 'PMC': 'PMC10082039', 'COIS': ['The authors declare no competing interests.'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 23:16'], 'PHST': ['2022/05/05 00:00 [received]', '2023/03/16 00:00 [accepted]', '2023/04/07 23:16 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['10.1038/s41598-023-31726-1 [pii]', '31726 [pii]', '10.1038/s41598-023-31726-1 [doi]'], 'PST': 'epublish', 'SO': 'Sci Rep. 2023 Apr 7;13(1):5700. doi: 10.1038/s41598-023-31726-1.'}, {'PMID': '37027819', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230407', 'IS': '1539-2864 (Electronic) 0275-004X (Linking)', 'DP': '2023 Apr 6', 'TI': 'Photobiomodulation therapy for large soft drusen and drusenoid pigment epithelial detachment in age-related macular degeneration: a single-center prospective pilot study.', 'LID': '10.1097/IAE.0000000000003805 [doi]', 'AB': 'PURPOSE: To evaluate visual acuity and morphologic changes after photobiomodulation (PBM) for patients affected with large soft drusen and/or drusenoid pigment epithelial detachment (dPED) associated to dry age-related macular degeneration (AMD). METHOD: Twenty eyes with large soft drusen and/or dPED AMD were included and treated with the LumiThera(R) ValedaTM Light Delivery System. All subjects underwent 2 treatments per week for 5 weeks. Outcome measures included best corrected visual acuity (BCVA), microperimetry- scotopic testing, drusen volume (DV), central drusen thickness (CDT), quality of life (QoL) score at baseline and month 6 (M6) follow up. Data of BCVA, DV and CDT was also recorded at week 5 (W5). RESULTS: BCVA significantly improved at M6 with a mean score gain of 5.5 letters (p = 0.007). Retinal sensitivity (RS) decreased by 0.1 dB (p=0.17). Mean fixation stability increased by 0.45 % (P=0.72). DV decreased by 0.11 mm3 (p=0.03). CDT was reduced by a mean of 17.05 microm (p=0.01). GA area increased by 0.06 mm2 (p=0.01) over a 6 months follow up, quality of life score increased by 3,07 points on average (p=0.05). One patient presented a dPED rupture at M6 after PBM treatment. CONCLUSION: The visual and anatomical improvements in our patients support previous reports on PBM. PBM may provide a valid therapeutic option for large soft drusen and dPED AMD and may potentially slow the natural course of the disease.', 'FAU': ['Benlahbib, Manal', 'Cohen, Salomon Yves', 'Torrell, Nuria', 'Colantuono, Donato', 'Crincoli, Emanuele', 'Amoroso, Francesca', 'Semoun, Oudy', 'Jung, Camille', 'Souied, Eric H'], 'AU': ['Benlahbib M', 'Cohen SY', 'Torrell N', 'Colantuono D', 'Crincoli E', 'Amoroso F', 'Semoun O', 'Jung C', 'Souied EH'], 'AD': ['Department of Ophthalmology, University of Paris Est - Creteil.', 'Department of Ophthalmology, University of Paris Est - Creteil.', 'Ophthalmology Center for Imaging and Laser, Paris, France.', 'Department of Ophthalmology, University of Paris Est - Creteil.', 'Department of Ophthalmology, University of Paris Est - Creteil.', 'Department of Ophthalmology, University of Paris Est - Creteil.', 'Department of Ophthalmology, University of Paris Est - Creteil.', 'Department of Ophthalmology, University of Paris Est - Creteil.', 'Clinical Research Center, CHI, Creteil, France.', 'Department of Ophthalmology, University of Paris Est - Creteil.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230406', 'PL': 'United States', 'TA': 'Retina', 'JT': 'Retina (Philadelphia, Pa.)', 'JID': '8309919', 'SB': 'IM', 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 16:12'], 'PHST': ['2023/04/07 16:12 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['00006982-990000000-00336 [pii]', '10.1097/IAE.0000000000003805 [doi]'], 'PST': 'aheadofprint', 'SO': 'Retina. 2023 Apr 6. doi: 10.1097/IAE.0000000000003805.'}, {'PMID': '37027535', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230407', 'IS': '1728-7731 (Electronic) 1726-4901 (Linking)', 'DP': '2023 Apr 10', 'TI': \"The Pathological Mechanisms and Novel Therapeutics for Leber's Hereditary Optic Neuropathy.\", 'LID': '10.1097/JCMA.0000000000000927 [doi]', 'AB': \"Optic neuropathies were estimated to affect 115 in 100,000 population in 2018. Leber's Hereditary Optic Neuropathy (LHON) as one of such optic neuropathy diseases that was first identified in 1871 and can be defined as a hereditary mitochondrial disease. LHON is associated with three mtDNA point mutations which are G11778A, T14484, and G3460A that affect the NADH dehydrogenase subunits of 4, 6, and 1, respectively. However, in most cases, only one point mutation is involved. Generally, in manifestation of the disease, there are no symptoms until the terminal dysfunction in the optic nerve is observed. Due to the mutations, nicotinamide adenine dinucleotide (NADH) dehydrogenase or complex I is absent and thus ATP production is stopped. This further causes the generation of reactive oxygen species (ROS) and retina ganglion cells (RGC) apoptosis. Aside from the mutations, there are several environmental factors such as smoking and alcohol consumption that can be pointed out as the risk factors of LHON. Nowadays, gene therapy has been intensively studied for LHON treatment. Disease models using human induced pluripotent stem cells (hiPSCs) have been utilized for LHON research.\", 'CI': ['Copyright (c) 2023, the Chinese Medical Association.'], 'FAU': ['Yang, Yi-Ping', 'Foustine, Shania', 'Hsiao, Yu-Jer', 'Tsai, En-Tung', 'Tsai, Fu-Ting', 'Wang, Chia-Lin', 'Ko, Yu-Ling', 'Tai, Hsiao-Yun', 'Tsai, Yi-Ching', 'Yang, Chang-Hao', 'Fu, Yun-Ju', 'Wang, An-Guor', 'Chien, Yueh'], 'AU': ['Yang YP', 'Foustine S', 'Hsiao YJ', 'Tsai ET', 'Tsai FT', 'Wang CL', 'Ko YL', 'Tai HY', 'Tsai YC', 'Yang CH', 'Fu YJ', 'Wang AG', 'Chien Y'], 'AD': ['Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.', 'Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.', 'Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan, ROC.', 'College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.', 'Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.', 'Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230410', 'PL': 'Netherlands', 'TA': 'J Chin Med Assoc', 'JT': 'Journal of the Chinese Medical Association : JCMA', 'JID': '101174817', 'SB': 'IM', 'COIS': ['Conflicts of interest: The authors declare that they have no conflicts of', 'interest related to the subject matter or materials discussed in this article.'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 15:13'], 'PHST': ['2023/04/07 15:13 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['02118582-990000000-00205 [pii]', '10.1097/JCMA.0000000000000927 [doi]'], 'PST': 'aheadofprint', 'SO': 'J Chin Med Assoc. 2023 Apr 10. doi: 10.1097/JCMA.0000000000000927.'}, {'PMID': '37026277', 'OWN': 'NLM', 'STAT': 'In-Process', 'LR': '20230407', 'IS': '1998-3689 (Electronic) 0301-4738 (Linking)', 'VI': '71', 'IP': '4', 'DP': '2023 Apr', 'TI': 'Rasch development and validation of the \"Medellin Dry Eye Inventory\" (ME.Dry), an instrument to measure multidimensional quality of life compromise in patients with dry eye disease.', 'PG': '1432-1440', 'LID': '10.4103/IJO.IJO_2993_22 [doi]', 'AB': 'PURPOSE: Dry eye disease (DED) is a common condition that affects the quality of life. There is a great need for better-developed scales that comply with Rasch model requirements. METHODS: Prospective study including patients with DED. A series of focus groups were performed to determine the best items to be included. A Rasch modeling methodology was used to validate the Medellin Dry Eye Inventory (ME.Dry). After iterative analysis and scale modification, a final version of the scale was attained which complied with the Rasch analysis expectations. Correlation between the different subscales of the ME.Dry and the Ocular Surface Disease Index (OSDI) was evaluated through Spearman correlation. RESULTS: A total of 166 patients with DED were included. Rasch modeling demonstrated an excellent behavior for the ME.Dry, including four subscales: Symptoms, Triggers, Activity Limitation, and Emotional Compromise. Infit and Outfit parameters were all between 0.50 and 1.50, with excellent category utilization. Person and item separation and reliability were excellent for all subscales. There was a need for a category collapsing for the Emotional Compromise subscale. There was a strong correlation between the different subscales of the ME.Dry except for the Emotional Compromise subscale, which seems to be independent. CONCLUSION: The ME.Dry is a reliable scale, complying with the Rasch model expectations, that allows for a reliable measurement of quality of life compromise in patients with DED. Emotional compromise secondary to DED does not seem to correlate with disease severity as assessed by the other quality-of-life subscales.', 'FAU': ['Balparda, Kepa', 'Herrera-Chalarca, Tatiana', 'Cardozo-Davila, Ximena', 'Pacheco, Maria A', 'Godin, Fernando', 'Nicholls-Molina, Maria A'], 'AU': ['Balparda K', 'Herrera-Chalarca T', 'Cardozo-Davila X', 'Pacheco MA', 'Godin F', 'Nicholls-Molina MA'], 'AD': ['Director of Research and Surgery, Black Mammoth Surgical, Medellin, Colombia.', 'Department of Clinical Research, Black Mammoth Surgical, Medellin, Colombia.', 'Private Practice, Medellin, Colombia.', 'Department of Ophthalmology, Universidad Del Norte, Barranquilla, Colombia.', 'Department of Ophthalmology, Universidad El Bosque, Grupo de investigacion y salud ocular, Unbosque, Universidad el Bosque, Bogota D.C, Colombia.', 'School of Medicine, Universidad Pontificia Bolivariana, Medellin, Antioquia, Colombia.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'PL': 'India', 'TA': 'Indian J Ophthalmol', 'JT': 'Indian journal of ophthalmology', 'JID': '0405376', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Dry eye disease', 'ocular surface disease', 'quality of life'], 'COIS': ['None'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 03:15'], 'PHST': ['2023/04/07 03:15 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['IndianJOphthalmol_2023_71_4_1432_373515 [pii]', '10.4103/IJO.IJO_2993_22 [doi]'], 'PST': 'ppublish', 'SO': 'Indian J Ophthalmol. 2023 Apr;71(4):1432-1440. doi: 10.4103/IJO.IJO_2993_22.'}, {'PMID': '37026265', 'OWN': 'NLM', 'STAT': 'In-Process', 'LR': '20230407', 'IS': '1998-3689 (Electronic) 0301-4738 (Linking)', 'VI': '71', 'IP': '4', 'DP': '2023 Apr', 'TI': 'Aqueous-deficient dry eye disease: Preferred practice pattern guidelines on clinical approach, diagnosis, and management.', 'PG': '1332-1347', 'LID': '10.4103/IJO.IJO_2808_22 [doi]', 'AB': 'Dry eye disease (DED) is a broad term that includes a diverse group of clinical disorders. Aqueous-deficient dry eye (ADDE), a subtype of DED, is characterized by decreased tear production by the lacrimal gland. It can be seen in up to one-third of individuals with DED and can be comorbid with a systemic autoimmune process or occur secondary to an environmental insult. Since ADDE can be a source of long-term suffering and severe visual impairment, early identification and adequate treatment are imperative. Multiple etiologies can underlie ADDE, and it is critical to identify the underlying cause to not only improve the ocular health but also to improve the overall quality of life and well-being of affected individuals. This review discusses the various etiologies of ADDE, highlights a pathophysiology-based approach for evaluating underlying contributors, outlines various diagnostic tests, and reviews treatment options. We present the current standards and discuss ongoing research in this field. Through this review, we propose a treatment algorithm that would be useful for an ophthalmologist in diagnosing and managing individuals with ADDE.', 'FAU': ['Donthineni, Pragnya R', 'Doctor, Mariya B', 'Shanbhag, Swapna', 'Kate, Anahita', 'Galor, Anat', 'Djalilian, Ali R', 'Singh, Swati', 'Basu, Sayan'], 'AU': ['Donthineni PR', 'Doctor MB', 'Shanbhag S', 'Kate A', 'Galor A', 'Djalilian AR', 'Singh S', 'Basu S'], 'AD': ['The Cornea Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India.', 'The Cornea Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India.', 'The Cornea Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India.', 'The Cornea Institute, KVC Campus, L V Prasad Eye Institute, Vijaywada, Andhra Pradesh, India.', 'Bascom Palmer Eye Institute, University of Miami Miller School of Medicine; Surgical Services, Miami Veterans Affairs Medical Center, Miami, FL, USA.', 'Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL, USA.', 'Ophthalmic Plastic Surgery Services, KAR Campus, L V Prasad Eye Institute, Hyderabad, Telangana, India.', 'The Cornea Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'PL': 'India', 'TA': 'Indian J Ophthalmol', 'JT': 'Indian journal of ophthalmology', 'JID': '0405376', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['ADDE', 'DED', \"Sjogren's syndrome\", 'aqueous deficiency dry eye disease', 'dry eye disease', 'lacrimal gland'], 'COIS': ['None'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 03:15'], 'PHST': ['2023/04/07 03:15 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['IndianJOphthalmol_2023_71_4_1332_373480 [pii]', '10.4103/IJO.IJO_2808_22 [doi]'], 'PST': 'ppublish', 'SO': 'Indian J Ophthalmol. 2023 Apr;71(4):1332-1347. doi: 10.4103/IJO.IJO_2808_22.'}, {'PMID': '37026263', 'OWN': 'NLM', 'STAT': 'In-Process', 'LR': '20230407', 'IS': '1998-3689 (Electronic) 0301-4738 (Linking)', 'VI': '71', 'IP': '4', 'DP': '2023 Apr', 'TI': 'Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review.', 'PG': '1316-1325', 'LID': '10.4103/IJO.IJO_2987_22 [doi]', 'AB': 'This study reviewed the efficacy and safety of intense pulsed light (IPL) for the treatment of dry eye disease (DED). The PubMed database was used to conduct the literature search, which used the keywords \"intense pulsed light\" and \"dry eye disease\". After the authors evaluated the articles for relevancy, 49 articles were reviewed. In general, all treatment modalities were proven to be clinically effective in reducing dry eye (DE) signs and symptoms; however, the level of improvement and persistence of outcomes differed amongst them. Meta-analysis indicated significant improvement in the Ocular Surface Disease Index (OSDI) scores post-treatment with a standardized mean difference (SMD) = -1.63; confidence interval (CI): -2.42 to -0.84. Moreover, a meta-analysis indicated a significant improvement in tear break-up time (TBUT) test values with SMD = 1.77; CI: 0.49 to 3.05. Research suggests that additive therapies, such as meibomian gland expression (MGX), sodium hyaluronate eye drops, heated eye mask, warm compress, lid hygiene, lid margin scrub, eyelid massage, antibiotic drops, cyclosporine drops, omega-3 supplements, steroid drops, and warm compresses along with IPL, have been found to work in tandem for greater effectiveness; however, in clinical practice, its feasibility and cost-effectiveness have to be taken into consideration. Current findings suggest that IPL therapy is suitable when lifestyle modifications such as reducing or eliminating the use of contact lenses, lubricating eye drops/gels, and warm compresses/eye masks fail to improve signs and symptoms of DE. Moreover, patients with compliance issues have been shown to benefit well as the effects of IPL therapy is sustained for over several months. DED is a multifactorial disorder, and IPL therapy has been found to be safe and efficient in reducing its signs and symptoms of meibomian gland dysfunction (MGD)-related DE. Although the treatment protocol varies among authors, current findings suggest that IPL has a positive effect on the signs and symptoms of MGD-related DE. However, patients in the early stages can benefit more from IPL therapy. Moreover, IPL has a better maintenance impact when used in conjunction with other traditional therapies. Further research is needed to assess cost-utility analysis for IPL.', 'FAU': ['Qin, Guanghao', 'Chen, Jiayan', 'Li, Liangzhe', 'Zhang, Qing', 'Xu, Ling', 'Yu, Sile', 'He, Wei', 'He, Xingru', 'Pazo, Emmanuel Eric'], 'AU': ['Qin G', 'Chen J', 'Li L', 'Zhang Q', 'Xu L', 'Yu S', 'He W', 'He X', 'Pazo EE'], 'AD': ['Department of Ophthalmology, He Eye Specialist Hospital, Liaoning, Shenyang, China.', 'Department of Ophthalmology, He Eye Specialist Hospital, Liaoning, Shenyang, China.', 'Department of Ophthalmology, He Eye Specialist Hospital, Liaoning, Shenyang, China.', 'Department of Ophthalmology, He Eye Specialist Hospital, Liaoning, Shenyang, China; Department of Ophthalmology, Tianjin Medical University Eye Hospital, Tianjin, China.', 'Department of Ophthalmology, He Eye Specialist Hospital, Liaoning, Shenyang, China.', 'Department of Ophthalmology, He Eye Specialist Hospital; School of Public Health, He University, Shenyang, Liaoning, Shenyang, China.', 'Department of Ophthalmology, He Eye Specialist Hospital, Liaoning, Shenyang, China.', 'School of Public Health, He University, Shenyang, Liaoning, Shenyang, China.', 'Department of Ophthalmology, He Eye Specialist Hospital, Liaoning, Shenyang, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'PL': 'India', 'TA': 'Indian J Ophthalmol', 'JT': 'Indian journal of ophthalmology', 'JID': '0405376', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Dry eye', 'intense pulsed light', 'meibomian gland dysfunction'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 03:15'], 'PHST': ['2023/04/07 03:15 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['IndianJOphthalmol_2023_71_4_1316_373514 [pii]', '10.4103/IJO.IJO_2987_22 [doi]'], 'PST': 'ppublish', 'SO': 'Indian J Ophthalmol. 2023 Apr;71(4):1316-1325. doi: 10.4103/IJO.IJO_2987_22.'}, {'PMID': '37026240', 'OWN': 'NLM', 'STAT': 'In-Process', 'LR': '20230407', 'IS': '1998-3689 (Electronic) 0301-4738 (Linking)', 'VI': '71', 'IP': '4', 'DP': '2023 Apr', 'TI': 'Role of in vivo confocal microscopy in dry eye disease and eye pain.', 'PG': '1099-1104', 'LID': '10.4103/IJO.IJO_3013_22 [doi]', 'AB': 'Dry eye disease is known to have a lot of variability in presentation with overlapping subtypes. Understanding the pathology of this condition will guide therapeutic options. In vivo confocal microscopy is a diagnostic and imaging modality that provides high magnification and high-resolution images of all layers of the cornea and ocular surface. Various structures in the cornea and their alterations due to dry eye have been imaged. The impact of the tear film instability, inflammation, and altered homeostasis on the corneal epithelium, nerves, keratocytes, and dendritic cells have been evaluated across different studies. In addition, key features of IVCM in patients with neuropathic pain have been highlighted in this paper.', 'FAU': ['Shetty, Rohit', 'Dua, Harminder S', 'Tong, Louis', 'Kundu, Gairik', 'Khamar, Pooja', 'Gorimanipalli, Bhavya', \"D'Souza, Sharon\"], 'AU': ['Shetty R', 'Dua HS', 'Tong L', 'Kundu G', 'Khamar P', 'Gorimanipalli B', \"D'Souza S\"], 'AD': ['Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Hospital, Bangalore, Karnataka, India.', 'Department of Ophthalmology and Visual Sciences, Queens Medical Centre, University of Nottingham, Nottingham, United Kingdom.', 'Cornea and External Eye Disease Service, Singapore National Eye Centre, Ocular Surface Research Group, Singapore Eye Research Institute, Eye Academic Clinical Program, Duke-National University of, Singapore.', 'Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Hospital, Bangalore, Karnataka, India.', 'Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Hospital, Bangalore, Karnataka, India.', 'Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Hospital, Bangalore, Karnataka, India.', 'Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Hospital, Bangalore, Karnataka, India.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'PL': 'India', 'TA': 'Indian J Ophthalmol', 'JT': 'Indian journal of ophthalmology', 'JID': '0405376', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Cornea', 'IVCM', 'eye pain', 'normal and dry eye'], 'COIS': ['None'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 03:15'], 'PHST': ['2023/04/07 03:15 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['IndianJOphthalmol_2023_71_4_1099_373517 [pii]', '10.4103/IJO.IJO_3013_22 [doi]'], 'PST': 'ppublish', 'SO': 'Indian J Ophthalmol. 2023 Apr;71(4):1099-1104. doi: 10.4103/IJO.IJO_3013_22.'}, {'PMID': '37025965', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230408', 'IS': '1663-4365 (Print) 1663-4365 (Electronic) 1663-4365 (Linking)', 'VI': '15', 'DP': '2023', 'TI': \"On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer's disease and Lewy body disease.\", 'PG': '1149036', 'LID': '10.3389/fnagi.2023.1149036 [doi] 1149036', 'AB': 'INTRODUCTION: Alzheimer\\'s disease (AD) and Lewy body disease (LBD) are the two most common neurodegenerative dementias and can occur in combination (AD+LBD). Due to overlapping biomarkers and symptoms, clinical differentiation of these subtypes could be difficult. However, it is unclear how the magnitude of diagnostic uncertainty varies across dementia spectra and demographic variables. We aimed to compare clinical diagnosis and post-mortem autopsy-confirmed pathological results to assess the clinical subtype diagnosis quality across these factors. METHODS: We studied data of 1,920 participants recorded by the National Alzheimer\\'s Coordinating Center from 2005 to 2019. Selection criteria included autopsy-based neuropathological assessments for AD and LBD, and the initial visit with Clinical Dementia Rating (CDR) stage of normal, mild cognitive impairment, or mild dementia. Longitudinally, we analyzed the first visit at each subsequent CDR stage. This analysis included positive predictive values, specificity, sensitivity and false negative rates of clinical diagnosis, as well as disparities by sex, race, age, and education. If autopsy-confirmed AD and/or LBD was missed in the clinic, the alternative clinical diagnosis was analyzed. FINDINGS: In our findings, clinical diagnosis of AD+LBD had poor sensitivities. Over 61% of participants with autopsy-confirmed AD+LBD were diagnosed clinically as AD. Clinical diagnosis of AD had a low sensitivity at the early dementia stage and low specificities at all stages. Among participants diagnosed as AD in the clinic, over 32% had concurrent LBD neuropathology at autopsy. Among participants diagnosed as LBD, 32% to 54% revealed concurrent autopsy-confirmed AD pathology. When three subtypes were missed by clinicians, \"No cognitive impairment\" and \"primary progressive aphasia or behavioral variant frontotemporal dementia\" were the leading primary etiologic clinical diagnoses. With increasing dementia stages, the clinical diagnosis accuracy of black participants became significantly worse than other races, and diagnosis quality significantly improved for males but not females. DISCUSSION: These findings demonstrate that clinical diagnosis of AD, LBD, and AD+LBD are inaccurate and suffer from significant disparities on race and sex. They provide important implications for clinical management, anticipatory guidance, trial enrollment and applicability of potential therapies for AD, and promote research into better biomarker-based assessment of LBD pathology.', 'CI': ['Copyright (c) 2023 Wei, Masurkar and Razavian.'], 'FAU': ['Wei, Hui', 'Masurkar, Arjun V', 'Razavian, Narges'], 'AU': ['Wei H', 'Masurkar AV', 'Razavian N'], 'AD': ['Manning College of Information and Computer Sciences, University of Massachusetts Amherst, Amherst, MA, United States.', 'Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.', 'Center for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, United States.', 'Neuroscience Institute, NYU Grossman School of Medicine, New York, NY, United States.', 'Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.', 'Department of Radiology, NYU Grossman School of Medicine, New York, NY, United States.', 'Center for Data Science, New York University, New York, NY, United States.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230321', 'PL': 'Switzerland', 'TA': 'Front Aging Neurosci', 'JT': 'Frontiers in aging neuroscience', 'JID': '101525824', 'PMC': 'PMC10070837', 'OTO': ['NOTNLM'], 'OT': [\"Alzheimer's disease\", 'Lewy body disease', 'autopsy-confirmed results', 'clinical diagnosis accuracy', 'dementia stages', 'disparity'], 'COIS': ['HW and NR report grants from Leon Lowenstein Foundation. NR and AM report grants', 'from National Institute of Health/National Institute on Aging (NIH/NIA) (grants', 'number P30AG066512). AM reports grants from NIH (grants numbers RF1AG072507,', 'R21AG070880, and P30AG008051), BrightFocus Foundation (grants number A2019602S),', \"and Alzheimer's Association (grants number AACF-17-524288). AM declares the\", 'payment from Rockefeller University (Nov. 2019) for education events. AM is a', \"member of the Alzheimer's Association International Research Grant Program\", 'Council and reports the payment in the form of waiving the ISTAART membership', \"fee: $150/year; AM is on the steering committee of the Alzheimer's Disease\", 'Cooperative Study with no payments. AM is on the Editorial Advisory Board of the', \"Journal of Neuro-ophthalmology and Editorial Board of Alzheimer's & Dementia:\", 'Translational Research and Clinical Interventions.'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:01', 'CRDT': ['2023/04/07 02:36'], 'PHST': ['2023/01/20 00:00 [received]', '2023/03/06 00:00 [accepted]', '2023/04/08 06:01 [medline]', '2023/04/07 02:36 [entrez]', '2023/04/08 06:00 [pubmed]'], 'AID': ['10.3389/fnagi.2023.1149036 [doi]'], 'PST': 'epublish', 'SO': 'Front Aging Neurosci. 2023 Mar 21;15:1149036. doi: 10.3389/fnagi.2023.1149036. eCollection 2023.'}, {'PMID': '37025947', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230408', 'IS': '2666-9145 (Electronic) 2666-9145 (Linking)', 'VI': '3', 'IP': '3', 'DP': '2023 Sep', 'TI': 'Five-Year Incidence of Proliferative Diabetic Retinopathy and Associated Risk Factors in a Nationwide Cohort of 201 945 Danish Patients with Diabetes.', 'PG': '100291', 'LID': '10.1016/j.xops.2023.100291 [doi] 100291', 'AB': 'PURPOSE: To evaluate the proliferative diabetic retinopathy (PDR) progression rates and identify the demographic and clinical characteristics of patients who later developed PDR compared with patients who did not progress to that state. DESIGN: A national 5-year register-based cohort study including 201 945 patients with diabetes. SUBJECTS: Patients with diabetes who had attended the Danish national screening program (2013-2018) for diabetic retinopathy (DR). METHODS: We used the first screening episode as the index date and included both eyes of patients with and without subsequent progression of PDR. Data were linked with various national health registries to investigate relevant clinical and demographic parameters. The International Clinical Retinopathy Disease Scale was used to classify DR, with no DR as level 0, mild DR as level 1, moderate DR as level 2, severe DR as level 3, and PDR as level 4. MAIN OUTCOME MEASURES: Hazard ratios (HRs) for incident PDR for all relevant demographic and clinical parameters and 1-, 3-, and 5-year incidence rates of PDR according to baseline DR level. RESULTS: Progression to PDR within 5 years was identified in 2384 eyes of 1780 patients. Proliferative diabetic retinopathy progression rates from baseline DR level 3 at 1, 3 and 5 years were 3.6%, 10.9%, and 14.7%, respectively. The median number of visits was 3 (interquartile range, 1-4). Progression to PDR was predicted in a multivariable model by duration of diabetes (HR, 4.66 per 10 years; 95% confidence interval [CI], 4.05-5.37), type 1 diabetes (HR, 9.61; 95% CI, 8.01-11.53), a Charlson Comorbidity Index score of > 0 (score 1: HR, 4.62; 95% CI, 4.14-5.15; score 2: HR, 2.28; 95% CI, 1.90-2.74; score >/= 3: HR, 4.28; 95% CI, 3.54-5.17), use of insulin (HR, 5.33; 95% CI, 4.49-6.33), and use of antihypertensive medications (HR, 2.23; 95% CI, 1.90-2.61). CONCLUSIONS: In a 5-year longitudinal study of an entire screening nation, we found increased risk of PDR with increasing baseline DR levels, longer duration of diabetes, type 1 diabetes, systemic comorbidity, use of insulin, and blood pressure-lowering medications. Most interestingly, we found lower risk of progression from DR level 3 to PDR compared with that in previous studies. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.', 'CI': ['(c) 2023 by the American Academy of Ophthalmology. This is.'], 'FAU': ['Dinesen, Sebastian', 'Stokholm, Lonny', 'Subhi, Yousif', 'Peto, Tunde', 'Savarimuthu, Thiusius Rajeeth', 'Andersen, Nis', 'Andresen, Jens', 'Bek, Toke', 'Hajari, Javad', 'Heegaard, Steffen', 'Hojlund, Kurt', 'Laugesen, Caroline Schmidt', 'Kawasaki, Ryo', 'Moller, Soren', 'Schielke, Katja', 'Thykjaer, Anne Suhr', 'Pedersen, Frederik', 'Grauslund, Jakob'], 'AU': ['Dinesen S', 'Stokholm L', 'Subhi Y', 'Peto T', 'Savarimuthu TR', 'Andersen N', 'Andresen J', 'Bek T', 'Hajari J', 'Heegaard S', 'Hojlund K', 'Laugesen CS', 'Kawasaki R', 'Moller S', 'Schielke K', 'Thykjaer AS', 'Pedersen F', 'Grauslund J'], 'AD': ['Department of Ophthalmology, Odense University Hospital, Odense, Denmark.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.', 'Open Patient Data Explorative Network, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.', \"Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.\", 'The Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense, Denmark.', 'Organization of Danish Practicing Ophthalmologists, Copenhagen, Denmark.', 'Organization of Danish Practicing Ophthalmologists, Copenhagen, Denmark.', 'Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.', 'Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.', 'Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.', 'Department of Ophthalmology, Zealand University Hospital Roskilde, Roskilde, Denmark.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Department of Vision Informatics, University of Osaka, Osaka, Japan.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Open Patient Data Explorative Network, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.', 'Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark.', 'Department of Ophthalmology, Odense University Hospital, Odense, Denmark.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Department of Ophthalmology, Odense University Hospital, Odense, Denmark.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Department of Ophthalmology, Odense University Hospital, Odense, Denmark.', 'Department of Clinical Research, University of Southern Denmark, Odense, Denmark.', 'Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230224', 'PL': 'Netherlands', 'TA': 'Ophthalmol Sci', 'JT': 'Ophthalmology science', 'JID': '9918230896206676', 'PMC': 'PMC10070897', 'OTO': ['NOTNLM'], 'OT': ['Epidemiology', 'Proliferative diabetic retinopathy', 'risk factor'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:01', 'CRDT': ['2023/04/07 02:35'], 'PHST': ['2022/06/17 00:00 [received]', '2023/02/16 00:00 [revised]', '2023/02/17 00:00 [accepted]', '2023/04/08 06:01 [medline]', '2023/04/07 02:35 [entrez]', '2023/04/08 06:00 [pubmed]'], 'AID': ['S2666-9145(23)00023-4 [pii]', '100291 [pii]', '10.1016/j.xops.2023.100291 [doi]'], 'PST': 'epublish', 'SO': 'Ophthalmol Sci. 2023 Feb 24;3(3):100291. doi: 10.1016/j.xops.2023.100291. eCollection 2023 Sep.'}, {'PMID': '37025946', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230408', 'IS': '2666-9145 (Electronic) 2666-9145 (Linking)', 'VI': '3', 'IP': '3', 'DP': '2023 Sep', 'TI': 'Joint Multimodal Deep Learning-based Automatic Segmentation of Indocyanine Green Angiography and OCT Images for Assessment of Polypoidal Choroidal Vasculopathy Biomarkers.', 'PG': '100292', 'LID': '10.1016/j.xops.2023.100292 [doi] 100292', 'AB': \"PURPOSE: To develop a fully-automatic hybrid algorithm to jointly segment and quantify biomarkers of polypoidal choroidal vasculopathy (PCV) on indocyanine green angiography (ICGA) and spectral domain-OCT (SD-OCT) images. DESIGN: Evaluation of diagnostic test or technology. PARTICIPANTS: Seventy-two participants with PCV enrolled in clinical studies at Singapore National Eye Center. METHODS: The dataset consisted of 2-dimensional (2-D) ICGA and 3-dimensional (3-D) SD-OCT images which were spatially registered and manually segmented by clinicians. A deep learning-based hybrid algorithm called PCV-Net was developed for automatic joint segmentation of biomarkers. The PCV-Net consisted of a 2-D segmentation branch for ICGA and 3-D segmentation branch for SD-OCT. We developed fusion attention modules to connect the 2-D and 3-D branches for effective use of the spatial correspondence between the imaging modalities by sharing learned features. We also used self-supervised pretraining and ensembling to further enhance the performance of the algorithm without the need for additional datasets. We compared the proposed PCV-Net to several alternative model variants. MAIN OUTCOME MEASURES: The PCV-Net was evaluated based on the Dice similarity coefficient (DSC) of the segmentations and the Pearson's correlation and absolute difference of the clinical measurements obtained from the segmentations. Manual grading was used as the gold standard. RESULTS: The PCV-Net showed good performance compared to manual grading and alternative model variants based on both quantitative and qualitative analyses. Compared to the baseline variant, PCV-Net improved the DSC by 0.04 to 0.43 across the different biomarkers, increased the correlations, and decreased the absolute differences of clinical measurements of interest. Specifically, the largest average (mean +/- standard error) DSC improvement was for intraretinal fluid, from 0.02 +/- 0.00 (baseline variant) to 0.45 +/- 0.06 (PCV-Net). In general, improving trends were observed across the model variants as more technical specifications were added, demonstrating the importance of each aspect of the proposed method. CONCLUSION: The PCV-Net has the potential to aid clinicians in disease assessment and research to improve clinical understanding and management of PCV. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.\", 'CI': ['(c) 2023 by the American Academy of Ophthalmology. This is.'], 'FAU': ['Loo, Jessica', 'Teo, Kelvin Y C', 'Vyas, Chinmayi H', 'Jordan-Yu, Janice Marie N', 'Juhari, Amalia B', 'Jaffe, Glenn J', 'Cheung, Chui Ming Gemmy', 'Farsiu, Sina'], 'AU': ['Loo J', 'Teo KYC', 'Vyas CH', 'Jordan-Yu JMN', 'Juhari AB', 'Jaffe GJ', 'Cheung CMG', 'Farsiu S'], 'AD': ['Department of Biomedical Engineering, Duke University, Durham, North Carolina.', 'Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore.', 'Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.', 'Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore.', 'Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore.', 'Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore.', 'Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.', 'Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore.', 'Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.', 'Department of Biomedical Engineering, Duke University, Durham, North Carolina.', 'Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230224', 'PL': 'Netherlands', 'TA': 'Ophthalmol Sci', 'JT': 'Ophthalmology science', 'JID': '9918230896206676', 'PMC': 'PMC10070921', 'OTO': ['NOTNLM'], 'OT': ['OCT', 'deep learning', 'indocyanine green angiography', 'multimodal image analysis', 'polypoidal choroidal vasculopathy'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:01', 'CRDT': ['2023/04/07 02:35'], 'PHST': ['2022/10/01 00:00 [received]', '2023/01/08 00:00 [revised]', '2023/02/17 00:00 [accepted]', '2023/04/08 06:01 [medline]', '2023/04/07 02:35 [entrez]', '2023/04/08 06:00 [pubmed]'], 'AID': ['S2666-9145(23)00024-6 [pii]', '100292 [pii]', '10.1016/j.xops.2023.100292 [doi]'], 'PST': 'epublish', 'SO': 'Ophthalmol Sci. 2023 Feb 24;3(3):100292. doi: 10.1016/j.xops.2023.100292. eCollection 2023 Sep.'}, {'PMID': '37025945', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230408', 'IS': '2666-9145 (Electronic) 2666-9145 (Linking)', 'VI': '3', 'IP': '3', 'DP': '2023 Sep', 'TI': 'A Multicenter Analysis of Nucleic Acid Quantification Using Aqueous Humor Liquid Biopsy in Retinoblastoma: Implications for Clinical Testing.', 'PG': '100289', 'LID': '10.1016/j.xops.2023.100289 [doi] 100289', 'AB': 'PURPOSE: Retinoblastoma (RB) is most often diagnosed with clinical features and not diagnosed with tumor biopsy. This study describes tumor-derived analyte concentrations from aqueous humor (AH) liquid biopsy and its use in clinical assays. DESIGN: Case series study. PARTICIPANTS: Sixty-two RB eyes from 55 children and 14 control eyes from 12 children from 4 medical centers. METHODS: This study included 128 RB AH samples including: diagnostic (DX) samples, samples from eyes undergoing treatment (TX), samples after completing treatment (END), and during bevacizumab injection for radiation therapy after completing RB treatment (BEV). Fourteen-control AH were analyzed for unprocessed analytes (double-stranded DNA [dsDNA], single-stranded DNA [ssDNA], micro-RNA [miRNA], RNA, and protein) with Qubit fluorescence assays. Double-stranded DNA from 2 RB AH samples underwent low-pass whole-genome sequencing to detect somatic copy number alterations. Logistic regression was used to predict disease burden given analyte concentrations. MAIN OUTCOME MEASURES: Unprocessed analyte (dsDNA, ssDNA, miRNA, RNA and protein) concentrations. RESULTS: Results revealed dsDNA, ssDNA, miRNA, and proteins, but not RNA, were quantifiable in most samples (up to 98%) with Qubit fluorescence assays. Median dsDNA concentration was significantly higher in DX (3.08 ng/mul) compared to TX (0.18 ng/mul; P < 0.0001) at an order of 17 times greater and 20 times greater than END samples (0.15 ng/mul; P = 0.001). Using logistic regression, nucleic acid concentrations were useful in predicting higher versus lower RB disease burden. Retinoblastoma somatic copy number alterations were identified in a TX, but not in a BEV sample, indicating the correlation with RB activity. CONCLUSIONS: Aqueous humor liquid biopsy in RB is a high-yield source of dsDNA, ssDNA, miRNA, and protein. Diagnostic samples are most useful for RB 1 gene mutational analyses. Genomic analysis may be more informative of tumor activity status than quantification alone and can be performed even with smaller analyte concentrations obtained from TX samples. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.', 'CI': ['(c) 2023 by the American Academy of Ophthalmology. This is.'], 'FAU': ['Im, Deborah H', 'Pike, Sarah', 'Reid, Mark W', 'Peng, Chen-Ching', 'Sirivolu, Shreya', 'Grossniklaus, Hans E', 'Hubbard, G Baker', 'Skalet, Alison H', 'Bellsmith, Kellyn N', 'Shields, Carol L', 'Lally, Sara E', 'Stacey, Andrew W', 'Reiser, Bibiana J', 'Nagiel, Aaron', 'Shah, Rachana', 'Xu, Liya', 'Berry, Jesse L'], 'AU': ['Im DH', 'Pike S', 'Reid MW', 'Peng CC', 'Sirivolu S', 'Grossniklaus HE', 'Hubbard GB', 'Skalet AH', 'Bellsmith KN', 'Shields CL', 'Lally SE', 'Stacey AW', 'Reiser BJ', 'Nagiel A', 'Shah R', 'Xu L', 'Berry JL'], 'AD': [\"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', 'Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia.', 'Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia.', 'Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon.', 'Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon.', 'Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.', 'Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.', \"Division of Ophthalmology, Department of Ophthalmology, Seattle Children's Hospital, University of Washington, Seattle, Washington.\", \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', \"Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California.\", \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', \"Department of Surgery, Division of Ophthalmology, The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.\", 'USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California.', 'Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.', \"The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California.\"], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230219', 'PL': 'Netherlands', 'TA': 'Ophthalmol Sci', 'JT': 'Ophthalmology science', 'JID': '9918230896206676', 'PMC': 'PMC10070901', 'OTO': ['NOTNLM'], 'OT': ['Aqueous humor', 'Circulating analytes', 'Liquid biopsy', 'Multicenter', 'Retinoblastoma'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:01', 'CRDT': ['2023/04/07 02:35'], 'PHST': ['2022/12/13 00:00 [received]', '2023/02/07 00:00 [revised]', '2023/02/13 00:00 [accepted]', '2023/04/08 06:01 [medline]', '2023/04/07 02:35 [entrez]', '2023/04/08 06:00 [pubmed]'], 'AID': ['S2666-9145(23)00021-0 [pii]', '100289 [pii]', '10.1016/j.xops.2023.100289 [doi]'], 'PST': 'epublish', 'SO': 'Ophthalmol Sci. 2023 Feb 19;3(3):100289. doi: 10.1016/j.xops.2023.100289. eCollection 2023 Sep.'}, {'PMID': '37025403', 'OWN': 'NLM', 'STAT': 'In-Process', 'LR': '20230408', 'IS': '1664-2392 (Print) 1664-2392 (Electronic) 1664-2392 (Linking)', 'VI': '14', 'DP': '2023', 'TI': 'Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients.', 'PG': '1140196', 'LID': '10.3389/fendo.2023.1140196 [doi] 1140196', 'AB': \"OBJECTIVE: To analyze the efficacy of mycophenolate mofetil (MMF) and glucocorticoid administration in patients with thyroid-associated ophthalmopathy (TAO). METHODS: Sixty patients with moderate to severe TAO treated in Jingzhou Central Hospital from January 2022 to June 2022 were selected and enrtolled in this study. The subjects were divided into experimental group (n=30) and control group (n=30) based on the random number table method. Glucocorticoid pulse therapy was provided in the control group, while MMF was given in the experimental group on the basis of Control group. Clinical activity score (CAS), quality of life (QOL), visual acuity, eyelid fissure width, intraocular pressure, and degree of exophthalmos were observed at the time of admission and at the 12(th) week and 24(th) post-treatment weeks. We compared the immune function (TRAb, IL-6, and CD4+/CD8+) of the two groups pre-treatment and 24 weeks post-treatment, and evaluated the clinical therapeutic effect. RESULTS: The clinical effective rates at 12 and 24 weeks in the experimental group were higher (73.3% and 83.3%) than those in the control group (46.7% and 60.0%) (P <0.05). After 12 weeks of treatment, patients' CAS scores, and bilateral lid fissure width decreased and right eye visual acuity increased in the control group compared with those before treatment (P < 0.05); further, after 24 weeks of treatment, patients' QOL scores and bilateral visual acuity increased and CAS scores, bilateral lid fissure width and proptosis decreased compared with those before treatment, and patients' QOL scores, CAS scores and bilateral proptosis improved more than those at 12 weeks of treatment (P <0.05). Additionally, greater improvements were observed in the patients' QOL and CAS scores, and proptosis after 24-week treatment than after 12-week treatment (P<0.05). In the experimental group, the QOL score and binocular visual acuity increased, whereas the CAS score, intraocular pressure, lid width, and proptosis decreased after 12 weeks of treatment as compared to the values of these parameters in the pre-treatment period (P < 0.05); after 24 weeks of treatment, greater improvements were established in the ocular-related indexes improved compared to the pre-treatment period and after 12 weeks of treatment (P < 0.05). After 12 weeks of treatment, the patients in the experimental group had more considerable improvements in the right visual acuity, right intraocular pressure, and left lid fissure width than the control group (P < 0.05); at 24 weeks of treatment, patients in the experimental group had greater improvements in the QOL score, bilateral visual acuity, intraocular pressure, bilateral lid fissure width, and bilateral proptosis than the control group (P < 0.05). No significant differences were found in the values of TRAb, IL-6, and CD4+/CD8+ between the two groups before treatment (P>0.05); the values of TRAb, IL-6, and CD4+/CD8+ in the experimental group was significantly lower than those before treatment and in the control group after 24weeks of treatment. (P>0.05). No statistically significant difference was observed in the incidence of liver damage and menstrual disorders between the two groups during the 24 weeks of treatment (P>0.05). CONCLUSION: The combination of oral MMF and glucocorticoid shock therapy is an effective drug for the treatment of patients with moderately active TAO.\", 'CI': ['Copyright (c) 2023 Li, Xue, Guan, Su, Wang and Zhang.'], 'FAU': ['Li, Lan-Fang', 'Xue, Jun-Li', 'Guan, Lei', 'Su, Fan-Fan', 'Wang, Hong', 'Zhang, Ding-Fu'], 'AU': ['Li LF', 'Xue JL', 'Guan L', 'Su FF', 'Wang H', 'Zhang DF'], 'AD': ['Department of Endocrinology, Jingzhou Cental Hospital, Jingzhou, China.', 'Department of Endocrinology, Jingzhou Cental Hospital, Jingzhou, China.', \"Department of Pediatrics, Jingzhou First People's Hospital, Jingzhou, China.\", 'Department of Ophthalmology, Jingzhou Cental Hospital, Jingzhou, China.', 'Department of Radiology, Jingzhou Cental Hospital, Jingzhou, China.', 'Department of Oncology, Jingzhou Cental Hospital, Jingzhou, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230321', 'PL': 'Switzerland', 'TA': 'Front Endocrinol (Lausanne)', 'JT': 'Frontiers in endocrinology', 'JID': '101555782', 'SB': 'IM', 'PMC': 'PMC10070944', 'OTO': ['NOTNLM'], 'OT': ['adverse reactions', 'glucocorticoid', 'mycophenolate mofetil', 'therapeutic outcomes', 'thyroid-associated ophthalmopathy'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/08 06:00', 'MHDA': '2023/04/08 06:00', 'CRDT': ['2023/04/07 02:29'], 'PHST': ['2023/01/08 00:00 [received]', '2023/03/06 00:00 [accepted]', '2023/04/07 02:29 [entrez]', '2023/04/08 06:00 [pubmed]', '2023/04/08 06:00 [medline]'], 'AID': ['10.3389/fendo.2023.1140196 [doi]'], 'PST': 'epublish', 'SO': 'Front Endocrinol (Lausanne). 2023 Mar 21;14:1140196. doi: 10.3389/fendo.2023.1140196. eCollection 2023.'}, {'PMID': '37024727', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1552-4469 (Electronic) 1552-4450 (Linking)', 'DP': '2023 Apr 6', 'TI': 'Design of cell-type-specific hyperstable IL-4 mimetics via modular de novo scaffolds.', 'LID': '10.1038/s41589-023-01313-6 [doi]', 'AB': 'The interleukin-4 (IL-4) cytokine plays a critical role in modulating immune homeostasis. Although there is great interest in harnessing this cytokine as a therapeutic in natural or engineered formats, the clinical potential of native IL-4 is limited by its instability and pleiotropic actions. Here, we design IL-4 cytokine mimetics (denoted Neo-4) based on a de novo engineered IL-2 mimetic scaffold and demonstrate that these cytokines can recapitulate physiological functions of IL-4 in cellular and animal models. In contrast with natural IL-4, Neo-4 is hyperstable and signals exclusively through the type I IL-4 receptor complex, providing previously inaccessible insights into differential IL-4 signaling through type I versus type II receptors. Because of their hyperstability, our computationally designed mimetics can directly incorporate into sophisticated biomaterials that require heat processing, such as three-dimensional-printed scaffolds. Neo-4 should be broadly useful for interrogating IL-4 biology, and the design workflow will inform targeted cytokine therapeutic development.', 'CI': ['(c) 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.'], 'FAU': ['Yang, Huilin', 'Ulge, Umut Y', 'Quijano-Rubio, Alfredo', 'Bernstein, Zachary J', 'Maestas, David R', 'Chun, Jung-Ho', 'Wang, Wentao', 'Lin, Jian-Xin', 'Jude, Kevin M', 'Singh, Srujan', 'Orcutt-Jahns, Brian T', 'Li, Peng', 'Mou, Jody', 'Chung, Liam', 'Kuo, Yun-Huai', 'Ali, Yasmin H', 'Meyer, Aaron S', 'Grayson, Warren L', 'Heller, Nicola M', 'Garcia, K Christopher', 'Leonard, Warren J', 'Silva, Daniel-Adriano', 'Elisseeff, Jennifer H', 'Baker, David', 'Spangler, Jamie B'], 'AU': ['Yang H', 'Ulge UY', 'Quijano-Rubio A', 'Bernstein ZJ', 'Maestas DR', 'Chun JH', 'Wang W', 'Lin JX', 'Jude KM', 'Singh S', 'Orcutt-Jahns BT', 'Li P', 'Mou J', 'Chung L', 'Kuo YH', 'Ali YH', 'Meyer AS', 'Grayson WL', 'Heller NM', 'Garcia KC', 'Leonard WJ', 'Silva DA', 'Elisseeff JH', 'Baker D', 'Spangler JB'], 'AD': ['Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA.', 'Department of Bioengineering, University of Washington, Seattle, WA, USA.', 'Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA.', 'Department of Bioengineering, University of Washington, Seattle, WA, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA.', 'Graduate Program in Biological Physics, Structure and Design, University of Washington, Seattle, WA, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.', 'Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.', 'Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Bioengineering, University of California, Los Angeles, CA, USA.', 'Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA.', 'Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'College of Medicine, Florida State University, Tallahassee, FL, USA.', 'Department of Bioengineering, University of California, Los Angeles, CA, USA.', 'Department of Bioinformatics, University of California, Los Angeles, CA, USA.', 'Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.', 'Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, USA.', 'Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA.', 'Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA.', 'Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.', 'Allergy and Clinical Immunology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.', 'Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.', 'Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.', 'Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.', 'Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA. dabaker@uw.edu.', 'Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA. dabaker@uw.edu.', 'Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA. jamie.spangler@jhu.edu.', 'Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.', 'Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.', 'Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA. jamie.spangler@jhu.edu.', 'Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.', 'Sidney Kimmel Cancer Center, The Johns Hopkins University, Baltimore, MD, USA. jamie.spangler@jhu.edu.', 'Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD, USA. jamie.spangler@jhu.edu.'], 'AUID': ['ORCID: 0000-0002-3675-5136', 'ORCID: 0000-0002-7498-4298', 'ORCID: 0000-0002-1436-1224', 'ORCID: 0000-0001-7247-2021', 'ORCID: 0000-0001-9273-0278', 'ORCID: 0000-0002-3195-9009', 'ORCID: 0000-0002-5066-1996', 'ORCID: 0000-0001-7896-6217', 'ORCID: 0000-0001-8187-3732'], 'LA': ['eng'], 'GR': ['U01AI148119/U.S. Department of Health & Human Services | National Institutes of', 'Health (NIH)/', 'R01AI5321/U.S. Department of Health & Human Services | National Institutes of', 'Health (NIH)/', 'N/A/U.S. Department of Health & Human Services | National Institutes of Health', '(NIH)/', \"Director's Pioneer Award/U.S. Department of Health & Human Services | National\", 'Institutes of Health (NIH)/', 'R01CA240339/U.S. Department of Health & Human Services | National Institutes of', 'Health (NIH)/', 'R01EB029455/U.S. Department of Health & Human Services | National Institutes of', 'Health (NIH)/', 'N/A/Howard Hughes Medical Institute (HHMI)/'], 'PT': ['Journal Article'], 'DEP': '20230406', 'PL': 'United States', 'TA': 'Nat Chem Biol', 'JT': 'Nature chemical biology', 'JID': '101231976', 'SB': 'IM', 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 23:27'], 'PHST': ['2022/08/23 00:00 [received]', '2023/03/10 00:00 [accepted]', '2023/04/06 23:27 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['10.1038/s41589-023-01313-6 [pii]', '10.1038/s41589-023-01313-6 [doi]'], 'PST': 'aheadofprint', 'SO': 'Nat Chem Biol. 2023 Apr 6. doi: 10.1038/s41589-023-01313-6.'}, {'PMID': '37024414', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1476-5411 (Electronic) 1367-0484 (Linking)', 'DP': '2023 Apr 4', 'TI': 'Italian translation and validation of the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8).', 'PG': '101842', 'LID': 'S1367-0484(23)00046-2 [pii] 10.1016/j.clae.2023.101842 [doi]', 'AB': 'PURPOSE: To translate and validate an Italian version of the CLDEQ-8 (CLDEQ-8_IT). METHODS: The study was carried out in two phases. In the first phase, a cross-cultural adaptation of CLDEQ-8 to Italian was performed by forward and backward translation in sequence. In the second phase, a multi-centre study was conducted for the validation of the questionnaire. Validity CLDEQ-8_IT was evaluated against three gestalt questions: overall opinion of soft contact lenses (CLs), global self-assessments of eye sensitivity and eye dryness. Reliability was evaluated by test-retest assessment in a subgroup of subjects. Finally, the psychometric properties of CLDEQ-8_IT were explored by Rasch analysis. RESULTS: Two hundred and forty soft CL wearers, fluent Italian speakers (73 males and 167 females), between 18 and 70 years of age were enrolled. A significant correlation was found between CLDEQ-8_IT and each of the three Gestalt questions. The cutoff score of 12 points demonstrated the best balance between sensitivity and specificity in differentiating wearers grading their CLs as \"Excellent/Very good\" from those reporting their overall opinion as \"Good/Fair/Poor\". The Intraclass Correlation Coefficient between test and retest was 0.88 (95% CI: 0.81-0.92). Finally, infit and outfit statistics using Rasch analysis for the 8 items were in a good range, however Principal Components Analysis revealed a certain degree of multi-dimensionality of the instrument. Also, item 8 analysis could be computed after merging the last two response categories. CONCLUSION: The CLDEQ-8_IT showed very good validity and reliability in measuring symptoms of CL wearers, comparable to the original English language version. A cut-off of 12 was confirmed as yielding the best balance between sensitivity and specificity in detecting CL wearers who could benefit from clinical management of their CL-related symptoms. Collapsing of the response options 5 and 6 in the last item of questionnaire could optimise its functioning.', 'CI': ['Copyright (c) 2023. Published by Elsevier Ltd.'], 'FAU': ['Zeri, Fabrizio', 'Tavazzi, Silvia', 'Naroo, Shehzad A', 'Recchioni, Alberto', 'Menduni, Francesco', 'Ponzini, Erika', 'Chalmers, Robin', 'Desiato, Alfredo'], 'AU': ['Zeri F', 'Tavazzi S', 'Naroo SA', 'Recchioni A', 'Menduni F', 'Ponzini E', 'Chalmers R', 'Desiato A'], 'AD': ['Department of Materials Science, University of Milano-Bicocca, Milan, Italy; Research Centre in Optics and Optometry (COMiB), University of Milano-Bicocca, Milan, Italy; College of Health and Life Sciences, Aston University, Birmingham, UK.', 'Department of Materials Science, University of Milano-Bicocca, Milan, Italy; Research Centre in Optics and Optometry (COMiB), University of Milano-Bicocca, Milan, Italy. Electronic address: silvia.tavazzi@unimib.it.', 'College of Health and Life Sciences, Aston University, Birmingham, UK.', 'College of Health and Life Sciences, Aston University, Birmingham, UK; Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, UK; Birmingham and Midland Eye Centre, Birmingham, UK.', 'College of Health and Life Sciences, Aston University, Birmingham, UK.', 'Department of Materials Science, University of Milano-Bicocca, Milan, Italy; Research Centre in Optics and Optometry (COMiB), University of Milano-Bicocca, Milan, Italy.', 'Clinical Trial Consultant, Atlanta, GA, USA.', 'College of Health and Life Sciences, Aston University, Birmingham, UK.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230404', 'PL': 'England', 'TA': 'Cont Lens Anterior Eye', 'JT': 'Contact lens & anterior eye : the journal of the British Contact Lens Association', 'JID': '9712714', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['CLDEQ-8_IT', 'Contact lens discomfort', 'Questionnaire', 'Symptoms'], 'COIS': ['Declaration of Competing Interest The authors declare that they have no known', 'competing financial interests or personal relationships that could have appeared', 'to influence the work reported in this paper.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 22:05'], 'PHST': ['2023/01/16 00:00 [received]', '2023/03/10 00:00 [revised]', '2023/03/31 00:00 [accepted]', '2023/04/06 22:05 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['S1367-0484(23)00046-2 [pii]', '10.1016/j.clae.2023.101842 [doi]'], 'PST': 'aheadofprint', 'SO': 'Cont Lens Anterior Eye. 2023 Apr 4:101842. doi: 10.1016/j.clae.2023.101842.'}, {'PMID': '37023997', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1873-1597 (Electronic) 1572-1000 (Linking)', 'DP': '2023 Apr 4', 'TI': 'PROGNOSIS EVALUATION WITH OPTICAL COHERENCE TOMOGRAPHY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.', 'PG': '103552', 'LID': 'S1572-1000(23)00279-X [pii] 10.1016/j.pdpdt.2023.103552 [doi]', 'AB': 'BACKGROUND: Central serous chorioretinopathy (CSCR) is the fourth most common retinopathy that causes severe vision loss and is frequently seen in young and active patients. Our aim in this study is to evaluate whether a foresight about the prognosis of patients with CSCR can be obtained by optical coherence tomography (OCT) findings. MATERIALS AND METHODS: Patients diagnosed with chronic CSCR at Fatih Sultan Mehmet Research and Training Hospital, Ophthalmology Department, were screened between January 2017 and September 2019, and 30 patients were included in the study. The anatomical and functional changes of the patients during the 6-month follow-up and the relationship between the OCT findings at baseline and the best corrected visual acuity (BCVA) in the sixth month were evaluated. RESULTS: All of the participants were treated with subthreshold micropulse laser therapy. BCVA increased significantly at first month and sixth month examinations compared to baseline, while the central macular thicknesses decreased significantly (p=0.01, p=0.00). Among the parameters examined in the baseline OCT, a positive correlation was found between the thickness of the outer nuclear layer (r=-0.520, p=0.003) and BCVA at sixth month. In addition, subretinal fluid density and the number of intra-subretinal hyperreflective dots negatively affected BCVA (r=0.371, p=0.044 and r=0.509, p=0.004). CONCLUSION: Outer nuclear layer thickness, subretinal fluid density and intra-subretinal hyperreflective dots were the OCT biomarkers related to sixth month BCVA. The clinical use of these biomarkers will help evaluate the prognosis of the CSCR.', 'CI': ['Copyright (c) 2023. Published by Elsevier B.V.'], 'FAU': ['Kaplan, Fatih Bilgehan', 'Acikalin, Banu', 'Ergin, Ayse', 'Kocapinar, Yildirim'], 'AU': ['Kaplan FB', 'Acikalin B', 'Ergin A', 'Kocapinar Y'], 'AD': ['University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Ophthalmology, Istanbul. Electronic address: fthkaplan@gmail.com.', 'University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Ophthalmology, Istanbul.', 'University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Ophthalmology, Istanbul.', 'Siirt Training and Research Hospital, Department of Ophthalmology, Siirt.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230404', 'PL': 'Netherlands', 'TA': 'Photodiagnosis Photodyn Ther', 'JT': 'Photodiagnosis and photodynamic therapy', 'JID': '101226123', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['CSCR', 'Central serous chorioretinopathy', 'optical coherence tomography'], 'COIS': ['Declaration of Competing Interest All authors declare that there is no conflict', 'of interest.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 19:27'], 'PHST': ['2023/02/04 00:00 [received]', '2023/03/28 00:00 [revised]', '2023/04/03 00:00 [accepted]', '2023/04/06 19:27 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['S1572-1000(23)00279-X [pii]', '10.1016/j.pdpdt.2023.103552 [doi]'], 'PST': 'aheadofprint', 'SO': 'Photodiagnosis Photodyn Ther. 2023 Apr 4:103552. doi: 10.1016/j.pdpdt.2023.103552.'}, {'PMID': '37023917', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1615-5947 (Electronic) 0890-5096 (Linking)', 'DP': '2023 Apr 4', 'TI': 'Gender Bias in Clinical Trial Enrollment: Female Authorship Matters.', 'LID': 'S0890-5096(23)00175-9 [pii] 10.1016/j.avsg.2023.03.008 [doi]', 'AB': 'BACKGROUND: Despite initiatives to promote equal enrollment of human subjects in clinical trials, females continue to be underrepresented. The goal of this work is to determine if female enrollment in human clinical trials published in three high-impact journals from 2015 to 2019 is correlated with gender of first and/or senior authors. METHODS: Clinical trials published in the Journal of the American Medical Association (JAMA), The Lancet, and the New England Journal of Medicine (NEJM) from January 1, 2015, to December 31, 2019, were reviewed. Trials were excluded for ongoing enrollment, sex-specific disease research, or author name without gender assignment. One-sample chi(2) pairwise comparisons and two-tailed proportion tests on the proportion of females between gender author pairings were done overall and for each subset analysis. RESULTS: 1,427 articles enrolled a total of 2,104,509 females and 2,616,981 males (44.6% vs. 55.4%, p </= 0.0001) in clinical trials. Overall, more females were enrolled if both first and senior authors were female (51.7% vs. 48.3%, p </= 0.0001). Proportion of females enrolled decreased with the following first and senior author pairings: female-male (48.9%), male-female (48.6%), and male-male (40.5%, p </= 0.0001 compared to female-female authorship). Greater female enrollment in clinical trials with female-female compared to male-male authorship persisted in subset analyses by funding source, phase, randomization for study participants, drug and/or device trial, and geographic location. Female enrollment was higher in 3 surgical specialties: neurosurgery (all authors: 52%, p </= 0.01), ophthalmology (all authors: 53.6%, p </= 0.0001), and surgery (all authors: 54.4%, p </= 0.0001). The majority of surgical specialties did not publish trials with female-female authorship but when stratifying by author gender pairing, surgical oncology had the highest female enrollment with female-female authorship (98.4%, p </= 0.0001). CONCLUSION: Female authorship of clinical trial publications, specifically having both first and senior authors as female, was correlated with higher female enrollment in clinical trials when compared to male authorship and endured with multiple subset analyses.', 'CI': ['Published by Elsevier Inc.'], 'FAU': ['Chhaya, Vina Y', 'Binion, C Chase', 'Mulles, Shanen M', 'Tannhauser, Paige A', 'Aziz, Daniel Z', 'Greenwood, James D', 'Barlek, Mark H', 'Rouan, Jessica R', 'Wyatt, Thomas G', 'Kibbe, Melina R'], 'AU': ['Chhaya VY', 'Binion CC', 'Mulles SM', 'Tannhauser PA', 'Aziz DZ', 'Greenwood JD', 'Barlek MH', 'Rouan JR', 'Wyatt TG', 'Kibbe MR'], 'AD': ['Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA.', 'Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22903, USA.', 'Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA.', 'Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA.', 'Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22903, USA.', 'Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA.', 'Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA; Department of Surgery, Allegheny Health Network, Pittsburgh, PA 15212, USA.', 'Department of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA.', 'Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA; Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX 79410, USA.', 'Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22903, USA. Electronic address: melinakibbe@virginia.edu.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230404', 'PL': 'Netherlands', 'TA': 'Ann Vasc Surg', 'JT': 'Annals of vascular surgery', 'JID': '8703941', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['clinical trials', 'female authorship', 'gender bias', 'sex bias'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 19:25'], 'PHST': ['2023/02/06 00:00 [received]', '2023/03/13 00:00 [revised]', '2023/03/21 00:00 [accepted]', '2023/04/06 19:25 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['S0890-5096(23)00175-9 [pii]', '10.1016/j.avsg.2023.03.008 [doi]'], 'PST': 'aheadofprint', 'SO': 'Ann Vasc Surg. 2023 Apr 4:S0890-5096(23)00175-9. doi: 10.1016/j.avsg.2023.03.008.'}, {'PMID': '37023911', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230408', 'IS': '1873-1708 (Electronic) 0890-6238 (Linking)', 'VI': '118', 'DP': '2023 Apr 5', 'TI': 'Iron deficiency and overload in men and woman of reproductive age, and pregnant women.', 'PG': '108381', 'LID': 'S0890-6238(23)00055-2 [pii] 10.1016/j.reprotox.2023.108381 [doi]', 'AB': 'Iron is an essential micronutrient for human biology and health, but high iron levels can be dangerous. Both iron deficiency and iron overload have been linked to reproductive health. This review summarizes the effects of iron deficiency and overload on omen of reproductive age (including pregnant women) and adult men. In addition, appropriate iron levels and the need for iron and nutritional supplements at different stages of life and pregnancy are discussed. In general, men should be aware of the risk of iron overload at any stage of life; women should take appropriate iron supplements before menopause; postmenopausal women should pay attention to the risk of iron overload; and pregnant women should receive reasonable iron supplementation in middle and late pregnancy. By summarizing evidence on the relationship between iron and reproductive health, this review aims to promote the development of strategies to optimize reproductive capacity from the perspective of nutrition. However, additional detailed experimental investigations and clinical studies are needed to assess the underlying causes and mechanisms of the observed associations between iron and reproductive health.', 'CI': ['Copyright (c) 2023 Elsevier Inc. All rights reserved.'], 'FAU': ['Li, Xiuyun', 'Duan, Xuexia', 'Tan, Dongmei', 'Zhang, Bin', 'Xu, Anran', 'Qiu, Ningning', 'Chen, Zhaowen'], 'AU': ['Li X', 'Duan X', 'Tan D', 'Zhang B', 'Xu A', 'Qiu N', 'Chen Z'], 'AD': ['Maternal and Child Health Development Research Center, Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.', 'Physical Examination Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.', 'Traditional Chinese Medicine Department, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.', 'Department of Ophthalmology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.', 'Reproductive Medicine Center, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.', 'Department of Anesthesiology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China. Electronic address: qiunn1983@163.com.', 'Obstetrics Department, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China. Electronic address: chenzhaowen567@126.com.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230405', 'PL': 'United States', 'TA': 'Reprod Toxicol', 'JT': 'Reproductive toxicology (Elmsford, N.Y.)', 'JID': '8803591', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Fetal development', 'Infertility', 'Iron deficiency reproduction', 'Iron overload', 'Pregnancy'], 'COIS': ['Declaration of Competing Interest The authors declare that they have no known', 'competing financial interests or personal relationships that could have appeared', 'to influence the work reported in this paper.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 19:25'], 'PHST': ['2022/11/15 00:00 [received]', '2023/03/06 00:00 [revised]', '2023/04/02 00:00 [accepted]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]', '2023/04/06 19:25 [entrez]'], 'AID': ['S0890-6238(23)00055-2 [pii]', '10.1016/j.reprotox.2023.108381 [doi]'], 'PST': 'aheadofprint', 'SO': 'Reprod Toxicol. 2023 Apr 5;118:108381. doi: 10.1016/j.reprotox.2023.108381.'}, {'PMID': '37023894', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1879-3304 (Electronic) 0039-6257 (Linking)', 'DP': '2023 Apr 4', 'TI': 'Fibrosis in neovascular age-related macular degeneration: A review of definitions based on clinical imaging.', 'LID': 'S0039-6257(23)00049-8 [pii] 10.1016/j.survophthal.2023.03.004 [doi]', 'AB': 'Despite the success of antiangiogenic therapy in controlling exudation in neovascular age-related macular degeneration (nAMD), the involvement of the outer retina in fibrosis results in gradual vision loss over time. The development of drugs that prevent or ameliorate fibrosis in nAMD requires that it is accurately detected and quantified with reliable endpoints and identification of robust biomarkers. Achievement of such an aim is currently challenging due to the lack of a consensus definition of fibrosis in nAMD. As a first step towards the establishment of a clear definition of fibrosis, we provide an extensive overview of the imaging modalities and criteria used to characterize fibrosis in nAMD. We observed variety in the selection of individual and combinations of imaging modalities, and criteria for detection. We also observed heterogeneity in classification systems and severity scales for fibrosis. The most commonly used imaging modalities were color fundus photography (CFP), fluorescence angiography (FA) and optical coherence tomography (OCT). A multimodal approach was frequently utilized. Our review suggests that OCT offers a more detailed, objective and sensitive characterization than CFP/FA. Thus, we recommend it as a primary modality for fibrosis evaluation. This review provides a basis for future discussions to reach a consensus definition using standardized terms based on a detailed characterization of fibrosis, its presence and evolution, and taking into consideration impact on visual function. Achieving this goal is of paramount importance for the development of antifibrotic therapies.', 'CI': ['Copyright (c) 2023. Published by Elsevier Inc.'], 'FAU': ['Bachmeier, Isabel', 'Armendariz, Beatriz Garcia', 'Yu, Siqing', 'Jager, Ralf Josef', 'Ebneter, Andreas', 'Glittenberg, Carl', 'Pauleikhoff, Daniel', 'Sadda, SriniVas R', 'Chakravarthy, Usha', 'Fauser, Sascha'], 'AU': ['Bachmeier I', 'Armendariz BG', 'Yu S', 'Jager RJ', 'Ebneter A', 'Glittenberg C', 'Pauleikhoff D', 'Sadda SR', 'Chakravarthy U', 'Fauser S'], 'AD': ['Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 124 Grenzacherstrasse, 4058 Basel, Switzerland.', 'Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 124 Grenzacherstrasse, 4058 Basel, Switzerland.', 'Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 124 Grenzacherstrasse, 4058 Basel, Switzerland.', 'Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 124 Grenzacherstrasse, 4058 Basel, Switzerland.', 'Department of Ophthalmology, Cantonal Hospital St. Gallen, University of Bern, Switzerland.', 'Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 124 Grenzacherstrasse, 4058 Basel, Switzerland.', 'Augenzentrum am St. Franziskus Hospital, Hohenzollernring 74, 48145 Munster, Germany.', 'Doheny Eye Institute, University of California - Los Angeles, 150 N. Orange Grove Blvd, Pasadena, CA 91103 USA.', 'Honorary and Emerita Professor of Ophthalmology, Queens University of Belfast, Institute of Clinical Science Block A, RVH site, Belfast BT12 6BA.', 'Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., 124 Grenzacherstrasse, 4058 Basel, Switzerland.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230404', 'PL': 'United States', 'TA': 'Surv Ophthalmol', 'JT': 'Survey of ophthalmology', 'JID': '0404551', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['consensus', 'definition', 'fibrosis', 'neovascular age-related macular degeneration', 'nomenclature', 'ocular imaging', 'optical coherence tomography'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 19:25'], 'PHST': ['2022/11/07 00:00 [received]', '2023/03/24 00:00 [revised]', '2023/03/27 00:00 [accepted]', '2023/04/06 19:25 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['S0039-6257(23)00049-8 [pii]', '10.1016/j.survophthal.2023.03.004 [doi]'], 'PST': 'aheadofprint', 'SO': 'Surv Ophthalmol. 2023 Apr 4:S0039-6257(23)00049-8. doi: 10.1016/j.survophthal.2023.03.004.'}, {'PMID': '37022475', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1433-8491 (Electronic) 0940-1334 (Linking)', 'DP': '2023 Apr 6', 'TI': 'Clinical and biological correlates of optical coherence tomography findings in schizophrenia.', 'LID': '10.1007/s00406-023-01587-w [doi]', 'AB': 'There is a growing body of evidence indicating retinal layer thinning in schizophrenia. However, neuropathological processes underlying these retinal structural changes and its clinical correlates are yet to be known. Here, we aim to investigate the clinical and biological correlates of OCT findings in schizophrenia. 50 schizophrenia patients and 40 healthy controls were recruited. Retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), and macular and choroidal thicknesses were recorded. A comprehensive battery of neuropsychological tests was applied. Fasting glucose, triglycerides and HDL-cholesterol levels, TNF-alpha, IL-1beta and IL-6 levels were measured. Right IPL was significantly thinner in patients than the controls after controlling for various confounders (F = 5.42, p = .02). Higher IL-6, IL-1beta, and TNF-alpha levels were associated with decreased left macular thickness (r =  - 0.26, p = .027, r =  - 0.30, p = 0.012, and r =  - 0.24, p = .046, respectively) and higher IL-6 was associated with thinning of right IPL (r =  - 0.27, p = 0.023) and left choroid (r =  - 0.23, p = .044) in the overall sample. Thinning of right IPL and left macula were also associated with worse executive functioning (r = 0.37, p = 0.004 and r = 0.33, p = 0.009) and attention (r = 0.31, p = 0.018 and r = 0.30, p = 0.025). In patients with schizophrenia, IPL thinning was associated with increased BMI (r =  - 0.44, p = 0.009) and decreased HDL levels (r = 0.43, p = 0.021). Decreased TNF-alpha level was related to IPL thinning, especially in the left eye (r = 0.40, p = 0.022). These findings support the hypothesis that OCT might provide the opportunity to establish an accessible and non-invasive probe of brain pathology in schizophrenia and related disorders. However, future studies investigating retinal structural changes as a biological marker for schizophrenia should also consider the metabolic state of the subjects.', 'CI': ['(c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.'], 'FAU': ['Kurtulmus, Ayse', 'Sahbaz, Cigdem', 'Elbay, Ahmet', 'Guler, Eray Metin', 'Sonmez Avaroglu, Gamze', 'Kocyigit, Abdurrahim', 'Ozdemir, Mehmet Hakan', 'Kirpinar, Ismet'], 'AU': ['Kurtulmus A', 'Sahbaz C', 'Elbay A', 'Guler EM', 'Sonmez Avaroglu G', 'Kocyigit A', 'Ozdemir MH', 'Kirpinar I'], 'AUID': ['ORCID: 0000-0001-8420-4761'], 'AD': ['Department of Psychiatry, Bezmialem Vakif University, Istanbul, Turkey. a_kurtulmus@hotmail.com.', 'Department od Psychiatry, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey. a_kurtulmus@hotmail.com.', 'Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.', 'Department of Ophthalmology, Bezmialem Vakif University, Istanbul, Turkey.', 'Department of Medical Biochemistry, Hamidiye School of Medicine, University of Health Sciences, Istanbul, Turkey.', 'Fatih Community Mental Health Centre, Haseki Research and Training Hospital, Istanbul, Turkey.', 'Department of Medical Biochemistry, Bezmialem Vakif University, Istanbul, Turkey.', 'Department of Ophthalmology, Bezmialem Vakif University, Istanbul, Turkey.', 'Department of Psychiatry, Bezmialem Vakif University, Istanbul, Turkey.'], 'LA': ['eng'], 'GR': ['Project ID: 1.2017/37/Bezmialem Vakif Universitesi/'], 'PT': ['Journal Article'], 'DEP': '20230406', 'PL': 'Germany', 'TA': 'Eur Arch Psychiatry Clin Neurosci', 'JT': 'European archives of psychiatry and clinical neuroscience', 'JID': '9103030', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Cognition', 'Cytokine', 'OCT', 'Retinal thickness', 'Schizophrenia'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 11:18'], 'PHST': ['2022/10/12 00:00 [received]', '2023/03/06 00:00 [accepted]', '2023/04/06 11:18 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['10.1007/s00406-023-01587-w [pii]', '10.1007/s00406-023-01587-w [doi]'], 'PST': 'aheadofprint', 'SO': 'Eur Arch Psychiatry Clin Neurosci. 2023 Apr 6. doi: 10.1007/s00406-023-01587-w.'}, {'PMID': '37021409', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1724-6016 (Electronic) 1120-6721 (Linking)', 'DP': '2023 Apr 6', 'TI': 'How many children with large clear cornea do not have glaucoma?', 'PG': '11206721231168147', 'LID': '10.1177/11206721231168147 [doi]', 'AB': 'PURPOSE: A horizontal corneal diameter greater than 2 standard deviations from the mean (9.8 mm) or greater than 11 mm in term infants defines megalocornea (herein referred to as a large clear cornea). The aim of the current study was to report on the incidence and clinical characteristics of children presenting with large clear cornea that do not suffer glaucoma. METHODS: A retrospective chart review of children presenting with large clear cornea to the pediatric ophthalmology unit of the ophthalmology department of Alexandria Main University Hospital in the period from March 2011 to December 2020 was conducted. A large clear cornea was defined as a horizontal white-to-white corneal diameter (as measured by calipers) greater than 12 mm. Glaucoma was diagnosed according to the childhood glaucoma research network (CGRN) criteria and the axial length was used to filter out eyes with large clear corneas due to congenital high myopia. RESULTS: Out of 120 eyes of 91 (58 males) children a total of 76 eyes of 67 (41 males) children were diagnosed with glaucoma and 44 eyes of 24 (17 males) children (36.7%) did not suffer glaucoma. Out of these, 30 eyes were classified as myopia and 14 eyes as congenital megalocornea. CONCLUSIONS: More than one third of eyes presenting with large clear corneas may not have glaucoma, and almost two thirds of these eyes (that are not suffering from glaucoma) demonstrate axial myopia.', 'FAU': ['Bayoumi, Nader', 'Elsayed, Eman Nabil', 'Saber, Ahmed'], 'AU': ['Bayoumi N', 'Elsayed EN', 'Saber A'], 'AUID': ['ORCID: 0000-0002-3140-5073'], 'AD': ['68789Ophthalmology Department, Alexandria University faculty of Medicine, Alexandria, Egypt.', '68789Ophthalmology Department, Alexandria University faculty of Medicine, Alexandria, Egypt.', 'Alexandria Main University Hospital, Alexandria, Alexandria, Egypt.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230406', 'PL': 'United States', 'TA': 'Eur J Ophthalmol', 'JT': 'European journal of ophthalmology', 'JID': '9110772', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Large clear cornea', 'congenital glaucoma', 'congenital high myopia', 'megalocornea', 'pediatric'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 03:33'], 'PHST': ['2023/04/06 03:33 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['10.1177/11206721231168147 [doi]'], 'PST': 'aheadofprint', 'SO': 'Eur J Ophthalmol. 2023 Apr 6:11206721231168147. doi: 10.1177/11206721231168147.'}, {'PMID': '37021337', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1528-1167 (Electronic) 0013-9580 (Linking)', 'DP': '2023 Apr 5', 'TI': 'Sex-based electroclinical differences and prognostic factors in epilepsy with eyelid myoclonia.', 'LID': '10.1111/epi.17609 [doi]', 'AB': 'Although a striking female preponderance has been consistently reported in epilepsy with eyelid myoclonia (EEM), no study has specifically explored the variability of clinical presentation according to sex in this syndrome. Here, we aimed to investigate sex-specific electroclinical differences and prognostic determinants in EEM. Data from 267 EEM patients were retrospectively analyzed by the EEM study group, and a dedicated multivariable logistic regression analysis was developed separately for each sex. We found that females with EEM showed a significantly higher rate of persistence of photosensitivity and eye closure sensitivity at the last visit, along with a higher prevalence of migraine with aura, whereas males with EEM presented a higher rate of borderline intellectual functioning/intellectual disability. In female patients, multivariable logistic regression analysis revealed age at epilepsy onset, eyelid myoclonia status epilepticus, psychiatric comorbidities and catamenial seizures as significant predictors of drug resistance. In male patients, a history of febrile seizures was the only predictor of drug resistance. Hence, our study reveals sex-specific differences both in terms of electroclinical features and prognostic factors. Our findings support the importance of a sex-based personalized approach in epilepsy care and research, especially in genetic generalized epilepsies.', 'CI': ['This article is protected by copyright. All rights reserved.'], 'FAU': ['Irelli, Emanuele Cerulli', 'Cocchi, Enrico', 'Ramantani, Georgia', 'Morano, Alessandra', 'Riva, Antonella', 'Caraballo, Roberto H', 'Giuliano, Loretta', 'Yilmaz, Tulay', 'Panagiotakaki, Eleni', 'Operto, Francesca F', 'Giraldez, Beatriz Gonzalez', 'Balestrini, Simona', 'Silvennoinen, Katri', 'Casciato, Sara', 'Comajuan, Marion', 'Fortunato, Francesco', 'Giallonardo, Anna T', 'Gamirova, Rimma', 'Coppola, Antonietta', 'Di Gennaro, Giancarlo', 'Labate, Angelo', 'Sofia, Vito', 'Kluger, Gerhard J', 'Gambardella, Antonio', 'Trenite, Dorothee Kasteleijn-Nolst', 'Baykan, Betul', 'Sisodiya, Sanjay M', 'Arzimanoglou, Alexis', 'Striano, Pasquale', 'Di Bonaventura, Carlo'], 'AU': ['Irelli EC', 'Cocchi E', 'Ramantani G', 'Morano A', 'Riva A', 'Caraballo RH', 'Giuliano L', 'Yilmaz T', 'Panagiotakaki E', 'Operto FF', 'Giraldez BG', 'Balestrini S', 'Silvennoinen K', 'Casciato S', 'Comajuan M', 'Fortunato F', 'Giallonardo AT', 'Gamirova R', 'Coppola A', 'Di Gennaro G', 'Labate A', 'Sofia V', 'Kluger GJ', 'Gambardella A', 'Trenite DK', 'Baykan B', 'Sisodiya SM', 'Arzimanoglou A', 'Striano P', 'Di Bonaventura C'], 'AD': ['Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy.', 'Department of Precision Medicine and Genomics, Department of Medicine, Columbia University, New York.', \"Department of Neuropediatrics, University Children's Hospital Zurich, Zurich, Switzerland.\", 'Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy.', 'Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.', 'Department of Neurology, Hospital de Pediatria \"Prof. Dr. Juan P Garrahan\", Buenos Aires, Argentina.', 'Department of Medical and Surgical Sciences and Advanced Technologies \"G.F. Ingrassia\", Section of Neurosciences, University of Catania, Catania, Italy.', 'Departments of Neurology and Clinical Neurophysiology, Istanbul University, Istanbul, Istanbul, Turkey.', 'Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.', 'Child and Adolescent Neuropsychiatry Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.', 'Epilepsy Unit, Neurology Service, Hospital Universitario and IIS Fundacion Jimenez Diaz and CIBERER, Madrid, Spain.', \"Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK and Chalfont Centre for Epilepsy, Bucks, UK; Neuroscience Department, Meyer Children's Hospital IRCSS-University of Florence, Member of the ERN EpiCARE, Florence, Italy.\", 'Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK and Chalfont Centre for Epilepsy, Bucks, UK.', 'IRCCS NEUROMED, Pozzilli, Isernia, Italy.', 'Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.', 'Institute of Neurology, University Magna Graecia, Catanzaro, Italy.', 'Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy.', 'Kazan Federal University, Russia.', 'Department of Neuroscience, Reproductive and Odontostomatological Sciences, Federico II University, Naples, Italy.', 'IRCCS NEUROMED, Pozzilli, Isernia, Italy.', 'Neurophysiopatology and Movement Disorders Clinic, University of Messina, Italy.', 'Department of Medical and Surgical Sciences and Advanced Technologies \"G.F. Ingrassia\", Section of Neurosciences, University of Catania, Catania, Italy.', 'Clinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schoen Clinic Vogtareuth, Vogtareuth, Germany; PMU, Salzburg, Salzburg, Austria.', 'Institute of Neurology, University Magna Graecia, Catanzaro, Italy.', 'Department of Neurosurgery and Epilepsy, University Medical Center, Member of the ERN EpiCARE, Utrecht University, Utrecht, The Netherlands; Nesmos Department, Faculty of Medicine and Psychology, Sapienza University, Rome, Italy.', 'Departments of Neurology and Clinical Neurophysiology, Istanbul University, Istanbul, Istanbul, Turkey.', 'Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK and Chalfont Centre for Epilepsy, Bucks, UK.', 'Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.', 'IRCCS Istituto \"Giannina Gaslini\", Member of the ERN EpiCARE, Genoa, Italy; Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.', 'Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy.'], 'AUID': ['ORCID: 0000-0002-7931-2327', 'ORCID: 0000-0001-9152-5571', 'ORCID: 0000-0003-0259-1046', 'ORCID: 0000-0003-2512-6972', 'ORCID: 0000-0002-2444-8761', 'ORCID: 0000-0001-6653-3027', 'ORCID: 0000-0001-5639-1969', 'ORCID: 0000-0001-8456-0029', 'ORCID: 0000-0001-8395-7809', 'ORCID: 0000-0002-4845-4293', 'ORCID: 0000-0001-7384-3074', 'ORCID: 0000-0002-6659-2614', 'ORCID: 0000-0002-1511-5893', 'ORCID: 0000-0002-7233-2771', 'ORCID: 0000-0002-6065-1476', 'ORCID: 0000-0003-1890-5409'], 'CN': ['EEM study group'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230405', 'PL': 'United States', 'TA': 'Epilepsia', 'JT': 'Epilepsia', 'JID': '2983306R', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Jeavons syndrome', 'catamenial seizures', 'drug resistance', 'genetic generalized epilepsy (GGE)', 'photosensitivity'], 'FIR': ['Fisco, Giacomo', 'Meletti, Stefano', 'Liukshina, Natalia', 'Tomenko, Tatiana', 'Gobbi, Giuseppe', 'Buti, Daniela', 'Casellato, Susanna', 'Striano, Salvatore', 'Messana, Tullio', 'Giordano, Lucio', 'Ferlazzo, Edoardo', 'Vignoli, Aglaia', 'Viri, Maurizio', 'Bagnasco, Irene', 'Bebek, Nerses', 'Altiokka-Uzun, Gunes'], 'IR': ['Fisco G', 'Meletti S', 'Liukshina N', 'Tomenko T', 'Gobbi G', 'Buti D', 'Casellato S', 'Striano S', 'Messana T', 'Giordano L', 'Ferlazzo E', 'Vignoli A', 'Viri M', 'Bagnasco I', 'Bebek N', 'Altiokka-Uzun G'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:00', 'CRDT': ['2023/04/06 02:32'], 'PHST': ['2023/03/30 00:00 [revised]', '2023/02/07 00:00 [received]', '2023/04/03 00:00 [accepted]', '2023/04/06 02:32 [entrez]', '2023/04/07 06:00 [pubmed]', '2023/04/07 06:00 [medline]'], 'AID': ['10.1111/epi.17609 [doi]'], 'PST': 'aheadofprint', 'SO': 'Epilepsia. 2023 Apr 5. doi: 10.1111/epi.17609.'}, {'PMID': '37021139', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230407', 'IS': '1662-4548 (Print) 1662-453X (Electronic) 1662-453X (Linking)', 'VI': '17', 'DP': '2023', 'TI': 'Cardiac autonomic control in Rett syndrome: Insights from heart rate variability analysis.', 'PG': '1048278', 'LID': '10.3389/fnins.2023.1048278 [doi] 1048278', 'AB': 'Rett syndrome (RTT) is a rare and severe neurological disorder mainly affecting females, usually linked to methyl-CpG-binding protein 2 (MECP2) gene mutations. Manifestations of RTT typically include loss of purposeful hand skills, gait and motor abnormalities, loss of spoken language, stereotypic hand movements, epilepsy, and autonomic dysfunction. Patients with RTT have a higher incidence of sudden death than the general population. Literature data indicate an uncoupling between measures of breathing and heart rate control that could offer insight into the mechanisms that lead to greater vulnerability to sudden death. Understanding the neural mechanisms of autonomic dysfunction and its correlation with sudden death is essential for patient care. Experimental evidence for increased sympathetic or reduced vagal modulation to the heart has spurred efforts to develop quantitative markers of cardiac autonomic profile. Heart rate variability (HRV) has emerged as a valuable non-invasive test to estimate the modulation of sympathetic and parasympathetic branches of the autonomic nervous system (ANS) to the heart. This review aims to provide an overview of the current knowledge on autonomic dysfunction and, in particular, to assess whether HRV parameters can help unravel patterns of cardiac autonomic dysregulation in patients with RTT. Literature data show reduced global HRV (total spectral power and R-R mean) and a shifted sympatho-vagal balance toward sympathetic predominance and vagal withdrawal in patients with RTT compared to controls. In addition, correlations between HRV and genotype and phenotype features or neurochemical changes were investigated. The data reported in this review suggest an important impairment in sympatho-vagal balance, supporting possible future research scenarios, targeting ANS.', 'CI': ['Copyright (c) 2023 Cordani, Tobaldini, Rodrigues, Giambersio, Veneruso, Chiarella,', 'Disma, De Grandis, Toschi-Dias, Furlan, Carandina, Prato, Nobili and Montano.'], 'FAU': ['Cordani, Ramona', 'Tobaldini, Eleonora', 'Rodrigues, Gabriel Dias', 'Giambersio, Donatella', 'Veneruso, Marco', 'Chiarella, Lorenzo', 'Disma, Nicola', 'De Grandis, Elisa', 'Toschi-Dias, Edgar', 'Furlan, Ludovico', 'Carandina, Angelica', 'Prato, Giulia', 'Nobili, Lino', 'Montano, Nicola'], 'AU': ['Cordani R', 'Tobaldini E', 'Rodrigues GD', 'Giambersio D', 'Veneruso M', 'Chiarella L', 'Disma N', 'De Grandis E', 'Toschi-Dias E', 'Furlan L', 'Carandina A', 'Prato G', 'Nobili L', 'Montano N'], 'AD': ['Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.', 'Unit for Research & Innovation in Anesthesia, IRCCS Istituto Giannina Gaslini, Genova, Italy.', 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.', \"Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.\", 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.', 'Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.', 'Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari \"Aldo Moro\", Bari, Italy.', 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.', 'Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.', 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.', 'Unit for Research & Innovation in Anesthesia, IRCCS Istituto Giannina Gaslini, Genova, Italy.', 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.', 'Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.', 'Health Psychology Program, Methodist University of Sao Paulo, Sao Paulo, Brazil.', 'Psychology, Development and Public Policy Program, Catholic University of Santos, Sao Paulo, Brazil.', \"Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.\", 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.', \"Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.\", 'Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.', 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.', 'Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.', 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.', \"Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.\"], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230320', 'PL': 'Switzerland', 'TA': 'Front Neurosci', 'JT': 'Frontiers in neuroscience', 'JID': '101478481', 'PMC': 'PMC10067665', 'OTO': ['NOTNLM'], 'OT': ['Rett syndrome (RTT)', 'autonomic nervous system', 'cardiac autonomic control', 'dysautonomia', 'heart rate variability (HRV)', 'methyl-CpG-binding protein 2 (MECP2)'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:01', 'CRDT': ['2023/04/06 02:16'], 'PHST': ['2022/09/19 00:00 [received]', '2023/02/17 00:00 [accepted]', '2023/04/07 06:01 [medline]', '2023/04/06 02:16 [entrez]', '2023/04/07 06:00 [pubmed]'], 'AID': ['10.3389/fnins.2023.1048278 [doi]'], 'PST': 'epublish', 'SO': 'Front Neurosci. 2023 Mar 20;17:1048278. doi: 10.3389/fnins.2023.1048278. eCollection 2023.'}, {'PMID': '37021010', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230407', 'IS': '1664-8021 (Print) 1664-8021 (Electronic) 1664-8021 (Linking)', 'VI': '14', 'DP': '2023', 'TI': 'Congenital insensitivity to pain associated with PRDM12 mutation: Two case reports and a literature review.', 'PG': '1139161', 'LID': '10.3389/fgene.2023.1139161 [doi] 1139161', 'AB': 'Background: PRDM12 is a newly discovered gene responsible for congenital insensitivity to pain (CIP). Its clinical manifestations are various and not widely known. Methods: The clinical data of two infants diagnosed with CIP associated with PRDM12 mutation were collected. A literature review was performed, and the clinical characteristics of 20 cases diagnosed with a mutation of PRDM12 were summarized and analyzed. Results: Two patients had pain insensitivity, tongue and lip defects, and corneal ulcers. The genomic analysis results showed that variants of PRDM12 were detected in the two families. The case 1 patient carried heterozygous variations of c.682+1G > A and c.502C > T (p.R168C), which were inherited from her father and mother, respectively. We enrolled 22 patients diagnosed with CIP through a literature review together with our cases. There were 16 male (72.7%) and 6 female (27.3%) patients. The age of onset ranged from 6 months to 57 years. The prevalence of clinic manifestation was 14 cases with insensitivity to pain (63.6%), 19 cases with self-mutilation behaviors (86.4%), 11 cases with tongue and lip defects (50%), 5 cases with mid-facial lesions (22.7%), 6 cases with distal phalanx injury (27.3%), 11 cases of recurrent infection (50%), 3 cases (13.6%) with anhidrosis, and 5 cases (22.7%) with global developmental delay. The prevalence of ocular symptoms was 11 cases (50%) with reduced tear secretion, 6 cases (27.3%) with decreased corneal sensitivity, 7 cases (31.8%) with disappeared corneal reflexes, 5.5 cases (25%, 0.5 indicated a single eye) with corneal opacity, 5 cases (22.7%) with corneal ulceration, and 1 case (4.5%) with a corneal scar. Conclusion: The syndrome caused by PRDM12 mutation is a clinically distinct and diagnosable disease that requires joint multidisciplinary management to control the development of the disease and minimize the occurrence of complications.', 'CI': ['Copyright (c) 2023 Yu, Wu, Cong, Chen, Huang, Yu and Wang.'], 'FAU': ['Yu, Hanrui', 'Wu, Jie', 'Cong, Jinju', 'Chen, Mingxiong', 'Huang, Yifei', 'Yu, Jifeng', 'Wang, Liqiang'], 'AU': ['Yu H', 'Wu J', 'Cong J', 'Chen M', 'Huang Y', 'Yu J', 'Wang L'], 'AD': ['Medical School of Chinese PLA, Beijing, China.', 'Department of Ophthalmology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.', 'Department of Ophthalmology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.', 'Aier Eye Hospital, Qianjiang, Hubei Province, China.', 'School of Medicine, Nankai University, Tianjin, China.', 'Department of Ophthalmology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.', \"Department of Ophthalmology, Beijing Children Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.\", 'Department of Ophthalmology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230320', 'PL': 'Switzerland', 'TA': 'Front Genet', 'JT': 'Frontiers in genetics', 'JID': '101560621', 'PMC': 'PMC10067717', 'OTO': ['NOTNLM'], 'OT': ['HSAN', 'Prdm12', 'corneal disease', 'hereditary and sensory autonomic neuropathy', 'insensitivity to pain', 'self-mutilation behavior'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:01', 'CRDT': ['2023/04/06 02:13'], 'PHST': ['2023/01/06 00:00 [received]', '2023/02/27 00:00 [accepted]', '2023/04/07 06:01 [medline]', '2023/04/06 02:13 [entrez]', '2023/04/07 06:00 [pubmed]'], 'AID': ['1139161 [pii]', '10.3389/fgene.2023.1139161 [doi]'], 'PST': 'epublish', 'SO': 'Front Genet. 2023 Mar 20;14:1139161. doi: 10.3389/fgene.2023.1139161. eCollection 2023.'}, {'PMID': '37020816', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230407', 'LR': '20230407', 'IS': '2296-2565 (Electronic) 2296-2565 (Linking)', 'VI': '11', 'DP': '2023', 'TI': 'Ocular biological parameters and prevalence of myopia in vocational high school and general high school in China.', 'PG': '1100437', 'LID': '10.3389/fpubh.2023.1100437 [doi] 1100437', 'AB': \"SIGNIFICANCE: Higher prevalence of myopia is possibly associated with more extended schooling schedules. Therefore, adjustments to high school curricula may aid in reducing the prevalence of myopia among adolescents. PURPOSE: To investigate the prevalence of myopia among 15- to 18-year-old adolescents in Tianjin, China, and to evaluate the impact of different educational schedules on the prevalence of myopia among high school students. METHODS: This is a school-based epidemiological study with a cross-sectional design. Ocular biological parameters and noncycloplegic photorefraction were examined using optical biometry devices and photoscreener devices. Each student's spherical equivalent (SE) and ocular biometry were recorded, and the prevalence of myopia was calculated. RESULTS: A total of 2,867 participants (1,519 males and 1,348 females) were tested for non-cycloplegic refraction, axial length (AL), central corneal thickness (CCT), anterior chamber depth (ACD) and lens thickness (LT). In this research, the overall prevalence of myopia was 81.6%, with high myopia accounting for 11.8%. Myopia prevalence was substantially higher in general high schools than in vocational high schools, with 86.1 and 70.1%, respectively. There were no significant differences in the prevalence of myopia (p = 0.744) or high myopia (p = 0.851) across the three vocational school years. In the general high school, however, there was an increase of 4.6% (p < 0.05) in myopia prevalence between year 10 and year12. CONCLUSION: Comparing vocational and standard high school students, there are considerable disparities in prevalence of myopia, spherical equivalent, and ocular biological parameters. The prevalence of myopia and high myopia increased among standard high school students, but remained relatively consistent among students in vocational schools.\", 'CI': ['Copyright (c) 2023 Liu, Meng, Wang, Wang, Xue, Hao and Zhang.'], 'FAU': ['Liu, Yang', 'Meng, Dexin', 'Wang, Yun', 'Wang, Xuechun', 'Xue, Caihong', 'Hao, Rui', 'Zhang, Wei'], 'AU': ['Liu Y', 'Meng D', 'Wang Y', 'Wang X', 'Xue C', 'Hao R', 'Zhang W'], 'AD': ['Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Nankai University Affiliated Eye Hospital, Clinical College of Ophthalmology Tianjin Medical University, Tianjin, China.', 'Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.', \"Tianjin Occupational Diseases Precaution and Therapeutic Hospital (Tianjin Workers' Hospital), Tianjin, China.\", 'Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Nankai University Affiliated Eye Hospital, Clinical College of Ophthalmology Tianjin Medical University, Tianjin, China.', 'Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Nankai University Affiliated Eye Hospital, Clinical College of Ophthalmology Tianjin Medical University, Tianjin, China.', 'Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Nankai University Affiliated Eye Hospital, Clinical College of Ophthalmology Tianjin Medical University, Tianjin, China.', 'Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Nankai University Affiliated Eye Hospital, Clinical College of Ophthalmology Tianjin Medical University, Tianjin, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230320', 'PL': 'Switzerland', 'TA': 'Front Public Health', 'JT': 'Frontiers in public health', 'JID': '101616579', 'SB': 'IM', 'MH': ['Male', 'Female', 'Adolescent', 'Humans', 'Prevalence', 'Cross-Sectional Studies', '*Eye', '*Myopia/epidemiology', 'Refraction, Ocular'], 'PMC': 'PMC10067628', 'OTO': ['NOTNLM'], 'OT': ['educational schedule', 'high school students', 'myopia', 'ocular biometry', 'prevalence'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 10:18', 'CRDT': ['2023/04/06 02:10'], 'PHST': ['2022/11/16 00:00 [received]', '2023/03/03 00:00 [accepted]', '2023/04/07 10:18 [medline]', '2023/04/06 02:10 [entrez]', '2023/04/07 06:00 [pubmed]'], 'AID': ['10.3389/fpubh.2023.1100437 [doi]'], 'PST': 'epublish', 'SO': 'Front Public Health. 2023 Mar 20;11:1100437. doi: 10.3389/fpubh.2023.1100437. eCollection 2023.'}, {'PMID': '37020797', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230407', 'IS': '1178-6973 (Print) 1178-6973 (Electronic) 1178-6973 (Linking)', 'VI': '16', 'DP': '2023', 'TI': 'Clinical Observation of Low-Temperature Plasma Ablation Combined with Drug Therapy in the Treatment of Fungal Keratitis.', 'PG': '1895-1904', 'LID': '10.2147/IDR.S399715 [doi]', 'AB': 'OBJECTIVE: To observe the efficacy and prognosis of low-temperature plasma ablation + drug therapy in the treatment of fungal corneal ulcers. METHODS: The present paper presents a retrospective clinical study with a subject base of 34 eyes. Patients with a fungal corneal ulcer who visited the Affiliated Eye Hospital of Nanchang University between August 2019 and December 2021 were selected as the study participants. They were found to have highly reflective fungal hyphae in the corneal stroma layer via confocal microscope examination, which were revealed to be positive on etiology examination, with the ulcer and infiltration depths </=1/2 of the corneal thickness. The efficacy and prognosis were observed after treatment with low-temperature plasma ablation + drug therapy. RESULTS: A total of 34 cases (34 eyes) had clinical manifestations of corneal infiltration and corneal ulcer formation, with a corneal lesion diameter of 1.31-8.64 mm (average = 4.79 +/- 2.03 mm). The average healing time of corneal ulcers was 6.2 +/- 1.7 days. Among a total of 34 cases (34 eyes) in patients with fungal keratitis, the infection was controlled and the ulcers gradually healed after treatment with low-temperature plasma system + drug therapy in a total of 30 cases (30 eyes, 88%). A total of three cases (3 eyes, 9%) exhibited no clear improvement after the treatment, and the patients underwent conjunctival flap covering surgery. One case (one eye, 3%) exhibited no clear improvement after further treatment, with the patient experiencing corneal perforation and ultimately undergoing penetrating keratoplasty. CONCLUSION: Low-temperature plasma ablation + drug therapy can effectively control the progression of fungal keratitis infection, as well as significantly shorten the ulcer healing time, and is, therefore, an effective method.', 'CI': ['(c) 2023 Sun et al.'], 'FAU': ['Sun, Tao', 'Zhang, Bo-Wen', 'Xiong, Rui', 'Zhou, Wen-Tian', 'Qiu, Jing-Jing'], 'AU': ['Sun T', 'Zhang BW', 'Xiong R', 'Zhou WT', 'Qiu JJ'], 'AD': [\"Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.\", \"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Research Institute of Ophthalmology and Visual Science, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Provincial Key Laboratory for Ophthalmology, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.\", \"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Research Institute of Ophthalmology and Visual Science, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Provincial Key Laboratory for Ophthalmology, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.\", \"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Research Institute of Ophthalmology and Visual Science, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Provincial Key Laboratory for Ophthalmology, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.\", \"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Research Institute of Ophthalmology and Visual Science, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Jiangxi Provincial Key Laboratory for Ophthalmology, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\", \"Department of Ophthalmology of The Second Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, 330006, People's Republic of China.\"], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230330', 'PL': 'New Zealand', 'TA': 'Infect Drug Resist', 'JT': 'Infection and drug resistance', 'JID': '101550216', 'PMC': 'PMC10069428', 'OTO': ['NOTNLM'], 'OT': ['antimicrobial therapy', 'fungal infection', 'keratitis', 'low-temperature plasma', 'ophthalmic surgery'], 'COIS': ['The authors report no conflicts of interest in this work.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:01', 'CRDT': ['2023/04/06 02:09'], 'PHST': ['2022/12/08 00:00 [received]', '2023/03/07 00:00 [accepted]', '2023/04/07 06:01 [medline]', '2023/04/06 02:09 [entrez]', '2023/04/07 06:00 [pubmed]'], 'AID': ['399715 [pii]', '10.2147/IDR.S399715 [doi]'], 'PST': 'epublish', 'SO': 'Infect Drug Resist. 2023 Mar 30;16:1895-1904. doi: 10.2147/IDR.S399715. eCollection 2023.'}, {'PMID': '37020677', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230407', 'IS': '2296-858X (Print) 2296-858X (Electronic) 2296-858X (Linking)', 'VI': '10', 'DP': '2023', 'TI': 'Knowledge domain, research hotspots and frontiers in physiology teaching reforms from 2012 to 2021: A bibliometric and knowledge-map analysis.', 'PG': '1031713', 'LID': '10.3389/fmed.2023.1031713 [doi] 1031713', 'AB': \"OBJECTIVE: To identify author collaborations and impact; participating countries, institutions, and journals; evaluate the knowledge base; and analyze research hotspots and frontiers in teaching reforms in physiology. METHODS: Articles and reviews related to teaching reforms in physiology published between January 1, 2012, and December 31, 2021, were obtained from the Web of Science Core Collection. Two Scientometric software applications (CiteSpace 5.7 and VOSviewer 1.6.15) were used to perform bibliometric and knowledge-map analysis, generate network maps, and identify research trends and top keywords, authors, co-cited authors, institutions, countries, journals, and references. RESULTS: The search identified a total of 2,882 papers in 466 academic journals by 13,895 authors from 4,072 organizations in 67 countries/regions. Physiology teaching reform-related publications increased rapidly over time. Arango-Lasprilla and Rivera published the most papers, while Moseley had the most co-citations. Active collaborations among physiology researchers were noted. Advances in Physiology Education published the most papers on physiology teaching reforms and was also the top co-cited journal in the Medicine/Medical/Clinical, Psychology/Education/Health, and Neurology/Sports/Ophthalmology fields. The United States and University of California published the most physiology teaching publications in the search criteria. Ten references (research articles and reviews) on mechanisms and diseases were identified as the knowledge base. The mainstream research directions were education, Alzheimer's disease, performance, physiology, and risk factors. Mental health and emotion regulation are increasing in significance and may become new hotspots. The research trend to move from the field of pain pathogenesis to the field of neuropsychiatry has become increasingly clear. This tendency away from peripheral system-based disorders to central system-based orders is inextricably linked to further developments in physiological understanding of the brain. CONCLUSION: This study analyzed the research hot spots and frontiers of teaching reforms on in physiology using bibliometric and visual methods. Based on the results, rehabilitation, neurosciences, and infectious disease are hot topics in physiology. In particular, the pathogenesis of neurological diseases, treatment strategies, and technology updates have gradually become research hotspots. We predict that this trend is closely related to the implementation of brain research programs in various countries. These findings provide helpful references for scholars focusing on physiology education.\", 'CI': ['Copyright (c) 2023 Xu, Sun, Zhao and Ma.'], 'FAU': ['Xu, Jia', 'Sun, Shimeng', 'Zhao, Yadong', 'Ma, Qing'], 'AU': ['Xu J', 'Sun S', 'Zhao Y', 'Ma Q'], 'AD': ['Department of Physiology and Pharmacology, NBU Health Science Center, Ningbo University, Ningbo, Zhejiang, China.', 'The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.', 'Department of Physiology and Pharmacology, NBU Health Science Center, Ningbo University, Ningbo, Zhejiang, China.', 'Department of Physiology and Pharmacology, NBU Health Science Center, Ningbo University, Ningbo, Zhejiang, China.', 'Department of Physiology and Pharmacology, NBU Health Science Center, Ningbo University, Ningbo, Zhejiang, China.', 'The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230320', 'PL': 'Switzerland', 'TA': 'Front Med (Lausanne)', 'JT': 'Frontiers in medicine', 'JID': '101648047', 'PMC': 'PMC10067749', 'OTO': ['NOTNLM'], 'OT': ['bibliometrics', 'knowledge-map', 'physiology', 'teaching reform', 'visualization'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:01', 'CRDT': ['2023/04/06 02:07'], 'PHST': ['2022/09/21 00:00 [received]', '2023/02/27 00:00 [accepted]', '2023/04/07 06:01 [medline]', '2023/04/06 02:07 [entrez]', '2023/04/07 06:00 [pubmed]'], 'AID': ['10.3389/fmed.2023.1031713 [doi]'], 'PST': 'epublish', 'SO': 'Front Med (Lausanne). 2023 Mar 20;10:1031713. doi: 10.3389/fmed.2023.1031713. eCollection 2023.'}, {'PMID': '37020561', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230407', 'LR': '20230407', 'IS': '1664-3224 (Electronic) 1664-3224 (Linking)', 'VI': '14', 'DP': '2023', 'TI': 'Characterization of dysbiosis of the conjunctival microbiome and nasal microbiome associated with allergic rhinoconjunctivitis and allergic rhinitis.', 'PG': '1079154', 'LID': '10.3389/fimmu.2023.1079154 [doi] 1079154', 'AB': 'BACKGROUND: Allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR) are prevalent allergic diseases. People are becoming increasingly aware of the impact of microbial disorders on host immunity and allergic diseases. Studies have demonstrated an association between allergic diseases and the microbiome, but much remains unknown. We assessed changes in the conjunctival microbiome and nasal microbiome in patients with ARC or AR. METHODS: Conjunctival swabs and nasal swabs were collected from each participant for 16S rRNA amplicon sequencing. Bacterial communities were analyzed. RESULTS: Forty patients with ARC, 20 patients suffering from AR, and 34 healthy controls (HCs) were recruited. This study found the abundance of conjunctival microbiome in patients with ARC or AR was significantly lower than that in HCs. The diversity of conjunctival microbiome in patients with AR was significantly lower than those in the other two groups. There is no significant difference in abundance of nasal microbiome between the three groups. The diversities of nasal microbiome in patients with ARC or AR were significantly lower than that in HCs. We found significant differences in microbiota compositions in patients with ARC or AR compared with those in HCs. However, no significant difference in microbiota compositions was found between patients with ARC and patients with AR. Microbiome functions in the ARC group and AR group were also altered compared with HCs. CONCLUSIONS: We revealed changes in the composition and function of the conjunctival microbiome and nasal microbiome of patients with ARC or AR, which suggests that there is a relationship between allergic conditions and the local microbiome.', 'CI': ['Copyright (c) 2023 Wang, Li, Gu and Fu.'], 'FAU': ['Wang, Yuan', 'Li, Xuan', 'Gu, Shuntong', 'Fu, Junhong'], 'AU': ['Wang Y', 'Li X', 'Gu S', 'Fu J'], 'AD': ['Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China.', 'Tianjin Eye Hospital, Tianjin Key Laboratory of Ophthalmology and Visual Science, Tianjin Eye Institute, Tianjin, China.', 'Department of Otolaryngology-Head & Neck Surgery, Tianjin TEDA Hospital, Tianjin, China.', 'Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China.', 'Tianjin Eye Hospital, Tianjin Key Laboratory of Ophthalmology and Visual Science, Tianjin Eye Institute, Tianjin, China.', 'Nankai University Affiliated Eye Hospital, Nankai University, Tianjin, China.', 'Department of General Surgery, Tianjin Fifth Central Hospital, Tianjin, China.', 'Department of Vascular Surgery, Tianjin Medical University General Hospital, Tianjin, China.', 'Department of Ophthalmology, Tianjin TEDA Hospital, Tianjin, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230320', 'PL': 'Switzerland', 'TA': 'Front Immunol', 'JT': 'Frontiers in immunology', 'JID': '101560960', 'RN': ['0 (RNA, Ribosomal, 16S)'], 'SB': 'IM', 'MH': ['Humans', 'Dysbiosis', 'RNA, Ribosomal, 16S/genetics', '*Rhinitis, Allergic/microbiology', 'Nose', '*Microbiota', '*Conjunctivitis'], 'PMC': 'PMC10068870', 'OTO': ['NOTNLM'], 'OT': ['16s rRNA amplicon sequencing', 'allergic rhinitis', 'allergic rhinoconjunctivitis', 'conjunctival', 'microbiome', 'nasal'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 10:18', 'CRDT': ['2023/04/06 02:05'], 'PHST': ['2022/10/25 00:00 [received]', '2023/03/08 00:00 [accepted]', '2023/04/07 10:18 [medline]', '2023/04/06 02:05 [entrez]', '2023/04/07 06:00 [pubmed]'], 'AID': ['10.3389/fimmu.2023.1079154 [doi]'], 'PST': 'epublish', 'SO': 'Front Immunol. 2023 Mar 20;14:1079154. doi: 10.3389/fimmu.2023.1079154. eCollection 2023.'}, {'PMID': '37020551', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230407', 'LR': '20230407', 'IS': '1664-3224 (Electronic) 1664-3224 (Linking)', 'VI': '14', 'DP': '2023', 'TI': 'Ankylosing spondylitis and glaucoma in European population: A Mendelian randomization study.', 'PG': '1120742', 'LID': '10.3389/fimmu.2023.1120742 [doi] 1120742', 'AB': \"BACKGROUND: The relationship between ankylosing spondylitis (AS) and glaucoma in the European population remains unclear. In the present study, we applied a two-sample Mendelian randomization (MR) method to investigate their causal relationship. METHODS: MR analysis was conducted to validate the causal associations between AS with glaucoma using summary statistics from the genome-wide association studies of AS (9,069 cases and 13,578 control subjects) and glaucoma (8,591 cases and 210,201 control subjects). The inverse variance weighting method was performed to evaluate the causal relationship. The MR-Egger regression approach was applied to assess pleiotropy, while Cochran's Q test was used to analyze heterogeneity. Subgroup analysis was performed according to primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). RESULTS: The results of the MR study reveal a risk-increasing causal relationship between AS and glaucoma among European populations (OR = 1.35, 95%CI = 1.16-1.57, P = 8.81 x 10(-5)). Pleiotropy and heterogeneity were not found in our study. In the subgroup analysis, AS was also causal with POAG (OR = 1.48, 95%CI = 1.17-1.86, P = 8.80 x 10(-4)) and PACG (OR = 1.91, 95%CI = 1.03-3.51, P = 3.88 x 10(-2)). CONCLUSION: The results of the MR analysis suggested a causal relationship between AS and glaucoma in the European population. Further studies are needed to identify the specific mechanism between these two diseases.\", 'CI': ['Copyright (c) 2023 Li, Chen, Zhang, Fang, Xiong and Bai.'], 'FAU': ['Li, Shengjie', 'Chen, Minting', 'Zhang, Qing', 'Fang, Meijin', 'Xiong, Wei', 'Bai, Lang'], 'AU': ['Li S', 'Chen M', 'Zhang Q', 'Fang M', 'Xiong W', 'Bai L'], 'AD': ['Department of Ophthalmology, Nanfang Hospital, Southern Medical University, Guangzhou, China.', 'Department of Ophthalmology, Nanfang Hospital, Southern Medical University, Guangzhou, China.', 'Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, China.', 'Department of Ophthalmology, Nanfang Hospital, Southern Medical University, Guangzhou, China.', 'Department of Ophthalmology, Nanfang Hospital, Southern Medical University, Guangzhou, China.', 'Department of Ophthalmology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230320', 'PL': 'Switzerland', 'TA': 'Front Immunol', 'JT': 'Frontiers in immunology', 'JID': '101560960', 'SB': 'IM', 'MH': ['Humans', '*Spondylitis, Ankylosing', 'Genome-Wide Association Study', '*Glaucoma, Open-Angle', 'Mendelian Randomization Analysis', '*Glaucoma'], 'PMC': 'PMC10067563', 'OTO': ['NOTNLM'], 'OT': ['Mendelian randomization', 'ankylosing spondylitis', 'causal relationship', 'glaucoma', 'risk factor'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/07 06:00', 'MHDA': '2023/04/07 06:42', 'CRDT': ['2023/04/06 02:05'], 'PHST': ['2022/12/10 00:00 [received]', '2023/03/06 00:00 [accepted]', '2023/04/07 06:42 [medline]', '2023/04/06 02:05 [entrez]', '2023/04/07 06:00 [pubmed]'], 'AID': ['10.3389/fimmu.2023.1120742 [doi]'], 'PST': 'epublish', 'SO': 'Front Immunol. 2023 Mar 20;14:1120742. doi: 10.3389/fimmu.2023.1120742. eCollection 2023.'}, {'PMID': '37019936', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230407', 'LR': '20230408', 'IS': '2041-1723 (Electronic) 2041-1723 (Linking)', 'VI': '14', 'IP': '1', 'DP': '2023 Apr 5', 'TI': 'Lateral septum adenosine A(2A) receptors control stress-induced depressive-like behaviors via signaling to the hypothalamus and habenula.', 'PG': '1880', 'LID': '10.1038/s41467-023-37601-x [doi] 1880', 'AB': 'Major depressive disorder ranks as a major burden of disease worldwide, yet the current antidepressant medications are limited by frequent non-responsiveness and significant side effects. The lateral septum (LS) is thought to control of depression, however, the cellular and circuit substrates are largely unknown. Here, we identified a subpopulation of LS GABAergic adenosine A(2A) receptors (A(2A)R)-positive neurons mediating depressive symptoms via direct projects to the lateral habenula (LHb) and the dorsomedial hypothalamus (DMH). Activation of A(2A)R in the LS augmented the spiking frequency of A(2A)R-positive neurons leading to a decreased activation of surrounding neurons and the bi-directional manipulation of LS-A(2A)R activity demonstrated that LS-A(2A)Rs are necessary and sufficient to trigger depressive phenotypes. Thus, the optogenetic modulation (stimulation or inhibition) of LS-A(2A)R-positive neuronal activity or LS-A(2A)R-positive neurons projection terminals to the LHb or DMH, phenocopied depressive behaviors. Moreover, A(2A)R are upregulated in the LS in two male mouse models of repeated stress-induced depression. This identification that aberrantly increased A(2A)R signaling in the LS is a critical upstream regulator of repeated stress-induced depressive-like behaviors provides a neurophysiological and circuit-based justification of the antidepressant potential of A(2A)R antagonists, prompting their clinical translation.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Wang, Muran', 'Li, Peijun', 'Li, Zewen', 'da Silva, Beatriz S', 'Zheng, Wu', 'Xiang, Zhenghua', 'He, Yan', 'Xu, Tao', 'Cordeiro, Cristina', 'Deng, Lu', 'Dai, Yuwei', 'Ye, Mengqian', 'Lin, Zhiqing', 'Zhou, Jianhong', 'Zhou, Xuzhao', 'Ye, Fenfen', 'Cunha, Rodrigo A', 'Chen, Jiangfan', 'Guo, Wei'], 'AU': ['Wang M', 'Li P', 'Li Z', 'da Silva BS', 'Zheng W', 'Xiang Z', 'He Y', 'Xu T', 'Cordeiro C', 'Deng L', 'Dai Y', 'Ye M', 'Lin Z', 'Zhou J', 'Zhou X', 'Ye F', 'Cunha RA', 'Chen J', 'Guo W'], 'AD': ['The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', \"Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.\", 'Key Laboratory of Structural Malformations in Children of Zhejiang Province, Wenzhou, 325000, Zhejiang Province, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'Faculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal.', 'Portuguese National Institute of Legal Medicine and Forensic Sciences (INMLCF, IP), Coimbra, Portugal.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'Department of Neurobiology, Key Laboratory of Molecular Neurobiology, Ministry of Education, Naval Medical University, Shanghai, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'Faculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal.', 'Portuguese National Institute of Legal Medicine and Forensic Sciences (INMLCF, IP), Coimbra, Portugal.', \"Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.\", 'Key Laboratory of Structural Malformations in Children of Zhejiang Province, Wenzhou, 325000, Zhejiang Province, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China.', 'Faculty of Medicine, University of Coimbra, 3004-504, Coimbra, Portugal.', 'CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504, Coimbra, Portugal.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China. chenjf555@gmail.com.', 'Oujiang Laboratory (Zhejiang Laboratory for Regenerative Medicine, Vision and Brain Health), School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China. chenjf555@gmail.com.', 'The Molecular Neuropharmacology Laboratory and the Eye-Brain Research Center, The State Key Laboratory of Ophthalmology, Optometry and Vision Science, Wenzhou Medical University, Wenzhou, China. guoweihaha@126.com.'], 'AUID': ['ORCID: 0000-0003-0701-3122', 'ORCID: 0000-0003-2550-6422', 'ORCID: 0000-0002-0446-3956', 'ORCID: 0000-0002-8560-6700'], 'LA': ['eng'], 'GR': ['No. 31970948, No. 81871035, No.82071378, No.80222014/National Natural Science', 'Foundation of China (National Science Foundation of China)/'], 'PT': ['Journal Article'], 'DEP': '20230405', 'PL': 'England', 'TA': 'Nat Commun', 'JT': 'Nature communications', 'JID': '101528555', 'RN': ['K72T3FS567 (Adenosine)', '0 (Receptor, Adenosine A2A)'], 'SB': 'IM', 'MH': ['Mice', 'Animals', 'Male', '*Habenula/physiology', 'Adenosine/pharmacology', '*Depressive Disorder, Major', 'Neurons/metabolism', 'Hypothalamus/metabolism', 'Receptor, Adenosine A2A/metabolism'], 'PMC': 'PMC10076302', 'COIS': ['The authors declare no competing interests.'], 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/07 06:42', 'CRDT': ['2023/04/05 23:17'], 'PHST': ['2022/08/28 00:00 [received]', '2023/03/23 00:00 [accepted]', '2023/04/07 06:42 [medline]', '2023/04/05 23:17 [entrez]', '2023/04/06 06:00 [pubmed]'], 'AID': ['10.1038/s41467-023-37601-x [pii]', '37601 [pii]', '10.1038/s41467-023-37601-x [doi]'], 'PST': 'epublish', 'SO': 'Nat Commun. 2023 Apr 5;14(1):1880. doi: 10.1038/s41467-023-37601-x.'}, {'PMID': '37019483', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230407', 'LR': '20230408', 'IS': '2044-6055 (Electronic) 2044-6055 (Linking)', 'VI': '13', 'IP': '4', 'DP': '2023 Apr 5', 'TI': 'Retrospective analysis of cataract surgery outcomes in China from 2009 to 2018: from a national registry system data.', 'PG': 'e070989', 'LID': '10.1136/bmjopen-2022-070989 [doi]', 'AB': \"OBJECTIVE: To evaluate patients' benefits after cataract surgery and to form recommendations for Chinese national health policy decision makers and administration departments based on the quality of cataract treatments. METHOD: An observational study based on real-world data source from the National Cataract Recovery Surgery Information Registration and Reporting System. RESULTS: A total of 14 157 463 original records were reported from 1 July 2009 to 31 December 2018. The factors that influenced the 3-day postsurgical best-corrected visual acuity (BCVA), the primary outcome, were analysed by logistic regression analysis. We found that a history of hypertension (OR=0.916) or diabetes (OR=0.912), presurgical pupil abnormality (OR=0.571) and high intraocular pressure (OR=0.578) were harmful to the postsurgical BCVA improvement (BCVA >/=6/20), while male sex (OR=1.113), better presurgical BCVA level (OR=5.996 for >/=6/12-<6/7.5 and OR=2.610 for >6/60-<6/12 taken </=6/60 as reference), age-related cataract (OR=1.825) and intraocular lens implantation (OR=1.886) were statistically beneficial to the postsurgical BCVA improvement. Compared with extracapsular cataract extraction (ECCE) with large incision, the ECCE with small incision (OR value=1.810) and the phacoemulsification (OR=1.420) significantly improved the benefit probability. CONCLUSION: ECCE with small incision has comparable effects on postsurgical BCVA improvement of phacoemulsification. Therefore, ECCE could be an alternative cataract surgical treatment in economically underdeveloped areas in China, provided the surgeons are adequately trained.\", 'CI': ['(c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No', 'commercial re-use. See rights and permissions. Published by BMJ.'], 'FAU': ['Feng, Jingjing', 'Jan, Catherine', 'Peng, Yaguang', 'He, Mingguang', 'An, Lei', 'Zhan, Leilei', 'Shi, Wei', 'Peng, Xiaoxia', 'Shang, Wenhan', 'Li, Wei', 'Xu, Xiao', 'Yao, Li'], 'AU': ['Feng J', 'Jan C', 'Peng Y', 'He M', 'An L', 'Zhan L', 'Shi W', 'Peng X', 'Shang W', 'Li W', 'Xu X', 'Yao L'], 'AD': ['Department of Nursing Administration and Rehabilitation Research, National Institute of Hospital Administration, Beijing, China.', \"Lost Child's Vision Project, Sydney, New South Wales, Australia.\", 'Centre for Eye Research Australia, Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.', \"Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Beijing, China.\", 'State Key Laboratory of Ophthalmology, Sun Yat-Sen University Zhongshan Ophthalmic Center, Guangzhou, China.', 'Department of Nursing Administration and Rehabilitation Research, National Institute of Hospital Administration, Beijing, China.', 'Department of Nursing Administration and Rehabilitation Research, National Institute of Hospital Administration, Beijing, China.', \"Department of Ophthalmology, Beijing Children's Hospital, Capital Medical University, Beijing, China.\", \"Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Beijing, China.\", 'Department of Nursing Administration and Rehabilitation Research, National Institute of Hospital Administration, Beijing, China.', 'Department of Nursing Administration and Rehabilitation Research, National Institute of Hospital Administration, Beijing, China.', 'Department of Healthcare Service and Safety Research, National Institute of Hospital Administration, Beijing, China po_niha@163.com.', 'Department of Nursing Administration and Rehabilitation Research, National Institute of Hospital Administration, Beijing, China.'], 'AUID': ['ORCID: 0000-0002-7987-6464', 'ORCID: 0000-0002-6912-2810', 'ORCID: 0000-0001-8789-469X', 'ORCID: 0000-0002-5262-7257'], 'LA': ['eng'], 'PT': ['Journal Article', 'Observational Study'], 'DEP': '20230405', 'PL': 'England', 'TA': 'BMJ Open', 'JT': 'BMJ open', 'JID': '101552874', 'SB': 'IM', 'MH': ['Humans', 'Male', 'Lens Implantation, Intraocular', 'Retrospective Studies', '*Cataract Extraction', '*Phacoemulsification', '*Cataract', 'China', 'Registries', 'Treatment Outcome'], 'OTO': ['NOTNLM'], 'OT': ['Cataract and refractive surgery', 'EPIDEMIOLOGY', 'Health policy'], 'COIS': ['Competing interests: None declared.'], 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/07 10:18', 'CRDT': ['2023/04/05 20:53'], 'PHST': ['2023/04/07 10:18 [medline]', '2023/04/05 20:53 [entrez]', '2023/04/06 06:00 [pubmed]'], 'AID': ['bmjopen-2022-070989 [pii]', '10.1136/bmjopen-2022-070989 [doi]'], 'PST': 'epublish', 'SO': 'BMJ Open. 2023 Apr 5;13(4):e070989. doi: 10.1136/bmjopen-2022-070989.'}, {'PMID': '37019422', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230405', 'IS': '1521-7035 (Electronic) 1521-6616 (Linking)', 'DP': '2023 Apr 3', 'TI': 'TET2-mediated upregulation of 5-hydroxymethylcytosine in LRRC39 promoter promotes Th1 responses in association with downregulated Treg response in Vogt-Koyanagi-Harada disease.', 'PG': '109323', 'LID': 'S1521-6616(23)00102-X [pii] 10.1016/j.clim.2023.109323 [doi]', 'AB': 'DNA 5-Hydroxymethylcytosine (5-hmC), an oxidative reaction mediated by the ten-eleven translocation (TET) family, has been reported to play an essential role in the progression of auto-inflammatory and autoimmune diseases. By far, little is known about the effect of DNA 5-hmC and the TET family on the development of Vogt-Koyanagi-Harada (VKH) disease. In this study, we discovered that the global DNA 5-hmC level and the TET activity were elevated in association with the up-regulated expression of TET2 at both mRNA and protein levels in CD4(+)T cells from active VKH patients compared to healthy controls. Integrated analysis of DNA 5-hmC pattern and transcription profile of CD4(+) T cells revealed that 6 candidate target genes were involved in the development of VKH disease. The promoter 5-hmC and mRNA levels of leucine rich repeat containing 39 (LRRC39) were verified to be elevated in active VKH patients. Functional experiments showed that TET2 could up-regulate LRRC39 mRNA expression by increasing the promoter 5-hmC level of LRRC39 in CD4(+) T cells from active VKH patients. Up-regulated LRRC39 expression could increase the frequencies of IFN-gamma(+) and IL-17(+) CD4(+) T cells as well as the secretions of IFN-gamma and IL-17 in association with the decreased frequency of CD4(+)CD25(+)FOXP3(+) regulatory T (Treg) cells and the reduced production of IL-10. Additionally, restoration of LRRC39 rescued TET2-silencing-mediated reduced frequency of IFN-gamma(+) CD4(+) T cells and increased frequency of CD4(+)CD25(+)FOXP3(+) Treg cells. Collectively, our study reveals a novel axis, TET2-5-hmC-LRRC39-Th1/Treg responses axis, in the pathogenesis of VKH and provides a potential target for further investigation into the epigenetic therapy of this disease.', 'CI': ['Copyright (c) 2023. Published by Elsevier Inc.'], 'FAU': ['Zhang, Wanyun', 'Chen, Zhijun', 'Yi, Kun', 'Su, Guannan', 'Liu, Yaning', 'Deng, Yang', 'Zhang, Yinan', 'Cao, Qingfeng', 'Pu, Yanlin', 'Luo, Xiang', 'Lai, Yujie', 'Yang, Peizeng'], 'AU': ['Zhang W', 'Chen Z', 'Yi K', 'Su G', 'Liu Y', 'Deng Y', 'Zhang Y', 'Cao Q', 'Pu Y', 'Luo X', 'Lai Y', 'Yang P'], 'AD': [\"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Henan Province Eye Hospital, Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Zhengzhou, People's Republic of China; The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.\", \"The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China. Electronic address: peizengycmu@126.com.\"], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230403', 'PL': 'United States', 'TA': 'Clin Immunol', 'JT': 'Clinical immunology (Orlando, Fla.)', 'JID': '100883537', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['5-hmC', 'Autoimmune disease', 'LRRC39', 'TET2', 'Transcriptomics', 'VKH disease'], 'COIS': ['Declaration of Competing Interest None.'], 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/06 06:00', 'CRDT': ['2023/04/05 19:28'], 'PHST': ['2023/03/06 00:00 [received]', '2023/03/31 00:00 [accepted]', '2023/04/05 19:28 [entrez]', '2023/04/06 06:00 [pubmed]', '2023/04/06 06:00 [medline]'], 'AID': ['S1521-6616(23)00102-X [pii]', '10.1016/j.clim.2023.109323 [doi]'], 'PST': 'aheadofprint', 'SO': 'Clin Immunol. 2023 Apr 3:109323. doi: 10.1016/j.clim.2023.109323.'}, {'PMID': '37018824', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230405', 'IS': '1678-2925 (Electronic) 0004-2749 (Linking)', 'DP': '2023 Apr 3', 'TI': 'Erdheim-Chester disease with chorioretinal and orbital involvement: a case report.', 'LID': 'S0004-27492023005001205 [pii] 10.5935/0004-2749.2022-0151 [doi]', 'AB': 'A 42-year-old woman presented with bilateral proptosis, chemosis, leg pain, and vision loss. Orbital, chorioretinal, and multi-organ involvement of Erdheim-Chester disease, a rare non-Langerhans histiocytosis, with a negative BRAF mutation was diagnosed based on clinical, radiological, and pathological findings. Interferon-alpha-2a (IFNalpha-2a) was started, and her clinical condition improved. However, 4 months later, she had vision loss with a history of IFNalpha-2a cessation. The same therapy was administered, and her clinical condition improved. The Erdheim-Chester disease is a rare chronic histiocytic proliferative disease that requires a multidisciplinary approach and can be fatal if left untreated because of multisystemic involvements.', 'FAU': ['Cabuk, Kubra Serefoglu', 'Tellioglu, Adem', 'Karabulut, Gamze Ozturk', 'Nacaroglu, Senay Asik', 'Fazil, Korhan', 'Elverdi, Tugrul', 'Taskapili, Muhittin', 'Karslioglu, Safak'], 'AU': ['Cabuk KS', 'Tellioglu A', 'Karabulut GO', 'Nacaroglu SA', 'Fazil K', 'Elverdi T', 'Taskapili M', 'Karslioglu S'], 'AD': ['Ophthalmic Plastic & Reconstructive Surgery, University of Health Sciences Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.', 'Ophthalmic Plastic & Reconstructive Surgery, University of Health Sciences Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.', 'Ophthalmology Department, Memorial Hospital, Faculty of Medicine, Arel University.', 'Ophthalmology Department, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.', 'Oculoplastic and Orbital Surgery and Ocular Oncology Center, Istanbul, Turkey.', 'Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.', 'Ophthalmic Plastic & Reconstructive Surgery, University of Health Sciences Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.', 'Oculoplastic and Orbital Surgery and Ocular Oncology Center, Istanbul, Turkey.'], 'AUID': ['ORCID: 0000-0001-5124-2374', 'ORCID: 0000-0003-0403-9749', 'ORCID: 0000-0003-1749-8119', 'ORCID: 0000-0002-3089-7782'], 'LA': ['eng'], 'PT': ['Letter'], 'DEP': '20230403', 'PL': 'Brazil', 'TA': 'Arq Bras Oftalmol', 'JT': 'Arquivos brasileiros de oftalmologia', 'JID': '0400645', 'SB': 'IM', 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/06 06:00', 'CRDT': ['2023/04/05 17:43'], 'PHST': ['2022/05/17 00:00 [received]', '2022/06/27 00:00 [accepted]', '2023/04/05 17:43 [entrez]', '2023/04/06 06:00 [pubmed]', '2023/04/06 06:00 [medline]'], 'AID': ['S0004-27492023005001205 [pii]', '10.5935/0004-2749.2022-0151 [doi]'], 'PST': 'aheadofprint', 'SO': 'Arq Bras Oftalmol. 2023 Apr 3:S0004-27492023005001205. doi: 10.5935/0004-2749.2022-0151.'}, {'PMID': '37018821', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230405', 'IS': '1678-2925 (Electronic) 0004-2749 (Linking)', 'DP': '2023 Apr 3', 'TI': 'PRPH2 mutation c.582-1G>A causing adult-onset macular dystrophy with a benign concentric annular macular dystrophy phenotype in a family.', 'LID': 'S0004-27492023005001202 [pii] 10.5935/0004-2749.2021-0478 [doi]', 'AB': 'The peripherin gene (PRPH2) mutation is associated with photoreceptor cell dysfunction as well as in several inherited retinal dystrophies. The PRPH2 mutation c.582-1G>A is a rare variant reported in retinitis pigmentosa and pattern dystrophy. Here Case 1 was of a 54-year-old woman with bilateral atrophy of the perifoveal retinal pigmentary epithelium and choriocapillaris with central foveolar respect. Autofluorescence and fluorescein angiography revealed perifoveal atrophy of the retinal pigmentary epithelium with an annular window effect without the \"dark choroid\" sign. Case 2 (mother of Case 1) presented with extensive atrophy of the retinal pigmentary epithelium and choriocapillaris. PRPH2 was evaluated and the c.582-1G>A mutation was identified in heterozygosity. An advanced adult-onset benign concentric annular macular dystrophy diagnosis was thereby proposed. The c.582-1G>A mutation is poorly known and not present in all common genomic databases. This case report is the first one to report a c.582-1G>A mutation associated with benign concentric annular macular dystrophy.', 'FAU': ['Fernandez-Berdasco, Karina', 'Galvez-Olortegui, Jose', \"Guillen-Lozada, Sussan's Pamela\", 'Gonzalez, Noelia Garcia', 'Castro-Navarro, Joaquin'], 'AU': ['Fernandez-Berdasco K', 'Galvez-Olortegui J', 'Guillen-Lozada SP', 'Gonzalez NG', 'Castro-Navarro J'], 'AUID': ['ORCID: 0000-0001-8080-6431', 'ORCID: 0000-0003-1818-9801', 'ORCID: 0000-0002-7079-6855'], 'AD': ['Ophthalmology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.', 'Ophthalmology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.', 'Evidence Based Ophthalmology Unit (Oftalmoevidencia), Scientia Clinical and Epidemiological Research Institute, Trujillo, Peru.', 'Ophthalmology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.', 'Genetics Department, Hospital Universitario Central de Asturias, Oviedo, Spain.', 'Ophthalmology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.'], 'LA': ['eng'], 'PT': ['Letter'], 'DEP': '20230403', 'PL': 'Brazil', 'TA': 'Arq Bras Oftalmol', 'JT': 'Arquivos brasileiros de oftalmologia', 'JID': '0400645', 'SB': 'IM', 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/06 06:00', 'CRDT': ['2023/04/05 17:43'], 'PHST': ['2021/11/17 00:00 [received]', '2022/07/30 00:00 [accepted]', '2023/04/05 17:43 [entrez]', '2023/04/06 06:00 [pubmed]', '2023/04/06 06:00 [medline]'], 'AID': ['S0004-27492023005001202 [pii]', '10.5935/0004-2749.2021-0478 [doi]'], 'PST': 'aheadofprint', 'SO': 'Arq Bras Oftalmol. 2023 Apr 3:S0004-27492023005001202. doi: 10.5935/0004-2749.2021-0478.'}, {'PMID': '37017958', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230407', 'LR': '20230409', 'IS': '2164-2591 (Electronic) 2164-2591 (Linking)', 'VI': '12', 'IP': '4', 'DP': '2023 Apr 3', 'TI': 'Biomechanical Responses of Different Cap Thicknesses of Corneas After Small Incision Lenticule Extraction: Finite Element Analysis.', 'PG': '5', 'LID': '10.1167/tvst.12.4.5 [doi] 5', 'AB': 'PURPOSE: This study analyzed the biomechanical responses of different corneal cap thicknesses after small incision lenticule extraction (SMILE). METHODS: Individual finite element models of myopic eyes were constructed based on the clinical data. Then, four types of corneal cap thicknesses after SMILE were included for each model. The biomechanical effects of material parameters and intraocular pressure on corneas with different cap thicknesses were analyzed. RESULTS: When the cap thickness increased, the vertex displacements of the anterior and posterior corneal surfaces decreased slightly. The corneal stress distributions demonstrated little change. Regarding wave-front aberrations caused by the displacements of the anterior surface, the absolute defocus value decreased slightly, but the magnitude of primary spherical aberration increased slightly. The horizontal coma increased, and the levels of other low-order and high-order aberrations were small and demonstrated little change. The corneal vertex displacement and wave-front aberration were significantly affected by elastic modulus and intraocular pressure, whereas the corneal stress distribution was greatly affected by intraocular pressure. There were obvious individual differences in the biomechanical responses of human eyes. CONCLUSIONS: The biomechanical difference of different corneal cap thicknesses after SMILE was small. The effect of corneal cap thickness was significantly less than that resulting from material parameters and intraocular pressure. TRANSLATIONAL RELEVANCE: Individual models were constructed based on the clinical data. The elastic modulus was controlled by programming to simulate its heterogeneous distribution in the actual human eye. The simulation was improved to bridge the gap between basic research and clinical care.', 'FAU': ['Fang, Lihua', 'Jin, Tianzi', 'Cao, Yu', 'Li, Xuefeng', 'Hu, Jialin', 'Zhao, Xinheng', 'Wang, Yan'], 'AU': ['Fang L', 'Jin T', 'Cao Y', 'Li X', 'Hu J', 'Zhao X', 'Wang Y'], 'AD': ['Key Laboratory of Nondestructive Test (Ministry of Education), Nanchang Hangkong University, Nanchang, China.', 'Key Laboratory of Nondestructive Test (Ministry of Education), Nanchang Hangkong University, Nanchang, China.', 'Key Laboratory of Nondestructive Test (Ministry of Education), Nanchang Hangkong University, Nanchang, China.', 'Key Laboratory of Nondestructive Test (Ministry of Education), Nanchang Hangkong University, Nanchang, China.', 'Key Laboratory of Nondestructive Test (Ministry of Education), Nanchang Hangkong University, Nanchang, China.', 'Key Laboratory of Nondestructive Test (Ministry of Education), Nanchang Hangkong University, Nanchang, China.', 'Tianjin Key Lab of Ophthalmology and Visual Science, Tianjin Eye Institute, Tianjin Eye Hospital; Nankai University Eye Institute, Nankai University; Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'PL': 'United States', 'TA': 'Transl Vis Sci Technol', 'JT': 'Translational vision science & technology', 'JID': '101595919', 'SB': 'IM', 'MH': ['Humans', 'Finite Element Analysis', 'Visual Acuity', '*Corneal Surgery, Laser/methods', 'Cornea', '*Myopia/surgery'], 'PMC': 'PMC10082386', 'COIS': ['Disclosure: L. Fang, None; T. Jin, None; Y. Cao, None; X. Li, None; J. Hu, None;', 'X. Zhao, None; Y. Wang, None'], 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/07 06:42', 'CRDT': ['2023/04/05 11:33'], 'PHST': ['2023/04/07 06:42 [medline]', '2023/04/05 11:33 [entrez]', '2023/04/06 06:00 [pubmed]'], 'AID': ['2785502 [pii]', 'TVST-22-4837 [pii]', '10.1167/tvst.12.4.5 [doi]'], 'PST': 'ppublish', 'SO': 'Transl Vis Sci Technol. 2023 Apr 3;12(4):5. doi: 10.1167/tvst.12.4.5.'}, {'PMID': '37017569', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230405', 'IS': '2198-3844 (Electronic) 2198-3844 (Linking)', 'DP': '2023 Apr 5', 'TI': 'Integrative Single-Cell Transcriptomics and Epigenomics Mapping of the Fetal Retina Developmental Dynamics.', 'PG': 'e2206623', 'LID': '10.1002/advs.202206623 [doi]', 'AB': 'The underlying mechanisms that determine gene expression and chromatin accessibility in retinogenesis are poorly understood. Herein, single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin sequencing are performed on human embryonic eye samples obtained 9-26 weeks after conception to explore the heterogeneity of retinal progenitor cells (RPCs) and neurogenic RPCs. The differentiation trajectory from RPCs to 7 major types of retinal cells are verified. Subsequently, diverse lineage-determining transcription factors are identified and their gene regulatory networks are refined at the transcriptomic and epigenomic levels. Treatment of retinospheres, with the inhibitor of RE1 silencing transcription factor, X5050, induces more neurogenesis with the regular arrangement, and a decrease in Muller glial cells. The signatures of major retinal cells and their correlation with pathogenic genes associated with multiple ocular diseases, including uveitis and age-related macular degeneration are also described. A framework for the integrated exploration of single-cell developmental dynamics of the human primary retina is provided.', 'CI': ['(c) 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.'], 'FAU': ['Li, Ruonan', 'Liu, Jiangyi', 'Yi, Ping', 'Yang, Xianli', 'Chen, Jun', 'Zhao, Chenyang', 'Liao, Xingyun', 'Wang, Xiaotang', 'Xu, Zongren', 'Lu, Huiping', 'Li, Hongshun', 'Zhang, Zhi', 'Liu, Xianyang', 'Xiang, Junjie', 'Hu, Ke', 'Qi, Hongbo', 'Yu, Jia', 'Yang, Peizeng', 'Hou, Shengping'], 'AU': ['Li R', 'Liu J', 'Yi P', 'Yang X', 'Chen J', 'Zhao C', 'Liao X', 'Wang X', 'Xu Z', 'Lu H', 'Li H', 'Zhang Z', 'Liu X', 'Xiang J', 'Hu K', 'Qi H', 'Yu J', 'Yang P', 'Hou S'], 'AD': ['The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, P. R. China.', 'Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, P. R. China.', \"Department of Obstetrics, Women and Children's Hospital of Chongqing Medical University, Chongqing, 401147, P. R. China.\", 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', \"Department of Obstetrics, Women and Children's Hospital of Chongqing Medical University, Chongqing, 401147, P. R. China.\", 'Chongqing Key Laboratory of Maternal and Fetal Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Haihe Laboratory of Cell Ecosystem, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, 100005, P. R. China.', 'The Key Laboratory of RNA and Hematopoietic Regulation, Chinese Academy of Medical Sciences, Beijing, 100005, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.', 'Chongqing Key Laboratory of Ophthalmology, Chongqing, 400016, P. R. China.', 'Chongqing Eye Institute, Chongqing, 400016, P. R. China.', 'Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, 400016, P. R. China.', 'Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing, 100730, P. R. China.'], 'AUID': ['ORCID: 0000-0002-7796-8891'], 'LA': ['eng'], 'GR': ['82070951/National Natural Science Foundation Project of China/', '82271078/National Natural Science Foundation Project of China/', 'CXQT19015/Innovative Research Group Project of Chongqing Education Commission/', 'cx2018010/Innovation Supporting Plan of Overseas Study of Chongqing/', 'National Key Clinical Specialties Construction Program of China/', 'Chongqing Branch of National Clinical Research Center for Ocular Diseases/', '2008CA5003/Chongqing Key Laboratory of Ophthalmology/', 'w0047/Program for Youth Innovation in Future Medicine, Chongqing Medical', 'University/'], 'PT': ['Journal Article'], 'DEP': '20230405', 'PL': 'Germany', 'TA': 'Adv Sci (Weinh)', 'JT': 'Advanced science (Weinheim, Baden-Wurttemberg, Germany)', 'JID': '101664569', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['fetal eye', 'gliogenesis', 'neurogenesis', 'retinal development', 'single-cell RNA sequencing', 'single-cell assay for transposase-accessible chromatin sequencing'], 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/06 06:00', 'CRDT': ['2023/04/05 10:07'], 'PHST': ['2023/02/24 00:00 [revised]', '2022/11/12 00:00 [received]', '2023/04/05 10:07 [entrez]', '2023/04/06 06:00 [pubmed]', '2023/04/06 06:00 [medline]'], 'AID': ['10.1002/advs.202206623 [doi]'], 'PST': 'aheadofprint', 'SO': 'Adv Sci (Weinh). 2023 Apr 5:e2206623. doi: 10.1002/advs.202206623.'}, {'PMID': '37017337', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230405', 'IS': '1460-2083 (Electronic) 0964-6906 (Linking)', 'DP': '2023 Apr 5', 'TI': 'Impact of the RNA allosteric effect triggered by single nucleotide polymorphisms on the splicing process.', 'LID': 'ddad057 [pii] 10.1093/hmg/ddad057 [doi]', 'AB': 'The susceptibility single nucleotide polymorphisms (SNPs) obtained by genome-wide association studies (GWAS) leave some thorny questions, such as prioritization, false positives, and unknown pathogenesis. Previous studies suggested that genetic variation may perturb the RNA secondary structure (RSS), influence protein recruitment and binding, and ultimately affect splicing processes. Therefore, exploring the perturbation of SNPs to structure-function correlations may provide an effective bridge toward understanding the genetic contribution to diseases. Here, aiming to decipher the regulatory mechanism of myopia susceptibility variants, we systematically evaluated the roles of SNP-induced structural changes during splicing. 7.53% of myopia-related SNPs exhibited significant global structural changes, 19.53% presented noteworthy local structural disturbance, and there were wide-ranging structural perturbations in the splice-related motifs. We established a comprehensive evaluation system for structural disturbance in the splicing-related motifs, and gave the priority ranking for the SNPs at RNA structural level. These high-priority SNPS were revealed to widely disturb the molecular interaction properties between splicing-related proteins and pre-mRNAs by HDOCK. Moreover, mini-gene assays confirmed that structural perturbation could influence splicing efficiency through structural remodelling. This study deepens our understanding of the potential molecular regulatory mechanisms of susceptible SNPs in myopia, and contributes to personalized diagnosis, personalized medicine, disease-risk prediction, and functional verification study by guiding the prioritization of the susceptibility SNPs.', 'CI': ['(c) The Author(s) 2023. Published by Oxford University Press. All rights reserved.', 'For Permissions, please email: journals.permissions@oup.com.'], 'FAU': ['Zhuang, Youyuan', 'Lu, Xiaoyan', 'Lin, Peng', 'Wang, Siyu', 'Sheng, Xiaoran', 'Chen, Chong', 'Zhang, Guosi', 'Wang, Zhiyi', 'Mei, Changqiu', 'Qu, Jia', 'Xu, Liangde', 'Wang, Hong'], 'AU': ['Zhuang Y', 'Lu X', 'Lin P', 'Wang S', 'Sheng X', 'Chen C', 'Zhang G', 'Wang Z', 'Mei C', 'Qu J', 'Xu L', 'Wang H'], 'AD': ['National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'Center of Optometry International Innovation of Wenzhou, Eye Valley, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'Center of Optometry International Innovation of Wenzhou, Eye Valley, Wenzhou, 325027, China.', 'National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'Center of Optometry International Innovation of Wenzhou, Eye Valley, Wenzhou, 325027, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230405', 'PL': 'England', 'TA': 'Hum Mol Genet', 'JT': 'Human molecular genetics', 'JID': '9208958', 'SB': 'IM', 'EDAT': '2023/04/06 06:00', 'MHDA': '2023/04/06 06:00', 'CRDT': ['2023/04/05 08:14'], 'PHST': ['2023/02/27 00:00 [received]', '2023/03/26 00:00 [revised]', '2023/04/05 08:14 [entrez]', '2023/04/06 06:00 [pubmed]', '2023/04/06 06:00 [medline]'], 'AID': ['7107871 [pii]', '10.1093/hmg/ddad057 [doi]'], 'PST': 'aheadofprint', 'SO': 'Hum Mol Genet. 2023 Apr 5:ddad057. doi: 10.1093/hmg/ddad057.'}, {'PMID': '37016462', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230407', 'IS': '2056-9920 (Print) 2056-9920 (Electronic) 2056-9920 (Linking)', 'VI': '9', 'IP': '1', 'DP': '2023 Apr 4', 'TI': 'Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice.', 'PG': '23', 'LID': '10.1186/s40942-023-00453-0 [doi] 23', 'AB': 'BACKGROUND: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are the standard of care for diabetic macular edema (DME), a common complication of diabetes. This study aimed to identify factors influencing DME intravitreal anti-VEGF treatment outcomes in real-world practice. METHODS: This was a multi-center retrospective observational study using medical chart review of participants receiving anti-VEGF injections for DME (N = 248). Demographic and clinical variables were assessed for association with best corrected visual acuity (BCVA) and central macular thickness (CMT) outcomes using regression models. RESULTS: There was a significant improvement in BCVA (p < 0.001) and CMT (p < 0.001) after 12 months of treatment, although 21% of participants had decreased BCVA, and 41% had a < 10% CMT reduction at 12 months. Higher baseline BCVA (p = 0.022, OR=-0.024, 95% CI=-0.046,-0.004) and longer duration of diabetic retinopathy (p = 0.048, OR=-0.064, 95% CI=-0.129,-0.001) were negative predictors for BCVA response, whereas Aflibercept treatment (p = 0.017, OR = 1.107, 95% CI = 0.220,2.051) compared with other drugs and a positive \"early functional response\" (p < 0.001, OR=-1.393, 95% CI=-1.946,-0.857) were positive predictors. A higher baseline CMT (p < 0.001, OR = 0.019, 95% CI = 0.012,0.0261) and an \"early anatomical response\", (p < 0.001, OR=-1.677, 95% CI=-2.456, -0.943) were predictors for greater reduction in CMT. Overall, the variables could predict only 23% of BCVA and 52% of CMT response. CONCLUSIONS: The study shows a significant proportion of DME patients do not respond to anti-VEGF therapy and identifies several clinical predictors for treatment outcomes. TRIAL REGISTRATION: The study was approved through the Human Research Ethics Committee, University of Tasmania (approval number H0012902), and the Southern Adelaide Clinical Human Research Ethics Committee (approval number 86 - 067).', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Gurung, Rajya L', 'FitzGerald, Liesel M', 'Liu, Ebony', 'McComish, Bennet J', 'Kaidonis, Georgia', 'Ridge, Bronwyn', 'Hewitt, Alex W', 'Vote, Brendan J', 'Verma, Nitin', 'Craig, Jamie E', 'Burdon, Kathryn P'], 'AU': ['Gurung RL', 'FitzGerald LM', 'Liu E', 'McComish BJ', 'Kaidonis G', 'Ridge B', 'Hewitt AW', 'Vote BJ', 'Verma N', 'Craig JE', 'Burdon KP'], 'AD': ['Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street (Private Bag 23), Hobart, TAS, 7000, Australia. rajyalaxmi.gurung@utas.edu.au.', 'Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street (Private Bag 23), Hobart, TAS, 7000, Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street (Private Bag 23), Hobart, TAS, 7000, Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street (Private Bag 23), Hobart, TAS, 7000, Australia.', 'School of Medicine, University of Tasmania, Hobart, TAS, Australia.', 'School of Medicine, University of Tasmania, Hobart, TAS, Australia.', 'School of Medicine, University of Tasmania, Hobart, TAS, Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street (Private Bag 23), Hobart, TAS, 7000, Australia.'], 'LA': ['eng'], 'GR': ['Tasmanian Community Fund/Tasmanian Community Fund/', 'GNT1116360/National Health and Medical Research Council (NHMRC) Australia Centre', 'for Research Excellence/', 'Royal Hobart Hospital Research Foundation/Royal Hobart Hospital Research', 'Foundation/', 'Diabetes Tasmania Post graduate research scholarship/Diabetes Tasmania Post', 'graduate research scholarship/', 'Patricia F Gordon Top Up Scholarship/Patricia F Gordon Top Up Scholarship/', 'Gerald Harvey Senior Research Fellowship/Gerald Harvey Senior Research', 'Fellowship/', 'Williams Oncology Royal Hobart Hospital Research Foundation Grant/Williams', 'Oncology Royal Hobart Hospital Research Foundation Grant/'], 'PT': ['Journal Article'], 'DEP': '20230404', 'PL': 'England', 'TA': 'Int J Retina Vitreous', 'JT': 'International journal of retina and vitreous', 'JID': '101677897', 'PMC': 'PMC10074667', 'OTO': ['NOTNLM'], 'OT': ['Anti-VEGF', 'Best-corrected visual acuity', 'Central macular thickness', 'Diabetic macular edema'], 'COIS': ['None declared.'], 'EDAT': '2023/04/05 06:00', 'MHDA': '2023/04/05 06:01', 'CRDT': ['2023/04/04 23:53'], 'PHST': ['2023/01/22 00:00 [received]', '2023/03/13 00:00 [accepted]', '2023/04/05 06:01 [medline]', '2023/04/04 23:53 [entrez]', '2023/04/05 06:00 [pubmed]'], 'AID': ['10.1186/s40942-023-00453-0 [pii]', '453 [pii]', '10.1186/s40942-023-00453-0 [doi]'], 'PST': 'epublish', 'SO': 'Int J Retina Vitreous. 2023 Apr 4;9(1):23. doi: 10.1186/s40942-023-00453-0.'}, {'PMID': '37016357', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230406', 'LR': '20230407', 'IS': '1471-2458 (Electronic) 1471-2458 (Linking)', 'VI': '23', 'IP': '1', 'DP': '2023 Apr 4', 'TI': 'Time outdoors positively associates with academic performance: a school-based study with objective monitoring of outdoor time.', 'PG': '645', 'LID': '10.1186/s12889-023-15532-y [doi] 645', 'AB': 'BACKGROUND: To explore the relationship between outdoor time and academic performance among school-aged children. METHODS: This study was designed as a cross-sectional study. Data were derived from a school-based prospective children myopia intervention study (STORM). Outdoor time was recorded by self-developed algorithm-validated wristwatches in real-time and calculated as the cumulative average of 10 months. The academic performance was recorded and provided by the participating schools and further standardized. Other information was collected using an online standardized questionnaire. Mixed-effects model and B-Spline method were used to investigate the association between time spent on different types of daily activity, including outdoor activity and academic performance. RESULTS: A total of 3291 children with mean age 9.25 years were included in the final analysis. Overall, outdoor time was associated with academic performance in a non-linear manner; specifically, not exceeding 2.3 h per day, outdoor time was positively associated with academic performance; exceeding 2.3 h per day, this association became non-significant. Likewise, daily sleep duration and out-of-school learning time were associated with academic performance in a non-linear manner, resulting in turning points of 11.3 and 1.4 h per day, respectively. Separate analysis showed that outdoor time and sleep duration but not out-of-school learning time were positively associated with academic performance in Chinese, mathematics and English. CONCLUSION: Outdoor time, sleep duration and out-of-school learning time were associated with academic performance in a non-linear manner. Promotion of outdoor time may not negatively impact on academic performance. TRIAL REGISTRATION: Our study was registered in ClinicalTrials.gov (Identifier: NCT02980445).', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Wang, Jingjing', 'Sankaridurg, Padmaja', 'Naduvilath, Thomas', 'Li, Wayne', 'Morgan, Ian G', 'Rose, Kathryn A', 'Weng, Rebecca', 'Xu, Xun', 'He, Xiangui'], 'AU': ['Wang J', 'Sankaridurg P', 'Naduvilath T', 'Li W', 'Morgan IG', 'Rose KA', 'Weng R', 'Xu X', 'He X'], 'AD': ['Shanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai Vision Health Center & Shanghai Children Myopia Institute, Shanghai, 200030, China.', 'Brien Holden Vision Institute, Sydney, Australia.', 'School of Optometry and Vision Science, University of New South Wales, Sydney, Australia.', 'Brien Holden Vision Institute, Sydney, Australia.', 'School of Optometry and Vision Science, University of New South Wales, Sydney, Australia.', 'Brien Holden Vision Institute, Sydney, Australia.', 'School of Optometry and Vision Science, University of New South Wales, Sydney, Australia.', 'Division of Biochemistry and Molecular Biology, Research School of Biology, Australian National University, Canberra, ACT, Australia.', 'Discipline of Orthoptics, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia.', 'Brien Holden Vision Institute, Sydney, Australia.', 'School of Optometry and Vision Science, University of New South Wales, Sydney, Australia.', 'Shanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai Vision Health Center & Shanghai Children Myopia Institute, Shanghai, 200030, China.', 'Department of Ophthalmology, National Clinical Research Center for Eye Diseases, Center of Eye Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.', 'Shanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai Vision Health Center & Shanghai Children Myopia Institute, Shanghai, 200030, China. xianhezi@163.com.', 'Department of Ophthalmology, National Clinical Research Center for Eye Diseases, Center of Eye Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China. xianhezi@163.com.'], 'LA': ['eng'], 'SI': ['ClinicalTrials.gov/NCT02980445'], 'PT': ['Journal Article', \"Research Support, Non-U.S. Gov't\"], 'DEP': '20230404', 'PL': 'England', 'TA': 'BMC Public Health', 'JT': 'BMC public health', 'JID': '100968562', 'SB': 'IM', 'MH': ['Child', 'Humans', 'Cross-Sectional Studies', 'Prospective Studies', '*Schools', '*Organizations', 'Surveys and Questionnaires'], 'PMC': 'PMC10071681', 'OTO': ['NOTNLM'], 'OT': ['Academic performance', 'Children', 'Myopia', 'Outdoor time'], 'COIS': ['The authors declare no competing interests.'], 'EDAT': '2023/04/05 06:00', 'MHDA': '2023/04/06 10:16', 'CRDT': ['2023/04/04 23:47'], 'PHST': ['2022/06/04 00:00 [received]', '2023/03/27 00:00 [accepted]', '2023/04/06 10:16 [medline]', '2023/04/04 23:47 [entrez]', '2023/04/05 06:00 [pubmed]'], 'AID': ['10.1186/s12889-023-15532-y [pii]', '15532 [pii]', '10.1186/s12889-023-15532-y [doi]'], 'PST': 'epublish', 'SO': 'BMC Public Health. 2023 Apr 4;23(1):645. doi: 10.1186/s12889-023-15532-y.'}, {'PMID': '37015785', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230406', 'LR': '20230408', 'IS': '2044-6055 (Electronic) 2044-6055 (Linking)', 'VI': '13', 'IP': '4', 'DP': '2023 Apr 4', 'TI': 'China Glaucoma Treatment Pattern Study I-Primary Angle-Closure Glaucoma: protocol for a multicentre, retrospective, observational study.', 'PG': 'e068048', 'LID': '10.1136/bmjopen-2022-068048 [doi]', 'AB': 'INTRODUCTION: Primary angle-closure glaucoma (PACG) is a leading cause of irreversible blindness globally, and the number of patients with PACG rises every year. Yet, there is a lack of knowledge about the clinical characteristics, therapeutic options and profile of patients with PACG in China. Hence, we design the China Glaucoma Treatment Pattern Study -Primary Angle-Closure Glaucoma (Ch-GTP). The objective of this paper is to describe the design and methodology of Ch-GTP. The aim of this study is to characterise the profile and trend associated with initial PACG treatment for the last 10 years in China. METHODS: Ch-GTP is a national multicentre retrospective observational study that will randomly sample from 50 hospitals throughout China. Over 7000 patient records hospitalised for initial PACG treatment from 2011 to 2020 will be selected randomly. The data from electronic medical records will be uploaded to an encrypted online platform that will receive and collate data from all collaborating hospitals. Data abstraction and monitoring will be performed in a standardised manner by trained statisticians to ensure consistency. Systematic data cleaning will also be conducted by statisticians to ensure data integrity before final data storage. The outcomes will include four broad categories: (1) demographics, (2) clinical characteristics, (3) therapeutic strategies and procedures and (4) early outcomes at discharge. The demographic characteristics and early outcomes will be summarised using descriptive statistics. Comparative analyses of characteristics and treatment pattern changing trends for different regions and years will be used to test for significant differences (t-test or Mann-Whitney U test). ETHICS AND DISSEMINATION: The collaborating hospitals obtained local approval based on a standard ethics application from internal ethics committees or acknowledged an existent ethics approval of the leading institution with approval from internal ethics committees. Due to the retrospective nature, written informed consent from patients was waived by the ethics committee. The results will be published in academic journals and presented at national and international academic conferences. TRIAL REGISTRATION NUMBER: ChiCTR2100054643.', 'CI': ['(c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No', 'commercial re-use. See rights and permissions. Published by BMJ.'], 'FAU': ['Chen, Jinyuan', 'Du, Jie', 'Xing, Xiaoli', 'Liu, Danyan', 'Jia, Zhiyang', 'Zheng, Yajuan', 'Wang, Dan', 'Guo, Wenyi', 'Jiang, Jian', 'Duan, Guoping', 'Tang, Li', 'Wu, Zhengzheng', 'Lv, Peng', 'Ma, Jianjun', 'Zhu, Yihua', 'Liang, Yuanbo', 'Sun, Xin', 'He, Mingguang'], 'AU': ['Chen J', 'Du J', 'Xing X', 'Liu D', 'Jia Z', 'Zheng Y', 'Wang D', 'Guo W', 'Jiang J', 'Duan G', 'Tang L', 'Wu Z', 'Lv P', 'Ma J', 'Zhu Y', 'Liang Y', 'Sun X', 'He M'], 'AD': ['Department of Ophthalmology, Fujian Medical University, Fuzhou, Fujian, China.', 'Department of Ophthalmology, Wenzhou Medical University Eye Hospital, Wenzhou, Zhejiang, China.', 'Department of Ophthalmology, Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China.', 'Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.', 'Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.', 'Department of Ophthalmology, Jilin University Second Hospital, Changchun, Jilin, China.', 'Department of Ophthalmology, Jilin Province Hospital of Chinese Medicine, Changchun, Jilin, China.', \"Department of Ophthalmology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, Shanghai, Shanghai, China.\", 'Eye Center, Xiangya Hospital Central South University, Changsha, Hunan, China.', 'Hunan Key Laboratory of Ophthalmology, Changsha, Hunan, China.', \"Hunan Provincial People's Hospital, Changsha, Hunan, China.\", 'Sichuan University West China Hospital, Chengdu, Sichuan, China.', \"Department of Ophthalmology, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.\", 'Department of Ophthalmology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.', \"Department of Ophthalmology, Gansu Provincial People's Hospital, Lanzhou, Gansu, China.\", 'Department of Ophthalmology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.', 'Wenzhou Medical University Eye Hospital, Wenzhou, Zhejiang, China yuanboliang@wmu.edu.cn.', 'Sichuan University West China Hospital, Wuhou, Sichuan, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China.', 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, Australia.'], 'AUID': ['ORCID: 0000-0003-2327-3733', 'ORCID: 0000-0003-1547-5511', 'ORCID: 0000-0001-9685-7356'], 'LA': ['eng'], 'SI': ['ChiCTR/ChiCTR2100054643'], 'PT': ['Journal Article', 'Multicenter Study', 'Observational Study', \"Research Support, Non-U.S. Gov't\"], 'DEP': '20230404', 'PL': 'England', 'TA': 'BMJ Open', 'JT': 'BMJ open', 'JID': '101552874', 'SB': 'IM', 'MH': ['Humans', 'Blindness', 'China', '*Glaucoma', '*Glaucoma, Angle-Closure/therapy', 'Intraocular Pressure', 'Retrospective Studies'], 'OTO': ['NOTNLM'], 'OT': ['Glaucoma', 'OPHTHALMOLOGY', 'Protocols & guidelines'], 'COIS': ['Competing interests: None declared.'], 'EDAT': '2023/04/05 06:00', 'MHDA': '2023/04/06 10:16', 'CRDT': ['2023/04/04 20:53'], 'PHST': ['2023/04/06 10:16 [medline]', '2023/04/04 20:53 [entrez]', '2023/04/05 06:00 [pubmed]'], 'AID': ['bmjopen-2022-068048 [pii]', '10.1136/bmjopen-2022-068048 [doi]'], 'PST': 'epublish', 'SO': 'BMJ Open. 2023 Apr 4;13(4):e068048. doi: 10.1136/bmjopen-2022-068048.'}, {'PMID': '37015771', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230404', 'IS': '1468-330X (Electronic) 0022-3050 (Linking)', 'DP': '2023 Apr 4', 'TI': 'Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy.', 'LID': 'jnnp-2022-331011 [pii] 10.1136/jnnp-2022-331011 [doi]', 'AB': \"BACKGROUND: To assess the ability of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) clinical criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) to include within their classification the whole spectrum of clinical heterogeneity of the disease and to define the clinical characteristics of the unclassifiable clinical forms. METHODS: The 2021 EAN/PNS clinical criteria for CIDP were applied to 329 patients fulfilling the electrodiagnostic (and in some cases also the supportive) criteria for the diagnosis of CIDP. Clinical characteristics were reviewed for each patient not strictly fulfilling the clinical criteria ('unclassifiable'). RESULTS: At study inclusion, 124 (37.5%) patients had an unclassifiable clinical presentation, including 110 (89%) with a typical CIDP-like clinical phenotype in whom some segments of the four limbs were unaffected by weakness ('incomplete typical CIDP'), 10 (8%) with a mild distal, symmetric, sensory or sensorimotor polyneuropathy confined to the lower limbs with cranial nerve involvement ('cranial nerve predominant CIDP') and 4 (1%) with a symmetric sensorimotor polyneuropathy limited to the proximal and distal areas of the lower limbs ('paraparetic CIDP'). Eighty-one (65%) patients maintained an unclassifiable presentation during the entire disease follow-up while 13 patients progressed to typical CIDP. Patients with the unclassifiable clinical forms compared with patients with typical CIDP had a milder form of CIDP, while there was no difference in the distribution patterns of demyelination. CONCLUSIONS: A proportion of patients with CIDP do not strictly fulfil the 2021 EAN/PNS clinical criteria for diagnosis. These unclassifiable clinical phenotypes may pose diagnostic challenges and thus deserve more attention in clinical practice and research.\", 'CI': ['(c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and', 'permissions. Published by BMJ.'], 'FAU': ['Doneddu, Pietro Emiliano', 'Akyil, Houseyin', 'Manganelli, Fiore', 'Briani, Chiara', 'Cocito, Dario', 'Benedetti, Luana', 'Mazzeo, Anna', 'Fazio, Raffaella', 'Filosto, Massimiliano', 'Cosentino, Giuseppe', 'Di Stefano, Vincenzo', 'Antonini, Giovanni', 'Marfia, Girolama Alessandra', 'Inghilleri, Maurizio', 'Siciliano, Gabriele', 'Clerici, Angelo Maurizio', 'Carpo, Marinella', 'Schenone, Angelo', 'Luigetti, Marco', 'Lauria, Giuseppe', 'Mata, Sabrina', 'Rosso, Tiziana', 'Minicuci, Giacomo Maria', 'Lucchetta, Marta', 'Cavaletti, Guido', 'Liberatore, Giuseppe', 'Spina, Emanuele', 'Campagnolo, Marta', 'Peci, Erdita', 'Germano, Francesco', 'Gentile, Luca', 'Strano, Camilla', 'Cotti Piccinelli, Stefano', 'Vegezzi, Elisa', 'Leonardi, Luca', 'Mataluni, Giorgia', 'Ceccanti, Marco', 'Schirinzi, Erika', 'Romozzi, Marina', 'Nobile-Orazio, Eduardo'], 'AU': ['Doneddu PE', 'Akyil H', 'Manganelli F', 'Briani C', 'Cocito D', 'Benedetti L', 'Mazzeo A', 'Fazio R', 'Filosto M', 'Cosentino G', 'Di Stefano V', 'Antonini G', 'Marfia GA', 'Inghilleri M', 'Siciliano G', 'Clerici AM', 'Carpo M', 'Schenone A', 'Luigetti M', 'Lauria G', 'Mata S', 'Rosso T', 'Minicuci GM', 'Lucchetta M', 'Cavaletti G', 'Liberatore G', 'Spina E', 'Campagnolo M', 'Peci E', 'Germano F', 'Gentile L', 'Strano C', 'Cotti Piccinelli S', 'Vegezzi E', 'Leonardi L', 'Mataluni G', 'Ceccanti M', 'Schirinzi E', 'Romozzi M', 'Nobile-Orazio E'], 'AD': ['Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy.', 'Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy.', 'Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy.', 'Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Napoli, Italy.', 'Department of Neuroscience, University of Padova, Padova, Italy.', 'SSD Patologie Neurologiche Specialistiche, AOU San Luigi, Torino, Italy.', 'IRCCS Ospedale Policlinico San Martino, Genova, Italy.', 'Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy.', 'Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milano, Italy.', 'Department of Clinical and Experimental Sciences, NeMO-Brescia Clinical Center for Neuromuscular Diseases, University of Brescia, Brescia, Italy.', 'IRCCS Mondino Foundation, Pavia, Italy.', 'Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.', 'Department of Biomedicine, Neuroscience, and advanced Diagnostic (BiND), University of Palermo, Palermo, Italy.', \"Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy.\", 'Dysimmune Neuropathies Unit, Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy.', \"Department of Neurology and Psychiatry, 'Sapienza' University of Rome, Rome, Italy.\", 'Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.', 'Neurology Unit, Circolo & Macchi Foundation Hospital, University of Insubria, Varese, Italy.', 'ASST Bergamo Ovest-Ospedale Treviglio, Milan, Italy.', 'IRCCS Ospedale Policlinico San Martino, Genova, Italy.', 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova, Italy.', 'UOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.', 'Universita Cattolica del Sacro Cuore. Sede di Roma, Roma, Italy.', \"Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milano, Italy.\", 'Department of Medical Biotechnology and Translational Medicine, Milan University, Milano, Italy.', 'Dipartimento Neuromuscoloscheletrico e degli organi di Senso, Neurology Unit, University Hospital Careggi, Firenze, Italy.', 'UOC di Neurologia, Ospedale San Bassiano, Vicenza, Italy.', 'Ospedale di Vicenza, Vicenza, Italy.', 'UOC Neurologia, Ospedale Santa Maria della Misericordia, Rovigo, Italy.', 'School of Medicine and surgery and experimental Neurology Unit, University of Milan-Bicocca, Milano, Italy.', 'Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy.', 'Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Napoli, Italy.', 'Department of Neuroscience, University of Padova, Padova, Italy.', 'SSD Patologie Neurologiche Specialistiche, AOU San Luigi, Torino, Italy.', 'IRCCS Ospedale Policlinico San Martino, Genova, Italy.', 'Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy.', 'Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milano, Italy.', 'Department of Clinical and Experimental Sciences, NeMO-Brescia Clinical Center for Neuromuscular Diseases, University of Brescia, Brescia, Italy.', 'IRCCS Mondino Foundation, Pavia, Italy.', \"Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy.\", 'Dysimmune Neuropathies Unit, Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy.', \"Department of Neurology and Psychiatry, 'Sapienza' University of Rome, Rome, Italy.\", 'Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.', 'Universita Cattolica del Sacro Cuore. Sede di Roma, Roma, Italy.', 'Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy eduardo.nobile@unimi.it.', 'Department of Medical Biotechnology and Translational Medicine, Milan University, Milano, Italy.'], 'AUID': ['ORCID: 0000-0001-8035-0200', 'ORCID: 0000-0002-6964-618X', 'ORCID: 0000-0002-9540-9727', 'ORCID: 0000-0002-2852-7512', 'ORCID: 0000-0001-9805-1655', 'ORCID: 0000-0001-9773-020X', 'ORCID: 0000-0003-2666-1678', 'ORCID: 0000-0002-2060-0279', 'ORCID: 0000-0001-8776-6831', 'ORCID: 0000-0002-3736-0048', 'ORCID: 0000-0001-6016-3141', 'ORCID: 0000-0003-2624-8138'], 'CN': ['Italian CIDP Database study group'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230404', 'PL': 'England', 'TA': 'J Neurol Neurosurg Psychiatry', 'JT': 'Journal of neurology, neurosurgery, and psychiatry', 'JID': '2985191R', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['NEUROIMMUNOLOGY', 'NEUROMUSCULAR', 'NEUROPATHY'], 'COIS': ['Competing interests: PED has received travel grants to attend scientific meetings', 'from CSL Behring and Kedrion. Fiore Manganelli reports personal fees for', 'scientific events from CSL Behring and has received travel grants to attend', 'scientific meetings from CSL Behring and Kedrion. Dario Cocito has received', 'honoraria for lecturing from Shire, CSL Behring, and Kedrion and travel grants to', 'attend scientific meeting from Shire, Kedrion and CSL Behring. RF has served on', 'scientific advisory boards for CSL Behring and has received travel grants from', 'Kedrion and CSL Behring to attend scientific meeting. CB has served on scientific', 'advisory boards for Pfizer, Alnylam, and Akcea, and has received travel grants', 'from Kedrion and CSL Behring to attend scientific meeting. AM has received travel', 'grants from Kedrion and CSL Behring to attend scientific meeting. MF has served', 'on scientific advisory boards for CSL Behring, Sanofi and Amicus and has received', 'travel grants from Sanofi, Biogen, Kedrion and CSL Behring to attend scientific', 'meeting. GC has received travel grants to attend scientific meetings from CSL', 'Behring and Kedrion. ML has received travel grants to attend scientific meetings', 'from Kedrion. GAM has received travel grants to attend scientific meetings from', 'CSL Behring and Kedrion. GL has received travel grants to attend scientific', 'meetings from CSL Behring and Kedrion. EP has received travel grants to attend', 'scientific meetings from CSL Behring. TR has received travel grants to attend', 'scientific meetings from CSL Behring. EN-O reports personal fees for Advisory or', 'Scientific Board from ArgenX-Belgium, Takeda-Italy and USA, CSL-Behring-Italy and', 'USA, Janssen-USA, Kedrion-Italy, LFB-France, Roche-Switzerland, Sanofi-USA. The', 'other authors declare no conflict of interest.'], 'FIR': ['Doneddu, Pietro Emiliano', 'Lorenzo, Alberto De', 'Liberatore, Giuseppe', 'Nobile-Orazio, Eduardo', 'Cocito, Dario', 'Manganelli, Fiore', 'Spina, Emanuele', 'Pisano, Enrica', 'Santoro, Lucio', 'Velardo, Daniele', 'Strano, Camilla', 'Fazio, Raffaella', 'Ruiz, Marta', 'Cacciavillani, Mario', 'Castellani, Francesca', 'Briani, Chiara', 'Piccinelli, Stefano Cotti', 'Caria, Filomena', 'Filosto, Massimiliano', 'Bianchi, Elisa', 'Beghi, Ettore', 'Verrengia, Elena Pinuccia', 'Jann, Stefano', 'Toscano, Antonio', 'Gentile, Luca', 'Russo, Massimo', 'Mazzeo, Anna', 'Leonardi, Luca', 'Antonini, Giovanni', 'Cosentino, Giuseppe', 'Callegari, Ilaria', 'Cortese, Andrea', 'Mataluni, Giorgia', 'Marfia, Girolama Alessandra', 'Clerici, Angelo Maurizio', 'Scrascia, Federica', 'Carpo, Marinella', 'Schenone, Angelo', 'Benedetti, Luana', 'Cabona, Corrado', 'Beronio, Alessandro', 'Schirinzi, Erika', 'Siciliano, Gabriele', 'Luigetti, Marco', 'Dacci, Patrizia', 'Lauria, Giuseppe', 'Rosso, Tiziana', 'Balducci, Claudia', 'Cavaletti, Guido', 'Sabatelli, Mario', 'Peci, Erdita'], 'IR': ['Doneddu PE', 'Lorenzo A', 'Liberatore G', 'Nobile-Orazio E', 'Cocito D', 'Manganelli F', 'Spina E', 'Pisano E', 'Santoro L', 'Velardo D', 'Strano C', 'Fazio R', 'Ruiz M', 'Cacciavillani M', 'Castellani F', 'Briani C', 'Piccinelli SC', 'Caria F', 'Filosto M', 'Bianchi E', 'Beghi E', 'Verrengia EP', 'Jann S', 'Toscano A', 'Gentile L', 'Russo M', 'Mazzeo A', 'Leonardi L', 'Antonini G', 'Cosentino G', 'Callegari I', 'Cortese A', 'Mataluni G', 'Marfia GA', 'Clerici AM', 'Scrascia F', 'Carpo M', 'Schenone A', 'Benedetti L', 'Cabona C', 'Beronio A', 'Schirinzi E', 'Siciliano G', 'Luigetti M', 'Dacci P', 'Lauria G', 'Rosso T', 'Balducci C', 'Cavaletti G', 'Sabatelli M', 'Peci E'], 'EDAT': '2023/04/05 06:00', 'MHDA': '2023/04/05 06:00', 'CRDT': ['2023/04/04 20:52'], 'PHST': ['2022/12/27 00:00 [received]', '2023/03/15 00:00 [accepted]', '2023/04/04 20:52 [entrez]', '2023/04/05 06:00 [pubmed]', '2023/04/05 06:00 [medline]'], 'AID': ['jnnp-2022-331011 [pii]', '10.1136/jnnp-2022-331011 [doi]'], 'PST': 'aheadofprint', 'SO': 'J Neurol Neurosurg Psychiatry. 2023 Apr 4:jnnp-2022-331011. doi: 10.1136/jnnp-2022-331011.'}, {'PMID': '37013445', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230404', 'IS': '1473-4877 (Electronic) 0300-7995 (Linking)', 'DP': '2023 Apr 4', 'TI': 'A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension.', 'PG': '1-13', 'LID': '10.1080/03007995.2023.2197496 [doi]', 'AB': 'Objective: To compare the efficacy and safety of two fixed combination, preservative-free eye drops (bimatoprost 0.01% in combination with either timolol 0.1% or 0.5%) in a gel formulation, with bimatoprost 0.03%/timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).Methods: Phase II, randomized, investigator-masked, multicenter, 3-arm parallel group (Eudract No. 2017-002823-46). Eighty-six patients aged >/=18 years with OAG or OHT, with intraocular pressure (IOP) initially controlled for at least 6 months by a combination therapy of a dual prostaglandin and timolol or insufficiently controlled by first-line monotherapy were included. Patients were randomized to receive T4030a (bimatoprost 0.01%/timolol 0.1%; N = 29), T4030c (bimatoprost 0.01%/timolol 0.5%; N = 29) or bimatoprost 0.03%/timolol 0.5% (N = 28), administered once daily in the evening for 12 weeks. Primary endpoint was defined as change in IOP from day 1 to week 12 measured at 08:00 (+/-1 hour). Further efficacy, safety and pharmacokinetic endpoints were assessed as secondary outcomes.Results: The mean change in IOP from baseline to week 12 was -9.8 +/- 2.1 mmHg for T4030a, -10.1 +/- 2.5 mmHg for T4030c and -10.0 +/- 2.8 mmHg for bimatoprost 0.03%/timolol 0.5%. All treatments were well tolerated with no safety issues identified in any group. In patients treated with T4030a, the systemic concentration of timolol was significantly lower after 12 weeks than in patients treated with T4030c or bimatoprost 0.03%/timolol0.5%.Conclusions: These study results suggest that the preservative-free ophthalmic formulation of T4030a (bimatoprost 0.01%/timolol 0.1%) can be regarded as a useful tool in the therapeutic management of OAG and OHT.', 'FAU': ['Mrukwa-Komine, Ewa', 'Misiuk-Hojlo, Marta', 'Csutak, Adrienne', 'Stalmans, Ingeborg', 'Garhofer, Gerhard'], 'AU': ['Mrukwa-Komine E', 'Misiuk-Hojlo M', 'Csutak A', 'Stalmans I', 'Garhofer G'], 'AD': ['Department of Ophthalmology, Professor K. Gibinski Clinical Center, Medical University of Silesia in Katowice, 40-514 Katowice, Poland.', 'Department of Ophthalmology, School of Medicine in Katowice, Medical University of Silesia in Katowice, 40-514 Katowice, Poland.', 'Department of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.', 'Department of Ophthalmology, Faculty of Medicine, University of Debrecen, Egyetem ter 1, 4032 Debrecen, Hungary.', 'Department of Ophthalmology, Faculty of Medicine, University of Pecs Rakoczi ut 2, 7623 Pecs, Hungary.', 'Department of ophthalmology, University Hospitals UZ Leuven, Herestraat 49, Leuven, Belgium.', 'Research Group of Ophthalmology, Catholic University KU Leuven, Herestraat 49, Leuven, Belgium.', 'Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230404', 'PL': 'England', 'TA': 'Curr Med Res Opin', 'JT': 'Current medical research and opinion', 'JID': '0351014', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Glaucoma', 'bimatoprost', 'ocular hypertension', 'pharmacokinetics', 'preservative-free', 'timolol'], 'EDAT': '2023/04/05 06:00', 'MHDA': '2023/04/05 06:00', 'CRDT': ['2023/04/04 03:23'], 'PHST': ['2023/04/04 03:23 [entrez]', '2023/04/05 06:00 [pubmed]', '2023/04/05 06:00 [medline]'], 'AID': ['10.1080/03007995.2023.2197496 [doi]'], 'PST': 'aheadofprint', 'SO': 'Curr Med Res Opin. 2023 Apr 4:1-13. doi: 10.1080/03007995.2023.2197496.'}, {'PMID': '37013361', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230404', 'IS': '1724-6016 (Electronic) 1120-6721 (Linking)', 'DP': '2023 Apr 3', 'TI': 'Sensitivity and specificity of optical coherence tomography angiography for diagnosis and classification of diabetic retinopathy; a systematic review and meta-analysis.', 'PG': '11206721231167458', 'LID': '10.1177/11206721231167458 [doi]', 'AB': 'BACKGROUND: Optical coherence tomography angiography (OCTA) is a noninvasive imaging method that can be used for the staging of diabetic retinopathy. In addition, alterations in OCTA parameters can precede the clinical fundus changes. In this review, we aimed to assess the accuracy of OCTA in diagnosis and staging of diabetic retinopathy. METHODS: Two independent reviewers participated in the literature search using electronic databases (PubMed, Embase, Cochrane Library Central Register of Controlled Trials, ISI, and Scopus) from inception till December 2020. The heterogeneity of data was assessed by Q statistics, Chi-square test and I(2) index. RESULTS: Forty-four articles published from 2015 to the end of 2020 were included in this meta-analysis. Of these, 27 were case-control studies, 9 were case series, and 8 were cohort studies. In total, 4284 eyes of 3553 patients were assessed in this study. OCTA could differentiate diabetic retinopathy from diabetes without diabetic retinopathy with a sensitivity of 88% (95% CI: 85% to 92%) and specificity of 88% (95% CI: 85% to 91%). In addition, it could differentiate proliferative diabetic retinopathy from non-proliferative diabetic retinopathy with a sensitivity of 91% (95% CI: 86% to 95%) and specificity of 91% (95% CI:86% to 96%). The sensitivity of OCTA for diagnosing diabetic retinopathy was increased by the size of scan (3 x 3 mm: 85%; 6 x 6 mm: 91%, 12 x 12 mm: 96%). CONCLUSION: OCTA, as a non-invasive method, has acceptable sensitivity and specificity for diagnosis and classification of diabetic retinopathy. A larger scan size is associated with more sensitivity for discriminating diabetic retinopathy.', 'FAU': ['Namvar, Ehsan', 'Ahmadieh, Hamid', 'Maleki, Alireza', 'Nowroozzadeh, Mohammad Hossein'], 'AU': ['Namvar E', 'Ahmadieh H', 'Maleki A', 'Nowroozzadeh MH'], 'AD': ['Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, 48435Shiraz University of Medical Sciences, Shiraz, Iran.', 'Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, 556492Shahid Beheshti University of Medical Sciences, Tehran, Iran.', 'Department of Ophthalmology, Alzahra Eye Hospital, 48538Zahedan University of Medical Sciences, Zahedan, Iran.', 'Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, 48435Shiraz University of Medical Sciences, Shiraz, Iran.'], 'AUID': ['ORCID: 0000-0002-8139-2661'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230403', 'PL': 'United States', 'TA': 'Eur J Ophthalmol', 'JT': 'European journal of ophthalmology', 'JID': '9110772', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['OCTA\\u200c', 'diabetic retinopathy', 'optical coherence tomography angiography', 'sensitivity', 'specificity'], 'EDAT': '2023/04/05 06:00', 'MHDA': '2023/04/05 06:00', 'CRDT': ['2023/04/04 02:52'], 'PHST': ['2023/04/04 02:52 [entrez]', '2023/04/05 06:00 [pubmed]', '2023/04/05 06:00 [medline]'], 'AID': ['10.1177/11206721231167458 [doi]'], 'PST': 'aheadofprint', 'SO': 'Eur J Ophthalmol. 2023 Apr 3:11206721231167458. doi: 10.1177/11206721231167458.'}, {'PMID': '37012598', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '0412-4081 (Print) 0412-4081 (Linking)', 'VI': '59', 'IP': '4', 'DP': '2023 Apr 11', 'TI': '[Research progress on the epidemiology and risk factors of dry eye in children].', 'PG': '321-325', 'LID': '10.3760/cma.j.cn112142-20220804-00379 [doi]', 'AB': \"The prevalence of dry eye in children is increasing with changes in the environment and the widespread use of electronic products. However, due to poor ability to express themselves and hidden symptoms of children, lack of understanding of dry eye in children, children with dry eye are likely to be misdiagnosed. Dry eye can seriously affect the quality of children's learning, life, vision and visual development. Therefore, it is urgent to raise awareness of clinical workers about dry eye in children, prevent the occurrence of related complications of dry eye, and avoid permanent visual damage to children. This review discusses and summarizes the epidemiology and common risk factors of children with dry eye, with the aim of improving doctors' understanding of dry eye in children.\", 'FAU': ['Xie, R', 'Wang, Z R', 'Zhu, Y T', 'Yu, J H', 'Zhuo, Y H'], 'AU': ['Xie R', 'Wang ZR', 'Zhu YT', 'Yu JH', 'Zhuo YH'], 'AD': ['Zhongshan Ophthalmic Center, SunYat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China.', 'Zhongshan Ophthalmic Center, SunYat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China.', 'Zhongshan Ophthalmic Center, SunYat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China.', 'Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University (Foshan Maternity & Child Healthcare Hospital), Foshan 528000, China.', 'Zhongshan Ophthalmic Center, SunYat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China.'], 'LA': ['chi'], 'GR': ['2020YFA0112700/National Key Research and Development Project of China/', '202102010216/Science and Technology Program of Guangzhou, China/'], 'PT': ['English Abstract', 'Journal Article', 'Review'], 'PL': 'China', 'TA': 'Zhonghua Yan Ke Za Zhi', 'JT': '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', 'JID': '16210540R', 'SB': 'IM', 'MH': ['Humans', 'Child', '*Dry Eye Syndromes/diagnosis', 'Risk Factors', 'Prevalence'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 23:32'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 23:32 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3760/cma.j.cn112142-20220804-00379 [doi]'], 'PST': 'ppublish', 'SO': 'Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):321-325. doi: 10.3760/cma.j.cn112142-20220804-00379.'}, {'PMID': '37012592', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '0412-4081 (Print) 0412-4081 (Linking)', 'VI': '59', 'IP': '4', 'DP': '2023 Apr 11', 'TI': '[Femtosecond laser-assisted minimally invasive lamellar keratoplasty for advanced keratoconus].', 'PG': '288-294', 'LID': '10.3760/cma.j.cn112142-20220517-00249 [doi]', 'AB': 'Objective: To evaluate the initial safety and efficacy of femtosecond laser-assisted minimally invasive lamellar keratoplasty (FL-MILK) for advanced keratoconus. Methods: It was a case series study. Patients with advanced keratoconus who underwent FL-MILK between August 2017 and April 2020 at Shandong Eye Hospital were prospectively included. The femtosecond laser was used to create an intrastromal pocket in the recipient cornea and a lamellar cornea in the donor. The lamellar cornea was then gently inserted into the intrastromal pocket through the incision and flattened. Clinical measurements included best-corrected visual acuity, 3-mm anterior corneal mean keratometry, anterior and posterior central corneal elevation, central corneal thickness, corneal biomechanics, and endothelial cell density. The follow-up was conducted at 1 month, 12 months, and 24 months after the operation. Results: There were 33 patients (35 eyes) in the study. Twenty-six patients were male and 7 patients were female. The mean age was (20.34+/-5.24) years old. All patients completed 12 months of follow-up, and 25 patients (27 eyes) completed 24 months of follow-up. No epithelial ingrowth, infection, or allogeneic rejection was observed. Compared with the preoperative data, the anterior central corneal elevation significantly decreased (P<0.001), the mean keratometry significantly decreased (P<0.05), and the central corneal thickness significantly increased (P<0.001). The corneal biomechanical strength was significantly improved, with the deformation amplitude ratio at 2.0 mm decreasing from 1.39+/-0.14 preoperatively to 1.21+/-0.10 at 24 months postoperatively (P<0.001) and the stiffness parameter at the first applanation increasing from 41.49+/-11.47 preoperatively to 88.41+/-18.17 at 24 months postoperatively (P<0.001). There were no significant changes in the mean best-corrected visual acuity, posterior corneal elevation, mean spherical equivalent, and endothelial cell density (all P>0.05). Conclusions: FL-MILK may be a feasible option for advanced keratoconus. This procedure may provide a new resolution for keratoconus.', 'FAU': ['Liu, M N', 'Li, N', 'Tian, G', 'Chen, T', 'Lin, Y', 'Li, S X', 'Qi, X L', 'Shi, W Y', 'Gao, H'], 'AU': ['Liu MN', 'Li N', 'Tian G', 'Chen T', 'Lin Y', 'Li SX', 'Qi XL', 'Shi WY', 'Gao H'], 'AD': ['Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.'], 'LA': ['chi'], 'GR': ['82070923, 81870639/National Natural Science Foundation of China/', '2022CXGC010505/Shandong Provincial Key Research and Development Program (Major', 'Scientific and Technological Innovation Project)/', '201812150, 20150215/Taishan Scholar Program/', 'ZR2020MH171/Shandong Provincial Natural Science Foundation of China/', '2019RC009/Academic Promotion Programme of Shandong First Medical University/'], 'PT': ['English Abstract', 'Journal Article'], 'PL': 'China', 'TA': 'Zhonghua Yan Ke Za Zhi', 'JT': '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', 'JID': '16210540R', 'SB': 'IM', 'MH': ['Humans', 'Male', 'Female', 'Adolescent', 'Young Adult', 'Adult', '*Keratoconus/surgery', 'Visual Acuity', '*Corneal Transplantation', 'Refraction, Ocular', 'Lasers', 'Corneal Topography', 'Follow-Up Studies'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 23:32'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 23:32 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3760/cma.j.cn112142-20220517-00249 [doi]'], 'PST': 'ppublish', 'SO': 'Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):288-294. doi: 10.3760/cma.j.cn112142-20220517-00249.'}, {'PMID': '37012591', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '0412-4081 (Print) 0412-4081 (Linking)', 'VI': '59', 'IP': '4', 'DP': '2023 Apr 11', 'TI': '[Analysis of clinical manifestations and imaging characteristics of in vivo confocal microscopy for Nocardia keratitis].', 'PG': '279-287', 'LID': '10.3760/cma.j.cn112142-20221001-00480 [doi]', 'AB': 'Objective: To analyze the clinical manifestations and imaging characteristics of in vivo confocal microscopy (IVCM) for Nocardia keratitis. Methods: It was a retrospective case series study. Medical records of 16 consecutive patients (16 eyes) with Nocardia keratitis were collected from the Department of Ophthalmology at Beijing Tongren Hospital, Capital Medical University between 2018 and 2022. The group consisted of 11 males and 5 females. The inclusion criteria for the study were the presence of typical clinical manifestations of Nocardia keratitis and at least one positive pathogenic test (corneal scraping or microbial culture) indicating Nocardia infection. The medical history, clinical and microbiological examination data of the patients were analyzed, including risk factors, diagnosis time, clinical manifestations, diagnostic methods, strain isolation, cure time, and best corrected visual acuity before and after treatment. This study utilized techniques such as slit lamp microscopy, in vivo confocal microscopy (IVCM), scraping cytology, microbial culture, and mass spectrometry identification. Results: The main risk factors for Nocardia keratitis included plant or foreign body injuries (5 out of 16 cases), contact lens use (4 out of 16 cases), and surgery (2 out of 16 cases). The average time to diagnosis was (20.8+/-11.8) days, with the shortest time being 8 days and the longest being 60 days. The best corrected visual acuity was less than 0.05 in 7 patients, between 0.05 to 0.3 in 7 patients, and greater than or equal to 0.3 in 2 patients. The typical symptoms included superficial gray-white infiltration in a wreath-like pattern on the cornea, corneal ulcers with dry and gray-white necrotic tissue coverage, and in severe cases, corneal ulcer perforation. Nocardia corneal infection was identified in 12 out of 16 cases by scraping cytology, 9 out of 16 cases by mass spectrometry, and 8 out of 16 cases by both methods. IVCM showed the presence of fine and moderately reflective filamentous hyphae in the subepithelial and superficial stromal layer of the cornea, arranged in elongated, beaded, and branched structures. Infiltration of many hyper-reflective round inflammatory cells was also seen around the hyphae. Fourteen cases were treated with medication and 2 cases were treated with corneal transplantation. The average cure time was (37.5+/-25.2) days and there were no cases of recurrence during the follow-up period (all greater than 6 months). Conclusions: Nocardia keratitis is primarily characterized by dense, round, or wreath-like infiltration in the early stage, and by gray-white dry necrotic secretion and hypopyon on the surface of corneal ulcers in the middle and late stages. Fine, branched or beaded, and moderately reflective filamentous structures are the hallmark of the corneal lesion on the IVCM images.', 'FAU': ['Guo, X Y', 'Wang, Z Q', 'Chen, K X', 'Zhang, Y', 'Wei, Z Y', 'Liang, Q F'], 'AU': ['Guo XY', 'Wang ZQ', 'Chen KX', 'Zhang Y', 'Wei ZY', 'Liang QF'], 'AD': ['Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.', 'Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.', 'Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.', 'Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.', 'Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.', 'Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing 100730, China.'], 'LA': ['chi'], 'GR': ['81470607/National Natural Science Foundation of China/', 'BHTR-KFJJ-202003/Open Research Fund from Beijing Advanced Innovation Center for', 'Big Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang University &', 'Capital Medical University/'], 'PT': ['English Abstract', 'Journal Article'], 'PL': 'China', 'TA': 'Zhonghua Yan Ke Za Zhi', 'JT': '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', 'JID': '16210540R', 'SB': 'IM', 'MH': ['Male', 'Female', 'Humans', '*Nocardia', 'Retrospective Studies', 'Ulcer', '*Keratitis/microbiology', '*Corneal Ulcer', 'Cornea', 'Microscopy, Confocal/methods'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 23:32'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 23:32 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3760/cma.j.cn112142-20221001-00480 [doi]'], 'PST': 'ppublish', 'SO': 'Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):279-287. doi: 10.3760/cma.j.cn112142-20221001-00480.'}, {'PMID': '37012589', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '0412-4081 (Print) 0412-4081 (Linking)', 'VI': '59', 'IP': '4', 'DP': '2023 Apr 11', 'TI': '[A multicenter clinical trial of collar-button type keratoprosthesis implantation for the treatment of corneal blindness in high-risk transplantation].', 'PG': '262-271', 'LID': '10.3760/cma.j.cn112142-20221103-00565 [doi]', 'AB': 'Objective: To evaluate the efficiency and safety of collar-button type keratoprosthesis (c-bKPro) implantation for corneal blindness in high-risk transplantation in China. Methods: It was a case series study. High-risk corneal blind patients who planned to undergo c-bKPro implantation were prospectively and continuously enrolled in the Eye Hospital of Shandong First Medical University, Ophthalmology Division of Chinese PLA General Hospital, Zhongshan Ophthalmic Center, Department of Ophthalmology in Eye & ENT Hospital of Fudan University, and Eye Hospital of Wenzhou Medical University from July 2019 to January 2020. The cure for blindness and surgical success were assessed based on visual acuity (VA)>/=0.05. The complications and keratoprosthesis retention rate were recorded to determine the safety of the surgery. Results: Thirty-seven subjects (eyes) were included, of which 32 were male and 5 were female, aged 27 to 72 years old. The indications of c-bKPro implantation were corneal graft failure (21 eyes, 56.8%), chemical injury (8 eyes, 21.6%), thermal burn (5 eyes, 13.5%), unexplained corneal opacity (2 eyes, 5.4%), and corneal perforation (1 eye, 2.7%). Two patients withdrew from the clinical trial at 3 months postoperatively. Thirty-five patients were followed up for 6 months, and 31 were followed up for 12 months. The VA was >/=0.05 in 83.8% of eyes at 6 months and in 81.8% of eyes at 12 months. Among the 11 eyes diagnosed with concurrent glaucoma, 6 eyes achieved a VA of >/=0.05. At 12 months, the c-bKPro retention rate was 100%. The surgical complications included retroprosthetic membrane formation (5 eyes, 16.1%), persistent corneal epithelial defects (5 eyes, 16.1%), macular edema (4 eyes, 12.9%), new-onset glaucoma (4 eyes, 12.5%; including one eye withdrawn from the study at 3 months), sterile corneal melting (2 eyes, 6.5%), sterile vitritis (1 eye, 3.2%), and infectious keratitis (1 eye, 3.2%). Conclusions: C-bKPro implantation is an effective and safe option for treating corneal blindness in high-risk transplantation in China. Improved visual outcomes could be achieved in most cases, with a relatively low incidence of postoperative complications.', 'FAU': ['Zhang, T', 'Wang, L L', 'Gu, J J', 'Xu, J J', 'Chen, W', 'Huang, Y F', 'Hong, J X', 'Wang, T', 'Li, S X', 'Gao, H', 'Wang, J T', 'Shi, W Y'], 'AU': ['Zhang T', 'Wang LL', 'Gu JJ', 'Xu JJ', 'Chen W', 'Huang YF', 'Hong JX', 'Wang T', 'Li SX', 'Gao H', 'Wang JT', 'Shi WY'], 'AD': ['Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Ophthalmology Division of Chinese PLA General Hospital, Beijing 100853, China.', 'Zhongshan Ophthalmic Center, Sun Yat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China.', 'Department of Ophthalmology, Eye & ENT Hospital of Fudan University, NHC Key Laboratory of Myopia, Key Laboratory of Myopia, Chinese Academy of Medical Science, Shanghai 200031, China.', 'Eye Hospital of Wenzhou Medical University, National Clinical Research Center for Ocular Diseases, Wenzhou 325027, China.', 'Ophthalmology Division of Chinese PLA General Hospital, Beijing 100853, China.', 'Department of Ophthalmology, Eye & ENT Hospital of Fudan University, NHC Key Laboratory of Myopia, Key Laboratory of Myopia, Chinese Academy of Medical Science, Shanghai 200031, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.', 'Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China.'], 'LA': ['chi'], 'GR': ['2022CXGC010505/Shandong Provincial Key Research and Development Program (Major', 'scientific and technological innovation project)/', 'tspd20221110, tsqn201812150/Taishan Scholar Program/'], 'PT': ['English Abstract', 'Journal Article', 'Multicenter Study'], 'PL': 'China', 'TA': 'Zhonghua Yan Ke Za Zhi', 'JT': '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', 'JID': '16210540R', 'SB': 'IM', 'MH': ['Humans', 'Male', 'Female', 'Adult', 'Middle Aged', 'Aged', 'Cornea/surgery', '*Corneal Diseases/surgery', 'Prostheses and Implants', '*Glaucoma/surgery', 'Prosthesis Implantation', 'Blindness', 'Postoperative Complications/surgery', '*Corneal Perforation/surgery', 'Retrospective Studies', '*Artificial Organs'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 23:32'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 23:32 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3760/cma.j.cn112142-20221103-00565 [doi]'], 'PST': 'ppublish', 'SO': 'Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):262-271. doi: 10.3760/cma.j.cn112142-20221103-00565.'}, {'PMID': '37012588', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '0412-4081 (Print) 0412-4081 (Linking)', 'VI': '59', 'IP': '4', 'DP': '2023 Apr 11', 'TI': '[Chinese expert consensus on meibomian gland dysfunction: definition and classification (2023)].', 'PG': '256-261', 'LID': '10.3760/cma.j.cn112142-20230114-00023 [doi]', 'AB': 'Meibomian gland dysfunction (MGD) is a common clinical ocular surface disease. In recent years, great progress has been made in basic and clinical research on MGD, and new diagnostic and therapeutic methods have been continuously applied to clinical practice. To improve the understanding of MGD among Chinese ophthalmologists and standardize the diagnosis and treatment of MGD, the Chinese Branch of the Asia Dry Eye Society and relevant academic groups organized experts to discuss the definition and classification of MGD based on recent research progress and clinical experience at home and abroad, forming consensus opinions for the reference of clinicians.', 'CN': ['Chinese Branch of the Asian Dry Eye Society', 'Ocular Surface and Tear Film Diseases Group of Ophthalmology Committee of', 'Cross-Straits Medicine Exchange Association', 'Ocular Surface and Dry Eye Group of Chinese Ophthalmologist Association'], 'LA': ['chi'], 'PT': ['English Abstract', 'Journal Article'], 'PL': 'China', 'TA': 'Zhonghua Yan Ke Za Zhi', 'JT': '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', 'JID': '16210540R', 'SB': 'IM', 'MH': ['Humans', '*Meibomian Gland Dysfunction', 'Meibomian Glands', '*Eyelid Diseases/diagnosis/therapy', 'Consensus', 'East Asian People', '*Dry Eye Syndromes/diagnosis/therapy', 'Tears'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 23:32'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 23:32 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3760/cma.j.cn112142-20230114-00023 [doi]'], 'PST': 'ppublish', 'SO': 'Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):256-261. doi: 10.3760/cma.j.cn112142-20230114-00023.'}, {'PMID': '37012587', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '0412-4081 (Print) 0412-4081 (Linking)', 'VI': '59', 'IP': '4', 'DP': '2023 Apr 11', 'TI': '[Chinese expert consensus on the diagnosis and treatment of drug-induced keratopathy (2023)].', 'PG': '250-255', 'LID': '10.3760/cma.j.cn112142-20220829-00418 [doi]', 'AB': 'Drug-induced keratopathy occurs when the use of certain drugs, particularly ophthalmic preparations, causes pathological changes in the cornea. These changes can be related to the toxic effects of the drugs themselves or drug preservatives. The disease is characterized by a range of clinical features and lacks specific diagnostic criteria, which can lead to misdiagnosis and inappropriate treatment. In order to address these challenges, the Cornea Group of the Ophthalmology Branch of the Chinese Medical Association has brought together leading experts in the field to review key techniques for the diagnosis and treatment of drug-induced keratopathy. As a result, they have developed this consensus to guide the prevention and treatment of this condition.', 'CN': ['Cornea Group of Ophthalmology Branch of Chinese Medical Association'], 'LA': ['chi'], 'GR': ['82271052, U20A20386/National Natural Science Foundation of China/', '2022CXGC010505/Shandong Provincial Key Research and Development Program/', 'tsqn201909188/Young Taishan Scholars/'], 'PT': ['English Abstract', 'Journal Article'], 'PL': 'China', 'TA': 'Zhonghua Yan Ke Za Zhi', 'JT': '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', 'JID': '16210540R', 'SB': 'IM', 'MH': ['Humans', 'Consensus', '*Corneal Diseases/chemically induced/diagnosis/therapy', 'Cornea'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 23:32'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 23:32 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3760/cma.j.cn112142-20220829-00418 [doi]'], 'PST': 'ppublish', 'SO': 'Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):250-255. doi: 10.3760/cma.j.cn112142-20220829-00418.'}, {'PMID': '37012586', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '0412-4081 (Print) 0412-4081 (Linking)', 'VI': '59', 'IP': '4', 'DP': '2023 Apr 11', 'TI': '[Challenges and countermeasures in the development of artificial intelligence research in ophthalmology].', 'PG': '245-249', 'LID': '10.3760/cma.j.cn112142-20230221-00061 [doi]', 'AB': 'The advent of artificial intelligence (AI) technology has led to revolutionary advancements in the diagnosis and treatment of ophthalmic diseases, introducing a novel AI-assisted diagnostic approach for ophthalmology that is rich in imaging diagnostic technologies. However, as clinical applications continue to evolve, AI research in ophthalmology faces challenges such as the lack of standardized datasets and innovative algorithm models, insufficient cross-modal information fusion, and limited clinical interpretability. In response to the growing demand for AI research in ophthalmology, it is essential to establish ophthalmic data standards and sharing platforms, innovate core algorithms, and develop clinical logic interpretable models for the screening, diagnosis, and prediction of eye diseases. Additionally, the deep integration of cutting-edge technologies such as 5G, virtual reality, and surgical robots would advance the development of ophthalmic intelligent medicine into a new phase.', 'FAU': ['Yuan, J', 'Xiao, P'], 'AU': ['Yuan J', 'Xiao P'], 'AD': ['Zhongshan Ophthalmic Center, SunYat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China.', 'Zhongshan Ophthalmic Center, SunYat-sen University, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China.'], 'LA': ['chi'], 'GR': ['82230033, 82271133/National Natural Science Foundation of China/', '2021TX06Y127, 2021TQ06Y137/Guangdong Province Department of Science and', 'Technology Fund Project/'], 'PT': ['English Abstract', 'Journal Article'], 'PL': 'China', 'TA': 'Zhonghua Yan Ke Za Zhi', 'JT': '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', 'JID': '16210540R', 'SB': 'IM', 'MH': ['Humans', 'Artificial Intelligence', '*Ophthalmology/methods', 'Algorithms', '*Eye Diseases/diagnosis'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 23:32'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 23:32 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3760/cma.j.cn112142-20230221-00061 [doi]'], 'PST': 'ppublish', 'SO': 'Zhonghua Yan Ke Za Zhi. 2023 Apr 11;59(4):245-249. doi: 10.3760/cma.j.cn112142-20230221-00061.'}, {'PMID': '37012508', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230403', 'IS': '1748-3395 (Electronic) 1748-3387 (Linking)', 'DP': '2023 Apr 3', 'TI': 'Ectopic expression of a mechanosensitive channel confers spatiotemporal resolution to ultrasound stimulations of neurons for visual restoration.', 'LID': '10.1038/s41565-023-01359-6 [doi]', 'AB': 'Remote and precisely controlled activation of the brain is a fundamental challenge in the development of brain-machine interfaces for neurological treatments. Low-frequency ultrasound stimulation can be used to modulate neuronal activity deep in the brain, especially after expressing ultrasound-sensitive proteins. But so far, no study has described an ultrasound-mediated activation strategy whose spatiotemporal resolution and acoustic intensity are compatible with the mandatory needs of brain-machine interfaces, particularly for visual restoration. Here we combined the expression of large-conductance mechanosensitive ion channels with uncustomary high-frequency ultrasonic stimulation to activate retinal or cortical neurons over millisecond durations at a spatiotemporal resolution and acoustic energy deposit compatible with vision restoration. The in vivo sonogenetic activation of the visual cortex generated a behaviour associated with light perception. Our findings demonstrate that sonogenetics can deliver millisecond pattern presentations via an approach less invasive than current brain-machine interfaces for visual restoration.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Cadoni, Sara', 'Demene, Charlie', 'Alcala, Ignacio', 'Provansal, Matthieu', 'Nguyen, Diep', 'Nelidova, Dasha', 'Labernede, Guillaume', 'Lubetzki, Jules', 'Goulet, Ruben', 'Burban, Emma', 'Degardin, Julie', 'Simonutti, Manuel', 'Gauvain, Gregory', 'Arcizet, Fabrice', 'Marre, Olivier', 'Dalkara, Deniz', 'Roska, Botond', 'Sahel, Jose Alain', 'Tanter, Mickael', 'Picaud, Serge'], 'AU': ['Cadoni S', 'Demene C', 'Alcala I', 'Provansal M', 'Nguyen D', 'Nelidova D', 'Labernede G', 'Lubetzki J', 'Goulet R', 'Burban E', 'Degardin J', 'Simonutti M', 'Gauvain G', 'Arcizet F', 'Marre O', 'Dalkara D', 'Roska B', 'Sahel JA', 'Tanter M', 'Picaud S'], 'AD': ['Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Physics for Medicine Paris, INSERM, CNRS, Ecole Superieure de Physique et de Chimie Industrielles (ESPCI Paris), Paris Sciences et Lettres (PSL) Research University, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France.', 'Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.', 'Department of Ophthalmology and Vitreo-Retinal Diseases, Fondation Ophtalmologique Rothschild, Paris, France.', \"Centre Hospitalier National d'Ophtalmologie des XV-XX, Paris, France.\", 'Physics for Medicine Paris, INSERM, CNRS, Ecole Superieure de Physique et de Chimie Industrielles (ESPCI Paris), Paris Sciences et Lettres (PSL) Research University, Paris, France.', 'Sorbonne Universite, INSERM, CNRS, Institut de la Vision, Paris, France. serge.picaud@inserm.fr.'], 'AUID': ['ORCID: 0000-0002-5329-700X', 'ORCID: 0000-0002-6784-4553', 'ORCID: 0000-0002-4260-238X', 'ORCID: 0000-0002-8345-9639', 'ORCID: 0000-0002-4831-1153', 'ORCID: 0000-0002-0548-5145'], 'LA': ['eng'], 'GR': ['ERC Grant Agreement #610110/EC | EC Seventh Framework Programm | FP7 Ideas:', 'European Research Council (FP7-IDEAS-ERC - Specific Programme: \"Ideas\"', 'Implementing the Seventh Framework Programme of the European Community for', 'Research, Technological Development and Demonstration Activities (2007 to 2013))/', 'ERC Grant Agreement #610110/EC | EC Seventh Framework Programm | FP7 Ideas:', 'European Research Council (FP7-IDEAS-ERC - Specific Programme: \"Ideas\"', 'Implementing the Seventh Framework Programme of the European Community for', 'Research, Technological Development and Demonstration Activities (2007 to 2013))/', 'ERC Grant Agreement #610110/EC | EC Seventh Framework Programm | FP7 Ideas:', 'European Research Council (FP7-IDEAS-ERC - Specific Programme: \"Ideas\"', 'Implementing the Seventh Framework Programme of the European Community for', 'Research, Technological Development and Demonstration Activities (2007 to 2013))/', 'FRM EQUIPE EQU202106012159/Fondation pour la Recherche Medicale (Foundation for', 'Medical Research in France)/', 'ANR-18-IAHU-0001/Agence Nationale de la Recherche (French National Research', 'Agency)/', 'ANR-10-LABX-0065/Agence Nationale de la Recherche (French National Research', 'Agency)/', 'ANR BrainOptoSight/Agence Nationale de la Recherche (French National Research', 'Agency)/', '785219 (Graphene Flagship Core 2)/EC | Horizon 2020 Framework Programme (EU', 'Framework Programme for Research and Innovation H2020)/', 'No. 881603 (Graphene flagship Core3)/EC | Horizon 2020 Framework Programme (EU', 'Framework Programme for Research and Innovation H2020)/'], 'PT': ['Journal Article'], 'DEP': '20230403', 'PL': 'England', 'TA': 'Nat Nanotechnol', 'JT': 'Nature nanotechnology', 'JID': '101283273', 'SB': 'IM', 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:00', 'CRDT': ['2023/04/03 23:29'], 'PHST': ['2021/12/12 00:00 [received]', '2023/02/13 00:00 [accepted]', '2023/04/03 23:29 [entrez]', '2023/04/04 06:00 [pubmed]', '2023/04/04 06:00 [medline]'], 'AID': ['10.1038/s41565-023-01359-6 [pii]', '10.1038/s41565-023-01359-6 [doi]'], 'PST': 'aheadofprint', 'SO': 'Nat Nanotechnol. 2023 Apr 3. doi: 10.1038/s41565-023-01359-6.'}, {'PMID': '37012014', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230408', 'IS': '2044-6055 (Electronic) 2044-6055 (Linking)', 'VI': '13', 'IP': '4', 'DP': '2023 Apr 3', 'TI': 'Diabetic retinopathy progression in patients under monitoring for treatment or vision loss: external validation and update of a multivariable prediction model.', 'PG': 'e073015', 'LID': '10.1136/bmjopen-2023-073015 [doi]', 'AB': 'INTRODUCTION: The number of people with diabetes mellitus is increasing globally and consequently so too is diabetic retinopathy (DR). Most patients with diabetes are monitored through the diabetic eye screening programme (DESP) until they have signs of retinopathy and these changes progress, requiring referral into hospital eye services (HES). Here, they continue to be monitored until they require treatment. Due to current pressures on HES, delays can occur, leading to harm. There is a need to triage patients based on their individual risk. At present, patients are stratified according to retinopathy stage alone, yet other risk factors like glycated haemoglobin (HbA1c) may be useful. Therefore, a prediction model that combines multiple prognostic factors to predict progression will be useful for triage in this setting to improve care.We previously developed a Diabetic Retinopathy Progression model to Treatment or Vision Loss (DRPTVL-UK) using a large primary care database. The aim of the present study is to externally validate the DRPTVL-UK model in a secondary care setting, specifically in a population under care by HES. This study will also provide an opportunity to update the model by considering additional predictors not previously available. METHODS AND ANALYSIS: We will use a retrospective cohort of 2400 patients with diabetes aged 12 years and over, referred from DESP to the NHS hospital trusts with referable DR between 2013 and 2016, with follow-up information recorded until December 2021.We will evaluate the external validity of the DRPTVL-UK model using measures of discrimination, calibration and net benefit. In addition, consensus meetings will be held to agree on acceptable risk thresholds for triage within the HES system. ETHICS AND DISSEMINATION: This study was approved by REC (ref 22/SC/0425, 05/12/2022, Hampshire A Research Ethics Committee). The results of the study will be published in a peer-reviewed journal, presented at clinical conferences. TRIAL REGISTRATION NUMBER: ISRCTN 10956293.', 'CI': ['(c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published', 'by BMJ.'], 'FAU': ['Haider, Sajjad', 'Adderley, Nicola', 'Tallouzi, Mohammad O', 'Sadiq, Salman Naveed', 'Steel, David H', 'Chavan, Randhir', 'Sheikh, Ijaz', 'Nirantharakumar, Krishnarajah', 'Snell, Kym I E'], 'AU': ['Haider S', 'Adderley N', 'Tallouzi MO', 'Sadiq SN', 'Steel DH', 'Chavan R', 'Sheikh I', 'Nirantharakumar K', 'Snell KIE'], 'AUID': ['ORCID: 0000-0001-8111-8577', 'ORCID: 0000-0003-0543-3254', 'ORCID: 0000-0002-6816-1279'], 'AD': ['Institute of Applied Health Research, University of Birmingham, Birmingham, UK S.Haider.2@bham.ac.uk.', 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.', 'Birmingham and Midland Eye Centre, Birmingham, UK.', 'Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.', 'Sunderland Eye Infirmary, Sunderland, UK.', 'Sunderland Eye Infirmary, Sunderland, UK.', 'Newcastle University Biosciences Institute, Newcastle upon Tyne, UK.', 'Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.', 'Eye Department, Surrey and Sussex Healthcare NHS Trust, Redhill, UK.', 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.', 'Centre for Prognosis Research, School of Medicine, Keele University, Keele, UK.'], 'LA': ['eng'], 'SI': ['ISRCTN/ISRCTN10956293'], 'PT': ['Journal Article', \"Research Support, Non-U.S. Gov't\"], 'DEP': '20230403', 'PL': 'England', 'TA': 'BMJ Open', 'JT': 'BMJ open', 'JID': '101552874', 'RN': ['0 (Glycated Hemoglobin)'], 'SB': 'IM', 'MH': ['Humans', '*Diabetic Retinopathy/diagnosis/therapy/epidemiology', 'Retrospective Studies', 'Vision Disorders', 'Risk Factors', 'Glycated Hemoglobin', '*Diabetes Mellitus'], 'OTO': ['NOTNLM'], 'OT': ['DIABETES & ENDOCRINOLOGY', 'Diabetic retinopathy', 'Medical retina', 'Ophthalmology'], 'COIS': ['Competing interests: None declared.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 21:12'], 'PHST': ['2023/04/05 06:42 [medline]', '2023/04/03 21:12 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['bmjopen-2023-073015 [pii]', '10.1136/bmjopen-2023-073015 [doi]'], 'PST': 'epublish', 'SO': 'BMJ Open. 2023 Apr 3;13(4):e073015. doi: 10.1136/bmjopen-2023-073015.'}, {'PMID': '37011101', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230406', 'IS': '1932-6203 (Electronic) 1932-6203 (Linking)', 'VI': '18', 'IP': '4', 'DP': '2023', 'TI': 'Risk factors for recurrences and visual impairment in patients with ocular toxoplasmosis: A systematic review and meta-analysis.', 'PG': 'e0283845', 'LID': '10.1371/journal.pone.0283845 [doi] e0283845', 'AB': 'BACKGROUND: Ocular toxoplasmosis (OT) is caused by the parasite Toxoplasma gondii. OT is the leading cause of posterior uveitis globally; it is a recurrent disease that may result in visual impairment and blindness. This systematic review and meta-analysis aim to summarize and evaluate the risk factors for recurrences, visual impairment, and blindness described in the literature worldwide. METHODS AND FINDINGS: We performed a systematic literature search in PubMed, Embase, VHL, Cochrane Library, Scopus, and DANS EASY Archive. All studies reporting patients with clinically and serologically confirmed OT presenting any clinical or paraclinical factor influencing recurrences, visual impairment, and blindness were included. Studies presenting secondary data, case reports, and case series were excluded. An initial selection was made by title and abstract, and then the studies were reviewed by full text where the eligible studies were selected. Then, the risk of bias was assessed through validated tools. Data were extracted using a validated extraction format. Qualitative synthesis and quantitative analysis were done. This study was registered on PROSPERO (CRD42022327836). RESULTS: Seventy two studies met the inclusion criteria. Fifty-three were summarized in the qualitative synthesis in three sections: clinical and environmental factors, parasite and host factors, and treatment-related factors. Of the 72 articles, 39 were included in the meta-analysis, of which 14 were conducted in South America, 13 in Europe, four in Asia, three multinational, two in North America and Central America, respectively, and only one in Africa. A total of 4,200 patients with OT were analyzed, mean age ranged from 7.3 to 65.1 year of age, with similar distribution by sex. The frequency of recurrences in patients with OT was 49% (95% CI 40%-58%), being more frequent in the South American population than in Europeans. Additionally, visual impairment was presented in 35% (95% CI 25%-48%) and blindness in 20% (95% CI 13%-30%) of eyes, with a similar predominance in South Americans than in Europeans. On the other hand, having lesions near the macula or adjacent to the optic nerve had an OR of 4.83 (95% CI; 2.72-8.59) for blindness, similar to having more than one recurrence that had an OR of 3.18 (95% CI; 1.59-6.38). Finally, the prophylactic therapy with Trimethoprim/Sulfamethoxazole versus the placebo showed a protective factor of 83% during the first year and 87% in the second year after treatment. CONCLUSION: Our Systematic Review showed that clinical factors such as being older than 40 years, patients with de novo OT lesions or with less than one year after the first episode, macular area involvement, lesions greater than 1 disc diameter, congenital toxoplasmosis, and bilateral compromise had more risk of recurrences. Also, environmental and parasite factors such as precipitations, geographical region where the infection is acquired, and more virulent strains confer greater risk of recurrences. Therefore, patients with the above mentioned clinical, environmental, and parasite factors could benefit from using prophylactic therapy.', 'CI': ['Copyright: (c) 2023 Cifuentes-Gonzalez et al. This is an open access article', 'distributed under the terms of the Creative Commons Attribution License, which', 'permits unrestricted use, distribution, and reproduction in any medium, provided', 'the original author and source are credited.'], 'FAU': ['Cifuentes-Gonzalez, Carlos', 'Rojas-Carabali, William', 'Perez, Alvaro Olate', 'Carvalho, Erika', 'Valenzuela, Felipe', 'Miguel-Escuder, Lucia', 'Ormaechea, Maria Soledad', 'Heredia, Milagros', 'Baquero-Ospina, Pablo', 'Adan, Alfredo', 'Curi, Andre', 'Schlaen, Ariel', 'Urzua, Cristhian Alejandro', 'Couto, Cristobal', 'Arellanes, Lourdes', 'de-la-Torre, Alejandra'], 'AU': ['Cifuentes-Gonzalez C', 'Rojas-Carabali W', 'Perez AO', 'Carvalho E', 'Valenzuela F', 'Miguel-Escuder L', 'Ormaechea MS', 'Heredia M', 'Baquero-Ospina P', 'Adan A', 'Curi A', 'Schlaen A', 'Urzua CA', 'Couto C', 'Arellanes L', 'de-la-Torre A'], 'AD': ['Neuroscience (NEUROS) Research Group, Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogota, Colombia.', 'Neuroscience (NEUROS) Research Group, Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogota, Colombia.', 'Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.', 'Clinical Research Laboratory of Infectious Diseases in Ophthalmogy, National Institute of Infectious Disease, INI-Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.', 'Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.', 'Hospital Clinic of Barcelona, Clinic Institute of Ophthalmology, University of Barcelona, Barcelona, Spain.', 'Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.', 'Department of Ophthalmology, Hospital Universitario Austral, Buenos Aires, Argentina.', 'Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.', 'Department of Ophthalmology, Hospital Universitario Austral, Buenos Aires, Argentina.', 'Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes\" Hospital, Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico City, CDMX, Mexico.', 'Hospital Clinic of Barcelona, Clinic Institute of Ophthalmology, University of Barcelona, Barcelona, Spain.', 'Red de Investigacion en Inmunologia Ocular de Latinoamerica (RIOLAT).', 'Clinical Research Laboratory of Infectious Diseases in Ophthalmogy, National Institute of Infectious Disease, INI-Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.', 'Red de Investigacion en Inmunologia Ocular de Latinoamerica (RIOLAT).', 'Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.', 'Department of Ophthalmology, Hospital Universitario Austral, Buenos Aires, Argentina.', 'Red de Investigacion en Inmunologia Ocular de Latinoamerica (RIOLAT).', 'Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.', 'Red de Investigacion en Inmunologia Ocular de Latinoamerica (RIOLAT).', 'Faculty of Medicine, Clinica Alemana-Universidad del Desarrollo, Santiago, Chile.', 'Department of Ophthalmology, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires City, Argentina.', 'Red de Investigacion en Inmunologia Ocular de Latinoamerica (RIOLAT).', 'Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes\" Hospital, Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico City, CDMX, Mexico.', 'Red de Investigacion en Inmunologia Ocular de Latinoamerica (RIOLAT).', 'Neuroscience (NEUROS) Research Group, Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogota, Colombia.', 'Red de Investigacion en Inmunologia Ocular de Latinoamerica (RIOLAT).'], 'AUID': ['ORCID: 0000-0001-6934-6550', 'ORCID: 0000-0001-6262-9558', 'ORCID: 0000-0003-1202-8660', 'ORCID: 0000-0003-0684-1989'], 'LA': ['eng'], 'PT': ['Journal Article', 'Meta-Analysis', 'Systematic Review'], 'DEP': '20230403', 'PL': 'United States', 'TA': 'PLoS One', 'JT': 'PloS one', 'JID': '101285081', 'SB': 'IM', 'MH': ['Humans', '*Toxoplasmosis, Ocular/complications/epidemiology/drug therapy', 'Neoplasm Recurrence, Local', 'Blindness/complications', '*Vision, Low/complications', 'Risk Factors', 'Recurrence'], 'PMC': 'PMC10069780', 'COIS': ['The authors have declared that no competing interests exist.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'CRDT': ['2023/04/03 14:13'], 'PHST': ['2022/12/22 00:00 [received]', '2023/03/19 00:00 [accepted]', '2023/04/05 06:42 [medline]', '2023/04/03 14:13 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['PONE-D-22-34874 [pii]', '10.1371/journal.pone.0283845 [doi]'], 'PST': 'epublish', 'SO': 'PLoS One. 2023 Apr 3;18(4):e0283845. doi: 10.1371/journal.pone.0283845. eCollection 2023.'}, {'PMID': '37011100', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230403', 'IS': '1545-7885 (Electronic) 1544-9173 (Linking)', 'VI': '21', 'IP': '4', 'DP': '2023 Apr 3', 'TI': 'BDNF signaling in correlation-dependent structural plasticity in the developing visual system.', 'PG': 'e3002070', 'LID': '10.1371/journal.pbio.3002070 [doi]', 'AB': 'During development, patterned neural activity instructs topographic map refinement. Axons with similar patterns of neural activity converge onto target neurons and stabilize their synapses with these postsynaptic partners, restricting exploratory branch elaboration (Hebbian structural plasticity). On the other hand, non-correlated firing in inputs leads to synapse weakening and increased exploratory growth of axons (Stentian structural plasticity). We used visual stimulation to control the correlation structure of neural activity in a few ipsilaterally projecting (ipsi) retinal ganglion cell (RGC) axons with respect to the majority contralateral eye inputs in the optic tectum of albino Xenopus laevis tadpoles. Multiphoton live imaging of ipsi axons, combined with specific targeted disruptions of brain-derived neurotrophic factor (BDNF) signaling, revealed that both presynaptic p75NTR and TrkB are required for Stentian axonal branch addition, whereas presumptive postsynaptic BDNF signaling is necessary for Hebbian axon stabilization. Additionally, we found that BDNF signaling mediates local suppression of branch elimination in response to correlated firing of inputs. Daily in vivo imaging of contralateral RGC axons demonstrated that p75NTR knockdown reduces axon branch elongation and arbor spanning field volume.', 'CI': ['Copyright: (c) 2023 Kutsarova et al. This is an open access article distributed', 'under the terms of the Creative Commons Attribution License, which permits', 'unrestricted use, distribution, and reproduction in any medium, provided the', 'original author and source are credited.'], 'FAU': ['Kutsarova, Elena', 'Schohl, Anne', 'Munz, Martin', 'Wang, Alex', 'Zhang, Yuan Yuan', 'Bilash, Olesia M', 'Ruthazer, Edward S'], 'AU': ['Kutsarova E', 'Schohl A', 'Munz M', 'Wang A', 'Zhang YY', 'Bilash OM', 'Ruthazer ES'], 'AD': ['Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.', 'Max Planck Institute for Brain Research, Frankfurt, Germany.', 'Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.', 'Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.', 'Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.', 'Department of Ophthalmology, University of Basel, Basel, Switzerland.', 'Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.', 'Interdepartmental Neuroscience, Yale University, New Haven, Connecticut, United States of America.', 'Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.', 'Faculty of Medicine, University of Ottawa, Ottawa, Canada.', 'Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.', 'NYU Neuroscience Institute, New York University, New York, New York, United States of America.', 'Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada.'], 'AUID': ['ORCID: 0000-0003-0452-3151'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230403', 'PL': 'United States', 'TA': 'PLoS Biol', 'JT': 'PLoS biology', 'JID': '101183755', 'SB': 'IM', 'COIS': ['The authors have declared that no competing interests exist.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:00', 'CRDT': ['2023/04/03 14:13'], 'PHST': ['2022/06/13 00:00 [received]', '2023/03/08 00:00 [accepted]', '2023/04/03 14:13 [entrez]', '2023/04/04 06:00 [pubmed]', '2023/04/04 06:00 [medline]'], 'AID': ['PBIOLOGY-D-22-01311 [pii]', '10.1371/journal.pbio.3002070 [doi]'], 'PST': 'aheadofprint', 'SO': 'PLoS Biol. 2023 Apr 3;21(4):e3002070. doi: 10.1371/journal.pbio.3002070.'}, {'PMID': '37010901', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '1469-493X (Electronic) 1361-6137 (Linking)', 'VI': '4', 'IP': '4', 'DP': '2023 Apr 3', 'TI': 'Anti-vascular endothelial growth factor for neovascular glaucoma.', 'PG': 'CD007920', 'LID': '10.1002/14651858.CD007920.pub4 [doi] CD007920', 'AB': \"BACKGROUND: Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization. Studies have reported the effectiveness of anti-VEGF medications for the control of intraocular pressure (IOP) in NVG. OBJECTIVES: To assess the effectiveness of intraocular anti-VEGF medications, alone or with one or more types of conventional therapy, compared with no anti-VEGF medications for the treatment of NVG. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register); MEDLINE; Embase; PubMed; and LILACS to 19 October 2021; metaRegister of Controlled Trials to 19 October 2021; and two additional trial registers to 19 October 2021. We did not use any date or language restrictions in the electronic search for trials. SELECTION CRITERIA: We included randomized controlled trials (RCTs) of people treated with anti-VEGF medications for NVG. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed the search results for trials, extracted data, and assessed risk of bias, and the certainty of the evidence. We resolved discrepancies through discussion. MAIN RESULTS: We included five RCTs (356 eyes of 353 participants). Each trial was conducted in a different country: two in China, and one each in Brazil, Egypt, and Japan. All five RCTs included both men and women; the mean age of participants was 55 years or older. Two RCTs compared intravitreal bevacizumab combined with Ahmed valve implantation and panretinal photocoagulation (PRP) with Ahmed valve implantation and PRP alone. One RCT randomized participants to receive an injection of either intravitreal aflibercept or placebo at the first visit, followed by non-randomized treatment according to clinical findings after one week. The remaining two RCTs randomized participants to PRP with and without ranibizumab, one of which had insufficient details for further analysis. We assessed the RCTs to have an unclear risk of bias for most domains due to insufficient information to permit judgment.   Four RCTs examined achieving control of IOP, three of which reported our time points of interest. Only one RCT reported our critical time point at one month; it found that the anti-VEGF group had a 1.3-fold higher chance of achieving control of IOP at one month (RR 1.32, 95% 1.10 to 1.59; 93 participants) than the non-anti-VEGF group (low certainty of evidence). For other time points, one RCT found a three-fold greater achievement in control of IOP in the anti-VEGF group when compared with the non-anti-VEGF group at one year (RR 3.00; 95% CI:1.35 to 6.68; 40 participants). However, another RCT found an inconclusive result at the time period ranging from 1.5 years to three years (RR 1.08; 95% CI: 0.67 to 1.75; 40 participants).  All five RCTs examined mean IOP, but at different time points. Very-low-certainty evidence showed that anti-VEGFs were effective in reducing mean IOP by 6.37 mmHg (95% CI: -10.09 to -2.65; 3 RCTs; 173 participants) at four to six weeks when compared with no anti-VEGFs.  Anti-VEGFs may reduce mean IOP at three months (MD -4.25; 95% CI -12.05 to 3.54; 2 studies; 75 participants), six months (MD -5.93; 95% CI -18.13 to 6.26; 2 studies; 75 participants), one year (MD -5.36; 95% CI -18.50 to 7.77; 2 studies; 75 participants), and more than one year (MD -7.05; 95% CI -16.61 to 2.51; 2 studies; 75 participants) when compared with no anti-VEGFs, but such effects remain uncertain. Two RCTs reported the proportion of participants who achieved an improvement in visual acuity with specified time points. Participants receiving anti-VEGFs had a 2.6 times (95% CI 1.60 to 4.08; 1 study; 93 participants) higher chance of improving visual acuity when compared with those not receiving anti-VEGFs at one month (very low certainty of evidence). Likewise, another RCT found a similar result at 18 months (RR 4.00, 95% CI 1.33 to 12.05; 1 study; 40 participants).  Two RCTs reported the outcome, complete regression of new iris vessels, at our time points of interest. Low-certainty evidence showed that anti-VEGFs had a nearly three times higher chance of complete regression of new iris vessels when compared with no anti-VEGFs (RR 2.63, 95% CI 1.65 to 4.18; 1 study; 93 participants). A similar finding was observed at more than one year in another RCT (RR 3.20, 95% CI 1.45 to 7.05; 1 study; 40 participants).  Regarding adverse events, there was no evidence that the risks of hypotony and tractional retinal detachment were different between the two groups (RR 0.67; 95% CI: 0.12 to 3.57 and RR 0.33; 95% CI: 0.01 to 7.72, respectively; 1 study; 40 participants). No RCTs reported incidents of endophthalmitis, vitreous hemorrhage, no light perception, and serious adverse events. Evidence for the adverse events of anti-VEGFs was low due to limitations in the study design due to insufficient information to permit judgments and imprecision of results due to the small sample size. No trial reported the proportion of participants with relief of pain and resolution of redness at any time point. AUTHORS' CONCLUSIONS: Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short- and long-term effectiveness and safety of anti-VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.\", 'CI': ['Copyright (c) 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.'], 'FAU': ['Rittiphairoj, Thanitsara', 'Roberti, Gloria', 'Michelessi, Manuele'], 'AU': ['Rittiphairoj T', 'Roberti G', 'Michelessi M'], 'AD': ['Department of Ophthalmology, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA.', 'Division of Health Systems Management, Department of Community Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.', 'Ophthalmology, Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS, Rome, Italy.', 'Ophthalmology, Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS, Rome, Italy.'], 'LA': ['eng'], 'SI': ['ClinicalTrials.gov/NCT02396316', 'ClinicalTrials.gov/NCT02914626'], 'GR': ['UG1 EY020522/EY/NEI NIH HHS/United States'], 'PT': ['Journal Article', 'Research Support, N.I.H., Extramural', \"Research Support, Non-U.S. Gov't\", 'Review', 'Systematic Review'], 'DEP': '20230403', 'PL': 'England', 'TA': 'Cochrane Database Syst Rev', 'JT': 'The Cochrane database of systematic reviews', 'JID': '100909747', 'RN': ['0 (Vascular Endothelial Growth Factor A)', '0 (Endothelial Growth Factors)', 'ZL1R02VT79 (Ranibizumab)', '2S9ZZM9Q9V (Bevacizumab)'], 'SB': 'IM', 'UOF': ['Cochrane Database Syst Rev. 2020 Feb 6;2:CD007920. PMID: 32027392'], 'MH': ['Male', 'Female', 'Humans', 'Middle Aged', '*Vascular Endothelial Growth Factor A', 'Endothelial Growth Factors/therapeutic use', '*Glaucoma, Neovascular/drug therapy', 'Ranibizumab/therapeutic use', 'Bevacizumab/therapeutic use'], 'PMC': 'PMC10069372', 'COIS': ['Thanitsara Rittiphairoj: none known\\u2028Gloria Roberti: none known\\u2028Manuele', 'Michelessi: Allergan (talk at educational course), Santen (travel accomodation', 'for attending eductional course)'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/05 06:42', 'PMCR': ['2024/04/03'], 'CRDT': ['2023/04/03 11:53'], 'PHST': ['2024/04/03 00:00 [pmc-release]', '2023/04/05 06:42 [medline]', '2023/04/03 11:53 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['CD007920.pub4 [pii]', '10.1002/14651858.CD007920.pub4 [doi]'], 'PST': 'epublish', 'SO': 'Cochrane Database Syst Rev. 2023 Apr 3;4(4):CD007920. doi: 10.1002/14651858.CD007920.pub4.'}, {'PMID': '37010586', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230403', 'IS': '1432-1335 (Electronic) 0171-5216 (Linking)', 'DP': '2023 Apr 3', 'TI': 'An update in the applications of exosomes in cancer theranostics: from research to clinical trials.', 'LID': '10.1007/s00432-023-04701-6 [doi]', 'AB': 'Exosomes are nanosized extracellular vesicles secreted by nearly all viable cells following the fusing of multivesicular bodies and the plasma membrane and discharged into the encircling bodily fluids. Exosomes can transport cell-specific components from the source cell to the target cell. Given the enormous potential of exosomes as non-invasive diagnostic biomarkers and therapeutic nanovehicles. Lately, accumulated evidence has demonstrated that exosomes serve an important role in prognosis, diagnosis, and even treatment strategies. While several reviews have collective information on the biomedical application of exosomes, a comprehensive review incorporating updated and improved methodologies for beneficial applications of such vesicles in cancer theranostics is indispensable. In the current review, we first provided a comprehensive review of the introduction of exosomes, featuring their discovery, separation, characterization, function, biogenesis, secretion. The implications of exosomes as promising nanovehicles for drug and gene delivery, application of exosome inhibitors in the management of cancers, completed and ongoing clinical trials on the biological relevance of exosomes are then discussed in detail. As the field of exosome research grows, a better understanding of the subcellular parts and mechanisms involved in exosome secretion and targeting of specific cells will help figure out what their exact physiological functions are in the body.', 'CI': ['(c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany,', 'part of Springer Nature.'], 'FAU': ['Shahraki, Kourosh', 'Boroumand, Paria Ghasemi', 'Lotfi, Hajie', 'Radnia, Fatemeh', 'Shahriari, Hossein', 'Sargazi, Saman', 'Mortazavi, Sedigheh Sadat', 'Shirvaliloo, Milad', 'Shirvalilou, Sakine', 'Sheervalilou, Roghayeh'], 'AU': ['Shahraki K', 'Boroumand PG', 'Lotfi H', 'Radnia F', 'Shahriari H', 'Sargazi S', 'Mortazavi SS', 'Shirvaliloo M', 'Shirvalilou S', 'Sheervalilou R'], 'AD': ['Department of Ophthalmology, Alzahra Eye Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.', 'ENT-Head and Neck Surgery Research Center and Department, Rasool Akram Hospital, Iran University of Medical Science, Tehran, Iran.', 'Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.', 'Department of Medical Biotechnology, Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.', 'Department of Immunology, School of Medicine, Clinical Immunology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.', 'Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran.', 'Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.', 'Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.', 'Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK.', 'Finetech in Medicine Research Center, Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. shirvaliloo.s@tak.iums.ac.ir.', 'Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. sheervalilour@tbzmed.ac.ir.'], 'AUID': ['ORCID: 0000-0003-3213-8824', 'ORCID: 0000-0001-7996-845X'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230403', 'PL': 'Germany', 'TA': 'J Cancer Res Clin Oncol', 'JT': 'Journal of cancer research and clinical oncology', 'JID': '7902060', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Cancer', 'Exosomes', 'Theranostics'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:00', 'CRDT': ['2023/04/03 11:15'], 'PHST': ['2023/01/25 00:00 [received]', '2023/03/17 00:00 [accepted]', '2023/04/03 11:15 [entrez]', '2023/04/04 06:00 [pubmed]', '2023/04/04 06:00 [medline]'], 'AID': ['10.1007/s00432-023-04701-6 [pii]', '10.1007/s00432-023-04701-6 [doi]'], 'PST': 'aheadofprint', 'SO': 'J Cancer Res Clin Oncol. 2023 Apr 3. doi: 10.1007/s00432-023-04701-6.'}, {'PMID': '37009774', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230403', 'IS': '1460-2202 (Electronic) 0271-3683 (Linking)', 'DP': '2023 Apr 3', 'TI': 'Correlation Between Lens Density Measured by Swept-Source Optical Coherence Tomography and Phacodynamic Parameters of Centurion Phacoemulsification.', 'PG': '1-9', 'LID': '10.1080/02713683.2023.2192896 [doi]', 'AB': 'PURPOSE: To evaluate the correlation between lens density measured by IOL-Master 700 based on swept-source optical coherence tomography (SS-OCT) technology and the phacodynamic parameters of Centurion phacoemulsification in cataract surgery. METHODS: This prospective study included 66 patients (83 eyes) with age-related cataracts. Using the Lens Opacities Classification System III (LOCS III), the lens nuclear color (NC), lens nuclear opalescence (NO), cortical (C), and posterior subcapsular (P) opacities were obtained. Six meridian orientations of IOL-Master 700 images were captured, and the lens and nuclear regions were analyzed using ImageJ to generate the average lens nucleus density (AND) and average lens density (ALD). Phacodynamic parameters were recorded. The correlation between lens density and the phacodynamic parameters was analyzed. According to the AND, patients were divided into four groups (soft, medium-hard, hard, and extremely hard nucleus), and the phacodynamic parameters were compared among groups. RESULTS: The correlation between the AND obtained by LOCS III grading and SS-OCT-based cataract quantification system score (NC and NO) was statistically significant (r(NC) = 0.795, r(NO)=0.794, both p = .000). AND correlated significantly with cumulative dissipated energy (CDE, r = 0.545, p = .000), total ultrasound time (TUST, r = 0.354, p = .001), and total torsional ultrasound time (TTUT, r = 0.314, p = .004). Among the four groups divided by AND, the difference in CDE (P(13) = 0.002, P(14) < 0.001, P(24) = 0.002) was statistically significant. CONCLUSION: AND measured by IOL-Master 700, SS-OCT correlated significantly with LOCS III classification and phacodynamic parameters of the Centurion system, especially with CDE, TUST, and TTUT. AND can be used as an indicator for quantitative evaluation and help inform the surgical plan.', 'FAU': ['Wu, Xueer', 'Chen, Lulu', 'Li, Zhangliang', 'Zhao, Yun-E'], 'AU': ['Wu X', 'Chen L', 'Li Z', 'Zhao YE'], 'AD': ['Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.', 'National Clinical Research Center for Ocular Diseases, Wenzhou, Zhejiang, China.', 'Eye Hospital of Wenzhou Medical University Hangzhou Branch, Hangzhou, Zhejiang, China.', 'Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.', 'National Clinical Research Center for Ocular Diseases, Wenzhou, Zhejiang, China.', 'Xuchang Central Hospital, Xuchang, Henan, China.', 'Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.', 'National Clinical Research Center for Ocular Diseases, Wenzhou, Zhejiang, China.', 'Eye Hospital of Wenzhou Medical University Hangzhou Branch, Hangzhou, Zhejiang, China.', 'Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.', 'National Clinical Research Center for Ocular Diseases, Wenzhou, Zhejiang, China.', 'Eye Hospital of Wenzhou Medical University Hangzhou Branch, Hangzhou, Zhejiang, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230403', 'PL': 'England', 'TA': 'Curr Eye Res', 'JT': 'Current eye research', 'JID': '8104312', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Swept source-optical coherence tomography', 'cataracts', 'centurion vision system', 'lens nucleus density', 'phacodynamic parameters'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:00', 'CRDT': ['2023/04/03 05:23'], 'PHST': ['2023/04/03 05:23 [entrez]', '2023/04/04 06:00 [pubmed]', '2023/04/04 06:00 [medline]'], 'AID': ['10.1080/02713683.2023.2192896 [doi]'], 'PST': 'aheadofprint', 'SO': 'Curr Eye Res. 2023 Apr 3:1-9. doi: 10.1080/02713683.2023.2192896.'}, {'PMID': '37009541', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '6', 'IP': '6', 'DP': '2022 Nov-Dec', 'TI': 'Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection.', 'PG': '443-451', 'LID': '10.1177/24741264221116487 [doi]', 'AB': 'Although infectious endophthalmitis after intravitreal antivascular endothelial growth factor injections is rare, it is the most feared and potentially devastating complication of this procedure. There is no high-level evidence to provide definitive guidance on the management of endophthalmitis occurring after intravitreal injection (IVI). This clinical practice update reviews the published literature regarding post-IVI endophthalmitis and highlights areas in which further research is needed to better guide its management.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Merani, Rohan', 'Johnson, Mark W', 'McCannel, Colin A', 'Flynn, Harry W Jr', 'Scott, Ingrid U', 'Hunyor, Alex P'], 'AU': ['Merani R', 'Johnson MW', 'McCannel CA', 'Flynn HW Jr', 'Scott IU', 'Hunyor AP'], 'AD': ['Concord Repatriation General Hospital, Sydney, NSW, Australia.', 'Save Sight Institute, Specialty of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.', 'Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW Australia.', 'Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.', 'UCLA Stein Eye Institute; Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.', 'Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USA.', 'Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Philadelphia, PA, USA.', 'Save Sight Institute, Specialty of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'], 'AUID': ['ORCID: 0000-0002-9990-7467', 'ORCID: 0000-0002-8182-6167'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20220908', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9954776', 'OTO': ['NOTNLM'], 'OT': ['endophthalmitis', 'intravitreal injection', 'vascular endothelial growth factor'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/09/08'], 'CRDT': ['2023/04/03 04:29'], 'PHST': ['2023/09/08 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 04:29 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221116487 [pii]', '10.1177/24741264221116487 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Sep 8;6(6):443-451. doi: 10.1177/24741264221116487. eCollection 2022 Nov-Dec.'}, {'PMID': '37009539', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '6', 'IP': '6', 'DP': '2022 Nov-Dec', 'TI': 'Management and Complications of Dexamethasone Intravitreal Implant Migration Into the Anterior Chamber.', 'PG': '432-436', 'LID': '10.1177/24741264221138166 [doi]', 'AB': 'PURPOSE: To report patient demographics, the clinical course, and visual outcomes across a case series of patients who experienced dexamethasone (DEX) intravitreal implant (Ozurdex, Allergan, Inc) migration into the anterior chamber (AC), with a focus on the corneal transplantation rate. METHODS: In this retrospective cross-sectional study, a chart review of all cases was performed. For numerical responses, means and SDs were calculated. Percentages and absolute numbers were used to report the proportion of patients who experienced various outcomes of interest. RESULTS: The study comprised 32 cases. All cases occurred in pseudophakic eyes; of those, 8 (25.0%) had posterior chamber intraocular lenses in the capsular bag with no known capsular or zonular issues. The mean duration from DEX implant injection to detection of migration was 19.4 +/- 14.5 days. The DEX implant was explanted in 21 patients (65.6%) and repositioned in the vitreous cavity or subconjunctival space in 6 patients (18.8%). Twelve patients (37.5%) ultimately required corneal transplantation. CONCLUSIONS: To our knowledge, this is the largest case series of DEX intravitreal implant migration into the AC compiled to date. Cases of migration occurred in individuals with no known history of significant prior zonule disruption. This potential complication should be discussed with all patients undergoing DEX implant injection, which may aid in earlier presentation and improved visual outcomes.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Betsch, Devin M', 'Gupta, R Rishi'], 'AU': ['Betsch DM', 'Gupta RR'], 'AD': ['Department of Ophthalmology & Visual Sciences, QEII Health Sciences Centre, Halifax, NS, Canada.', 'Department of Ophthalmology & Visual Sciences, QEII Health Sciences Centre, Halifax, NS, Canada.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20221207', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9954786', 'OTO': ['NOTNLM'], 'OT': ['corneal transplant', 'dexamethasone intravitreal implant', 'implant migration'], 'COIS': ['The author(s) declared the following potential conflicts of interest with respect', 'to the research, authorship, and/or publication of this article: The following', 'authors declare conflicts of interest: Andy Kalevar:', 'Bayer/Novartis/Allergan/Alcon (Consulting fees, honoraria for', 'lectures/educational events, leadership role) John Galic: Bayer (honoraria for', 'lectures/educational events) Nimesh Patel: Allergan/Eye Point/Alimera/Genentech', '(participation on Data Safety Monitoring or Advisory Board) Tom Sheidow: Bayer', '(lecture honoraria), Roche/Novartis (Advisory panel) Renaud Duval: Bayer', '(educational and research grant), Bayer/Novartis/Roche (consulting fees),', 'Bayer/Novartis (honoraria for lectures/educational events), Bayer/Novartis/Roche', '(participation on Data Safety Monitoring or Advisory Board) Landon Rohowetz: NIH', 'Center Core Grant, Research to Prevent Blindness Grant Emmanuel Chang:', 'Genentech/Regeneron/Allergan (Advisory board) Nicholas Yannuzzi:', 'Genentech/Regenxbio (advisory/consulting) Mark Seamone: Novartis (Advisory board,', 'consulting fees, honoraria for lectures) Arif Samad: Ozurdex (Review of Ozurdex', 'submission to Health Canada) Geoff Williams: Bayer/Novartis/Roche (Advisory', 'board), Bayer/Novartis/Roche/Allergan/AbbVie/Chengdu Kanghong (Clinical trials),', 'Bayer (travel grant) Amin Kherani:', 'Abbvie/Alcon/Bayer/Bausch+Lomb/Novartis/Allergan/Roche/Appellis (Advisory board),', 'Bayer/Novartis/Roche/Genentech/Allergan/Abbvie/Chengdu Kanghong', 'Biotechnology/Ophthotech/Regeneron/Regenexbio/Iveris Bio INC/Opthea/Alexion', '(Clinical trials) Serge Bourgault: AbbVie/Bayer/Novartis (Advisory board) All', 'other authors declare that there is no conflict of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 04:29'], 'PHST': ['2023/04/04 06:01 [medline]', '2023/04/03 04:29 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221138166 [pii]', '10.1177/24741264221138166 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Dec 7;6(6):432-436. doi: 10.1177/24741264221138166. eCollection 2022 Nov-Dec.'}, {'PMID': '37009538', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '6', 'IP': '6', 'DP': '2022 Nov-Dec', 'TI': 'Posterior Polar Hemispheric Choroidal Dystrophy: Case Report and Presentation of Genetic Screening.', 'PG': '485-490', 'LID': '10.1177/24741264221080381 [doi]', 'AB': 'PURPOSE: Posterior polar hemispheric choroidal dystrophy is a rare dystrophy affecting the choroid and retina with a characteristic clinical appearance that distinguishes it from a broad variety of other retinal diseases. The disease process has a morphology described in the literature that preferentially affects the outer macula and spares the fovea with no arteriolar attenuation or optic nerve pallor. METHODS: This case report illustrates the use of multimodal retinal imaging, visual field testing, electroretinogram, and genetic testing of a patient who we believe fits the clinical pattern established by previous studies describing this condition. RESULTS: Fundus imaging in addition to further imaging modalities such as fluorescein angiography helped further characterize this disease process and aided in the diagnosis. In addition, genetic testing revealed unique allele variants found in this patient. CONCLUSIONS: By taking a multifaceted approach to the diagnosis of retinal pathology, clinicians can make informed decisions regarding patient care.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Tabbaa, Tarek', 'Daroszewski, Daniel', 'Sobol, Warren'], 'AU': ['Tabbaa T', 'Daroszewski D', 'Sobol W'], 'AD': ['Department of Ophthalmology-Vitreoretinal Surgery, Case Western Reserve University-University Hospitals, Cleveland, OH, USA.', 'Department of Ophthalmology-Vitreoretinal Surgery, Case Western Reserve University-University Hospitals, Cleveland, OH, USA.', 'Department of Ophthalmology-Vitreoretinal Surgery, Case Western Reserve University-University Hospitals, Cleveland, OH, USA.'], 'LA': ['eng'], 'PT': ['Case Reports'], 'DEP': '20220513', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9954778', 'OTO': ['NOTNLM'], 'OT': ['ERG', 'genetic testing', 'inherited retinal disease', 'posterior polar annular choroidal dystrophy', 'posterior polar hemispheric choroidal dystrophy'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/05/13'], 'CRDT': ['2023/04/03 04:29'], 'PHST': ['2023/05/13 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 04:29 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221080381 [pii]', '10.1177/24741264221080381 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 May 13;6(6):485-490. doi: 10.1177/24741264221080381. eCollection 2022 Nov-Dec.'}, {'PMID': '37009530', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '6', 'IP': '6', 'DP': '2022 Nov-Dec', 'TI': 'Paradoxical Exudative Retinopathy and Macular Star Formation After Treatment Initiation in Coats Disease.', 'PG': '452-456', 'LID': '10.1177/24741264221075962 [doi]', 'AB': 'Purpose: This work describes a unique clinical feature in Coats disease. Methods: A retrospective series of 2 cases is reported. Results: Two pediatric patients receiving treatment for Coats disease were included. In both cases, vision worsened secondary to paradoxically increased exudation and macular star formation following standard treatment with intravitreal bevacizumab, sub-Tenon triamcinolone acetonide, and laser photocoagulation. After serial treatments under general anesthesia, the exudates in both cases consolidated. Conclusions: A paradoxical exudative retinopathy can occur in some patients when initiating standard treatment of Coats disease. Longitudinal follow-up with continued intravitreal antivascular endothelial growth factor agents, laser photocoagulation, and corticosteroids might help control persistent exudation in these cases.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Kalavar, Meghana', 'Ashkenazy, Noy', 'Acon Ramirez, Dhariana', 'Berrocal, Audina'], 'AU': ['Kalavar M', 'Ashkenazy N', 'Acon Ramirez D', 'Berrocal A'], 'AD': ['Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, Miami, FL, USA.', 'Department of Ophthalmology, Havener Eye Institute, Ohio State University, Columbus, OH, USA.', 'Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, Miami, FL, USA.', 'Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, Miami, FL, USA.', 'Department of Ophthalmology, Hospital Calderon Guardia, San Jose, Costa Rica, USA.', 'Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, Miami, FL, USA.'], 'AUID': ['ORCID: 0000-0001-7497-4439', 'ORCID: 0000-0002-2446-2184'], 'LA': ['eng'], 'PT': ['Case Reports'], 'DEP': '20220808', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9954773', 'OTO': ['NOTNLM'], 'OT': ['Coats disease', 'exudative retinopathy', 'laser photocoagulation', 'macular star exudation'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/08/08'], 'CRDT': ['2023/04/03 04:29'], 'PHST': ['2023/08/08 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 04:29 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221075962 [pii]', '10.1177/24741264221075962 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Aug 8;6(6):452-456. doi: 10.1177/24741264221075962. eCollection 2022 Nov-Dec.'}, {'PMID': '37009284', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2296-2360 (Print) 2296-2360 (Electronic) 2296-2360 (Linking)', 'VI': '11', 'DP': '2023', 'TI': 'Case report: Prader-Willi syndrome and inflammatory arthritis-An important consideration.', 'PG': '1102382', 'LID': '10.3389/fped.2023.1102382 [doi] 1102382', 'AB': 'BACKGROUND: Prader-Willi syndrome (PWS) is a multisystemic genetically determined disorder. Musculoskeletal manifestations are common in most patients. We report the cases of two children with PWS who developed inflammatory arthritis, complicated with chronic anterior bilateral uveitis in one case. To our knowledge, no previous reports of such an association exist. CASE PRESENTATION: Case 1 was of a 3-year-old girl diagnosed with PWS who developed arthritis of the right knee with morning stiffness, joint swelling, and limited range of motion. Other causes of arthritis were ruled out. Increased inflammatory markers, antinuclear antibody (ANA) positivity, and hypertrophic synovitis on ultrasound confirmed the diagnosis of inflammatory arthritis compatible with juvenile idiopathic arthritis (JIA). Despite the treatment with methotrexate, arthritis progressed, and etanercept was added. The patient reached and maintained articular remission while on combined MTX and etanercept treatment during 9 years of follow-up. Case 2 was of a 6-year-old boy diagnosed with PWS who developed arthritis of the right knee. Laboratory investigations showed mildly increased acute phase reactants, microcytic anemia, and ANA positivity at high titer (titer 1:1,280). Infectious and other causes of arthritis were excluded. Ultrasound confirmed the presence of joint effusion and synovial thickening, and synovial fluid analysis was consistent with inflammatory arthrosynovitis (white blood cell count of 14,200/microl) compatible with JIA. Shortly after the diagnosis, the ophthalmologic evaluation revealed the presence of bilateral anterior uveitis. Despite MTX and topical corticosteroid, ocular inflammation persisted and adalimumab was added. At the last follow-up, 9 months later, the child experienced inactivity of arthritis and uveitis with normal growth. CONCLUSIONS: We aim to raise awareness of this possible association among pediatricians since arthritis might be underestimated due to high pain tolerance, behavioral disturbances, and other musculoskeletal abnormalities in PWS patients.', 'CI': ['(c) 2023 Marelli, Dallos, Miserocchi, Nucci, Tombolini, Lucia, Gattinara, Caporali', 'and Marino.'], 'FAU': ['Marelli, Luca', 'Dallos, Tomas', 'Miserocchi, Elisabetta', 'Nucci, Paolo', 'Tombolini, Beatrice', 'De Lucia, Orazio', 'Gattinara, Maurizio', 'Caporali, Roberto', 'Marino, Achille'], 'AU': ['Marelli L', 'Dallos T', 'Miserocchi E', 'Nucci P', 'Tombolini B', 'De Lucia O', 'Gattinara M', 'Caporali R', 'Marino A'], 'AD': ['Eye Clinic San Giuseppe Hospital, IRCCS Multimedica Scientific Institute, Milan, Italy.', 'Second Department of Pediatrics, Comenius University Medical School, Bratislava, Slovakia.', 'School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.', 'Division of Head and Neck, Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.', 'Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.', 'School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.', 'Division of Head and Neck, Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.', 'Division of Clinical Rheumatology, ASST G.Pini-CTO, Milano, Italy.', 'Unit of Pediatric Rheumatology, ASST G.Pini-CTO, Milan, Italy.', 'Division of Clinical Rheumatology, ASST G.Pini-CTO, Milano, Italy.', 'Unit of Pediatric Rheumatology, ASST G.Pini-CTO, Milan, Italy.', 'Department of Clinical Sciences and Community Health and Research Center for Pediatric and Adult Rheumatic Diseases (RECAP.RD), University of Milan, Milan, Italy.', 'Unit of Pediatric Rheumatology, ASST G.Pini-CTO, Milan, Italy.'], 'LA': ['eng'], 'PT': ['Case Reports'], 'DEP': '20230317', 'PL': 'Switzerland', 'TA': 'Front Pediatr', 'JT': 'Frontiers in pediatrics', 'JID': '101615492', 'PMC': 'PMC10063871', 'OTO': ['NOTNLM'], 'OT': ['Prader-Willi syndrome', 'arthritis', 'genetic disorders', 'human growth hormone', 'juvenile Idiopathic arthritis', 'obesity', 'uveitis'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 04:25'], 'PHST': ['2022/11/18 00:00 [received]', '2023/02/20 00:00 [accepted]', '2023/04/04 06:01 [medline]', '2023/04/03 04:25 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3389/fped.2023.1102382 [doi]'], 'PST': 'epublish', 'SO': 'Front Pediatr. 2023 Mar 17;11:1102382. doi: 10.3389/fped.2023.1102382. eCollection 2023.'}, {'PMID': '37008547', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '6', 'IP': '3', 'DP': '2022 May-Jun', 'TI': 'Optical Coherence Tomography Angiography: Clinical Utility and Future Directions.', 'PG': '229-242', 'LID': '10.1177/24741264221080376 [doi]', 'AB': 'PURPOSE: This work aims to review the principles of optical coherence tomography angiography (OCTA), to survey its clinical utility, and to highlight the strengths of this technology as well as barriers to adoption. METHODS: A literature review with editorial discussion of the current applications for OCTA is presented. RESULTS: There have been recent advances in multiple domains in OCTA imaging, including devices, algorithms, and new observations pertaining to a range of pathologies. New devices have improved the scanning speed, signal-to-noise ratio, and spatial resolution and offer an increased field of view. New algorithms have been proposed to optimize image processing and reduce artifacts. Numerous studies employing OCTA have been published describing changes to the microvasculature in diabetic retinopathy, age-related macular degeneration, central serous chorioretinopathy, retinal vein occlusion, and uveitis. CONCLUSIONS: OCTA provides noninvasive, high-resolution volumetric scans of the retinal and choroidal vasculature. OCTA can provide valuable data to augment traditional dye-based angiography in a range of chorioretinal diseases.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Foulsham, William', 'Chien, Jason', 'Lenis, Tamara Lee', 'Papakostas, Thanos D'], 'AU': ['Foulsham W', 'Chien J', 'Lenis TL', 'Papakostas TD'], 'AUID': ['ORCID: 0000-0002-7088-605X'], 'AD': ['Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA.', 'Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA.', 'Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA.', 'Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA.', 'The Retina Institute, St Louis, MO, USA.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20220513', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9976135', 'OTO': ['NOTNLM'], 'OT': ['optical coherence tomography angiography'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/05/13'], 'CRDT': ['2023/04/03 04:13'], 'PHST': ['2023/05/13 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 04:13 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221080376 [pii]', '10.1177/24741264221080376 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 May 13;6(3):229-242. doi: 10.1177/24741264221080376. eCollection 2022 May-Jun.'}, {'PMID': '37008402', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '7', 'IP': '1', 'DP': '2023 Jan-Feb', 'TI': 'Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.', 'PG': '8-15', 'LID': '10.1177/24741264221126061 [doi]', 'AB': 'PURPOSE: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular degeneration (nAMD). METHODS: Eyes were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + aflibercept 2 mg (HD combo), or IAI 2 mg at baseline, week 4, and week 8. The LD combo was continued every 8 weeks (q8w). At week 12, the HD combo was re-randomized to q8w or every 12 weeks (q12w) and IAI was re-randomized to q8w, q12w, or HD combo q8w through week 32. RESULTS: The study comprised 365 eyes. At week 12, the mean best-corrected visual acuity (BCVA) gains from baseline were similar in the LD combo group, HD combo group, and IAI group (5.2 letters, 5.6 letters, and 5.4 letters, respectively); the mean central subfield thickness (CST) reductions were similar (182.2 microm, 200.0 microm, and 178.6 microm, respectively). The mean changes in BCVA and CST through week 36 were similar across groups. At week 12, complete retinal fluid resolution was observed in 49.1% (LD combo), 50.8% (HD combo), and 43.6% (IAI) of eyes; the proportions with a CST of 300 mum or less were similar across groups. Numerical trends at week 32 toward complete retinal fluid resolution with combination treatment were not maintained at week 36. Serious ocular adverse events were infrequent and comparable across groups. CONCLUSIONS: In nAMD, nesvacumab + aflibercept showed no additional BCVA or CST benefit over IAI monotherapy.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Heier, Jeffrey S', 'Ho, Allen C', 'Boyer, David S', 'Csaky, Karl', 'Vitti, Robert', 'Perlee, Lorah', 'Chu, Karen W', 'Asmus, Friedrich', 'Leal, Sergio', 'Zeitz, Oliver', 'Cheng, Yenchieh', 'Schmelter, Thomas', 'Brown, David M'], 'AU': ['Heier JS', 'Ho AC', 'Boyer DS', 'Csaky K', 'Vitti R', 'Perlee L', 'Chu KW', 'Asmus F', 'Leal S', 'Zeitz O', 'Cheng Y', 'Schmelter T', 'Brown DM'], 'AD': ['Ophthalmic Consultants of Boston, Boston, MA, USA.', 'Wills Eye Hospital, Philadelphia, PA, USA.', 'Retina-Vitreous Associates Medical Group, Beverly Hills, CA, USA.', 'Retina Foundation of the Southwest, Dallas, TX, USA.', 'Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.', 'Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.', 'Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.', 'Bayer AG, Berlin, Germany.', 'Bayer Consumer Care AG, Basel, Switzerland.', 'Bayer AG, Berlin, Germany.', 'Department of Ophthalmology, Charite Universitatsmedizin Berlin, Berlin, Germany.', 'Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.', 'Bayer AG, Berlin, Germany.', 'Retina Consultants of Texas (Retina Consultants of America), Houston, TX, USA.'], 'AUID': ['ORCID: 0000-0001-9219-1614', 'ORCID: 0000-0003-1358-3172'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20221230', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9954160', 'OTO': ['NOTNLM'], 'OT': ['age-related macular degeneration', 'angiopoietin-2', 'investigational clinical trials', 'vascular endothelial growth factor'], 'COIS': ['The author(s) declared the following potential conflicts of interest with respect', 'to the research, authorship, and/or publication of this article: Jeffrey S. Heier', 'reports consulting for 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Allegro, Alzheon,', 'Annexon, Apellis, Aprea, Asclepix, Aviceda, Beaver-Visitec, Bionic Vision', 'Technologies, DTx, Eloxx, Galimedix, Genentech, Graybug, Gyroscope, Horizon', 'Therapeutics, iRenix, Iveric, JCyte, Chengdu Kanghong Biotechnology, LensGen,', 'NGM, Notal Vision, Novartis, Ocular Therapeutix, OccuTerra, Oxurion, Palatin,', 'Regeneron Pharmaceuticals, Inc, RegenXBio, Stealth, Thea, Verseon, Vinci, and', 'Voyant; and research grants from Aerpio, Aldeyra, Apellis, Asclepix, Bayer,', 'Genentech, Graybug, Gyroscope, Hermera, Iveric, Janssen R&D, JCyte, Chengdu', 'Kanghong Biotechnology, Kodiak, Novartis, Regeneron Pharmaceuticals, Inc,', 'RegenXBio, and Stealth. Allen C. Ho reports consulting for and receiving research', 'grant support from Adverum, Aerie, AGTC, Alcon Laboratories, Inc, Aldeyra,', 'Allergan, Apellis, Asclepix, Atsena, Beaver-Visitec International, Inc, Chengdu', 'Kanghong Biotechnology, Clearside, Covalent Medical, Genentech, Graybug,', 'Gyroscope, Iveric, Janssen/Johnson & Johnson, Lineage, Lumithera, National Eye', 'Institute, Notal, Novartis, Ocular Therapeutics, ONL, ProQR, Regeneron', 'Pharmaceuticals, Inc, and RegenXBio. David S. Boyer reports consulting for', 'Genentech, Regeneron Pharmaceuticals, Inc, Roche, Bayer, Allergan, Chengdu', 'Kanghong Biotechnology, Clearside Biomedical, Boehringer Ingelheim, Kodiak,', 'Novartis, Adverum, RegenXBio, and Graybug. Karl Csaky reports consulting for', 'Genentech, Roche, Allergan, Novartis, and Regeneron Pharmaceuticals, Inc. Robert', 'Vitti, Lorah Perlee, Karen W. Chu, and Yenchieh Cheng are employees of and', 'stockholders in Regeneron Pharmaceuticals, Inc. Friedrich Asmus was an employee', 'of Bayer AG at the time of the study. Sergio Leal is an employee of and', 'stockholder in Bayer Consumer Care AG. Oliver Zeitz reports consulting and', 'serving as a speaker for Allergan, Bayer, Boehringer-Ingelheim, and Novartis;', 'consulting for Omeicos and Oxular; and research support from Bayer,', 'Boehringer-Ingelheim, and Novartis. He was an employee of Bayer until September', '30, 2016. Thomas Schmelter is an employee of and stockholder in Bayer AG. David', 'M. Brown reports consulting for and receiving research funding from Regeneron', 'Pharmaceuticals, Inc, Genentech/Roche, Novartis, Heidelberg, Allergan, Chengdu', 'Kanghong Biotechnology, Santen, OHR, Clearside Biomedical, Adverum, RegenXBio,', 'and Samsung; and consulting for Bayer, Optos, Kodiak, Senju, and Biotime, outside', 'of the submitted work.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 04:11'], 'PHST': ['2023/04/04 06:01 [medline]', '2023/04/03 04:11 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221126061 [pii]', '10.1177/24741264221126061 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Dec 30;7(1):8-15. doi: 10.1177/24741264221126061. eCollection 2023 Jan-Feb.'}, {'PMID': '37008401', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '7', 'IP': '1', 'DP': '2023 Jan-Feb', 'TI': 'Clinical Outcomes of Combined Phacoemulsification With Intraocular Lens Placement and Microincision Vitrectomy in Adult Vitreoretinal Disease.', 'PG': '27-32', 'LID': '10.1177/24741264221118185 [doi]', 'AB': 'PURPOSE: To evaluate the safety and clinical outcomes of combined phacoemulsification with intraocular lens (IOL) placement and microincision vitrectomy surgery (MIVS) in adult patients with concomitant cataract and vitreoretinal disease. METHODS: A consecutive series of patients with comorbid vitreoretinal disease and cataract who had combined phacoemulsification with IOL placement and MIVS was retrospectively analyzed. The main outcome measures were visual acuity (VA) and intraoperative and postoperative complications. RESULTS: The analysis comprised 648 eyes of 611 patients. The median follow-up was 26.9 months (range, 12-60 months). The most common vitreoretinal pathology was intraocular tumor (53%). The best-corrected Snellen VA improved from 20/192 at baseline to 20/46 at the 12-month follow-up. The most frequent intraoperative complication was capsule tear (3.9%). The most common postoperative adverse events after 3 months of follow-up (mean, 24 months) were vitreous hemorrhage (3.2%) and retinal detachment (1.8%). No patient developed endophthalmitis. CONCLUSIONS: Combined phacoemulsification with IOL placement and MIVS is a safe, effective technique to manage a broad range of vitreoretinal diseases in patients with significant cataract.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Muns, Sofia M', 'Villegas, Victor M', 'Murray, Timothy G', 'Latiff, Azeema', 'Gold, Aaron S'], 'AU': ['Muns SM', 'Villegas VM', 'Murray TG', 'Latiff A', 'Gold AS'], 'AUID': ['ORCID: 0000-0002-1713-8474'], 'AD': ['Department of Ophthalmology, University of Puerto Rico, San Juan, PR, USA.', 'Department of Ophthalmology, University of Puerto Rico, San Juan, PR, USA.', 'Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.', 'Department of Surgery, Ponce Health Sciences University, School of Medicine, Ponce, PR, USA.', 'Miami Ocular Oncology and Retina, Miami, FL, USA.', 'Miami Ocular Oncology and Retina, Miami, FL, USA.', 'Miami Ocular Oncology and Retina, Miami, FL, USA.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20221114', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9954161', 'OTO': ['NOTNLM'], 'OT': ['combined surgery', 'microincision vitrectomy surgery', 'phacoemulsification', 'phacovitrectomy'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/11/14'], 'CRDT': ['2023/04/03 04:11'], 'PHST': ['2023/11/14 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 04:11 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221118185 [pii]', '10.1177/24741264221118185 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Nov 14;7(1):27-32. doi: 10.1177/24741264221118185. eCollection 2023 Jan-Feb.'}, {'PMID': '37008218', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '1662-4548 (Print) 1662-453X (Electronic) 1662-453X (Linking)', 'VI': '17', 'DP': '2023', 'TI': 'Upregulation of C-X-C motif chemokine 12 in the spinal cord alleviated the symptoms of experimental autoimmune encephalomyelitis in Lewis rats.', 'PG': '1105530', 'LID': '10.3389/fnins.2023.1105530 [doi] 1105530', 'AB': 'BACKGROUND: C-X-C motif chemokine 12 (CXCL12) is a chemokine that performs many functions. Studies have shown that CXCL12 can aggravate inflammatory symptoms in the central nervous system (CNS). Evidence also indicates that CXCL12 can promote the repair of myelin sheaths in the CNS in experimental autoimmune encephalomyelitis (EAE). Here, we investigated the function of CXCL12 in CNS inflammation by upregulating CXCL12 in the spinal cord and subsequently inducing EAE. MATERIALS AND METHODS: CXCL12 upregulation in the spinal cords of Lewis rats was induced by the injection of adeno-associated virus 9 (AAV9)/eGFP-P2A-CXCL12 after intrathecal catheter implantation. Twenty-one days after AAV injection, EAE was induced and clinical score was collected; Immunofluorescence staining, WB and LFB-PAS staining were used to evaluate the effect of CXCL12 upregulation. In the in vitro study, oligodendrocyte precursor cells (OPCs) were harvested, cultured with CXCL12 and AMD3100, and subjected to immunofluorescence staining for functional assessment. RESULTS: CXCL12 was upregulated in the lumbar enlargement of the spinal cord by AAV injection. In each stage of EAE, upregulation of CXCL12 significantly alleviated clinical scores by inhibiting leukocyte infiltration and promoting remyelination. In contrast, the addition of AMD3100, which is a CXCR4 antagonist, inhibited the effect of CXCL12. In vitro, 10 ng/ml CXCL12 promoted the differentiation of OPCs into oligodendrocytes. CONCLUSION: AAV-mediated upregulation of CXCL12 in the CNS can alleviate the clinical signs and symptoms of EAE and significantly decrease the infiltration of leukocytes in the peak stage of EAE. CXCL12 can promote the maturation and differentiation of OPCs into oligodendrocytes in vitro. These data indicate that CXCL12 effectively promotes remyelination in the spinal cord and decreases the signs and symptoms of EAE.', 'CI': ['Copyright (c) 2023 Lin, Liu, Song, Chen, Fu, Sun, Zhou, Bai, Wei and Li.'], 'FAU': ['Lin, Dahe', 'Liu, Hongjuan', 'Song, Honglu', 'Chen, Biyue', 'Fu, Junxia', 'Sun, Mingming', 'Zhou, Huanfen', 'Bai, Wenhao', 'Wei, Shihui', 'Li, Hongen'], 'AU': ['Lin D', 'Liu H', 'Song H', 'Chen B', 'Fu J', 'Sun M', 'Zhou H', 'Bai W', 'Wei S', 'Li H'], 'AD': [\"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", 'Fujian Provincial Key Laboratory of Ecology-Toxicological Effects and Control for Emerging Contaminants, College of Environmental and Biological Engineering, Putian University, Putian, Fujian, China.', 'Key Laboratory of Ecological Environment and Information Atlas, Fujian Provincial University (Putian University), Putian, Fujian, China.', \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", 'Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing, China.', \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", \"Department of Ophthalmology, The 980th Hospital of the Chinese People's Liberation Army (PLA) Joint Logistics Support Force, Shijiazhuang, Hebei, China.\", \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", \"Department of Ophthalmology, The Third Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\", \"Department of Ophthalmology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.\"], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230316', 'PL': 'Switzerland', 'TA': 'Front Neurosci', 'JT': 'Frontiers in neuroscience', 'JID': '101478481', 'PMC': 'PMC10060838', 'OTO': ['NOTNLM'], 'OT': ['AAV', 'CXCL12', 'EAE', 'neuroinflammation', 'remyelination'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 04:08'], 'PHST': ['2022/11/22 00:00 [received]', '2023/02/14 00:00 [accepted]', '2023/04/04 06:01 [medline]', '2023/04/03 04:08 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3389/fnins.2023.1105530 [doi]'], 'PST': 'epublish', 'SO': 'Front Neurosci. 2023 Mar 16;17:1105530. doi: 10.3389/fnins.2023.1105530. eCollection 2023.'}, {'PMID': '37007927', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '6', 'IP': '4', 'DP': '2022 Jul-Aug', 'TI': 'Correlation of Change in Macular Thickness With Change in Visual Acuity in Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials.', 'PG': '284-289', 'LID': '10.1177/24741264221099429 [doi]', 'AB': 'Purpose: To assess the correlation between the change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in eyes with diabetic macular edema (DME) treated with fixed-dosing intravitreal aflibercept injection (IAI). Methods: This post hoc analysis of the VISTA and VIVID randomized controlled clinical trials, in which 862 eyes with central-involved DME were randomly assigned to IAI 2 mg every 4 weeks (2q4; 290 eyes), IAI 2 mg every 8 weeks after 5 initial monthly doses (2q8; 286 eyes), or macular laser (286 eyes) and followed through 100 weeks. Correlations between the change in CST and change in BCVA from baseline to weeks 12, 52, and 100 were assessed using the Pearson correlation. Results: The respective correlations (r [95% CI]) at weeks 12, 52, and 100 were -0.39 (-0.49 to -0.29), -0.27 (-0.38 to -0.15), and -0.30 (-0.41 to -0.17) in the 2q4 arm and -0.28 (-0.39 to -0.17), -0.29 (-0.41 to -0.17), and -0.33 (-0.44 to -0.20) in the 2q8 arm. Linear regression analysis of the correlation at week 100, adjusted for relevant baseline factors, showed CST changes accounted for 17% of the variance in BCVA changes; every 100-microm decrease in CST was associated with a 1.2-letter increase in BCVA (P = .001). Conclusions: Correlations between the change in CST and change in BCVA after 2q4 or 2q8 fixed-dosing IAI for DME were modest. Although a change in CST might be important in determining the need for antivascular endothelial growth factor for DME at follow-up, it was not a good surrogate for VA outcomes.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Nanegrungsunk, Onnisa', 'Gu, Sophie Z', 'Bressler, Susan B', 'Du, Weiming', 'Amer, Fouad', 'Moini, Hadi', 'Bressler, Neil M'], 'AU': ['Nanegrungsunk O', 'Gu SZ', 'Bressler SB', 'Du W', 'Amer F', 'Moini H', 'Bressler NM'], 'AD': ['Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Retina Division, Department of Ophthalmology, Chiang Mai University, Chiang Mai, Thailand.', 'Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.', 'Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.', 'Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.', 'Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.', 'Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.', 'Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20220727', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9976035', 'OTO': ['NOTNLM'], 'OT': ['aflibercept', 'anti-VEGF', 'central subfield thickness', 'correlation', 'diabetic macular edema', 'visual acuity'], 'COIS': ['The author(s) declared the following potential conflicts of interest with respect', 'to the research, authorship, and/or publication of this article: Drs', 'Nanegrungsunk and Gu declare no conflict of interest. Dr S. Bressler has received', 'grants to Johns Hopkins University School of Medicine from Bayer, Biocon, Biogen,', 'Boehringer-Ingleheim Pharma GmbH & Co, EyePoint, Genentech (Roche), Mylan Inc,', 'Notal Vision, Novartis, and Regeneron Pharmaceuticals Inc, and has a contract', 'with Amgen as chair of the Data and Safety Monitoring Committee; Drs Du, Amer,', 'and Moini are salaried employees with and have stock ownership in Regeneron', 'Pharmaceuticals, Inc. Dr N. Bressler has received grants to Johns Hopkins', 'University from Bayer, Biogen, Genentech (Roche), Novartis, Regeneron', 'Pharmaceuticals, Inc, and Samsung Bioepis, and has contract with the American', 'Medical Association as editor-in-chief of JAMA Ophthalmology.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/07/27'], 'CRDT': ['2023/04/03 04:05'], 'PHST': ['2023/07/27 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 04:05 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221099429 [pii]', '10.1177/24741264221099429 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Jul 27;6(4):284-289. doi: 10.1177/24741264221099429. eCollection 2022 Jul-Aug.'}, {'PMID': '37007922', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '6', 'IP': '4', 'DP': '2022 Jul-Aug', 'TI': 'Opportunity Cost of Retinal Detachment Surgery vs Office-Based Patient Care.', 'PG': '278-283', 'LID': '10.1177/24741264221098669 [doi]', 'AB': \"Purpose: This work compares physician reimbursements for retinal detachment (RD) surgery with office-based patient care. Methods: A theoretical model was constructed from the physician's perspective for performing a 90-minute uncomplicated RD surgery with its associated perioperative work in the global period (Current Procedural Terminology code 67108) compared with managing 40 patients per 8-hour clinic day in the equivalent time period. The reimbursement rates were based on the 2019 values set by the US Centers for Medicare and Medicaid Services (CMS). Sensitivity analyses were performed varying the perioperative times, clinical productivity, and postoperative visits. Results: The CMS physician reimbursement rate for 67108 surgery was 17.13 work relative value units (wRVUs); meanwhile, the physician in the reference case could have generated 40.89 wRVUs in the office. CMS reimbursement therefore represented a 58% opportunity cost relative to lost office productivity for the physician. A significant disparity was still present even when modeling 30 patients per day. In sensitivity analyses, clinical productivity exceeded surgical compensation in 99% of modeled scenarios. In threshold analyses, the surgeon in the reference case would have to complete the surgery and all immediate perioperative care within 18 minutes to equal the total CMS valuation. Conclusions: CMS reimbursement for RD surgery resulted in a significant opportunity cost for the physician relative to office-based patient care, which was more pronounced for more efficient clinicians in the office. The sensitivity analyses supported the robustness of the model. Reductions in surgery reimbursements relative to office-based patient care might disincentivize busy clinicians.\", 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Leung, Ella H', 'Leder, Henry A', 'Patel, Shriji', 'Reddy, Rahul', 'Boucher, Nick', 'Sharma, Chakshu', 'Blim, Jill', 'Awh, Carl', 'Hahn, Paul'], 'AU': ['Leung EH', 'Leder HA', 'Patel S', 'Reddy R', 'Boucher N', 'Sharma C', 'Blim J', 'Awh C', 'Hahn P'], 'AD': ['Georgia Retina, Atlanta, GA, USA.', 'Leder Retina, Jacksonville, FL, USA.', 'Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, TN, USA.', 'Department of Ophthalmology, University of Arizona College of Medicine, Phoenix, AZ, USA.', 'Vestrum Health, Naperville, IL, USA.', 'Vestrum Health, Naperville, IL, USA.', 'American Society of Retina Specialists, Chicago, IL, USA.', 'Tennessee Retina, Nashville, TN, USA.', 'NJRetina, Teaneck, NJ, USA.'], 'AUID': ['ORCID: 0000-0002-6574-388X'], 'CN': ['American Society of Retina Specialists Health Economics Committee'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20220716', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC9976036', 'OTO': ['NOTNLM'], 'OT': ['opportunity cost', 'pars plana vitrectomy', 'relative value units', 'retinal detachment', 'work RVU'], 'COIS': ['The authors declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of the article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/07/16'], 'CRDT': ['2023/04/03 04:05'], 'PHST': ['2023/07/16 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 04:05 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221098669 [pii]', '10.1177/24741264221098669 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Jul 16;6(4):278-283. doi: 10.1177/24741264221098669. eCollection 2022 Jul-Aug.'}, {'PMID': '37007786', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2296-858X (Print) 2296-858X (Electronic) 2296-858X (Linking)', 'VI': '10', 'DP': '2023', 'TI': 'Characteristics of eye-related emergency visits and triage differences by nurses and ophthalmologists: Perspective from a single eye center in southern China.', 'PG': '1091128', 'LID': '10.3389/fmed.2023.1091128 [doi] 1091128', 'AB': 'PURPOSE: To describe characteristics of eye-related emergency department (ED) visits and investigate differences in priorities assigned to patients by triage nurses and ophthalmologists. METHODS: A prospective survey was conducted at the ED of Zhongshan Ophthalmic Center from January 1, 2021, to May 31, 2021. Clinical data from patients with acute ophthalmic conditions lasting less than 7 days were collected via a standard questionnaire and the urgency levels assigned by nurses and physicians were also recorded. Binary logistic regression was performed to identify characteristics associated with truly emergency conditions and up- or down-triage. RESULTS: A total of 1907 patients were enrolled, with 582 (30.5%) classified as \"non-emergency.\" Red eye (69.7%), eye pain (53.0%), ocular trauma (44.1%), tearing (43.6%), and blurred vision (43.1%) were the most common complaints. Truly emergency tended to be male (OR 2.019, p < 0.001) and with unilateral eye involvement (OR 2.992, p < 0.001). Nurses prioritized conjunctival, scleral, closed ocular trauma and eyelid diseases over doctors while giving less priority to open ocular trauma, cornea, uveitis, and vitreoretinal diseases (p < 0.05). Overemphasis on mild blurred vision (OR 3.718, p = 0.001) and insufficient understanding of conjunctival diseases without red eye (OR 0.254, p = 0.001) were associated with conjunctival disease \"up-triage.\" Insufficient awareness of moderate and severe blurred vision was associated with \"down-triage\" for ocular trauma (OR 3.475, p = 0.001 and OR 2.422, p = 0.020, respectively). CONCLUSION: Ophthalmic EDs are typically flooded with patients suffering from acute ocular problems, with a considerable portion for non-emergency conditions. The identification of characteristics associated with truly emergency cases and nurses\\' triage preferences is valuable in providing target guidance for future ED practice and facilitating the proper allocation of emergency resources.', 'CI': ['Copyright (c) 2023 Chen, Chen, Zhong and Zheng.'], 'FAU': ['Chen, Juan', 'Chen, Chen-Mei', 'Zheng, Yongxin', 'Zhong, Liuxueying'], 'AU': ['Chen J', 'Chen CM', 'Zheng Y', 'Zhong L'], 'AD': ['State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, Guangdong, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, Guangdong, China.', 'Guangzhou Aier Eye Hospital, Guangzhou, Guangdong, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, Guangdong, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, Guangdong, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230316', 'PL': 'Switzerland', 'TA': 'Front Med (Lausanne)', 'JT': 'Frontiers in medicine', 'JID': '101648047', 'PMC': 'PMC10061012', 'OTO': ['NOTNLM'], 'OT': ['characteristics', 'emergency department', 'nurses', 'ophthalmic emergencies', 'triage'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 04:03'], 'PHST': ['2022/11/06 00:00 [received]', '2023/03/06 00:00 [accepted]', '2023/04/04 06:01 [medline]', '2023/04/03 04:03 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3389/fmed.2023.1091128 [doi]'], 'PST': 'epublish', 'SO': 'Front Med (Lausanne). 2023 Mar 16;10:1091128. doi: 10.3389/fmed.2023.1091128. eCollection 2023.'}, {'PMID': '37007779', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2296-858X (Print) 2296-858X (Electronic) 2296-858X (Linking)', 'VI': '10', 'DP': '2023', 'TI': 'The impact of the image conversion factor and image centration on retinal vessel geometric characteristics.', 'PG': '1112652', 'LID': '10.3389/fmed.2023.1112652 [doi] 1112652', 'AB': 'BACKGROUND: This study aims to use fundus image material from a long-term retinopathy follow-up study to identify problems created by changing imaging modalities or imaging settings (e.g., image centering, resolution, viewing angle, illumination wavelength). Investigating the relationship of image conversion factor and imaging centering on retinal vessel geometric characteristics (RVGC), offers solutions for longitudinal retinal vessel analysis for data obtained in clinical routine. METHODS: Retinal vessel geometric characteristics were analyzed in scanned fundus photographs with Singapore-I-Vessel-Assessment using a constant image conversion factor (ICF) and an individual ICF, applying them to macula centered (MC) and optic disk centered (ODC) images. The ICF is used to convert pixel measurements into mum for vessel diameter measurements and to establish the size of the measuring zone. Calculating a constant ICF, the width of all analyzed optic disks is included, and it is used for all images of a cohort. An individual ICF, in turn, uses the optic disk diameter of the eye analyzed. To investigate agreement, Bland-Altman mean difference was calculated between ODC images analyzed with individual and constant ICF and between MC and ODC images. RESULTS: With constant ICF (n = 104 eyes of 52 patients) the mean central retinal equivalent was 160.9 +/- 17.08 mum for arteries (CRAE) and 208.7 +/- 14.7.4 mum for veins (CRVE). The individual ICFs resulted in a mean CRAE of 163.3 +/- 15.6 mum and a mean CRVE of 219.0 +/- 22.3 mum. On Bland-Altman analysis, the individual ICF RVGC are more positive, resulting in a positive mean difference for most investigated parameters. Arteriovenous ratio (p = 0.86), simple tortuosity (p = 0.08), and fractal dimension (p = 0.80) agreed well between MC and ODC images, while the vessel diameters were significantly smaller in MC images (p < 0.002). CONCLUSION: Scanned images can be analyzed using vessel assessment software. Investigations of individual ICF versus constant ICF point out the asset of utilizing an individual ICF. Image settings (ODC vs. MC) were shown to have good agreement.', 'CI': ['Copyright (c) 2023 Schanner, Hautala, Rauscher and Falck.'], 'FAU': ['Schanner, Carolin', 'Hautala, Nina', 'Rauscher, Franziska G', 'Falck, Aura'], 'AU': ['Schanner C', 'Hautala N', 'Rauscher FG', 'Falck A'], 'AD': ['Department of Ophthalmology and Medical Research Center, Oulu University Hospital, Oulu, Finland.', 'PEDEGO Research Unit, University of Oulu, Oulu, Finland.', 'Institute for Medical Informatics, Statistics, and Epidemiology, Leipzig University, Leipzig, Germany.', 'Department of Ophthalmology and Medical Research Center, Oulu University Hospital, Oulu, Finland.', 'PEDEGO Research Unit, University of Oulu, Oulu, Finland.', 'Institute for Medical Informatics, Statistics, and Epidemiology, Leipzig University, Leipzig, Germany.', 'Department of Ophthalmology and Medical Research Center, Oulu University Hospital, Oulu, Finland.', 'PEDEGO Research Unit, University of Oulu, Oulu, Finland.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230317', 'PL': 'Switzerland', 'TA': 'Front Med (Lausanne)', 'JT': 'Frontiers in medicine', 'JID': '101648047', 'PMC': 'PMC10063888', 'OTO': ['NOTNLM'], 'OT': ['diabetic retinopathy', 'ophthalmology', 'retina', 'retinal image analysis', 'retinal microvasculature', 'retinal vessel geometric characteristics (RVGC)', 'retinal vessel parameter'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 04:03'], 'PHST': ['2022/11/30 00:00 [received]', '2023/03/02 00:00 [accepted]', '2023/04/04 06:01 [medline]', '2023/04/03 04:03 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3389/fmed.2023.1112652 [doi]'], 'PST': 'epublish', 'SO': 'Front Med (Lausanne). 2023 Mar 17;10:1112652. doi: 10.3389/fmed.2023.1112652. eCollection 2023.'}, {'PMID': '37007646', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2666-9145 (Electronic) 2666-9145 (Linking)', 'VI': '3', 'IP': '3', 'DP': '2023 Sep', 'TI': 'No Strong Association between the Apolipoprotein E E4 Allele and Glaucoma: A Multicohort Study.', 'PG': '100287', 'LID': '10.1016/j.xops.2023.100287 [doi] 100287', 'AB': \"PURPOSE: To elucidate a potential association between the apolipoprotein E (APOE) E4 allele and glaucoma prevalence in large cohorts. DESIGN: A cross-sectional analysis of baseline and prospectively collected cohort data. PARTICIPANTS: UK Biobank (UKBB) participants of genetically determined European ancestry (n = 438 711). Replication analyses were performed using clinical and genotyping data collected from European participants recruited to the Canadian Longitudinal Study of Aging (CLSA; n = 18 199), the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG; n = 1970), and the Blue Mountains Eye Study (BMES; n = 2440). METHODS: Apolipoprotein E alleles and genotypes were determined, and their distributions were compared on the basis of glaucoma status. Similar analyses were performed using positive control outcomes associated with the APOE E4 allele (death, dementia, age-related macular degeneration) and negative control outcomes not associated with the APOE E4 allele (cataract, diabetic eye disease). Outcome phenotypes were also correlated with Alzheimer's dementia (AD), a clinical outcome highly associated with the APOE E4 allele. MAIN OUTCOME MEASURES: Results of APOE E4 genotype-phenotype comparisons were reported as odds ratios (ORs) with 95% confidence intervals (CIs). Replication analyses investigated APOE E4 associations in 2 replication cohorts (CLSA and ANZRAG/BMES). RESULTS: The APOE E4 allele was inversely associated with glaucoma (OR, 0.96; 95% CI, 0.93-0.99; P = 0.016) and both negative controls (cataract: OR, 0.98; 95% CI, 0.96-0.99; P = 0.015; diabetic eye disease: OR, 0.92; 95% CI, 0.87-0.97; P = 0.003) in the UKBB cohort. A paradoxical positive association was observed between AD and both glaucoma (OR, 1.30; 95% CI, 1.08-1.54; P < 0.01) and cataract (OR, 1.15; 1.04-1.28; P = 0.018). No association between the APOE E4 allele and glaucoma was observed in either replication cohort (CLSA: OR, 1.03; 95% CI, 0.89-1.19; P = 0.66; ANZRAG/BMES: OR, 0.97; 95% CI, 0.84-1.12; P = 0.65). CONCLUSIONS: A small negative association observed between APOE E4 and glaucoma within the UKBB was not evident in either replication cohort and may represent an artifact of glaucoma underdiagnosis in APOE E4 carriers. FINANCIAL DISCLOSURES: The author(s) have no proprietary or commercial interest in any materials discussed in this article.\", 'CI': ['(c) 2023 by the American Academy of Ophthalmology. This.'], 'FAU': ['Mullany, Sean', 'Diaz-Torres, Santiago', 'Schmidt, Joshua M', 'Thomson, Daniel', 'Qassim, Ayub', 'Marshall, Henry N', 'Knight, Lachlan S W', 'Berry, Ella C', 'Kolovos, Antonia', 'Dimasi, David', 'Lake, Stewart', 'Mills, Richard A', 'Landers, John', 'Mitchell, Paul', 'Healey, Paul R', 'Commerford, Toby', 'Klebe, Sonja', 'Souzeau, Emmanuelle', 'Hassall, Mark M', 'MacGregor, Stuart', 'Gharahkhani, Puya', 'Siggs, Owen M', 'Craig, Jamie E'], 'AU': ['Mullany S', 'Diaz-Torres S', 'Schmidt JM', 'Thomson D', 'Qassim A', 'Marshall HN', 'Knight LSW', 'Berry EC', 'Kolovos A', 'Dimasi D', 'Lake S', 'Mills RA', 'Landers J', 'Mitchell P', 'Healey PR', 'Commerford T', 'Klebe S', 'Souzeau E', 'Hassall MM', 'MacGregor S', 'Gharahkhani P', 'Siggs OM', 'Craig JE'], 'AD': ['Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Centre for Vision Research, University of Sydney, Sydney, Australia.', 'Centre for Vision Research, University of Sydney, Sydney, Australia.', 'Department of Geriatric Medicine, Royal Adelaide Hospital, Adelaide, South Australia.', 'Department of Pathology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.', 'Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.', 'Garvan Institute of Medical Research, Darlinghurst, New South Wales.', 'Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230213', 'PL': 'Netherlands', 'TA': 'Ophthalmol Sci', 'JT': 'Ophthalmology science', 'JID': '9918230896206676', 'PMC': 'PMC10064233', 'OTO': ['NOTNLM'], 'OT': ['APOE', \"Alzheimer's dementia\", 'Apolipoprotein E', 'Glaucoma', 'POAG'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 04:02'], 'PHST': ['2022/12/07 00:00 [received]', '2023/01/22 00:00 [revised]', '2023/02/08 00:00 [accepted]', '2023/04/04 06:01 [medline]', '2023/04/03 04:02 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['S2666-9145(23)00019-2 [pii]', '100287 [pii]', '10.1016/j.xops.2023.100287 [doi]'], 'PST': 'epublish', 'SO': 'Ophthalmol Sci. 2023 Feb 13;3(3):100287. doi: 10.1016/j.xops.2023.100287. eCollection 2023 Sep.'}, {'PMID': '37007255', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '0974-620X (Print) 0974-7842 (Electronic) 0974-620X (Linking)', 'VI': '16', 'IP': '1', 'DP': '2023 Jan-Apr', 'TI': 'Clinical and multimodal imaging characteristics of eyes with Vogt-Koyanagi-Harada disease: An Egyptian experience.', 'PG': '88-93', 'LID': '10.4103/ojo.ojo_376_21 [doi]', 'AB': 'BACKGROUND: Vogt-Koyanagi-Harada (VKH) disease is a vision-threatening inflammatory disorder that is challenging in diagnosis and management. METHODS: Retrospective, record-based analysis of 54 eyes belonging to 27 adult patients that fulfilled the revised diagnostic criteria for VKH between January 2018 and January 2021. Demographic, clinical, and imaging data on presentation and during follow-up visits were collected for each patient. Available imaging studies included B-scan ultrasonography (B-scan US), spectral domain optical coherence tomography (OCT), fundus fluorescein angiography (FFA), and OCT angiography (OCT-A). RESULTS: The female-to-male ratio was 2.38:1. Nineteen patients (70.37%) presented during an initial attack, while eight patients (29.63%) presented during recurrence. The most commonly presenting sign in the posterior segment was exudative retinal detachment (44 eyes, 81.48%). B-scan US was utilized in 4 eyes (7.41%), OCT was utilized in 48 eyes (88.89%) with the most common finding being subretinal fluid (43 eyes, 89.58%), FFA was performed in 39 eyes (72.22%) with the most common finding being punctate hyperfluorescence and late dye pooling (33 eyes, 84.62%), and OCT-A was performed in 30 eyes (55.56%), in which choriocapillaris flow deficit that correlated with disease activity was detectable in 25 eyes (83.33%). Improved visual acuity was noted in 85% of the eyes that were followed up. CONCLUSION: Early diagnosis and treatment of VKH result in favorable visual outcome. Multimodal imaging, with the recent addition of OCT-A, provides complementary data that could serve in diagnosis and monitoring.', 'CI': ['Copyright: (c) 2023 Oman Ophthalmic Society.'], 'FAU': ['Mekkawy, Mahmood O', 'Fouad, Yousef Ahmed', 'Nowara, Mohamed', 'Aziz, Ihab Abdel'], 'AU': ['Mekkawy MO', 'Fouad YA', 'Nowara M', 'Aziz IA'], 'AD': ['Al Mashreq Eye Center, Cairo, Egypt.', 'Al Mashreq Eye Center, Cairo, Egypt.', 'Department of Ophthalmology, Ain Shams University Hospitals, Giza, Egypt.', 'Al Mashreq Eye Center, Cairo, Egypt.', 'Department of Ophthalmology, Electricity Hospital, Cairo, Egypt.', 'Al Mashreq Eye Center, Cairo, Egypt.', 'Vitreoretinal Service, The Memorial Institute for Ophthalmic Research, Giza, Egypt.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230221', 'PL': 'India', 'TA': 'Oman J Ophthalmol', 'JT': 'Oman journal of ophthalmology', 'JID': '101519430', 'PMC': 'PMC10062084', 'OTO': ['NOTNLM'], 'OT': ['Choroiditis', 'Harada disease', 'Vogt-Koyanagi-Harada disease', 'multimodal imaging', 'optical coherence tomography angiography'], 'COIS': ['There are no conflicts of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 03:57'], 'PHST': ['2021/12/30 00:00 [received]', '2022/12/17 00:00 [revised]', '2023/01/12 00:00 [accepted]', '2023/04/04 06:01 [medline]', '2023/04/03 03:57 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['OJO-16-88 [pii]', '10.4103/ojo.ojo_376_21 [doi]'], 'PST': 'epublish', 'SO': 'Oman J Ophthalmol. 2023 Feb 21;16(1):88-93. doi: 10.4103/ojo.ojo_376_21. eCollection 2023 Jan-Apr.'}, {'PMID': '37007240', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '0974-620X (Print) 0974-7842 (Electronic) 0974-620X (Linking)', 'VI': '16', 'IP': '1', 'DP': '2023 Jan-Apr', 'TI': 'Optic neuritis presented as the only manifestation of neurosyphilis.', 'PG': '161-164', 'LID': '10.4103/ojo.ojo_66_22 [doi]', 'AB': 'Here, we report a case of syphilis presented with optic neuritis to consider neurosyphilis as one of the differential diagnoses of optic neuritis. A 25-year-old male attended at outpatient department of chittagong eye infirmary and training complex institute with a history of a sudden loss of vision in the left eye for 20 days. On eye examination, the patient had reduced visual acuity on the left eye (6/60), and the left pupil showed a relative afferent pupillary defect and swollen left optic disc. No other abnormalities were found in a routine blood test and magnetic resonance imaging of the brain. Intravenous corticosteroid was administered for 3 days followed by oral corticosteroid. His vision was gradually improving within a month and became 6/9 in the left eye, but after a month, the patient returned with the blurring of vision in the same eye for 3 days. An extensive serum biochemical and serological test and cerebrospinal fluid (CSF) analysis was done including syphilis serology and human immunodeficiency virus (HIV) serology. Venereal disease research laboratory (VDRL) test and Treponema pallidum hemagglutination assay (TPHA) were found positive with high titer (1:1280) and rapid plasma reagin (RPR) titer of 1:64 in blood. The CSF analysis showed leukocytosis, and VDRL and TPHA were also found positive with high RPR titer. The HIV serology test was negative. The patient was treated with injectable ceftriaxone 2 g intravenously for 14 days and also injectable corticosteroid. His vision was improved within this period. Unilateral optic neuritis due to syphilis without other ocular features is uncommon but should be considered if a patient presents with visual loss and optic disc swelling. Early diagnosis based on clinical suspicion and prompt management is important to prevent visual impairment and subsequent neurological complications.', 'CI': ['Copyright: (c) 2023 Oman Ophthalmic Society.'], 'FAU': ['Roy, Tanima', 'Gupta, Anusen Das', 'Islam, Aneeka Rahnuma'], 'AU': ['Roy T', 'Gupta AD', 'Islam AR'], 'AD': ['Neuro-Ophthalmology Unit, Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.', 'Department of Internal Medicine, Chittagong Medical College, Chittagong, Bangladesh.', 'Ministry of Health and Family Welfare, Government of Bangladesh, Bangladesh.', 'Neuro-Ophthalmology Unit, Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.'], 'LA': ['eng'], 'PT': ['Case Reports'], 'DEP': '20230221', 'PL': 'India', 'TA': 'Oman J Ophthalmol', 'JT': 'Oman journal of ophthalmology', 'JID': '101519430', 'PMC': 'PMC10062096', 'OTO': ['NOTNLM'], 'OT': ['Cerebrospinal fluid analysis', 'injectable ceftriaxone', 'neurosyphilis', 'optic neuritis'], 'COIS': ['There are no conflicts of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'CRDT': ['2023/04/03 03:57'], 'PHST': ['2022/03/13 00:00 [received]', '2022/08/29 00:00 [revised]', '2022/12/10 00:00 [accepted]', '2023/04/04 06:01 [medline]', '2023/04/03 03:57 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['OJO-16-161 [pii]', '10.4103/ojo.ojo_66_22 [doi]'], 'PST': 'epublish', 'SO': 'Oman J Ophthalmol. 2023 Feb 21;16(1):161-164. doi: 10.4103/ojo.ojo_66_22. eCollection 2023 Jan-Apr.'}, {'PMID': '37006670', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '7', 'IP': '2', 'DP': '2023 Mar-Apr', 'TI': 'Pediatric Rhegmatogenous Retinal Detachments: Etiologies, Clinical Course, and Surgical Outcomes.', 'PG': '139-143', 'LID': '10.1177/24741264221150595 [doi]', 'AB': 'Purpose: To describe the predisposing factors, clinical course, and surgical methods of pediatric rhegmatogenous retinal detachment (RRD) and determine which factors affect anatomic success. Methods: Data of patients 18 years or younger who had surgical repair for RRD from January 1, 2004, to June 31, 2020, with a minimum of 6 months of follow-up were retrospectively analyzed. Results: The study evaluated 101 eyes of 94 patients. Of the eyes, 90% had at least 1 predisposing factor to pediatric RRD, including trauma (46%), myopia (41%), prior intraocular surgery (26%), and congenital anomaly (23%); 81% had macula-off detachments and 34% had proliferative vitreoretinopathy (PVR) grade C or worse at presentation. The presence of PVR grade C or worse (P = .0002), total RRD (P = .014), and vitrectomy alone at first surgery (P = .0093) were associated with worse outcomes. Patients who had scleral buckle (SB) alone at the first surgery had statistically higher rates of anatomic success than those who had vitrectomy alone or combined with SB (P = .0002). After the final surgery, 74% of patients achieved anatomic success. Discussion: The majority of cases in this study were associated with 1 of the 4 risk factors predisposing to pediatric RRD. These patients often present late with macula-off detachments and PVR grade C or worse. The majority of patients achieved anatomic success after surgical repair using SB, vitrectomy, or a combination.', 'CI': ['(c) The Author(s) 2023.'], 'FAU': ['Sparks, Madeline E', 'Davila, Pedro J', 'He, Yu-Guang', 'Wang, Angeline L'], 'AU': ['Sparks ME', 'Davila PJ', 'He YG', 'Wang AL'], 'AUID': ['ORCID: 0000-0002-9589-4638', 'ORCID: 0000-0002-7228-3930', 'ORCID: 0000-0002-5552-371X'], 'AD': ['University of Texas Southwestern Medical Center, Dallas, TX, USA.', \"Children's Health, Dallas, TX, USA.\", 'University of Texas Southwestern Medical Center, Dallas, TX, USA.', \"Children's Health, Dallas, TX, USA.\", 'University of Texas Southwestern Medical Center, Dallas, TX, USA.', \"Children's Health, Dallas, TX, USA.\", 'University of Texas Southwestern Medical Center, Dallas, TX, USA.', \"Children's Health, Dallas, TX, USA.\"], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230203', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC10037755', 'OTO': ['NOTNLM'], 'OT': ['giant retinal tear', 'pediatric ophthalmology', 'retina', 'rhegmatogenous retinal detachments', 'scleral buckle', 'vitrectomy'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2024/02/03'], 'CRDT': ['2023/04/03 03:49'], 'PHST': ['2024/02/03 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 03:49 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221150595 [pii]', '10.1177/24741264221150595 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2023 Feb 3;7(2):139-143. doi: 10.1177/24741264221150595. eCollection 2023 Mar-Apr.'}, {'PMID': '37006669', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '7', 'IP': '2', 'DP': '2023 Mar-Apr', 'TI': 'Intravitreal Rituximab-Associated Retinal Occlusive Vasculitis.', 'PG': '160-164', 'LID': '10.1177/24741264221123440 [doi]', 'AB': 'PURPOSE: To describe a 90-year-old patient who was referred to a private retina specialist with gradually worsening vision and floaters in the left eye. METHODS: A retrospective case report is presented. RESULTS: The patient was treated with intravitreal rituximab injections for intraocular lymphoma with resulting vision loss to the level of hand motions from severe granulomatous uveitis and retinal occlusive vasculitis. CONCLUSIONS: Retinal occlusive vasculopathy secondary to rituximab intravitreal injections is a rare clinical entity with only a single previous case reported in the literature. However, there are reports of systemic vasculitis after systemic administration of rituximab. Clinicians should be aware of the possibility of ocular hypertension, granulomatous anterior uveitis, and/or retinal occlusive vasculitis after intravitreal rituximab use. Consideration should be given to the inflammatory risk of rituximab intravitreal injections to reduce the potential for treatment-induced vision loss.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['McAllister, Mark A', 'Moore, Spencer M', 'Harris, April E'], 'AU': ['McAllister MA', 'Moore SM', 'Harris AE'], 'AUID': ['ORCID: 0000-0002-2020-4196'], 'AD': ['Department of Ophthalmology and Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.', 'Department of Ophthalmology and Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.', 'Department of Ophthalmology and Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.', 'Retina Associates Southwest, Tucson, AZ, USA.'], 'LA': ['eng'], 'PT': ['Case Reports'], 'DEP': '20221011', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC10037759', 'OTO': ['NOTNLM'], 'OT': ['intravitreal rituximab', 'retinal vasculitis', 'vasculopathy'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/10/11'], 'CRDT': ['2023/04/03 03:49'], 'PHST': ['2023/10/11 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 03:49 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221123440 [pii]', '10.1177/24741264221123440 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Oct 11;7(2):160-164. doi: 10.1177/24741264221123440. eCollection 2023 Mar-Apr.'}, {'PMID': '37006667', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '7', 'IP': '2', 'DP': '2023 Mar-Apr', 'TI': 'Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations: Critical Role of Retina Specialists.', 'PG': '171-177', 'LID': '10.1177/24741264221129095 [doi]', 'AB': 'PURPOSE: To describe a case of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) to enhance early recognition of this often-missed diagnosis. METHODS: A case report is presented. RESULTS: A 50-year-old woman with a history of Raynaud phenomenon, memory difficulties, and a family history of strokes was referred for evaluation of a bilateral, small-vessel, occlusive disease refractory to immunosuppressive therapy. An extensive workup for treatable causes was unrevealing. Fifteen months after presentation, brain imaging showed white-matter lesions and dystrophic calcification, which led to the discovery of a pathogenic variant in TREX1 and the diagnosis of RVCL-S. CONCLUSIONS: Retina specialists play a critical role in the timely diagnosis of RVCL-S. Although the findings in this condition can mimic those in other common retinal vascular disorders, there are key characteristics that increase the suspicion for RVCL-S. Early recognition might decrease unnecessary therapies and procedures.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['Houghton, Odette M', 'Carter, Jonathan', 'Dhamija, Radhika'], 'AU': ['Houghton OM', 'Carter J', 'Dhamija R'], 'AUID': ['ORCID: 0000-0002-9186-9371'], 'AD': ['Department of Ophthalmology, Mayo Clinic, Scottsdale, AZ, USA.', 'Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.', 'Department of Clinical Genomics, Mayo Clinic, Scottsdale, AZ, USA.'], 'LA': ['eng'], 'PT': ['Case Reports'], 'DEP': '20221203', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC10037756', 'OTO': ['NOTNLM'], 'OT': ['TREX1', 'cerebroretinal vasculopathy', 'hereditary cerebral vasculopathy', 'hereditary endotheliopathy with retinopathy', 'inherited neurodegenerative disorder', 'nephropathy and stroke and hereditary vascular retinopathy', 'retinal vasculitis', 'retinal vasculopathy with cerebral leukoencephalopathy and systemic', 'manifestations', 'white-matter abnormalities'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/12/03'], 'CRDT': ['2023/04/03 03:49'], 'PHST': ['2023/12/03 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 03:49 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221129095 [pii]', '10.1177/24741264221129095 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Dec 3;7(2):171-177. doi: 10.1177/24741264221129095. eCollection 2023 Mar-Apr.'}, {'PMID': '37006666', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '7', 'IP': '2', 'DP': '2023 Mar-Apr', 'TI': 'Telangiectatic Capillaries in Retinal Vascular Occlusions: Multimodal Imaging in a Case Series.', 'PG': '154-159', 'LID': '10.1177/24741264221149295 [doi]', 'AB': \"Introduction: To report a cases series of retinal vascular occlusions with telangiectatic capillaries (TelCaps) seen on indocyanine green angiography (ICGA) and multimodal imaging. Methods: In this case series, a new finding (TelCaps) was seen on clinical examination, fundus evaluation, fluorescein angiography, ICGA, and optical coherence tomography (OCT). Results: This series comprised 3 patients with TelCaps findings on ICGA after retinal vascular occlusions. The patients' ages ranged from 52 years to 71 years and the best-corrected visual acuity in the affected eye, from 20/25 to 20/80. Fundus evaluation showed small, hard exudates in the vascular termination close to the macula with a reduction of the foveal reflex. The OCT images showed marginal hyperreflectivity and inner hyporeflectivity that were suggestive of a TelCaps lesion, which was confirmed by hyperfluorescence in the late phase of ICGA. Conclusions: This study highlights the importance of performing multimodal imaging evaluation, including ICGA, in eyes with retinal vein occlusions for early identification and management of the associated lesions.\", 'CI': ['(c) The Author(s) 2023.'], 'FAU': ['De Oliveira, Marcela R V', 'Mota, Isabela', 'Higino, Taciana Mm', 'Ventura, Camila V', 'Japiassu, R M', 'Gantois, Michelle'], 'AU': ['De Oliveira MRV', 'Mota I', 'Higino TM', 'Ventura CV', 'Japiassu RM', 'Gantois M'], 'AD': ['Department of Ophthalmology, Altino Ventura Foundation, Pernambuco, Brazil.', 'Department of Ophthalmology, Altino Ventura Foundation, Pernambuco, Brazil.', 'Research Department, Altino Ventura Foundation, Pernambuco, Brazil.', 'Department of Ophthalmology, Altino Ventura Foundation, Pernambuco, Brazil.', 'Research Department, Altino Ventura Foundation, Pernambuco, Brazil.', 'Department of Ophthalmology, HOPE Hospital, Pernambuco, Brazil.', 'Pontificia Universidade Catolica, Rio de Janeiro, Brazil.', 'Department of Ophthalmology, Altino Ventura Foundation, Pernambuco, Brazil.', 'Department of Ophthalmology, HOPE Hospital, Pernambuco, Brazil.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230216', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC10037749', 'OTO': ['NOTNLM'], 'OT': ['microaneurysm', 'retina', 'retinal vein', 'retinal vein occlusion', 'retinal vessels', 'telangiectasia'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2024/02/16'], 'CRDT': ['2023/04/03 03:49'], 'PHST': ['2024/02/16 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 03:49 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221149295 [pii]', '10.1177/24741264221149295 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2023 Feb 16;7(2):154-159. doi: 10.1177/24741264221149295. eCollection 2023 Mar-Apr.'}, {'PMID': '37006665', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2474-1272 (Electronic) 2474-1264 (Print) 2474-1264 (Linking)', 'VI': '7', 'IP': '2', 'DP': '2023 Mar-Apr', 'TI': 'Intraocular Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy: A Review.', 'PG': '144-153', 'LID': '10.1177/24741264221135799 [doi]', 'AB': 'PURPOSE: To review the current literature on the use of intravitreal methotrexate (IVT MTX) for the treatment and prevention of proliferative vitreoretinopathy (PVR). METHODS: All reports of IVT MTX to treat and prevent PVR published in PubMed, Google Scholar, and EBSCOhost were reviewed. The relevant current studies are included in this report. RESULTS: The literature search yielded 32 articles describing the use of MTX in PVR. These included preclinical studies, 1 case report, and several case series. Early studies found that IVT MTX is a promising medication for the treatment and prevention of PVR. MTX works as a potent anti-inflammatory agent through a new mechanism of action different from that of other medications for use in PVR. Few side effects have been reported and were mostly limited to mild reversible corneal keratopathy. There are 2 current ongoing randomized controlled clinical trials to further evaluate the efficacy of MTX for PVR. CONCLUSIONS: MTX is a safe and potentially efficacious medication for the treatment and prevention of PVR. Additional clinical trials are needed to further establish this effect.', 'CI': ['(c) The Author(s) 2022.'], 'FAU': ['McAllister, Mark A', 'Moore, Spencer M', 'Bullock, Brenna', 'Christoforidis, John B'], 'AU': ['McAllister MA', 'Moore SM', 'Bullock B', 'Christoforidis JB'], 'AUID': ['ORCID: 0000-0002-2020-4196', 'ORCID: 0000-0002-0240-5963'], 'AD': ['Department of Ophthalmology & Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.', 'Department of Ophthalmology & Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.', 'Department of Ophthalmology & Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.', 'Department of Ophthalmology & Vision Science, University of Arizona College of Medicine, Tucson, AZ, USA.', 'Retina Specialists of Southern Arizona, Tucson, AZ, USA.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20221210', 'PL': 'United States', 'TA': 'J Vitreoretin Dis', 'JT': 'Journal of vitreoretinal diseases', 'JID': '101700301', 'PMC': 'PMC10037751', 'OTO': ['NOTNLM'], 'OT': ['IVT MTX', 'IVT methotrexate', 'PVR', 'intra-silicone methotrexate', 'intraocular methotrexate', 'intravitreal methotrexate', 'methotrexate', 'proliferative vitreoretinopathy'], 'COIS': ['The author(s) declared no potential conflicts of interest with respect to the', 'research, authorship, and/or publication of this article.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:01', 'PMCR': ['2023/12/10'], 'CRDT': ['2023/04/03 03:49'], 'PHST': ['2023/12/10 00:00 [pmc-release]', '2023/04/04 06:01 [medline]', '2023/04/03 03:49 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1177_24741264221135799 [pii]', '10.1177/24741264221135799 [doi]'], 'PST': 'epublish', 'SO': 'J Vitreoretin Dis. 2022 Dec 10;7(2):144-153. doi: 10.1177/24741264221135799. eCollection 2023 Mar-Apr.'}, {'PMID': '37006552', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230405', 'LR': '20230405', 'IS': '2296-2565 (Electronic) 2296-2565 (Linking)', 'VI': '11', 'DP': '2023', 'TI': 'Sensory impairments and subjective well-being status in middle-aged and older Chinese population: Cross-sectional and longitudinal analyses of a nationally representative survey.', 'PG': '1099754', 'LID': '10.3389/fpubh.2023.1099754 [doi] 1099754', 'AB': 'PURPOSE: To investigate the impacts of sensory impairments (SIs) including single vision impairment (SVI), single hearing impairment (SHI) and dual sensory impairment (DSI) on subjective wellbeing measurements including life expectancy (LE), life satisfaction (LS) and self-rated health (SRH) in middle-aged and older Chinese population. METHODS: We obtained data from the China Health and Retirement Longitudinal Survey (CHARLS). In total, 9,293 Chinese middle-aged and older adults aging over 45 were included at baseline 2011 in this study, and 3,932 participants who accomplished all 4 interviews from 2011 to 2018 were adapted for longitudinal analyses. Sensory status and subjective wellbeing measurements were collected. Other covariates included socio-demographic characteristics, medical condition and lifestyle-related factors. The impacts of baseline sensory status on LE, LS and SRH were assessed using univariate and multivariate logistic regression analyses. A linear regression analysis with generalized estimating equations (GEE) was used to assess the association between time-varying sensory statuses with LE, LS and SRH over 8 years after being adjusted with multi-confounding factors. RESULTS: Participants with SIs had significantly lower level of LE, LS, and SRH, compared to those who were free of SI. All kinds of SIs were significantly associated with LE, LS, and SRH according to cross-sectional data. The correlations between SIs and LE or SRH over 8 years were also noticed. However, only SHI and DSI were found to be significantly associated with LS according to longitudinal data (all p values < 0.05). CONCLUSION: Sensory impairments had explicitly detrimental effects on subjective wellbeing status over time among middle-aged and older Chinese population.', 'CI': ['Copyright (c) 2023 Zhou, Lu, Liu, Hou, Qian, Abuduxukuer, Xiang, Peng and Luo.'], 'FAU': ['Zhou, Yifan', 'Lu, Yan', 'Liu, Ye', 'Hou, Yanan', 'Qian, Xinyi', 'Abuduxukuer, Kaiweisa', 'Xiang, Minhong', 'Peng, Qing', 'Luo, Jianfeng'], 'AU': ['Zhou Y', 'Lu Y', 'Liu Y', 'Hou Y', 'Qian X', 'Abuduxukuer K', 'Xiang M', 'Peng Q', 'Luo J'], 'AD': [\"Department of Ophthalmology, Putuo People's Hospital, Tongji University, Shanghai, China.\", 'Office of Party and Government Affairs, Healthcare Services Center, Yichuan Street Community, Putuo, Shanghai, China.', 'Department of Clinical Medicine, School of Medicine, Soochow University, Suzhou, China.', 'Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.', 'NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.', 'Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.', 'Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.', \"Department of Endocrine and Metabolic Diseases, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.\", 'Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai, China.', 'Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.', 'NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.', 'Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.', 'Department of Ophthalmology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.', \"Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, China.\", 'Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.', 'NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.', 'Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230316', 'PL': 'Switzerland', 'TA': 'Front Public Health', 'JT': 'Frontiers in public health', 'JID': '101616579', 'SB': 'IM', 'MH': ['Aged', 'Humans', 'Middle Aged', 'Aging', 'Cross-Sectional Studies', '*East Asian People', '*Hearing Loss', 'Longitudinal Studies', 'Surveys and Questionnaires', '*Deaf-Blind Disorders', '*Vision Disorders'], 'PMC': 'PMC10064882', 'OTO': ['NOTNLM'], 'OT': ['China health and retirement longitudinal study', 'life expectancy', 'life satisfaction', 'self-rated health', 'sensory impairment'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:42', 'CRDT': ['2023/04/03 03:48'], 'PHST': ['2022/11/16 00:00 [received]', '2023/02/22 00:00 [accepted]', '2023/04/04 06:42 [medline]', '2023/04/03 03:48 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.3389/fpubh.2023.1099754 [doi]'], 'PST': 'epublish', 'SO': 'Front Public Health. 2023 Mar 16;11:1099754. doi: 10.3389/fpubh.2023.1099754. eCollection 2023.'}, {'PMID': '37006128', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230403', 'IS': '1460-2156 (Electronic) 0006-8950 (Linking)', 'DP': '2023 Apr 3', 'TI': \"Widespread genomic influences on phenotype in Dravet syndrome, a 'monogenic' condition.\", 'LID': 'awad111 [pii] 10.1093/brain/awad111 [doi]', 'AB': 'Dravet syndrome is an archetypal rare severe epilepsy, considered \"monogenic\", typically caused by loss-of-function SCN1A variants. Despite a recognisable core phenotype, its marked phenotypic heterogeneity is incompletely explained by differences in the causal SCN1A variant or clinical factors. In 34 adults with SCN1A-related Dravet syndrome, we show additional genomic variation beyond SCN1A contributes to phenotype and its diversity, with an excess of rare variants in epilepsy-related genes as a set and examples of blended phenotypes, including one individual with an ultra-rare DEPDC5 variant and focal cortical dysplasia. Polygenic risk scores for intelligence are lower, and for longevity, higher, in Dravet syndrome than in epilepsy controls. The causal, major-effect, SCN1A variant may need to act against a broadly compromised genomic background to generate the full Dravet syndrome phenotype, whilst genomic resilience may help to ameliorate the risk of premature mortality in adult Dravet syndrome survivors.', 'CI': ['(c) The Author(s) 2023. Published by Oxford University Press on behalf of the', 'Guarantors of Brain.'], 'FAU': ['Martins Custodio, Helena', 'Clayton, Lisa M', 'Bellampalli, Ravishankara', 'Pagni, Susanna', 'Silvennoinen, Katri', 'Caswell, Richard', 'Brunklaus, Andreas', 'Guerrini, Renzo', 'Koeleman, Bobby P C', 'Lemke, Johannes R', 'Moller, Rikke S', 'Scheffer, Ingrid E', 'Weckhuysen, Sarah', 'Zara, Federico', 'Zuberi, Sameer', 'Kuchenbaecker, Karoline', 'Balestrini, Simona', 'Mills, James D', 'Sisodiya, Sanjay M'], 'AU': ['Martins Custodio H', 'Clayton LM', 'Bellampalli R', 'Pagni S', 'Silvennoinen K', 'Caswell R', 'Brunklaus A', 'Guerrini R', 'Koeleman BPC', 'Lemke JR', 'Moller RS', 'Scheffer IE', 'Weckhuysen S', 'Zara F', 'Zuberi S', 'Kuchenbaecker K', 'Balestrini S', 'Mills JD', 'Sisodiya SM'], 'AD': ['University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.', 'University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.', 'University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.', 'University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.', 'University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.', 'Kuopio Epilepsy Center, Neurocenter, Kuopio University Hospital, Kuopio 70210, Finland.', 'Exeter Genomics Laboratory, Royal Devon University Healthcare NHS Foundation Trust, Exeter, EX2 5DW, UK.', 'Paediatric Neuroscience Research Group, Royal Hospital for Children, Glasgow, G51 4TF, UK.', 'Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8TB, UK.', \"Neuroscience Department, Meyer Children's Hospital IRCSS, University of Florence, 50139 Florence, Italy.\", 'Department of Genetics, University Medical Centre Utrecht, Universiteitsweg 100, 3584CX, Utrecht, The Netherlands.', 'Institute of Human Genetics, University of Leipzig Medical Center, Leipzig 04103, Germany.', 'Center for Rare Diseases, University of Leipzig Medical Center, Leipzig, 04103, Germany.', 'Danish Epilepsy Centre, Department of Epilepsy Genetics and Personalized Medicine, DK-4293 Dianalund, Denmark.', 'Department of Regional Health Research, University of Southern Denmark, DK-5230 Odense, Denmark.', \"Epilepsy Research Centre, Florey Institute, University of Melbourne, Austin Health and Royal Children's Hospital, Melbourne, VIC 3084, Australia.\", \"Murdoch Children's Research Institute, 50 Flemington Road, Parkville, VIC, 3052, Australia.\", 'Applied and Translational Neurogenomics Group, VIB Centre for Molecular Neurology, VIB, Antwerp 2610, Belgium.', 'Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp 2650, Belgium.', 'Department of Neurology, University Hospital Antwerp, Antwerp 2650, Belgium.', 'microNEURO Research Centre of Excellence, University of Antwerp, Antwerp 2610, Belgium.', 'Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147 Genoa, Italy.', 'Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Paolo Daneo 3, 16132 Genoa, Italy.', 'Paediatric Neuroscience Research Group, Royal Hospital for Children, Glasgow, G51 4TF, UK.', 'Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8TB, UK.', 'University College London Division of Psychiatry, Maple House, London, W1T 7BN, UK.', 'University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.', \"Neuroscience Department, Meyer Children's Hospital IRCSS, University of Florence, 50139 Florence, Italy.\", 'University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.', 'Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.', 'University College London Queen Square Institute of Neurology, London, WC1N 3BG, UK.', 'Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, UK.'], 'AUID': ['ORCID: 0000-0002-2271-8094', 'ORCID: 0000-0003-0713-4602', 'ORCID: 0000-0002-7728-6903', 'ORCID: 0000-0002-4435-6610', 'ORCID: 0000-0002-2311-2174', 'ORCID: 0000-0002-4489-4697', 'ORCID: 0000-0001-9726-603X', 'ORCID: 0000-0001-5639-1969', 'ORCID: 0000-0002-1511-5893'], 'CN': ['Genomics England Research Consortium'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230403', 'PL': 'England', 'TA': 'Brain', 'JT': 'Brain : a journal of neurology', 'JID': '0372537', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['SCN1A', 'Dravet syndrome', 'blended phenotypes', 'polygenic risk scores', 'polymorphism'], 'FIR': ['Ambrose, John C', 'Arumugam, Prabhu', 'Bevers, Roel', 'Bleda, Marta', 'Boardman-Pretty, Freya', 'Boustred, Christopher R', 'Brittain, Helen', 'Brown, Matthew A', 'Caulfield, Mark J', 'Chan, Georgia C', 'Giess, Adam', 'Griffin, John N', 'Hamblin, Angela', 'Henderson, Shirley', 'Hubbard, Tim J P', 'Jackson, Rob', 'Jones, Louise J', 'Kasperaviciute, Dalia', 'Kayikci, Melis', 'Kousathanas, Athanasios', 'Lahnstein, Lea', 'Lakey, Anna', 'Leigh, Sarah E A', 'Leong, Ivonne U S', 'Lopez, Javier F', 'Maleady-Crowe, Fiona', 'McEntagart, Meriel', 'Minneci, Federico', 'Mitchell, Jonathan', 'Moutsianas, Loukas', 'Mueller, Michael', 'Murugaesu, Nirupa', 'Need, Anna C', \"O'Donovan, Peter\", 'Odhams, Chris A', 'Patch, Christine', 'Perez-Gil, Daniel', 'Pereira, Marina B', 'Pullinger, John', 'Rahim, Tahrima', 'Rendon, Augusto', 'Rogers, Tim', 'Savage, Kevin', 'Sawant, Kushmita', 'Scott, Richard H', 'Siddiq, Afshan', 'Sieghart, Alexander', 'Smith, Samuel C', 'Sosinsky, Alona', 'Stuckey, Alexander', 'Tanguy, Melanie', 'Tavares, Ana Lisa Taylor', 'Thomas, Ellen R A', 'Thompson, Simon R', 'Tucci, Arianna', 'Welland, Matthew J', 'Williams, Eleanor', 'Witkowska, Katarzyna', 'Wood, Suzanne M', 'Zarowiecki, Magdalena'], 'IR': ['Ambrose JC', 'Arumugam P', 'Bevers R', 'Bleda M', 'Boardman-Pretty F', 'Boustred CR', 'Brittain H', 'Brown MA', 'Caulfield MJ', 'Chan GC', 'Giess A', 'Griffin JN', 'Hamblin A', 'Henderson S', 'Hubbard TJP', 'Jackson R', 'Jones LJ', 'Kasperaviciute D', 'Kayikci M', 'Kousathanas A', 'Lahnstein L', 'Lakey A', 'Leigh SEA', 'Leong IUS', 'Lopez JF', 'Maleady-Crowe F', 'McEntagart M', 'Minneci F', 'Mitchell J', 'Moutsianas L', 'Mueller M', 'Murugaesu N', 'Need AC', \"O'Donovan P\", 'Odhams CA', 'Patch C', 'Perez-Gil D', 'Pereira MB', 'Pullinger J', 'Rahim T', 'Rendon A', 'Rogers T', 'Savage K', 'Sawant K', 'Scott RH', 'Siddiq A', 'Sieghart A', 'Smith SC', 'Sosinsky A', 'Stuckey A', 'Tanguy M', 'Tavares ALT', 'Thomas ERA', 'Thompson SR', 'Tucci A', 'Welland MJ', 'Williams E', 'Witkowska K', 'Wood SM', 'Zarowiecki M'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:00', 'CRDT': ['2023/04/03 03:02'], 'PHST': ['2022/07/19 00:00 [received]', '2023/02/01 00:00 [revised]', '2023/03/12 00:00 [accepted]', '2023/04/03 03:02 [entrez]', '2023/04/04 06:00 [pubmed]', '2023/04/04 06:00 [medline]'], 'AID': ['7099704 [pii]', '10.1093/brain/awad111 [doi]'], 'PST': 'aheadofprint', 'SO': 'Brain. 2023 Apr 3:awad111. doi: 10.1093/brain/awad111.'}, {'PMID': '37005981', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230403', 'IS': '1720-8386 (Electronic) 0391-4097 (Linking)', 'DP': '2023 Apr 1', 'TI': \"Facial expression of patients with Graves' orbitopathy.\", 'LID': '10.1007/s40618-023-02054-y [doi]', 'AB': \"PURPOSE: Patients with Graves' orbitopathy (GO) have characteristic facial expressions that are different from those of healthy individuals due to the combination of somatic and psychiatric symptoms. However, the facial expressions of GO patients have not yet been described and analyzed systematically. Thus, the present study aimed to present the facial expressions of GO patients and explore their applications in clinical practice. METHODS: Facial image and clinical data of 943 GO patients were included, and 126 patients answered quality of life (GO-QOL) questionnaires. Each patient was labeled for one facial expression. Then, a portrait was drawn for every facial expression. Logistic and linear regression was performed to analyze the correlation between facial expression and clinical indicators, including QOL, disease activity and severity. The VGG-19 network model was utilized to discriminate facial expressions automatically. RESULTS: Two groups, i.e., the non-negative emotion (neutral, happy) and the negative emotion (disgust, angry, fear, sadness, surprise), and seven expressions of GO patients were systematically analyzed. Facial expression was statistically associated with GO activity (P = 0.002), severity (P < 0.001), QOL visual functioning subscale scores (P = 0.001), and QOL appearance subscale score (P = 0.012). The deep learning model achieved satisfactory results (accuracy 0.851, sensitivity 0.899, precision 0.899, specificity 0.720, F1 score 0.899, and AUC 0.847). CONCLUSIONS: As a novel clinical sign, facial expression holds the potential to be incorporated into GO assessment system in the future. The discrimination model may assist clinicians in real-life patient care.\", 'CI': ['(c) 2023. The Author(s), under exclusive licence to Italian Society of', 'Endocrinology (SIE).'], 'FAU': ['Lei, C', 'Qu, M', 'Sun, H', 'Huang, J', 'Huang, J', 'Song, X', 'Zhai, G', 'Zhou, H'], 'AU': ['Lei C', 'Qu M', 'Sun H', 'Huang J', 'Huang J', 'Song X', 'Zhai G', 'Zhou H'], 'AD': [\"Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.\", 'Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.', \"Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.\", 'Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.', 'School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.', 'School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China.', \"Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.\", 'Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.', \"Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. songxuefei@shsmu.edu.cn.\", 'Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China. songxuefei@shsmu.edu.cn.', 'School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China. zhaiguangtao@sjtu.edu.cn.', \"Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. fangzzfang@sjtu.edu.cn.\", 'Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China. fangzzfang@sjtu.edu.cn.'], 'AUID': ['ORCID: 0000-0002-8636-861X'], 'LA': ['eng'], 'GR': ['2018YFC1106100/the National Key R&D Program of China/', '2018YFC1106101/the National Key R&D Program of China/', 'ZH2018QNA07/School of Medicine, Shanghai Jiao Tong University/', 'ZH2018ZDA12/School of Medicine, Shanghai Jiao Tong University/', '19410761100/the Science and Technology Commission of Shanghai/', '19DZ2331400/the Science and Technology Commission of Shanghai/', \"JYJC202115/Cross disciplinary Research Fund of Shanghai Ninth People's Hospital,\", 'Shanghai JiaoTong university School of Medicine/', 'SHSMU-ZDCX20210901/Innovative Research Team of High-Level Local Universities in', 'Shanghai/', '2022ZZ01003/Shanghai Key Clinical Specialty, Shanghai Eye Disease Research', 'Center/'], 'PT': ['Journal Article'], 'DEP': '20230401', 'PL': 'Italy', 'TA': 'J Endocrinol Invest', 'JT': 'Journal of endocrinological investigation', 'JID': '7806594', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Deep learning', 'Facial expression', \"Graves' orbitopathy\", 'Patient-reported outcome', 'Quality of life'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:00', 'CRDT': ['2023/04/03 02:45'], 'PHST': ['2023/01/18 00:00 [received]', '2023/02/27 00:00 [accepted]', '2023/04/03 02:45 [entrez]', '2023/04/04 06:00 [pubmed]', '2023/04/04 06:00 [medline]'], 'AID': ['10.1007/s40618-023-02054-y [pii]', '10.1007/s40618-023-02054-y [doi]'], 'PST': 'aheadofprint', 'SO': 'J Endocrinol Invest. 2023 Apr 1. doi: 10.1007/s40618-023-02054-y.'}, {'PMID': '37005490', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230403', 'IS': '2523-3548 (Electronic) 2523-3548 (Linking)', 'DP': '2023 Apr 2', 'TI': 'Tumor microenvironment signaling and therapeutics in cancer progression.', 'LID': '10.1002/cac2.12416 [doi]', 'AB': 'Tumor development and metastasis are facilitated by the complex interactions between cancer cells and their microenvironment, which comprises stromal cells and extracellular matrix (ECM) components, among other factors. Stromal cells can adopt new phenotypes to promote tumor cell invasion. A deep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions. In this review, we describe the tumor microenvironment (TME) components and associated therapeutics. We discuss the clinical advances in the prevalent and newly discovered signaling pathways in the TME, the immune checkpoints and immunosuppressive chemokines, and currently used inhibitors targeting these pathways. These include both intrinsic and non-autonomous tumor cell signaling pathways in the TME: protein kinase C (PKC) signaling, Notch, and transforming growth factor (TGF-beta) signaling, Endoplasmic Reticulum (ER) stress response, lactate signaling, Metabolic reprogramming, cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) and Siglec signaling pathways. We also discuss the recent advances in Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), T-cell immunoglobulin mucin-3 (TIM-3) and Lymphocyte Activating Gene 3 (LAG3) immune checkpoint inhibitors along with the C-C chemokine receptor 4 (CCR4)- C-C class chemokines 22 (CCL22)/ and 17 (CCL17), C-C chemokine receptor type 2 (CCR2)- chemokine (C-C motif) ligand 2 (CCL2), C-C chemokine receptor type 5 (CCR5)- chemokine (C-C motif) ligand 3 (CCL3) chemokine signaling axis in the TME. In addition, this review provides a holistic understanding of the TME as we discuss the three-dimensional and microfluidic models of the TME, which are believed to recapitulate the original characteristics of the patient tumor and hence may be used as a platform to study new mechanisms and screen for various anti-cancer therapies. We further discuss the systemic influences of gut microbiota in TME reprogramming and treatment response. Overall, this review provides a comprehensive analysis of the diverse and most critical signaling pathways in the TME, highlighting the associated newest and critical preclinical and clinical studies along with their underlying biology. We highlight the importance of the most recent technologies of microfluidics and lab-on-chip models for TME research and also present an overview of extrinsic factors, such as the inhabitant human microbiome, which have the potential to modulate TME biology and drug responses.', 'CI': ['(c) 2023 The Authors. Cancer Communications published by John Wiley & Sons', 'Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.'], 'FAU': ['Goenka, Anshika', 'Khan, Fatima', 'Verma, Bhupender', 'Sinha, Priyanka', 'Dmello, Crismita C', 'Jogalekar, Manasi P', 'Gangadaran, Prakash', 'Ahn, Byeong-Cheol'], 'AU': ['Goenka A', 'Khan F', 'Verma B', 'Sinha P', 'Dmello CC', 'Jogalekar MP', 'Gangadaran P', 'Ahn BC'], 'AD': ['The Ken & Ruth Davee Department of Neurology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, 60611, IL, USA.', 'Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, 60611, IL, USA.', 'Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 02114, MA, USA.', 'Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, 02129, MA, USA.', 'Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, 60611, IL, USA.', 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, 94143, CA, USA.', 'BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, 41944, South Korea.', 'Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.', 'BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, 41944, South Korea.', 'Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, 41944, South Korea.'], 'AUID': ['ORCID: 0000-0002-8860-0339', 'ORCID: 0000-0001-7700-3929'], 'LA': ['eng'], 'GR': ['NRF-2022R1A2C2005057/National Research Foundation of Korea (NRF) grant funded by', 'the Korea government (MSIT)/'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230402', 'PL': 'United States', 'TA': 'Cancer Commun (Lond)', 'JT': 'Cancer communications (London, England)', 'JID': '101723675', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['3D-model', 'cancer therapy', 'gut microbiota', 'immune signaling', 'metabolism', 'signaling', 'tumor microenvironment'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:00', 'CRDT': ['2023/04/03 00:40'], 'PHST': ['2023/02/22 00:00 [revised]', '2022/10/24 00:00 [received]', '2023/03/20 00:00 [accepted]', '2023/04/03 00:40 [entrez]', '2023/04/04 06:00 [pubmed]', '2023/04/04 06:00 [medline]'], 'AID': ['10.1002/cac2.12416 [doi]'], 'PST': 'aheadofprint', 'SO': 'Cancer Commun (Lond). 2023 Apr 2. doi: 10.1002/cac2.12416.'}, {'PMID': '37005436', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230404', 'LR': '20230405', 'IS': '2045-2322 (Electronic) 2045-2322 (Linking)', 'VI': '13', 'IP': '1', 'DP': '2023 Apr 1', 'TI': 'Exploring the components and mechanisms of Shen-qi-wang-mo granule in the treatment of retinal vein occlusion by UPLC-Triple TOF MS/MS and network pharmacology.', 'PG': '5330', 'LID': '10.1038/s41598-023-32472-0 [doi] 5330', 'AB': 'This study aimed to explore the substance basis and mechanisms of Shen-qi-wang-mo Granule (SQWMG), a traditional Chinese medicine prescription that had been clinically utilized to treat retinal vein occlusion (RVO) for 38 years. Components in SQWMG were analyzed by UPLC-Triple-TOF/MS and a total of 63 components were identified with ganoderic acids (GA) being the largest proportion. Potential targets of active components were retrieved from SwissTargetPrediction. RVO-related targets were acquired from related disease databases. Core targets of SQWMG against RVO were acquired by overlapping the above targets. The 66 components (including 5 isomers) and 169 targets were obtained and concluded into a component-target network. Together with biological enrichment analysis of targets, it revealed the crucial role of the \"PI3K-Akt signaling pathway\", \"MAPK signaling pathway\" and their downstream factor iNOS and TNF-alpha. The 20 key targets of SQWMG in treating RVO were acquired from the network and pathway analysis. The effects of SQWMG on targets and pathways were validated by molecular docking based on AutoDock Vina and qPCR experiment. The molecular docking showed great affinity for these components and targets, especially on ganoderic acids (GA) and alisols (AS), which were both triterpenoids and qPCR exhibited remarkably reduced inflammatory factor gene expression through regulation of these two pathways. Finally, the key components were also identified from rat serum after treatment of SQWMG.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Zhao, Yi', 'Ma, Cui', 'Qiu, Qinghua', 'Huang, Xucong', 'Qiaolongbatu, Xijier', 'Qu, Han', 'Wu, Jiaqi', 'Fan, Guorong', 'Wu, Zhenghua'], 'AU': ['Zhao Y', 'Ma C', 'Qiu Q', 'Huang X', 'Qiaolongbatu X', 'Qu H', 'Wu J', 'Fan G', 'Wu Z'], 'AD': [\"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China.\", \"School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China.\", \"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China.\", \"Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China.\", \"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China.\", \"School of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China.\", \"School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China.\", \"School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China.\", \"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China.\", \"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China. fanguorong@sjtu.edu.cn.\", \"Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China. zhenghua.wu@shgh.cn.\"], 'LA': ['eng'], 'GR': ['81793289/National Natural Science Foundation of China/', '22S21902000/Shanghai Scientific and Technological Committee/', '320.6750.2021-2-75/Wu Jieping Medical Foundation/', '2020SJ277/Shanghai Songjiang District Science and technology research project/'], 'PT': ['Journal Article'], 'DEP': '20230401', 'PL': 'England', 'TA': 'Sci Rep', 'JT': 'Scientific reports', 'JID': '101563288', 'RN': ['EC 2.7.1.- (Phosphatidylinositol 3-Kinases)', '0 (ganoderic acid)', '0 (Drugs, Chinese Herbal)'], 'SB': 'IM', 'MH': ['Animals', 'Rats', 'Network Pharmacology', 'Molecular Docking Simulation', 'Phosphatidylinositol 3-Kinases', '*Retinal Vein Occlusion/drug therapy', 'Tandem Mass Spectrometry', '*Drugs, Chinese Herbal/pharmacology/therapeutic use'], 'PMC': 'PMC10066998', 'COIS': ['The authors declare no competing interests.'], 'EDAT': '2023/04/04 06:00', 'MHDA': '2023/04/04 06:42', 'CRDT': ['2023/04/03 00:36'], 'PHST': ['2022/12/20 00:00 [received]', '2023/03/28 00:00 [accepted]', '2023/04/04 06:42 [medline]', '2023/04/03 00:36 [entrez]', '2023/04/04 06:00 [pubmed]'], 'AID': ['10.1038/s41598-023-32472-0 [pii]', '32472 [pii]', '10.1038/s41598-023-32472-0 [doi]'], 'PST': 'epublish', 'SO': 'Sci Rep. 2023 Apr 1;13(1):5330. doi: 10.1038/s41598-023-32472-0.'}, {'PMID': '37004107', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230404', 'IS': '2326-0254 (Print) 2326-0254 (Electronic) 2326-0254 (Linking)', 'VI': '10', 'IP': '1', 'DP': '2023 Apr 1', 'TI': 'Metabolomic analysis of aqueous humor reveals potential metabolite biomarkers for differential detection of macular edema.', 'PG': '14', 'LID': '10.1186/s40662-023-00331-8 [doi] 14', 'AB': 'BACKGROUND: Macular edema (ME) is a major complication of retinal disease with multiple mechanisms involved in its development. This study aimed to investigate the metabolite profile of aqueous humor (AH) in patients with ME of different etiologies and identify potential metabolite biomarkers for early diagnosis of ME. METHODS: Samples of AH were collected from 60 patients with ME and 20 age- and sex-matched controls and analyzed by liquid chromatography-mass spectrometry (LC/MS)-based metabolomics. A series of univariate and multivariate statistical analyses were performed to identify differential metabolites and enriched metabolite pathways. RESULTS: The metabolic profile of AH differed significantly between ME patients and healthy controls, and differentially expressed metabolites were identified. Pathway analysis revealed that these differentially expressed metabolites are mainly involved in lipid metabolism and amino acid metabolism. Moreover, significant differences were identified in the metabolic composition of AH from patients with ME due to different retinal diseases including age-related macular degeneration (AMD-ME), diabetic retinopathy (DME) and branch retinal vein occlusion (BRVO-ME). In total, 39 and 79 etiology-specific altered metabolites were identified for AMD-ME and DME, respectively. Finally, an AH-derived machine learning-based diagnostic model was developed and successfully validated in the test cohort with an area under the receiver operating characteristic (ROC) curve of 0.79 for AMD-ME, 0.94 for DME and 0.77 for BRVO-ME. CONCLUSIONS: Our study illustrates the potential underlying metabolic basis of AH of different etiologies across ME populations. We also identify AH-derived metabolite biomarkers that may improve the differential diagnosis and treatment stratification of ME patients with different etiologies.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Jiang, Dan', 'Yan, Congcong', 'Ge, Lina', 'Yang, Chun', 'Huang, Ying', 'Chan, Yau Kei', 'Chen, Chonghua', 'Chen, Wei', 'Zhou, Meng', 'Lin, Bing'], 'AU': ['Jiang D', 'Yan C', 'Ge L', 'Yang C', 'Huang Y', 'Chan YK', 'Chen C', 'Chen W', 'Zhou M', 'Lin B'], 'AD': ['National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China. zhoumeng@wmu.edu.cn.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China. lbing124@126.com.'], 'AUID': ['ORCID: 0000-0002-9587-7731'], 'LA': ['eng'], 'GR': ['82000909/Young Scientists Fund/'], 'PT': ['Journal Article'], 'DEP': '20230401', 'PL': 'England', 'TA': 'Eye Vis (Lond)', 'JT': 'Eye and vision (London, England)', 'JID': '101664982', 'PMC': 'PMC10067239', 'OTO': ['NOTNLM'], 'OT': ['Liquid chromatography-mass spectrometry', 'Macular edema', 'Metabolic biomarkers', 'Metabolomics'], 'COIS': ['The authors declare that they have no competing interests.'], 'EDAT': '2023/04/03 06:00', 'MHDA': '2023/04/03 06:01', 'CRDT': ['2023/04/02 00:30'], 'PHST': ['2022/07/23 00:00 [received]', '2023/02/13 00:00 [accepted]', '2023/04/03 06:01 [medline]', '2023/04/02 00:30 [entrez]', '2023/04/03 06:00 [pubmed]'], 'AID': ['10.1186/s40662-023-00331-8 [pii]', '331 [pii]', '10.1186/s40662-023-00331-8 [doi]'], 'PST': 'epublish', 'SO': 'Eye Vis (Lond). 2023 Apr 1;10(1):14. doi: 10.1186/s40662-023-00331-8.'}, {'PMID': '37002709', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230401', 'IS': '1398-9995 (Electronic) 0105-4538 (Linking)', 'DP': '2023 Apr 1', 'TI': 'Organ-specific allergen challenges in airway allergy: current utilities and future directions.', 'LID': '10.1111/all.15731 [doi]', 'AB': 'Atopy has been long used as the screening method for airway allergy. Nevertheless, aeroallergens can trigger respiratory symptoms not only in atopic patients (atopic respiratory allergy, ARA), but also in non-atopic subjects (local respiratory allergy, LRA). Moreover, ARA and LRA can coexist in the same patient, and this clinical scenario has been called dual respiratory allergy (DRA). When the clinical history cannot determine the relevance of sensitizations in ARA patients, nasal, conjunctival or bronchial allergen challenges (NAC, CAC and BAC, respectively) should be conducted. Moreover, these tests are required to identify patients with LRA and DRA. The clarification of the allergic triggers of airway diseases has a profound impact on the management strategies the patients can be offered. Importantly, allergen immunotherapy (AIT) remains as the only disease-modifying intervention for ARA. Recent data indicate that AIT might have a similar effect on LRA patients. Nevertheless, AIT success relies largely on the correct phenotyping of allergic individuals, and NAC, CAC and BAC are very helpful tools in this regard. In this review, we will summarize the main indications and methodology of CAC, NAC and BAC. Importantly, the clinical implementation of these tests might translate into precision medicine approaches and better health outcomes for patients with airway allergy.', 'CI': ['This article is protected by copyright. All rights reserved.'], 'FAU': ['Fauquert, J L', 'Alba-Linero, C', 'Gherasim, A', 'Testera-Montes, A', 'Bentabol-Ramos, G', 'de Santa Maria-Garcia, R Saenz', 'Torres, M J', 'Eguiluz-Gracia, I', 'Rondon, C'], 'AU': ['Fauquert JL', 'Alba-Linero C', 'Gherasim A', 'Testera-Montes A', 'Bentabol-Ramos G', 'de Santa Maria-Garcia RS', 'Torres MJ', 'Eguiluz-Gracia I', 'Rondon C'], 'AUID': ['ORCID: 0000-0002-6929-9819', 'ORCID: 0000-0002-3198-1396', 'ORCID: 0000-0001-5228-471X', 'ORCID: 0000-0002-3774-931X', 'ORCID: 0000-0003-0976-3402'], 'AD': ['University Hospital, Clermont-Ferrand, France.', 'Ophthalmology Unit, Hospital Clinico Virgen de la Victoria. Malaga, Spain.', 'Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND. RICORS \"Inflammatory diseases\". Malaga, Spain.', 'Universidad de Malaga. Malaga, Spain.', 'ALYATEC Environmental Exposure Chamber, Strasbourg, France.', 'Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND. RICORS \"Inflammatory diseases\". Malaga, Spain.', 'Allergy Unit, Hospital Regional Universitario de Malaga. Malaga, Spain.', 'Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND. RICORS \"Inflammatory diseases\". Malaga, Spain.', 'Pulmonology Unit, Hospital Regional Universitario de Malaga. Malaga, Spain.', 'Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND. RICORS \"Inflammatory diseases\". Malaga, Spain.', 'Allergy Unit, Hospital Regional Universitario de Malaga. Malaga, Spain.', 'Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND. RICORS \"Inflammatory diseases\". Malaga, Spain.', 'Universidad de Malaga. Malaga, Spain.', 'Allergy Unit, Hospital Regional Universitario de Malaga. Malaga, Spain.', 'Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND. RICORS \"Inflammatory diseases\". Malaga, Spain.', 'Allergy Unit, Hospital Regional Universitario de Malaga. Malaga, Spain.', 'Allergy Research Group, Instituto de Investigacion Biomedica de Malaga (IBIMA)-Plataforma BIONAND. RICORS \"Inflammatory diseases\". Malaga, Spain.', 'Allergy Unit, Hospital Regional Universitario de Malaga. Malaga, Spain.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230401', 'PL': 'Denmark', 'TA': 'Allergy', 'JT': 'Allergy', 'JID': '7804028', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['allergic asthma', 'allergic rhinitis', 'bronchial allergen challenge', 'conjunctival allergen challenge', 'nasal allergen challenge'], 'EDAT': '2023/04/02 06:00', 'MHDA': '2023/04/02 06:00', 'CRDT': ['2023/04/01 03:42'], 'PHST': ['2023/03/07 00:00 [revised]', '2022/07/30 00:00 [received]', '2023/03/26 00:00 [accepted]', '2023/04/01 03:42 [entrez]', '2023/04/02 06:00 [pubmed]', '2023/04/02 06:00 [medline]'], 'AID': ['10.1111/all.15731 [doi]'], 'PST': 'aheadofprint', 'SO': 'Allergy. 2023 Apr 1. doi: 10.1111/all.15731.'}, {'PMID': '37002618', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230401', 'IS': '1708-8267 (Electronic) 1081-5589 (Linking)', 'DP': '2023 Mar 31', 'TI': 'Building a new regional home for implementation science: Annual Midwest Clinical & Translational Research Meetings.', 'PG': '10815589231166102', 'LID': '10.1177/10815589231166102 [doi]', 'AB': 'The vision of the Central Society for Clinical and Translational Research (CSCTR) is to \"promote a vibrant, supportive community of multidisciplinary, clinical, and translational medical research to benefit humanity.\" Together with the Midwestern Section of the American Federation for Medical Research, CSCTR hosts an Annual Midwest Clinical & Translational Research Meeting, a regional multispecialty meeting that provides the opportunity for trainees and early-stage investigators to present their research to leaders in their fields. There is an increasing national and global interest in implementation science (IS), the systematic study of activities (or strategies) to facilitate the successful uptake of evidence-based health interventions in clinical and community settings. Given the growing importance of this field and its relevance to the goals of the CSCTR, in 2022, the Midwest Clinical & Translational Research Meeting incorporated new initiatives and sessions in IS. In this report, we describe the role of IS in the translational research spectrum, provide a summary of sessions from the 2022 Midwest Clinical & Translational Research Meeting, and highlight initiatives to complement national efforts to build capacity for IS through the annual meetings.', 'FAU': ['Scanzera, Angelica C', 'Nyenhuis, Sharmilee M', 'Rudd, Brittany N', 'Ramaswamy, Megha', 'Mazzucca, Stephanie', 'Castro, Mario', 'Kennedy, David J', 'Mermelstein, Robin J', 'Chambers, David A', 'Dudek, Steven M', 'Krishnan, Jerry A'], 'AU': ['Scanzera AC', 'Nyenhuis SM', 'Rudd BN', 'Ramaswamy M', 'Mazzucca S', 'Castro M', 'Kennedy DJ', 'Mermelstein RJ', 'Chambers DA', 'Dudek SM', 'Krishnan JA'], 'AD': ['Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois Chicago, Chicago, IL, USA.', 'Department of Pediatrics, University of Chicago, Chicago, IL, USA.', 'Institute for Juvenile Research, University of Illinois Chicago, Chicago, IL, USA.', 'KU Medical Center, University of Kansas, Kansas City, KS, USA.', 'Brown School, Washington University in St Louis, St Louis, MO, USA.', 'KU Medical Center, University of Kansas, Kansas City, KS, USA.', 'Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.', 'Institute for Health Research and Policy, University of Illinois Chicago, Chicago, IL, USA.', 'Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.', 'Department of Medicine, University of Illinois Chicago, Chicago, IL, USA.', 'Department of Medicine, University of Illinois Chicago, Chicago, IL, USA.', 'Population Health Sciences Program, University of Illinois Chicago, Chicago, IL, USA.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230331', 'PL': 'England', 'TA': 'J Investig Med', 'JT': 'Journal of investigative medicine : the official publication of the American Federation for Clinical Research', 'JID': '9501229', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Translational medical research', 'diabetes mellitus', 'diabetic retinopathy', 'implementation science'], 'EDAT': '2023/04/02 06:00', 'MHDA': '2023/04/02 06:00', 'CRDT': ['2023/04/01 01:52'], 'PHST': ['2023/04/01 01:52 [entrez]', '2023/04/02 06:00 [pubmed]', '2023/04/02 06:00 [medline]'], 'AID': ['10.1177/10815589231166102 [doi]'], 'PST': 'aheadofprint', 'SO': 'J Investig Med. 2023 Mar 31:10815589231166102. doi: 10.1177/10815589231166102.'}, {'PMID': '37002599', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230405', 'IS': '1096-9861 (Electronic) 0021-9967 (Linking)', 'DP': '2023 Mar 31', 'TI': 'Expression of alpha-Synuclein in the mouse retina is confined to inhibitory presynaptic elements.', 'LID': '10.1002/cne.25481 [doi]', 'AB': \"alpha-Synuclein (alpha-Syn) is enriched in presynaptic terminals of the central nervous system including the retina and plays a role in the synaptic vesicle cycle and synaptic transmission. Abnormal aggregation of alpha-Syn is considered to be the main component of the Lewy bodies that are the pathological hallmarks of Parkinson's disease. Although expression pattern of alpha-Syn has been described in the retinas, its precise cellular and subcellular locations are poorly understood. We investigated the precise expression of alpha-Syn using light microscopy (LM) and electron microscopy (EM) with antibodies against alpha-Syn in the mouse retina. We found that the majority of alpha-Syn immunoreactivity (IR) is located in GABAergic, glycinergic, and dopaminergic amacrine cells, and their processes often make a direct synapse to other labeled or unlabeled amacrine profiles, bipolar cell terminals, or ganglion cell dendrites. Further, our LM and immuno-EM results confirm the absence of alpha-Syn in excitatory photoreceptors, bipolar cell bodies, and their ribbon synapses, providing evidence, for the first time, that ribbon synapses do not express alpha-Syn. Additionally, alpha-Syn IR is located in the ganglion cells, some of which are intrinsically photosensitive retinal ganglion cells. These results reveal a previously unappreciated inhibitory synapse-specific expression pattern of alpha-Syn in the retina, suggesting that alpha-Syn may play a distinct role in the modulation and integration of inhibitory synaptic transmission in the retina.\", 'CI': ['(c) 2023 Wiley Periodicals LLC.'], 'FAU': ['Yang, Qingwen', 'Lin, Xin', 'Xiao, Jiayi', 'Zhong, Wenhui', 'Wang, Fenglan', 'Tan, Hang', 'Rao, Bilin', 'Qu, Jia', 'Zhang, Jun'], 'AU': ['Yang Q', 'Lin X', 'Xiao J', 'Zhong W', 'Wang F', 'Tan H', 'Rao B', 'Qu J', 'Zhang J'], 'AD': ['Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'State Key Laboratory of Ophthalmology, Optometry and Vision Science, Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'Laboratory of Retinal Physiology and Disease, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'State Key Laboratory of Ophthalmology, Optometry and Vision Science, Eye Hospital, Wenzhou Medical University, Wenzhou, China.', 'National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China.'], 'AUID': ['ORCID: 0000-0002-4796-8479'], 'LA': ['eng'], 'GR': ['89219003/Start-up Foundation of Wenzhou Medical University/', '4241320001G/State Key Laboratory of Ophthalmology, Optometry and Visual Science/', 'LY21H120004/Zhejiang Provincial Natural Science Foundation of China/', 'Y20190168/Wenzhou Natural Science Foundation of China/'], 'PT': ['Journal Article'], 'DEP': '20230331', 'PL': 'United States', 'TA': 'J Comp Neurol', 'JT': 'The Journal of comparative neurology', 'JID': '0406041', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['amacrine cells', 'excitatory ribbon synapses', 'inhibitory synapses', 'retina', 'alpha-Synuclein'], 'EDAT': '2023/04/02 06:00', 'MHDA': '2023/04/02 06:00', 'CRDT': ['2023/04/01 01:32'], 'PHST': ['2023/01/18 00:00 [revised]', '2022/08/29 00:00 [received]', '2023/03/13 00:00 [accepted]', '2023/04/02 06:00 [pubmed]', '2023/04/02 06:00 [medline]', '2023/04/01 01:32 [entrez]'], 'AID': ['10.1002/cne.25481 [doi]'], 'PST': 'aheadofprint', 'SO': 'J Comp Neurol. 2023 Mar 31. doi: 10.1002/cne.25481.'}, {'PMID': '37001972', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230331', 'IS': '1468-2079 (Electronic) 0007-1161 (Linking)', 'DP': '2023 Mar 31', 'TI': 'Distribution and determinants of choroidal vascularity index in healthy eyes from deep-learning choroidal analysis: a population-based SS-OCT study.', 'LID': 'bjo-2023-323224 [pii] 10.1136/bjo-2023-323224 [doi]', 'AB': 'AIMS: To quantify the profiles of choroidal vascularity index (CVI) using fully artificial intelligence (AI)-based algorithm applied to swept-source optical coherence tomography (SS-OCT) images and evaluate the determinants of CVI in a population-based study. METHODS: This cross-sectional study included adults aged >/=35 years residing in the Yuexiu District of Guangzhou, China, a follow-up population-based study. All participants (n=646) underwent comprehensive ophthalmic examinations, including SS-OCT for quantifying choroidal parameters. The CVI and subfoveal choroidal thickness (SFCT) were measured by a novel AI-based system. RESULTS: A total of 556 participants were included, with a mean age of 56.4+/-9.9 years and 44.96% women. The average CVI and SFCT of the overall population were 69.7% (95% CI 69.2 to 70.3) and 263.0 microm (95% CI 257.2 to 268.8), respectively. After adjusting for other factors, older age and longer AL were significantly associated with a lower CVI. The CVI decreased by -0.13% (-0.19 to -0.06, p<0.001) with each 1-year increase in age, -2.10% (-3.29 to -0.92, p=0.001) with each 1 mm increase in AL. Furthermore, significantly positive correlation between CVI and SFCT has been observed, with coefficient of 0.059 (0.052 to 0.065, p<0.001). CONCLUSION: Using new AI-based choroidal segmentation software, we provided a fast, reliable and objective CVI profile for large-scale samples. Older age and longer AL were independent correlates of choroidal thinning and CVI decline. These factors should be considered when interpreting SS-OCT-based choroidal measurements.', 'CI': ['(c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and', 'permissions. Published by BMJ.'], 'FAU': ['Xuan, Meng', 'Li, Cong', 'Kong, Xiangbin', 'Zhang, Jian', 'Wang, Wei', 'He, Mingguang'], 'AU': ['Xuan M', 'Li C', 'Kong X', 'Zhang J', 'Wang W', 'He M'], 'AD': ['State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'Department of Ophthalmology, Affiliated Foshan Hospital, Southern Medical University, Foshan, Guangdong, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China wangwei@gzzoc.com mingguang.he@unimelb.edu.au.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China wangwei@gzzoc.com mingguang.he@unimelb.edu.au.', 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.', 'School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.', 'Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong, China.', 'Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong, China.'], 'AUID': ['ORCID: 0000-0002-5273-3332'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230331', 'PL': 'England', 'TA': 'Br J Ophthalmol', 'JT': 'The British journal of ophthalmology', 'JID': '0421041', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Anatomy', 'Choroid', 'Epidemiology', 'Imaging', 'Public health'], 'COIS': ['Competing interests: None declared.'], 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/01 06:00', 'CRDT': ['2023/03/31 21:02'], 'PHST': ['2023/01/10 00:00 [received]', '2023/03/14 00:00 [accepted]', '2023/03/31 21:02 [entrez]', '2023/04/01 06:00 [pubmed]', '2023/04/01 06:00 [medline]'], 'AID': ['bjo-2023-323224 [pii]', '10.1136/bjo-2023-323224 [doi]'], 'PST': 'aheadofprint', 'SO': 'Br J Ophthalmol. 2023 Mar 31:bjo-2023-323224. doi: 10.1136/bjo-2023-323224.'}, {'PMID': '37001788', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230331', 'IS': '1879-1891 (Electronic) 0002-9394 (Linking)', 'DP': '2023 Mar 29', 'TI': 'Reply to Comment on \"Choriocapillaris flow deficit as a biomarker for diabetic retinopathy and diabetic macular edema: 3-year longitudinal cohort\".', 'LID': 'S0002-9394(23)00131-9 [pii] 10.1016/j.ajo.2023.03.020 [doi]', 'FAU': ['Chen, Yanping', 'Wang, Wei'], 'AU': ['Chen Y', 'Wang W'], 'AD': ['State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.', 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China. Electronic address: wangwei@gzzoc.com.'], 'LA': ['eng'], 'PT': ['Letter'], 'DEP': '20230329', 'PL': 'United States', 'TA': 'Am J Ophthalmol', 'JT': 'American journal of ophthalmology', 'JID': '0370500', 'SB': 'IM', 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/01 06:00', 'CRDT': ['2023/03/31 19:32'], 'PHST': ['2023/03/20 00:00 [received]', '2023/03/20 00:00 [accepted]', '2023/03/31 19:32 [entrez]', '2023/04/01 06:00 [pubmed]', '2023/04/01 06:00 [medline]'], 'AID': ['S0002-9394(23)00131-9 [pii]', '10.1016/j.ajo.2023.03.020 [doi]'], 'PST': 'aheadofprint', 'SO': 'Am J Ophthalmol. 2023 Mar 29:S0002-9394(23)00131-9. doi: 10.1016/j.ajo.2023.03.020.'}, {'PMID': '37001772', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230406', 'IS': '1879-0003 (Electronic) 0141-8130 (Linking)', 'VI': '239', 'DP': '2023 Mar 29', 'TI': 'The impact of non-coding RNAs in the pathobiology of eye disorders.', 'PG': '124245', 'LID': 'S0141-8130(23)01139-X [pii] 10.1016/j.ijbiomac.2023.124245 [doi]', 'AB': 'Eye disorders are common disorders with significant effects on personal, economic, and social aspects of life. These disorders have a genetic background and are associated with dysregulation of non-coding RNAs. Three classes of these transcripts, namely long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and microRNAs (miRNAs) have established roles in the regulation of gene expression and pathoetiology of ocular disorders. H19, MEG3, BANCR, UCA1, HOTAIR, ANRIL, XIST and MIAT are among important lncRNAs in ocular disorders. CircRNAs from ZBTB44, HIPK3, circ-PSEN1, COL1A2, ZNF532 and FAM158A loci have also been found to affect pathoetiology of ocular disorders. Both lncRNAs and circRNAs can serve as molecular sponges for miRNAs. In this review, we searched PubMed and Google Scholar databases to find the research articles summarizing the impact of non-coding RNAs in ocular disorders. The results of these studies would help in identification of suitable targets for treatment of ocular disorders.', 'CI': ['Copyright (c) 2023 Elsevier B.V. All rights reserved.'], 'FAU': ['Moallemi Rad, Lina', 'Sadoughi, Mohammad Mehdi', 'Nicknam, Amir', 'Colagar, Abasalt Hosseinzadeh', 'Hussen, Bashdar Mahmud', 'Taheri, Mohammad', 'Ghafouri-Fard, Soudeh'], 'AU': ['Moallemi Rad L', 'Sadoughi MM', 'Nicknam A', 'Colagar AH', 'Hussen BM', 'Taheri M', 'Ghafouri-Fard S'], 'AD': ['Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran.', 'Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.', 'Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.', 'Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran.', 'Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq.', 'Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Institute of Human Genetics, Jena University Hospital, Jena, Germany. Electronic address: mohammad.taheri@uni-jena.de.', 'Department of Medical Genetics, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: s.ghafourifard@sbmu.ac.ir.'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230329', 'PL': 'Netherlands', 'TA': 'Int J Biol Macromol', 'JT': 'International journal of biological macromolecules', 'JID': '7909578', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['Eye disorder', 'circRNA', 'lncRNA', 'miRNA'], 'COIS': ['Declaration of competing interest The authors declare they have no conflict of', 'interest.'], 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/01 06:00', 'CRDT': ['2023/03/31 19:32'], 'PHST': ['2022/09/24 00:00 [received]', '2023/03/06 00:00 [revised]', '2023/03/15 00:00 [accepted]', '2023/04/01 06:00 [pubmed]', '2023/04/01 06:00 [medline]', '2023/03/31 19:32 [entrez]'], 'AID': ['S0141-8130(23)01139-X [pii]', '10.1016/j.ijbiomac.2023.124245 [doi]'], 'PST': 'aheadofprint', 'SO': 'Int J Biol Macromol. 2023 Mar 29;239:124245. doi: 10.1016/j.ijbiomac.2023.124245.'}, {'PMID': '37001522', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230331', 'IS': '2666-6340 (Electronic) 2666-6340 (Linking)', 'DP': '2023 Mar 22', 'TI': 'In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening.', 'LID': 'S2666-6340(23)00097-1 [pii] 10.1016/j.medj.2023.03.001 [doi]', 'AB': 'BACKGROUND: The GNAO1 gene, encoding the major neuronal G protein Galphao, is mutated in a subset of pediatric encephalopathies. Most such mutations consist of missense variants. METHODS: In this study, we present a precision medicine workflow combining next-generation sequencing (NGS) diagnostics, molecular etiology analysis, and personalized drug discovery. FINDINGS: We describe a patient carrying a de novo intronic mutation (NM_020988.3:c.724-8G>A), leading to epilepsy-negative encephalopathy with motor dysfunction from the second decade. Our data show that this mutation creates a novel splice acceptor site that in turn causes an in-frame insertion of two amino acid residues, Pro-Gln, within the regulatory switch III region of Galphao. This insertion misconfigures the switch III loop and creates novel interactions with the catalytic switch II region, resulting in increased GTP uptake, defective GTP hydrolysis, and aberrant interactions with effector proteins. In contrast, intracellular localization, Gbetagamma interactions, and G protein-coupled receptor (GPCR) coupling of the Galphao[insPQ] mutant protein remain unchanged. CONCLUSIONS: This in-depth analysis characterizes the heterozygous c.724-8G>A mutation as partially dominant negative, providing clues to the molecular etiology of this specific pathology. Further, this analysis allows us to establish and validate a high-throughput screening platform aiming at identifying molecules that could correct the aberrant biochemical functions of the mutant Galphao. FUNDING: This work was supported by the Joint Seed Money Funding scheme between the University of Geneva and the Hebrew University of Jerusalem.', 'CI': ['Copyright (c) 2023 Elsevier Inc. All rights reserved.'], 'FAU': ['Koval, Alexey', 'Larasati, Yonika A', 'Savitsky, Mikhail', 'Solis, Gonzalo P', 'Good, Jean-Marc', 'Quinodoz, Mathieu', 'Rivolta, Carlo', 'Superti-Furga, Andrea', 'Katanaev, Vladimir L'], 'AU': ['Koval A', 'Larasati YA', 'Savitsky M', 'Solis GP', 'Good JM', 'Quinodoz M', 'Rivolta C', 'Superti-Furga A', 'Katanaev VL'], 'AD': ['Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.', 'Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.', 'Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.', 'Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.', 'Division of Genetic Medicine, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.', 'Institute of Molecular and Clinical Ophthalmology Basel (IOB), 4031 Basel, Switzerland; Department of Ophthalmology, University of Basel, 4031 Basel, Switzerland; Department of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.', 'Institute of Molecular and Clinical Ophthalmology Basel (IOB), 4031 Basel, Switzerland; Department of Ophthalmology, University of Basel, 4031 Basel, Switzerland; Department of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.', 'Division of Genetic Medicine, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.', 'Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Institute of Life Sciences and Biomedicine, Far Eastern Federal University, 690090 Vladivostok, Russia. Electronic address: vladimir.katanaev@unige.ch.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230322', 'PL': 'United States', 'TA': 'Med', 'JT': 'Med (New York, N.Y.)', 'JID': '101769215', 'SB': 'IM', 'OTO': ['NOTNLM'], 'OT': ['G protein', 'GNAO1', 'Translation to patients', 'drug discovery', 'pediatric encephalopathy', 'personalized medicine', 'signaling'], 'COIS': ['Declaration of interests The authors declare no competing interests.'], 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/01 06:00', 'CRDT': ['2023/03/31 18:42'], 'PHST': ['2022/11/02 00:00 [received]', '2023/03/01 00:00 [revised]', '2023/03/07 00:00 [accepted]', '2023/03/31 18:42 [entrez]', '2023/04/01 06:00 [pubmed]', '2023/04/01 06:00 [medline]'], 'AID': ['S2666-6340(23)00097-1 [pii]', '10.1016/j.medj.2023.03.001 [doi]'], 'PST': 'aheadofprint', 'SO': 'Med. 2023 Mar 22:S2666-6340(23)00097-1. doi: 10.1016/j.medj.2023.03.001.'}, {'PMID': '37000700', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230404', 'LR': '20230404', 'IS': '1536-4798 (Electronic) 0277-3740 (Linking)', 'VI': '42', 'IP': '5', 'DP': '2023 May 1', 'TI': 'Long-Term Clinical Outcomes of Keratolimbal Allograft Alone or in Combination With Keratoplasty in Chronic and Delayed-Onset Mustard Gas Keratopathy.', 'PG': '536-543', 'LID': '10.1097/ICO.0000000000003066 [doi]', 'AB': 'PURPOSE: The purpose of this study was to investigate the long-term clinical outcome of keratolimbal allograft (KLAL) alone or in combination with keratoplasty, in the management of patients with chronic and delayed-onset mustard gas keratopathy (MGK). METHODS: Patients who had KLAL for MGK with or without corneal transplantation between 2002 and 2016 were recalled to be enrolled in this retrospective interventional case series. The primary outcome was the success rate of the KLAL demonstrated by Kaplan-Meier cumulative survival analysis. The secondary outcomes were postoperative BCVA and the need for further surgery. RESULTS: A total of 108 eyes of 68 patients with MGK underwent KLAL. All patients were male with an average age of 54 +/- 6 years with an average follow-up duration of 81.9 +/- 38.4 months. Sectoral KLAL alone was performed in 62 eyes (57.4%), combined with lamellar keratoplasty (LKP) in 40 eyes (37%) and combined with penetrating keratoplasty in 6 eyes (5.6%). The cumulative probability of success was 75% within the follow-up duration. The mean duration of successful KLAL survival was 80.6 +/- 38 months. 88.1% of these eyes needed only 1 operation to stabilize the ocular surface. Average BCVA did not improve significantly after KLAL alone, except in those accompanied by keratoplasty. KLAL combined with LKP achieved the superior clinical outcome compared with KLAL alone. Infectious keratitis occurred in 6 eyes (5.5%). No adverse event due to postoperative systemic immunosuppression was observed. CONCLUSIONS: KLAL alone or combined with LKP is effective, durable, and visually acceptable in the reconstruction of ocular surface in patients with limbal stem cell deficiency secondary to MGK.', 'CI': ['Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.'], 'FAU': ['Karimian, Farid', 'Jafarinasab, Mohammad-Reza', 'Feizi, Sepehr', 'Javadi, Mohammadali', 'Ansari, Mohammad-Hassan', 'Hassanpour, Kiana'], 'AU': ['Karimian F', 'Jafarinasab MR', 'Feizi S', 'Javadi M', 'Ansari MH', 'Hassanpour K'], 'AUID': ['ORCID: 0000-0001-6758-7457'], 'AD': ['Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20220525', 'PL': 'United States', 'TA': 'Cornea', 'JT': 'Cornea', 'JID': '8216186', 'RN': ['T8KEC9FH9P (Mustard Gas)'], 'SB': 'IM', 'MH': ['Humans', 'Male', 'Middle Aged', 'Female', '*Mustard Gas', 'Retrospective Studies', 'Stem Cell Transplantation', '*Limbus Corneae/surgery', '*Corneal Diseases/surgery', '*Corneal Transplantation', 'Keratoplasty, Penetrating', 'Allografts'], 'COIS': ['The authors have no funding or conflicts of interest to disclose.'], 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/04 06:42', 'CRDT': ['2023/03/31 13:33'], 'PHST': ['2021/12/31 00:00 [received]', '2022/03/27 00:00 [accepted]', '2023/04/04 06:42 [medline]', '2023/03/31 13:33 [entrez]', '2023/04/01 06:00 [pubmed]'], 'AID': ['00003226-202305000-00002 [pii]', '10.1097/ICO.0000000000003066 [doi]'], 'PST': 'ppublish', 'SO': 'Cornea. 2023 May 1;42(5):536-543. doi: 10.1097/ICO.0000000000003066. Epub 2022 May 25.'}, {'PMID': '37000404', 'OWN': 'NLM', 'STAT': 'Publisher', 'LR': '20230331', 'IS': '2193-8245 (Print)', 'DP': '2023 Mar 31', 'TI': 'Potential Protective Function of Adiponectin in Diabetic Retinopathy.', 'LID': '10.1007/s40123-023-00702-3 [doi]', 'AB': 'Adiponectin, one of the most ubiquitous adipokines found in the blood, plays a major role in glucolipid metabolism and energy metabolism and regulation. In recent years, a growing body of research indicates that adiponectin also plays a significant role in diabetic retinopathy. In the present review, we specifically address the protective effects of adiponectin on the development and progression of diabetic retinopathy through improvement in insulin resistance, alleviation of oxidative stress, limiting of inflammation, and prevention of vascular remodeling, with the aim to explore new potential approaches and targets for the prevention and treatment of diabetic retinopathy.', 'CI': ['(c) 2023. The Author(s).'], 'FAU': ['Deng, Hui', 'Ai, Meichen', 'Cao, Yuchen', 'Cai, Liyang', 'Guo, Xi', 'Yang, Xiongyi', 'Yi, Guoguo', 'Fu, Min'], 'AU': ['Deng H', 'Ai M', 'Cao Y', 'Cai L', 'Guo X', 'Yang X', 'Yi G', 'Fu M'], 'AD': ['Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Industrial Avenue Middle, Haizhu, Guangzhou, 510280, Guangdong, China.', 'The Second Clinical School of Southern Medical University, Guangzhou, 510280, Guangdong, China.', 'Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Industrial Avenue Middle, Haizhu, Guangzhou, 510280, Guangdong, China.', 'The Second Clinical School of Southern Medical University, Guangzhou, 510280, Guangdong, China.', 'Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Industrial Avenue Middle, Haizhu, Guangzhou, 510280, Guangdong, China.', 'The Second Clinical School of Southern Medical University, Guangzhou, 510280, Guangdong, China.', 'Plastic Surgery Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100144, China.', 'Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Industrial Avenue Middle, Haizhu, Guangzhou, 510280, Guangdong, China.', 'The Second Clinical School of Southern Medical University, Guangzhou, 510280, Guangdong, China.', 'School of Rehabilitation Sciences, Southern Medical University, Guangzhou, 510280, Guangdong, China.', 'Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Industrial Avenue Middle, Haizhu, Guangzhou, 510280, Guangdong, China.', 'The Second Clinical School of Southern Medical University, Guangzhou, 510280, Guangdong, China.', 'Department of Ophthalmology, The Sixth Affiliated Hospital of Sun Yat-Sen University, No. 26, Erheng Road, Yuancun, Tianhe, Guangzhou, 510230, Guangdong, China. yigg@mail.sysu.edu.cn.', 'Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Industrial Avenue Middle, Haizhu, Guangzhou, 510280, Guangdong, China. min_fu1212@163.com.', 'The Second Clinical School of Southern Medical University, Guangzhou, 510280, Guangdong, China. min_fu1212@163.com.'], 'AUID': ['ORCID: 0000-0003-2638-1756'], 'LA': ['eng'], 'PT': ['Journal Article', 'Review'], 'DEP': '20230331', 'PL': 'England', 'TA': 'Ophthalmol Ther', 'JT': 'Ophthalmology and therapy', 'JID': '101634502', 'OTO': ['NOTNLM'], 'OT': ['Adiponectin', 'Diabetic retinopathy', 'Therapy targets'], 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/01 06:00', 'CRDT': ['2023/03/31 11:24'], 'PHST': ['2023/02/15 00:00 [received]', '2023/03/06 00:00 [accepted]', '2023/03/31 11:24 [entrez]', '2023/04/01 06:00 [pubmed]', '2023/04/01 06:00 [medline]'], 'AID': ['10.1007/s40123-023-00702-3 [pii]', '10.1007/s40123-023-00702-3 [doi]'], 'PST': 'aheadofprint', 'SO': 'Ophthalmol Ther. 2023 Mar 31. doi: 10.1007/s40123-023-00702-3.'}, {'PMID': '36998647', 'OWN': 'NLM', 'STAT': 'PubMed-not-MEDLINE', 'LR': '20230401', 'IS': '2516-0230 (Electronic) 2516-0230 (Linking)', 'VI': '5', 'IP': '7', 'DP': '2023 Mar 28', 'TI': 'Sustained release of tumor cell lysate and CpG from an injectable, cytotoxic hydrogel for melanoma immunotherapy.', 'PG': '2071-2084', 'LID': '10.1039/d2na00911k [doi]', 'AB': 'Many basic research studies have shown the potential of autologous cancer vaccines in the treatment of melanoma. However, some clinical trials showed that simplex whole tumor cell vaccines can only elicit weak CD8(+) T cell-mediated antitumor responses which were not enough for effective tumor elimination. So efficient cancer vaccine delivery strategies with improved immunogenicity are needed. Herein, we described a novel hybrid vaccine \"MCL\" (Melittin-RADA(32)-CpG-Lysate) which was composed of melittin, RADA(32), CpG and tumor lysate. In this hybrid vaccine, antitumor peptide melittin and self-assembling fusion peptide RADA(32) were assembled to form the hydrogel framework melittin-RADA(32)(MR). Then, whole tumor cell lysate and immune adjuvant CpG-ODN were loaded into MR to develop an injectable and cytotoxic hydrogel MCL. MCL showed excellent ability for sustained drug release, to activate dendritic cells and directly kill melanoma cells in vitro. In vivo, MCL not only exerted direct antitumor activity, but also had robust immune initiation effects including the activation of dendritic cells in draining lymph nodes and the infiltration of cytotoxic T lymphocytes (CTLs) in tumor microenvironment. In addition, MCL can efficiently inhibit melanoma growth in B16-F10 tumor bearing mice, which suggested that MCL is a potential cancer vaccine strategy for melanoma treatment.', 'CI': ['This journal is (c) The Royal Society of Chemistry.'], 'FAU': ['Yang, Kui', 'Zhou, Yuhan', 'Huang, Biwang', 'Zhao, Guifang', 'Geng, Yuan', 'Wan, Chao', 'Jiang, Fagang', 'Jin, Honglin', 'Ye, Chengzhi', 'Chen, Jing'], 'AU': ['Yang K', 'Zhou Y', 'Huang B', 'Zhao G', 'Geng Y', 'Wan C', 'Jiang F', 'Jin H', 'Ye C', 'Chen J'], 'AD': ['Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China chenjingwh@hust.edu.cn.', 'Department of Neurology, General Hospital of The Yang Tze River Shipping, Wuhan Brain Hospital Wuhan China.', 'Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China chenjingwh@hust.edu.cn.', 'School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.', 'Orthopaedic Department, General Hospital of Central Theater Command of PLA Wuhan China.', 'Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China chenjingwh@hust.edu.cn.', \"Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College Nanchang China.\", 'College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University Wuhan China.', 'Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China chenjingwh@hust.edu.cn.', 'Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.', 'Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China chenjingwh@hust.edu.cn.', 'College of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University Wuhan China.', 'Department of Pediatrics, Renmin Hospital of Wuhan University Wuhan China ycz15391569970@163.com.', 'Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China chenjingwh@hust.edu.cn.'], 'AUID': ['ORCID: 0000-0003-0206-9290'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230314', 'PL': 'England', 'TA': 'Nanoscale Adv', 'JT': 'Nanoscale advances', 'JID': '101738708', 'PMC': 'PMC10044724', 'COIS': ['There are no conflicts of interest to declare.'], 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/01 06:01', 'CRDT': ['2023/03/31 02:09'], 'PHST': ['2022/12/13 00:00 [received]', '2023/02/24 00:00 [accepted]', '2023/04/01 06:01 [medline]', '2023/03/31 02:09 [entrez]', '2023/04/01 06:00 [pubmed]'], 'AID': ['d2na00911k [pii]', '10.1039/d2na00911k [doi]'], 'PST': 'epublish', 'SO': 'Nanoscale Adv. 2023 Mar 14;5(7):2071-2084. doi: 10.1039/d2na00911k. eCollection 2023 Mar 28.'}, {'PMID': '36998473', 'OWN': 'NLM', 'STAT': 'MEDLINE', 'DCOM': '20230403', 'LR': '20230403', 'IS': '1664-2392 (Print) 1664-2392 (Electronic) 1664-2392 (Linking)', 'VI': '14', 'DP': '2023', 'TI': 'Investigating the change in gene expression profile of blood mononuclear cells post-laparoscopic sleeve gastrectomy in Chinese obese patients.', 'PG': '1049484', 'LID': '10.3389/fendo.2023.1049484 [doi] 1049484', 'AB': \"BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) is a sustainable technique that effectively treats morbid obesity. However, the molecular mechanisms underlying the improvement of metabolic health following this process warrants more investigation. This study investigates LSG-related molecules and uses bulk RNA-sequencing high-throughput analysis to unravel their regulatory mechanisms. METHODS: Peripheral blood mononuclear cells (PBMC) were collected from ten obese patients with BMI >/= 32.5 kg/m(2) in the Department of General Surgery of Kunming First People's Hospital. After LSG, patients were followed up for one month, and blood samples were retaken. Blood samples from ten patients before and after LSG and bulk RNA-Seq data were analyzed in this study. LSG-associated gene expression was detected by weighted gene coexpression network analysis (WGCNA) and differential analysis. Subsequently, essential signature genes were identified using logistic least absolute shrinkage and selection operator (LASSO) and support vector machine-recursive feature elimination (SVM-RFE) algorithms. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and single-sample gene set enrichment analysis (ssGSEA) were utilized to reveal the potential functions of the target genes. Furthermore, the Pearson correlation of signature genes with leptin and lipocalin was also explored. Finally, we constructed a robust endogenous RNA (ceRNA) network based on miRWalk and starBase databases. RESULTS: We identified 18 overlapping genes from 91 hub genes, and 165 differentially expressed mRNAs (DE-mRNA), which were revealed to be significantly associated with immune cells, immune response, inflammatory response, lipid storage, and localization upon functional enrichment analysis. Three signature genes, IRF1, NFKBIA, and YRDC, were identified from the 18 overlapping genes by LASSO and SVM-REF algorithms. The logistic regression model based on the three signature genes highlighted how robustly they discriminated between samples. ssGSEA indicated these genes to be involved in lipid metabolism and degradation pathways. Moreover, leptin levels were significantly reduced in patients undergoing LSG, and NFKBIA significantly negatively correlated with leptin. Finally, we identified how the long non-coding RNA (lncRNA) ATP2B1-AS1 regulated the expression of the signature genes by competitively binding to six microRNAs (miRNAs), which were hsa-miR-6509-5p, hsa-miR-330-5P, hsa-miR-154-5P, hsa-miR-145-5P, hsa-miR4726-5P and hsa-miR-134-5P. CONCLUSION: This study identified three critical regulatory genes significantly differentiated between patients before and after LSG treatment and highlighted their potentially crucial role after bariatric surgery. This provides novel insights to increase our understanding of the underlying mechanisms of weight loss and associated metabolic improvement after bariatric surgery.\", 'CI': ['Copyright (c) 2023 Liu, Chen, Ran, Yin, Zhang, Yang, Cen, Dai, Zhou, Gao, Zhang,', 'Liu, Chen and Wang.'], 'FAU': ['Liu, Na', 'Chen, Xiaolei', 'Ran, Jianghua', 'Yin, Jianhui', 'Zhang, Lijun', 'Yang, Yuelin', 'Cen, Jianchang', 'Dai, Hongmei', 'Zhou, Jiali', 'Gao, Kui', 'Zhang, Jihong', 'Liu, Liyin', 'Chen, Zhiyuan', 'Wang, Haibin'], 'AU': ['Liu N', 'Chen X', 'Ran J', 'Yin J', 'Zhang L', 'Yang Y', 'Cen J', 'Dai H', 'Zhou J', 'Gao K', 'Zhang J', 'Liu L', 'Chen Z', 'Wang H'], 'AD': [\"Department of Endocrinology, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of Endocrinology, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of Endocrinology, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of General Surgery, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of General Surgery, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Clinical Laboratory, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of Vascular Surgery, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Ophthalmology, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of Endocrinology, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of Endocrinology, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of General Surgery, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", \"Department of General Surgery, The First People's Hospital of Kunming, Kunming, Yunnan, China.\", 'Faculty of Physical Education, Kunming University of Science and Technology, Kunming, Yunnan, China.', 'Department of Infectious Diseases, The Affiliated Hospital of YunNan University, Kunming, Yunnan, China.'], 'LA': ['eng'], 'PT': ['Journal Article'], 'DEP': '20230314', 'PL': 'Switzerland', 'TA': 'Front Endocrinol (Lausanne)', 'JT': 'Frontiers in endocrinology', 'JID': '101555782', 'RN': ['0 (Leptin)', '0 (MIRN6509 microRNA, human)', 'EC 3.6.1.- (YRDC protein, human)', '0 (RNA-Binding Proteins)', 'EC 3.6.1.- (GTP-Binding Proteins)', '0 (ATP2B1 protein, human)', 'EC 3.6.3.8 (Plasma Membrane Calcium-Transporting ATPases)', '0 (MIRN145 microRNA, human)', '0 (MicroRNAs)', '0 (MIRN154 microRNA, human)', '0 (MIRN330 microRNA, human)'], 'SB': 'IM', 'MH': ['Humans', 'Leptin', 'Leukocytes, Mononuclear', 'Transcriptome', 'East Asian People', '*Obesity, Morbid/genetics/surgery', '*Laparoscopy', 'RNA-Binding Proteins', 'GTP-Binding Proteins', 'Plasma Membrane Calcium-Transporting ATPases', '*MicroRNAs'], 'PMC': 'PMC10043499', 'OTO': ['NOTNLM'], 'OT': ['bioinformatics', 'high-throughput sequencing', 'laparoscopic sleeve gastrectomy (LSG)', 'leptin', 'obesity'], 'COIS': ['The authors declare that the research was conducted in the absence of any', 'commercial or financial relationships that could be construed as a potential', 'conflict of interest.'], 'EDAT': '2023/04/01 06:00', 'MHDA': '2023/04/03 06:41', 'CRDT': ['2023/03/31 02:06'], 'PHST': ['2022/10/12 00:00 [received]', '2023/02/27 00:00 [accepted]', '2023/04/03 06:41 [medline]', '2023/03/31 02:06 [entrez]', '2023/04/01 06:00 [pubmed]'], 'AID': ['10.3389/fendo.2023.1049484 [doi]'], 'PST': 'epublish', 'SO': 'Front Endocrinol (Lausanne). 2023 Mar 14;14:1049484. doi: 10.3389/fendo.2023.1049484. eCollection 2023.'}]\n"
     ]
    }
   ],
   "source": [
    "# Define your search query\n",
    "query = \"clinical research in ophthalmology\"\n",
    "Entrez.email = \"pa7wel@gmail.com\"\n",
    "\n",
    "# Function to search PubMed\n",
    "def search_pubmed(query, retmax=100):\n",
    "    handle = Entrez.esearch(db=\"pubmed\", term=query, retmax=retmax)\n",
    "    record = Entrez.read(handle)\n",
    "    return record[\"IdList\"]\n",
    "\n",
    "# Function to fetch article metadata and abstract\n",
    "def fetch_article_data(pubmed_ids):\n",
    "    article_data = []\n",
    "    handle = Entrez.efetch(db=\"pubmed\", id=','.join(pubmed_ids), rettype=\"medline\", retmode=\"text\")\n",
    "    records = Medline.parse(handle)\n",
    "    for record in records:\n",
    "        article_data.append(record)\n",
    "    return article_data\n",
    "\n",
    "# Search PubMed and fetch article metadata and abstracts\n",
    "pubmed_ids = search_pubmed(query)\n",
    "article_data = fetch_article_data(pubmed_ids)\n",
    "\n",
    "# # Save the data in CSV format\n",
    "with open(\"pubmed_abstracts.csv\", \"w\", newline='', encoding=\"utf-8\") as csvfile:\n",
    "    writer = csv.writer(csvfile)\n",
    "    writer.writerow([\"Title\", \"Journal\", \"Publication Date\", \"PubMed ID\", \"Abstract\"])\n",
    "    for article in article_data:\n",
    "        writer.writerow([\n",
    "            article.get(\"TI\", \"N/A\"),\n",
    "            article.get(\"JT\", \"N/A\"),\n",
    "            article.get(\"DP\", \"N/A\"),\n",
    "            article.get(\"PMID\", \"N/A\"),\n",
    "            article.get(\"AB\", \"N/A\"),\n",
    "        ])\n",
    "\n",
    "print(\"CSV file created: pubmed_abstracts.csv\")\n",
    "print(article_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['Serum metabolomic profiles and semaphorin-3A as biomarkers of diabetic retinopathy progression.', 'The Egyptian journal of immunology', '2023 Apr', '37031410', 'Diabetic retinopathy (DR) is a typical microvascular complication of diabetes mellitus (DM) and it remains one of the leading causes of vision loss worldwide. Studies postulated that a distinct metabolic signature of DR exists and can be resolved from that of diabetes alone. Serum Semaphorin3A (Sema3A) levels have also been found to be correlated with the phenotypes of diabetic retinopathy. We aimed to analyze and identify serum metabolites and serum Sema3A levels that could be useful biomarkers of DR progression. This cross-sectional study included 45 type 2 diabetes (T2D) patients. Diabetic patients were divided into three groups based on the status of their complications: non-DR (NDR, n=15), non-proliferative DR (NPDR, n=15), and proliferative DR (PDR, n=15) groups. Serum metabolomic profiles of these patients were determined by using high-performance liquid chromatography-mass spectrometry (HPLC-MS), and serum Sema3A levels measured by ELISA. Metabolomics analysis revealed a set of metabolites that were altered in the serum of PDR patients as compared with NPDR and NDR groups. Among these metabolites total asymmetric dimethylarginine (ADMA) and Kynurenine were potential predictors of PDR patients. Significantly higher serum levels of Sema3A in PDR patients as compared with NPDR and NDR groups (p < 0.001), their serum levels were positively correlated with the central macular thickness (r= 0.952, p < 0.001) and negatively correlated with the superficial macular density (r=-0.952, p < 0.001). In conclusion, the metabolite signatures identified in this study and serum Sema3A levels could be proposed as biomarkers for DR development and progression in T2D patients. However, Sema3A was superior to metabolomics in the prediction of the severity of DR.'], ['BDNF signaling in correlation-dependent structural plasticity in the developing visual system.', 'PLoS biology', '2023 Apr 3', '37011100', 'During development, patterned neural activity instructs topographic map refinement. Axons with similar patterns of neural activity converge onto target neurons and stabilize their synapses with these postsynaptic partners, restricting exploratory branch elaboration (Hebbian structural plasticity). On the other hand, non-correlated firing in inputs leads to synapse weakening and increased exploratory growth of axons (Stentian structural plasticity). We used visual stimulation to control the correlation structure of neural activity in a few ipsilaterally projecting (ipsi) retinal ganglion cell (RGC) axons with respect to the majority contralateral eye inputs in the optic tectum of albino Xenopus laevis tadpoles. Multiphoton live imaging of ipsi axons, combined with specific targeted disruptions of brain-derived neurotrophic factor (BDNF) signaling, revealed that both presynaptic p75NTR and TrkB are required for Stentian axonal branch addition, whereas presumptive postsynaptic BDNF signaling is necessary for Hebbian axon stabilization. Additionally, we found that BDNF signaling mediates local suppression of branch elimination in response to correlated firing of inputs. Daily in vivo imaging of contralateral RGC axons demonstrated that p75NTR knockdown reduces axon branch elongation and arbor spanning field volume.'], ['Aqueous-deficient dry eye disease: Preferred practice pattern guidelines on clinical approach, diagnosis, and management.', 'Indian journal of ophthalmology', '2023 Apr', '37026265', 'Dry eye disease (DED) is a broad term that includes a diverse group of clinical disorders. Aqueous-deficient dry eye (ADDE), a subtype of DED, is characterized by decreased tear production by the lacrimal gland. It can be seen in up to one-third of individuals with DED and can be comorbid with a systemic autoimmune process or occur secondary to an environmental insult. Since ADDE can be a source of long-term suffering and severe visual impairment, early identification and adequate treatment are imperative. Multiple etiologies can underlie ADDE, and it is critical to identify the underlying cause to not only improve the ocular health but also to improve the overall quality of life and well-being of affected individuals. This review discusses the various etiologies of ADDE, highlights a pathophysiology-based approach for evaluating underlying contributors, outlines various diagnostic tests, and reviews treatment options. We present the current standards and discuss ongoing research in this field. Through this review, we propose a treatment algorithm that would be useful for an ophthalmologist in diagnosing and managing individuals with ADDE.'], ['Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy.', 'Journal of neurology, neurosurgery, and psychiatry', '2023 Apr 4', '37015771', \"BACKGROUND: To assess the ability of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) clinical criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) to include within their classification the whole spectrum of clinical heterogeneity of the disease and to define the clinical characteristics of the unclassifiable clinical forms. METHODS: The 2021 EAN/PNS clinical criteria for CIDP were applied to 329 patients fulfilling the electrodiagnostic (and in some cases also the supportive) criteria for the diagnosis of CIDP. Clinical characteristics were reviewed for each patient not strictly fulfilling the clinical criteria ('unclassifiable'). RESULTS: At study inclusion, 124 (37.5%) patients had an unclassifiable clinical presentation, including 110 (89%) with a typical CIDP-like clinical phenotype in whom some segments of the four limbs were unaffected by weakness ('incomplete typical CIDP'), 10 (8%) with a mild distal, symmetric, sensory or sensorimotor polyneuropathy confined to the lower limbs with cranial nerve involvement ('cranial nerve predominant CIDP') and 4 (1%) with a symmetric sensorimotor polyneuropathy limited to the proximal and distal areas of the lower limbs ('paraparetic CIDP'). Eighty-one (65%) patients maintained an unclassifiable presentation during the entire disease follow-up while 13 patients progressed to typical CIDP. Patients with the unclassifiable clinical forms compared with patients with typical CIDP had a milder form of CIDP, while there was no difference in the distribution patterns of demyelination. CONCLUSIONS: A proportion of patients with CIDP do not strictly fulfil the 2021 EAN/PNS clinical criteria for diagnosis. These unclassifiable clinical phenotypes may pose diagnostic challenges and thus deserve more attention in clinical practice and research.\"], ['Role of in vivo confocal microscopy in dry eye disease and eye pain.', 'Indian journal of ophthalmology', '2023 Apr', '37026240', 'Dry eye disease is known to have a lot of variability in presentation with overlapping subtypes. Understanding the pathology of this condition will guide therapeutic options. In vivo confocal microscopy is a diagnostic and imaging modality that provides high magnification and high-resolution images of all layers of the cornea and ocular surface. Various structures in the cornea and their alterations due to dry eye have been imaged. The impact of the tear film instability, inflammation, and altered homeostasis on the corneal epithelium, nerves, keratocytes, and dendritic cells have been evaluated across different studies. In addition, key features of IVCM in patients with neuropathic pain have been highlighted in this paper.'], ['Exploring the components and mechanisms of Shen-qi-wang-mo granule in the treatment of retinal vein occlusion by UPLC-Triple TOF MS/MS and network pharmacology.', 'Scientific reports', '2023 Apr 1', '37005436', 'This study aimed to explore the substance basis and mechanisms of Shen-qi-wang-mo Granule (SQWMG), a traditional Chinese medicine prescription that had been clinically utilized to treat retinal vein occlusion (RVO) for 38 years. Components in SQWMG were analyzed by UPLC-Triple-TOF/MS and a total of 63 components were identified with ganoderic acids (GA) being the largest proportion. Potential targets of active components were retrieved from SwissTargetPrediction. RVO-related targets were acquired from related disease databases. Core targets of SQWMG against RVO were acquired by overlapping the above targets. The 66 components (including 5 isomers) and 169 targets were obtained and concluded into a component-target network. Together with biological enrichment analysis of targets, it revealed the crucial role of the \"PI3K-Akt signaling pathway\", \"MAPK signaling pathway\" and their downstream factor iNOS and TNF-alpha. The 20 key targets of SQWMG in treating RVO were acquired from the network and pathway analysis. The effects of SQWMG on targets and pathways were validated by molecular docking based on AutoDock Vina and qPCR experiment. The molecular docking showed great affinity for these components and targets, especially on ganoderic acids (GA) and alisols (AS), which were both triterpenoids and qPCR exhibited remarkably reduced inflammatory factor gene expression through regulation of these two pathways. Finally, the key components were also identified from rat serum after treatment of SQWMG.'], ['Tumor microenvironment signaling and therapeutics in cancer progression.', 'Cancer communications (London, England)', '2023 Apr 2', '37005490', 'Tumor development and metastasis are facilitated by the complex interactions between cancer cells and their microenvironment, which comprises stromal cells and extracellular matrix (ECM) components, among other factors. Stromal cells can adopt new phenotypes to promote tumor cell invasion. A deep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions. In this review, we describe the tumor microenvironment (TME) components and associated therapeutics. We discuss the clinical advances in the prevalent and newly discovered signaling pathways in the TME, the immune checkpoints and immunosuppressive chemokines, and currently used inhibitors targeting these pathways. These include both intrinsic and non-autonomous tumor cell signaling pathways in the TME: protein kinase C (PKC) signaling, Notch, and transforming growth factor (TGF-beta) signaling, Endoplasmic Reticulum (ER) stress response, lactate signaling, Metabolic reprogramming, cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) and Siglec signaling pathways. We also discuss the recent advances in Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), T-cell immunoglobulin mucin-3 (TIM-3) and Lymphocyte Activating Gene 3 (LAG3) immune checkpoint inhibitors along with the C-C chemokine receptor 4 (CCR4)- C-C class chemokines 22 (CCL22)/ and 17 (CCL17), C-C chemokine receptor type 2 (CCR2)- chemokine (C-C motif) ligand 2 (CCL2), C-C chemokine receptor type 5 (CCR5)- chemokine (C-C motif) ligand 3 (CCL3) chemokine signaling axis in the TME. In addition, this review provides a holistic understanding of the TME as we discuss the three-dimensional and microfluidic models of the TME, which are believed to recapitulate the original characteristics of the patient tumor and hence may be used as a platform to study new mechanisms and screen for various anti-cancer therapies. We further discuss the systemic influences of gut microbiota in TME reprogramming and treatment response. Overall, this review provides a comprehensive analysis of the diverse and most critical signaling pathways in the TME, highlighting the associated newest and critical preclinical and clinical studies along with their underlying biology. We highlight the importance of the most recent technologies of microfluidics and lab-on-chip models for TME research and also present an overview of extrinsic factors, such as the inhabitant human microbiome, which have the potential to modulate TME biology and drug responses.'], ['Characteristics of eye-related emergency visits and triage differences by nurses and ophthalmologists: Perspective from a single eye center in southern China.', 'Frontiers in medicine', '2023', '37007786', 'PURPOSE: To describe characteristics of eye-related emergency department (ED) visits and investigate differences in priorities assigned to patients by triage nurses and ophthalmologists. METHODS: A prospective survey was conducted at the ED of Zhongshan Ophthalmic Center from January 1, 2021, to May 31, 2021. Clinical data from patients with acute ophthalmic conditions lasting less than 7 days were collected via a standard questionnaire and the urgency levels assigned by nurses and physicians were also recorded. Binary logistic regression was performed to identify characteristics associated with truly emergency conditions and up- or down-triage. RESULTS: A total of 1907 patients were enrolled, with 582 (30.5%) classified as \"non-emergency.\" Red eye (69.7%), eye pain (53.0%), ocular trauma (44.1%), tearing (43.6%), and blurred vision (43.1%) were the most common complaints. Truly emergency tended to be male (OR 2.019, p < 0.001) and with unilateral eye involvement (OR 2.992, p < 0.001). Nurses prioritized conjunctival, scleral, closed ocular trauma and eyelid diseases over doctors while giving less priority to open ocular trauma, cornea, uveitis, and vitreoretinal diseases (p < 0.05). Overemphasis on mild blurred vision (OR 3.718, p = 0.001) and insufficient understanding of conjunctival diseases without red eye (OR 0.254, p = 0.001) were associated with conjunctival disease \"up-triage.\" Insufficient awareness of moderate and severe blurred vision was associated with \"down-triage\" for ocular trauma (OR 3.475, p = 0.001 and OR 2.422, p = 0.020, respectively). CONCLUSION: Ophthalmic EDs are typically flooded with patients suffering from acute ocular problems, with a considerable portion for non-emergency conditions. The identification of characteristics associated with truly emergency cases and nurses\\' triage preferences is valuable in providing target guidance for future ED practice and facilitating the proper allocation of emergency resources.'], ['Knowledge domain, research hotspots and frontiers in physiology teaching reforms from 2012 to 2021: A bibliometric and knowledge-map analysis.', 'Frontiers in medicine', '2023', '37020677', \"OBJECTIVE: To identify author collaborations and impact; participating countries, institutions, and journals; evaluate the knowledge base; and analyze research hotspots and frontiers in teaching reforms in physiology. METHODS: Articles and reviews related to teaching reforms in physiology published between January 1, 2012, and December 31, 2021, were obtained from the Web of Science Core Collection. Two Scientometric software applications (CiteSpace 5.7 and VOSviewer 1.6.15) were used to perform bibliometric and knowledge-map analysis, generate network maps, and identify research trends and top keywords, authors, co-cited authors, institutions, countries, journals, and references. RESULTS: The search identified a total of 2,882 papers in 466 academic journals by 13,895 authors from 4,072 organizations in 67 countries/regions. Physiology teaching reform-related publications increased rapidly over time. Arango-Lasprilla and Rivera published the most papers, while Moseley had the most co-citations. Active collaborations among physiology researchers were noted. Advances in Physiology Education published the most papers on physiology teaching reforms and was also the top co-cited journal in the Medicine/Medical/Clinical, Psychology/Education/Health, and Neurology/Sports/Ophthalmology fields. The United States and University of California published the most physiology teaching publications in the search criteria. Ten references (research articles and reviews) on mechanisms and diseases were identified as the knowledge base. The mainstream research directions were education, Alzheimer's disease, performance, physiology, and risk factors. Mental health and emotion regulation are increasing in significance and may become new hotspots. The research trend to move from the field of pain pathogenesis to the field of neuropsychiatry has become increasingly clear. This tendency away from peripheral system-based disorders to central system-based orders is inextricably linked to further developments in physiological understanding of the brain. CONCLUSION: This study analyzed the research hot spots and frontiers of teaching reforms on in physiology using bibliometric and visual methods. Based on the results, rehabilitation, neurosciences, and infectious disease are hot topics in physiology. In particular, the pathogenesis of neurological diseases, treatment strategies, and technology updates have gradually become research hotspots. We predict that this trend is closely related to the implementation of brain research programs in various countries. These findings provide helpful references for scholars focusing on physiology education.\"], ['Correlation of Change in Macular Thickness With Change in Visual Acuity in Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials.', 'Journal of vitreoretinal diseases', '2022 Jul-Aug', '37007927', 'Purpose: To assess the correlation between the change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in eyes with diabetic macular edema (DME) treated with fixed-dosing intravitreal aflibercept injection (IAI). Methods: This post hoc analysis of the VISTA and VIVID randomized controlled clinical trials, in which 862 eyes with central-involved DME were randomly assigned to IAI 2 mg every 4 weeks (2q4; 290 eyes), IAI 2 mg every 8 weeks after 5 initial monthly doses (2q8; 286 eyes), or macular laser (286 eyes) and followed through 100 weeks. Correlations between the change in CST and change in BCVA from baseline to weeks 12, 52, and 100 were assessed using the Pearson correlation. Results: The respective correlations (r [95% CI]) at weeks 12, 52, and 100 were -0.39 (-0.49 to -0.29), -0.27 (-0.38 to -0.15), and -0.30 (-0.41 to -0.17) in the 2q4 arm and -0.28 (-0.39 to -0.17), -0.29 (-0.41 to -0.17), and -0.33 (-0.44 to -0.20) in the 2q8 arm. Linear regression analysis of the correlation at week 100, adjusted for relevant baseline factors, showed CST changes accounted for 17% of the variance in BCVA changes; every 100-microm decrease in CST was associated with a 1.2-letter increase in BCVA (P = .001). Conclusions: Correlations between the change in CST and change in BCVA after 2q4 or 2q8 fixed-dosing IAI for DME were modest. Although a change in CST might be important in determining the need for antivascular endothelial growth factor for DME at follow-up, it was not a good surrogate for VA outcomes.'], ['Rasch development and validation of the \"Medellin Dry Eye Inventory\" (ME.Dry), an instrument to measure multidimensional quality of life compromise in patients with dry eye disease.', 'Indian journal of ophthalmology', '2023 Apr', '37026277', 'PURPOSE: Dry eye disease (DED) is a common condition that affects the quality of life. There is a great need for better-developed scales that comply with Rasch model requirements. METHODS: Prospective study including patients with DED. A series of focus groups were performed to determine the best items to be included. A Rasch modeling methodology was used to validate the Medellin Dry Eye Inventory (ME.Dry). After iterative analysis and scale modification, a final version of the scale was attained which complied with the Rasch analysis expectations. Correlation between the different subscales of the ME.Dry and the Ocular Surface Disease Index (OSDI) was evaluated through Spearman correlation. RESULTS: A total of 166 patients with DED were included. Rasch modeling demonstrated an excellent behavior for the ME.Dry, including four subscales: Symptoms, Triggers, Activity Limitation, and Emotional Compromise. Infit and Outfit parameters were all between 0.50 and 1.50, with excellent category utilization. Person and item separation and reliability were excellent for all subscales. There was a need for a category collapsing for the Emotional Compromise subscale. There was a strong correlation between the different subscales of the ME.Dry except for the Emotional Compromise subscale, which seems to be independent. CONCLUSION: The ME.Dry is a reliable scale, complying with the Rasch model expectations, that allows for a reliable measurement of quality of life compromise in patients with DED. Emotional compromise secondary to DED does not seem to correlate with disease severity as assessed by the other quality-of-life subscales.'], [\"Widespread genomic influences on phenotype in Dravet syndrome, a 'monogenic' condition.\", 'Brain : a journal of neurology', '2023 Apr 3', '37006128', 'Dravet syndrome is an archetypal rare severe epilepsy, considered \"monogenic\", typically caused by loss-of-function SCN1A variants. Despite a recognisable core phenotype, its marked phenotypic heterogeneity is incompletely explained by differences in the causal SCN1A variant or clinical factors. In 34 adults with SCN1A-related Dravet syndrome, we show additional genomic variation beyond SCN1A contributes to phenotype and its diversity, with an excess of rare variants in epilepsy-related genes as a set and examples of blended phenotypes, including one individual with an ultra-rare DEPDC5 variant and focal cortical dysplasia. Polygenic risk scores for intelligence are lower, and for longevity, higher, in Dravet syndrome than in epilepsy controls. The causal, major-effect, SCN1A variant may need to act against a broadly compromised genomic background to generate the full Dravet syndrome phenotype, whilst genomic resilience may help to ameliorate the risk of premature mortality in adult Dravet syndrome survivors.'], ['Intravitreal Rituximab-Associated Retinal Occlusive Vasculitis.', 'Journal of vitreoretinal diseases', '2023 Mar-Apr', '37006669', 'PURPOSE: To describe a 90-year-old patient who was referred to a private retina specialist with gradually worsening vision and floaters in the left eye. METHODS: A retrospective case report is presented. RESULTS: The patient was treated with intravitreal rituximab injections for intraocular lymphoma with resulting vision loss to the level of hand motions from severe granulomatous uveitis and retinal occlusive vasculitis. CONCLUSIONS: Retinal occlusive vasculopathy secondary to rituximab intravitreal injections is a rare clinical entity with only a single previous case reported in the literature. However, there are reports of systemic vasculitis after systemic administration of rituximab. Clinicians should be aware of the possibility of ocular hypertension, granulomatous anterior uveitis, and/or retinal occlusive vasculitis after intravitreal rituximab use. Consideration should be given to the inflammatory risk of rituximab intravitreal injections to reduce the potential for treatment-induced vision loss.'], ['Time outdoors positively associates with academic performance: a school-based study with objective monitoring of outdoor time.', 'BMC public health', '2023 Apr 4', '37016357', 'BACKGROUND: To explore the relationship between outdoor time and academic performance among school-aged children. METHODS: This study was designed as a cross-sectional study. Data were derived from a school-based prospective children myopia intervention study (STORM). Outdoor time was recorded by self-developed algorithm-validated wristwatches in real-time and calculated as the cumulative average of 10 months. The academic performance was recorded and provided by the participating schools and further standardized. Other information was collected using an online standardized questionnaire. Mixed-effects model and B-Spline method were used to investigate the association between time spent on different types of daily activity, including outdoor activity and academic performance. RESULTS: A total of 3291 children with mean age 9.25 years were included in the final analysis. Overall, outdoor time was associated with academic performance in a non-linear manner; specifically, not exceeding 2.3 h per day, outdoor time was positively associated with academic performance; exceeding 2.3 h per day, this association became non-significant. Likewise, daily sleep duration and out-of-school learning time were associated with academic performance in a non-linear manner, resulting in turning points of 11.3 and 1.4 h per day, respectively. Separate analysis showed that outdoor time and sleep duration but not out-of-school learning time were positively associated with academic performance in Chinese, mathematics and English. CONCLUSION: Outdoor time, sleep duration and out-of-school learning time were associated with academic performance in a non-linear manner. Promotion of outdoor time may not negatively impact on academic performance. TRIAL REGISTRATION: Our study was registered in ClinicalTrials.gov (Identifier: NCT02980445).'], ['Telangiectatic Capillaries in Retinal Vascular Occlusions: Multimodal Imaging in a Case Series.', 'Journal of vitreoretinal diseases', '2023 Mar-Apr', '37006666', \"Introduction: To report a cases series of retinal vascular occlusions with telangiectatic capillaries (TelCaps) seen on indocyanine green angiography (ICGA) and multimodal imaging. Methods: In this case series, a new finding (TelCaps) was seen on clinical examination, fundus evaluation, fluorescein angiography, ICGA, and optical coherence tomography (OCT). Results: This series comprised 3 patients with TelCaps findings on ICGA after retinal vascular occlusions. The patients' ages ranged from 52 years to 71 years and the best-corrected visual acuity in the affected eye, from 20/25 to 20/80. Fundus evaluation showed small, hard exudates in the vascular termination close to the macula with a reduction of the foveal reflex. The OCT images showed marginal hyperreflectivity and inner hyporeflectivity that were suggestive of a TelCaps lesion, which was confirmed by hyperfluorescence in the late phase of ICGA. Conclusions: This study highlights the importance of performing multimodal imaging evaluation, including ICGA, in eyes with retinal vein occlusions for early identification and management of the associated lesions.\"], ['Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection.', 'Journal of vitreoretinal diseases', '2022 Nov-Dec', '37009541', 'Although infectious endophthalmitis after intravitreal antivascular endothelial growth factor injections is rare, it is the most feared and potentially devastating complication of this procedure. There is no high-level evidence to provide definitive guidance on the management of endophthalmitis occurring after intravitreal injection (IVI). This clinical practice update reviews the published literature regarding post-IVI endophthalmitis and highlights areas in which further research is needed to better guide its management.'], ['Gender Bias in Clinical Trial Enrollment: Female Authorship Matters.', 'Annals of vascular surgery', '2023 Apr 4', '37023917', 'BACKGROUND: Despite initiatives to promote equal enrollment of human subjects in clinical trials, females continue to be underrepresented. The goal of this work is to determine if female enrollment in human clinical trials published in three high-impact journals from 2015 to 2019 is correlated with gender of first and/or senior authors. METHODS: Clinical trials published in the Journal of the American Medical Association (JAMA), The Lancet, and the New England Journal of Medicine (NEJM) from January 1, 2015, to December 31, 2019, were reviewed. Trials were excluded for ongoing enrollment, sex-specific disease research, or author name without gender assignment. One-sample chi(2) pairwise comparisons and two-tailed proportion tests on the proportion of females between gender author pairings were done overall and for each subset analysis. RESULTS: 1,427 articles enrolled a total of 2,104,509 females and 2,616,981 males (44.6% vs. 55.4%, p </= 0.0001) in clinical trials. Overall, more females were enrolled if both first and senior authors were female (51.7% vs. 48.3%, p </= 0.0001). Proportion of females enrolled decreased with the following first and senior author pairings: female-male (48.9%), male-female (48.6%), and male-male (40.5%, p </= 0.0001 compared to female-female authorship). Greater female enrollment in clinical trials with female-female compared to male-male authorship persisted in subset analyses by funding source, phase, randomization for study participants, drug and/or device trial, and geographic location. Female enrollment was higher in 3 surgical specialties: neurosurgery (all authors: 52%, p </= 0.01), ophthalmology (all authors: 53.6%, p </= 0.0001), and surgery (all authors: 54.4%, p </= 0.0001). The majority of surgical specialties did not publish trials with female-female authorship but when stratifying by author gender pairing, surgical oncology had the highest female enrollment with female-female authorship (98.4%, p </= 0.0001). CONCLUSION: Female authorship of clinical trial publications, specifically having both first and senior authors as female, was correlated with higher female enrollment in clinical trials when compared to male authorship and endured with multiple subset analyses.'], ['[Challenges and countermeasures in the development of artificial intelligence research in ophthalmology].', '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', '2023 Apr 11', '37012586', 'The advent of artificial intelligence (AI) technology has led to revolutionary advancements in the diagnosis and treatment of ophthalmic diseases, introducing a novel AI-assisted diagnostic approach for ophthalmology that is rich in imaging diagnostic technologies. However, as clinical applications continue to evolve, AI research in ophthalmology faces challenges such as the lack of standardized datasets and innovative algorithm models, insufficient cross-modal information fusion, and limited clinical interpretability. In response to the growing demand for AI research in ophthalmology, it is essential to establish ophthalmic data standards and sharing platforms, innovate core algorithms, and develop clinical logic interpretable models for the screening, diagnosis, and prediction of eye diseases. Additionally, the deep integration of cutting-edge technologies such as 5G, virtual reality, and surgical robots would advance the development of ophthalmic intelligent medicine into a new phase.'], ['Lateral septum adenosine A(2A) receptors control stress-induced depressive-like behaviors via signaling to the hypothalamus and habenula.', 'Nature communications', '2023 Apr 5', '37019936', 'Major depressive disorder ranks as a major burden of disease worldwide, yet the current antidepressant medications are limited by frequent non-responsiveness and significant side effects. The lateral septum (LS) is thought to control of depression, however, the cellular and circuit substrates are largely unknown. Here, we identified a subpopulation of LS GABAergic adenosine A(2A) receptors (A(2A)R)-positive neurons mediating depressive symptoms via direct projects to the lateral habenula (LHb) and the dorsomedial hypothalamus (DMH). Activation of A(2A)R in the LS augmented the spiking frequency of A(2A)R-positive neurons leading to a decreased activation of surrounding neurons and the bi-directional manipulation of LS-A(2A)R activity demonstrated that LS-A(2A)Rs are necessary and sufficient to trigger depressive phenotypes. Thus, the optogenetic modulation (stimulation or inhibition) of LS-A(2A)R-positive neuronal activity or LS-A(2A)R-positive neurons projection terminals to the LHb or DMH, phenocopied depressive behaviors. Moreover, A(2A)R are upregulated in the LS in two male mouse models of repeated stress-induced depression. This identification that aberrantly increased A(2A)R signaling in the LS is a critical upstream regulator of repeated stress-induced depressive-like behaviors provides a neurophysiological and circuit-based justification of the antidepressant potential of A(2A)R antagonists, prompting their clinical translation.'], ['Clinical and biological correlates of optical coherence tomography findings in schizophrenia.', 'European archives of psychiatry and clinical neuroscience', '2023 Apr 6', '37022475', 'There is a growing body of evidence indicating retinal layer thinning in schizophrenia. However, neuropathological processes underlying these retinal structural changes and its clinical correlates are yet to be known. Here, we aim to investigate the clinical and biological correlates of OCT findings in schizophrenia. 50 schizophrenia patients and 40 healthy controls were recruited. Retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), and macular and choroidal thicknesses were recorded. A comprehensive battery of neuropsychological tests was applied. Fasting glucose, triglycerides and HDL-cholesterol levels, TNF-alpha, IL-1beta and IL-6 levels were measured. Right IPL was significantly thinner in patients than the controls after controlling for various confounders (F = 5.42, p = .02). Higher IL-6, IL-1beta, and TNF-alpha levels were associated with decreased left macular thickness (r =  - 0.26, p = .027, r =  - 0.30, p = 0.012, and r =  - 0.24, p = .046, respectively) and higher IL-6 was associated with thinning of right IPL (r =  - 0.27, p = 0.023) and left choroid (r =  - 0.23, p = .044) in the overall sample. Thinning of right IPL and left macula were also associated with worse executive functioning (r = 0.37, p = 0.004 and r = 0.33, p = 0.009) and attention (r = 0.31, p = 0.018 and r = 0.30, p = 0.025). In patients with schizophrenia, IPL thinning was associated with increased BMI (r =  - 0.44, p = 0.009) and decreased HDL levels (r = 0.43, p = 0.021). Decreased TNF-alpha level was related to IPL thinning, especially in the left eye (r = 0.40, p = 0.022). These findings support the hypothesis that OCT might provide the opportunity to establish an accessible and non-invasive probe of brain pathology in schizophrenia and related disorders. However, future studies investigating retinal structural changes as a biological marker for schizophrenia should also consider the metabolic state of the subjects.'], ['Reply to Comment on \"Choriocapillaris flow deficit as a biomarker for diabetic retinopathy and diabetic macular edema: 3-year longitudinal cohort\".', 'American journal of ophthalmology', '2023 Mar 29', '37001788', 'N/A'], ['Organ-specific allergen challenges in airway allergy: current utilities and future directions.', 'Allergy', '2023 Apr 1', '37002709', 'Atopy has been long used as the screening method for airway allergy. Nevertheless, aeroallergens can trigger respiratory symptoms not only in atopic patients (atopic respiratory allergy, ARA), but also in non-atopic subjects (local respiratory allergy, LRA). Moreover, ARA and LRA can coexist in the same patient, and this clinical scenario has been called dual respiratory allergy (DRA). When the clinical history cannot determine the relevance of sensitizations in ARA patients, nasal, conjunctival or bronchial allergen challenges (NAC, CAC and BAC, respectively) should be conducted. Moreover, these tests are required to identify patients with LRA and DRA. The clarification of the allergic triggers of airway diseases has a profound impact on the management strategies the patients can be offered. Importantly, allergen immunotherapy (AIT) remains as the only disease-modifying intervention for ARA. Recent data indicate that AIT might have a similar effect on LRA patients. Nevertheless, AIT success relies largely on the correct phenotyping of allergic individuals, and NAC, CAC and BAC are very helpful tools in this regard. In this review, we will summarize the main indications and methodology of CAC, NAC and BAC. Importantly, the clinical implementation of these tests might translate into precision medicine approaches and better health outcomes for patients with airway allergy.'], ['[Analysis of clinical manifestations and imaging characteristics of in vivo confocal microscopy for Nocardia keratitis].', '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', '2023 Apr 11', '37012591', 'Objective: To analyze the clinical manifestations and imaging characteristics of in vivo confocal microscopy (IVCM) for Nocardia keratitis. Methods: It was a retrospective case series study. Medical records of 16 consecutive patients (16 eyes) with Nocardia keratitis were collected from the Department of Ophthalmology at Beijing Tongren Hospital, Capital Medical University between 2018 and 2022. The group consisted of 11 males and 5 females. The inclusion criteria for the study were the presence of typical clinical manifestations of Nocardia keratitis and at least one positive pathogenic test (corneal scraping or microbial culture) indicating Nocardia infection. The medical history, clinical and microbiological examination data of the patients were analyzed, including risk factors, diagnosis time, clinical manifestations, diagnostic methods, strain isolation, cure time, and best corrected visual acuity before and after treatment. This study utilized techniques such as slit lamp microscopy, in vivo confocal microscopy (IVCM), scraping cytology, microbial culture, and mass spectrometry identification. Results: The main risk factors for Nocardia keratitis included plant or foreign body injuries (5 out of 16 cases), contact lens use (4 out of 16 cases), and surgery (2 out of 16 cases). The average time to diagnosis was (20.8+/-11.8) days, with the shortest time being 8 days and the longest being 60 days. The best corrected visual acuity was less than 0.05 in 7 patients, between 0.05 to 0.3 in 7 patients, and greater than or equal to 0.3 in 2 patients. The typical symptoms included superficial gray-white infiltration in a wreath-like pattern on the cornea, corneal ulcers with dry and gray-white necrotic tissue coverage, and in severe cases, corneal ulcer perforation. Nocardia corneal infection was identified in 12 out of 16 cases by scraping cytology, 9 out of 16 cases by mass spectrometry, and 8 out of 16 cases by both methods. IVCM showed the presence of fine and moderately reflective filamentous hyphae in the subepithelial and superficial stromal layer of the cornea, arranged in elongated, beaded, and branched structures. Infiltration of many hyper-reflective round inflammatory cells was also seen around the hyphae. Fourteen cases were treated with medication and 2 cases were treated with corneal transplantation. The average cure time was (37.5+/-25.2) days and there were no cases of recurrence during the follow-up period (all greater than 6 months). Conclusions: Nocardia keratitis is primarily characterized by dense, round, or wreath-like infiltration in the early stage, and by gray-white dry necrotic secretion and hypopyon on the surface of corneal ulcers in the middle and late stages. Fine, branched or beaded, and moderately reflective filamentous structures are the hallmark of the corneal lesion on the IVCM images.'], ['Sustained release of tumor cell lysate and CpG from an injectable, cytotoxic hydrogel for melanoma immunotherapy.', 'Nanoscale advances', '2023 Mar 28', '36998647', 'Many basic research studies have shown the potential of autologous cancer vaccines in the treatment of melanoma. However, some clinical trials showed that simplex whole tumor cell vaccines can only elicit weak CD8(+) T cell-mediated antitumor responses which were not enough for effective tumor elimination. So efficient cancer vaccine delivery strategies with improved immunogenicity are needed. Herein, we described a novel hybrid vaccine \"MCL\" (Melittin-RADA(32)-CpG-Lysate) which was composed of melittin, RADA(32), CpG and tumor lysate. In this hybrid vaccine, antitumor peptide melittin and self-assembling fusion peptide RADA(32) were assembled to form the hydrogel framework melittin-RADA(32)(MR). Then, whole tumor cell lysate and immune adjuvant CpG-ODN were loaded into MR to develop an injectable and cytotoxic hydrogel MCL. MCL showed excellent ability for sustained drug release, to activate dendritic cells and directly kill melanoma cells in vitro. In vivo, MCL not only exerted direct antitumor activity, but also had robust immune initiation effects including the activation of dendritic cells in draining lymph nodes and the infiltration of cytotoxic T lymphocytes (CTLs) in tumor microenvironment. In addition, MCL can efficiently inhibit melanoma growth in B16-F10 tumor bearing mice, which suggested that MCL is a potential cancer vaccine strategy for melanoma treatment.'], ['[Femtosecond laser-assisted minimally invasive lamellar keratoplasty for advanced keratoconus].', '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', '2023 Apr 11', '37012592', 'Objective: To evaluate the initial safety and efficacy of femtosecond laser-assisted minimally invasive lamellar keratoplasty (FL-MILK) for advanced keratoconus. Methods: It was a case series study. Patients with advanced keratoconus who underwent FL-MILK between August 2017 and April 2020 at Shandong Eye Hospital were prospectively included. The femtosecond laser was used to create an intrastromal pocket in the recipient cornea and a lamellar cornea in the donor. The lamellar cornea was then gently inserted into the intrastromal pocket through the incision and flattened. Clinical measurements included best-corrected visual acuity, 3-mm anterior corneal mean keratometry, anterior and posterior central corneal elevation, central corneal thickness, corneal biomechanics, and endothelial cell density. The follow-up was conducted at 1 month, 12 months, and 24 months after the operation. Results: There were 33 patients (35 eyes) in the study. Twenty-six patients were male and 7 patients were female. The mean age was (20.34+/-5.24) years old. All patients completed 12 months of follow-up, and 25 patients (27 eyes) completed 24 months of follow-up. No epithelial ingrowth, infection, or allogeneic rejection was observed. Compared with the preoperative data, the anterior central corneal elevation significantly decreased (P<0.001), the mean keratometry significantly decreased (P<0.05), and the central corneal thickness significantly increased (P<0.001). The corneal biomechanical strength was significantly improved, with the deformation amplitude ratio at 2.0 mm decreasing from 1.39+/-0.14 preoperatively to 1.21+/-0.10 at 24 months postoperatively (P<0.001) and the stiffness parameter at the first applanation increasing from 41.49+/-11.47 preoperatively to 88.41+/-18.17 at 24 months postoperatively (P<0.001). There were no significant changes in the mean best-corrected visual acuity, posterior corneal elevation, mean spherical equivalent, and endothelial cell density (all P>0.05). Conclusions: FL-MILK may be a feasible option for advanced keratoconus. This procedure may provide a new resolution for keratoconus.'], ['Biomechanical Responses of Different Cap Thicknesses of Corneas After Small Incision Lenticule Extraction: Finite Element Analysis.', 'Translational vision science & technology', '2023 Apr 3', '37017958', 'PURPOSE: This study analyzed the biomechanical responses of different corneal cap thicknesses after small incision lenticule extraction (SMILE). METHODS: Individual finite element models of myopic eyes were constructed based on the clinical data. Then, four types of corneal cap thicknesses after SMILE were included for each model. The biomechanical effects of material parameters and intraocular pressure on corneas with different cap thicknesses were analyzed. RESULTS: When the cap thickness increased, the vertex displacements of the anterior and posterior corneal surfaces decreased slightly. The corneal stress distributions demonstrated little change. Regarding wave-front aberrations caused by the displacements of the anterior surface, the absolute defocus value decreased slightly, but the magnitude of primary spherical aberration increased slightly. The horizontal coma increased, and the levels of other low-order and high-order aberrations were small and demonstrated little change. The corneal vertex displacement and wave-front aberration were significantly affected by elastic modulus and intraocular pressure, whereas the corneal stress distribution was greatly affected by intraocular pressure. There were obvious individual differences in the biomechanical responses of human eyes. CONCLUSIONS: The biomechanical difference of different corneal cap thicknesses after SMILE was small. The effect of corneal cap thickness was significantly less than that resulting from material parameters and intraocular pressure. TRANSLATIONAL RELEVANCE: Individual models were constructed based on the clinical data. The elastic modulus was controlled by programming to simulate its heterogeneous distribution in the actual human eye. The simulation was improved to bridge the gap between basic research and clinical care.'], ['Integrative Single-Cell Transcriptomics and Epigenomics Mapping of the Fetal Retina Developmental Dynamics.', 'Advanced science (Weinheim, Baden-Wurttemberg, Germany)', '2023 Apr 5', '37017569', 'The underlying mechanisms that determine gene expression and chromatin accessibility in retinogenesis are poorly understood. Herein, single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin sequencing are performed on human embryonic eye samples obtained 9-26 weeks after conception to explore the heterogeneity of retinal progenitor cells (RPCs) and neurogenic RPCs. The differentiation trajectory from RPCs to 7 major types of retinal cells are verified. Subsequently, diverse lineage-determining transcription factors are identified and their gene regulatory networks are refined at the transcriptomic and epigenomic levels. Treatment of retinospheres, with the inhibitor of RE1 silencing transcription factor, X5050, induces more neurogenesis with the regular arrangement, and a decrease in Muller glial cells. The signatures of major retinal cells and their correlation with pathogenic genes associated with multiple ocular diseases, including uveitis and age-related macular degeneration are also described. A framework for the integrated exploration of single-cell developmental dynamics of the human primary retina is provided.'], ['Characterization of dysbiosis of the conjunctival microbiome and nasal microbiome associated with allergic rhinoconjunctivitis and allergic rhinitis.', 'Frontiers in immunology', '2023', '37020561', 'BACKGROUND: Allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR) are prevalent allergic diseases. People are becoming increasingly aware of the impact of microbial disorders on host immunity and allergic diseases. Studies have demonstrated an association between allergic diseases and the microbiome, but much remains unknown. We assessed changes in the conjunctival microbiome and nasal microbiome in patients with ARC or AR. METHODS: Conjunctival swabs and nasal swabs were collected from each participant for 16S rRNA amplicon sequencing. Bacterial communities were analyzed. RESULTS: Forty patients with ARC, 20 patients suffering from AR, and 34 healthy controls (HCs) were recruited. This study found the abundance of conjunctival microbiome in patients with ARC or AR was significantly lower than that in HCs. The diversity of conjunctival microbiome in patients with AR was significantly lower than those in the other two groups. There is no significant difference in abundance of nasal microbiome between the three groups. The diversities of nasal microbiome in patients with ARC or AR were significantly lower than that in HCs. We found significant differences in microbiota compositions in patients with ARC or AR compared with those in HCs. However, no significant difference in microbiota compositions was found between patients with ARC and patients with AR. Microbiome functions in the ARC group and AR group were also altered compared with HCs. CONCLUSIONS: We revealed changes in the composition and function of the conjunctival microbiome and nasal microbiome of patients with ARC or AR, which suggests that there is a relationship between allergic conditions and the local microbiome.'], ['Diabetic retinopathy progression in patients under monitoring for treatment or vision loss: external validation and update of a multivariable prediction model.', 'BMJ open', '2023 Apr 3', '37012014', 'INTRODUCTION: The number of people with diabetes mellitus is increasing globally and consequently so too is diabetic retinopathy (DR). Most patients with diabetes are monitored through the diabetic eye screening programme (DESP) until they have signs of retinopathy and these changes progress, requiring referral into hospital eye services (HES). Here, they continue to be monitored until they require treatment. Due to current pressures on HES, delays can occur, leading to harm. There is a need to triage patients based on their individual risk. At present, patients are stratified according to retinopathy stage alone, yet other risk factors like glycated haemoglobin (HbA1c) may be useful. Therefore, a prediction model that combines multiple prognostic factors to predict progression will be useful for triage in this setting to improve care.We previously developed a Diabetic Retinopathy Progression model to Treatment or Vision Loss (DRPTVL-UK) using a large primary care database. The aim of the present study is to externally validate the DRPTVL-UK model in a secondary care setting, specifically in a population under care by HES. This study will also provide an opportunity to update the model by considering additional predictors not previously available. METHODS AND ANALYSIS: We will use a retrospective cohort of 2400 patients with diabetes aged 12 years and over, referred from DESP to the NHS hospital trusts with referable DR between 2013 and 2016, with follow-up information recorded until December 2021.We will evaluate the external validity of the DRPTVL-UK model using measures of discrimination, calibration and net benefit. In addition, consensus meetings will be held to agree on acceptable risk thresholds for triage within the HES system. ETHICS AND DISSEMINATION: This study was approved by REC (ref 22/SC/0425, 05/12/2022, Hampshire A Research Ethics Committee). The results of the study will be published in a peer-reviewed journal, presented at clinical conferences. TRIAL REGISTRATION NUMBER: ISRCTN 10956293.'], ['PROGNOSIS EVALUATION WITH OPTICAL COHERENCE TOMOGRAPHY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.', 'Photodiagnosis and photodynamic therapy', '2023 Apr 4', '37023997', 'BACKGROUND: Central serous chorioretinopathy (CSCR) is the fourth most common retinopathy that causes severe vision loss and is frequently seen in young and active patients. Our aim in this study is to evaluate whether a foresight about the prognosis of patients with CSCR can be obtained by optical coherence tomography (OCT) findings. MATERIALS AND METHODS: Patients diagnosed with chronic CSCR at Fatih Sultan Mehmet Research and Training Hospital, Ophthalmology Department, were screened between January 2017 and September 2019, and 30 patients were included in the study. The anatomical and functional changes of the patients during the 6-month follow-up and the relationship between the OCT findings at baseline and the best corrected visual acuity (BCVA) in the sixth month were evaluated. RESULTS: All of the participants were treated with subthreshold micropulse laser therapy. BCVA increased significantly at first month and sixth month examinations compared to baseline, while the central macular thicknesses decreased significantly (p=0.01, p=0.00). Among the parameters examined in the baseline OCT, a positive correlation was found between the thickness of the outer nuclear layer (r=-0.520, p=0.003) and BCVA at sixth month. In addition, subretinal fluid density and the number of intra-subretinal hyperreflective dots negatively affected BCVA (r=0.371, p=0.044 and r=0.509, p=0.004). CONCLUSION: Outer nuclear layer thickness, subretinal fluid density and intra-subretinal hyperreflective dots were the OCT biomarkers related to sixth month BCVA. The clinical use of these biomarkers will help evaluate the prognosis of the CSCR.'], ['Investigating the change in gene expression profile of blood mononuclear cells post-laparoscopic sleeve gastrectomy in Chinese obese patients.', 'Frontiers in endocrinology', '2023', '36998473', \"BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) is a sustainable technique that effectively treats morbid obesity. However, the molecular mechanisms underlying the improvement of metabolic health following this process warrants more investigation. This study investigates LSG-related molecules and uses bulk RNA-sequencing high-throughput analysis to unravel their regulatory mechanisms. METHODS: Peripheral blood mononuclear cells (PBMC) were collected from ten obese patients with BMI >/= 32.5 kg/m(2) in the Department of General Surgery of Kunming First People's Hospital. After LSG, patients were followed up for one month, and blood samples were retaken. Blood samples from ten patients before and after LSG and bulk RNA-Seq data were analyzed in this study. LSG-associated gene expression was detected by weighted gene coexpression network analysis (WGCNA) and differential analysis. Subsequently, essential signature genes were identified using logistic least absolute shrinkage and selection operator (LASSO) and support vector machine-recursive feature elimination (SVM-RFE) algorithms. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and single-sample gene set enrichment analysis (ssGSEA) were utilized to reveal the potential functions of the target genes. Furthermore, the Pearson correlation of signature genes with leptin and lipocalin was also explored. Finally, we constructed a robust endogenous RNA (ceRNA) network based on miRWalk and starBase databases. RESULTS: We identified 18 overlapping genes from 91 hub genes, and 165 differentially expressed mRNAs (DE-mRNA), which were revealed to be significantly associated with immune cells, immune response, inflammatory response, lipid storage, and localization upon functional enrichment analysis. Three signature genes, IRF1, NFKBIA, and YRDC, were identified from the 18 overlapping genes by LASSO and SVM-REF algorithms. The logistic regression model based on the three signature genes highlighted how robustly they discriminated between samples. ssGSEA indicated these genes to be involved in lipid metabolism and degradation pathways. Moreover, leptin levels were significantly reduced in patients undergoing LSG, and NFKBIA significantly negatively correlated with leptin. Finally, we identified how the long non-coding RNA (lncRNA) ATP2B1-AS1 regulated the expression of the signature genes by competitively binding to six microRNAs (miRNAs), which were hsa-miR-6509-5p, hsa-miR-330-5P, hsa-miR-154-5P, hsa-miR-145-5P, hsa-miR4726-5P and hsa-miR-134-5P. CONCLUSION: This study identified three critical regulatory genes significantly differentiated between patients before and after LSG treatment and highlighted their potentially crucial role after bariatric surgery. This provides novel insights to increase our understanding of the underlying mechanisms of weight loss and associated metabolic improvement after bariatric surgery.\"], ['Italian translation and validation of the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8).', 'Contact lens & anterior eye : the journal of the British Contact Lens Association', '2023 Apr 4', '37024414', 'PURPOSE: To translate and validate an Italian version of the CLDEQ-8 (CLDEQ-8_IT). METHODS: The study was carried out in two phases. In the first phase, a cross-cultural adaptation of CLDEQ-8 to Italian was performed by forward and backward translation in sequence. In the second phase, a multi-centre study was conducted for the validation of the questionnaire. Validity CLDEQ-8_IT was evaluated against three gestalt questions: overall opinion of soft contact lenses (CLs), global self-assessments of eye sensitivity and eye dryness. Reliability was evaluated by test-retest assessment in a subgroup of subjects. Finally, the psychometric properties of CLDEQ-8_IT were explored by Rasch analysis. RESULTS: Two hundred and forty soft CL wearers, fluent Italian speakers (73 males and 167 females), between 18 and 70 years of age were enrolled. A significant correlation was found between CLDEQ-8_IT and each of the three Gestalt questions. The cutoff score of 12 points demonstrated the best balance between sensitivity and specificity in differentiating wearers grading their CLs as \"Excellent/Very good\" from those reporting their overall opinion as \"Good/Fair/Poor\". The Intraclass Correlation Coefficient between test and retest was 0.88 (95% CI: 0.81-0.92). Finally, infit and outfit statistics using Rasch analysis for the 8 items were in a good range, however Principal Components Analysis revealed a certain degree of multi-dimensionality of the instrument. Also, item 8 analysis could be computed after merging the last two response categories. CONCLUSION: The CLDEQ-8_IT showed very good validity and reliability in measuring symptoms of CL wearers, comparable to the original English language version. A cut-off of 12 was confirmed as yielding the best balance between sensitivity and specificity in detecting CL wearers who could benefit from clinical management of their CL-related symptoms. Collapsing of the response options 5 and 6 in the last item of questionnaire could optimise its functioning.'], ['Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.', 'Journal of vitreoretinal diseases', '2023 Jan-Feb', '37008402', 'PURPOSE: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular degeneration (nAMD). METHODS: Eyes were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + aflibercept 2 mg (HD combo), or IAI 2 mg at baseline, week 4, and week 8. The LD combo was continued every 8 weeks (q8w). At week 12, the HD combo was re-randomized to q8w or every 12 weeks (q12w) and IAI was re-randomized to q8w, q12w, or HD combo q8w through week 32. RESULTS: The study comprised 365 eyes. At week 12, the mean best-corrected visual acuity (BCVA) gains from baseline were similar in the LD combo group, HD combo group, and IAI group (5.2 letters, 5.6 letters, and 5.4 letters, respectively); the mean central subfield thickness (CST) reductions were similar (182.2 microm, 200.0 microm, and 178.6 microm, respectively). The mean changes in BCVA and CST through week 36 were similar across groups. At week 12, complete retinal fluid resolution was observed in 49.1% (LD combo), 50.8% (HD combo), and 43.6% (IAI) of eyes; the proportions with a CST of 300 mum or less were similar across groups. Numerical trends at week 32 toward complete retinal fluid resolution with combination treatment were not maintained at week 36. Serious ocular adverse events were infrequent and comparable across groups. CONCLUSIONS: In nAMD, nesvacumab + aflibercept showed no additional BCVA or CST benefit over IAI monotherapy.'], ['Opportunity Cost of Retinal Detachment Surgery vs Office-Based Patient Care.', 'Journal of vitreoretinal diseases', '2022 Jul-Aug', '37007922', \"Purpose: This work compares physician reimbursements for retinal detachment (RD) surgery with office-based patient care. Methods: A theoretical model was constructed from the physician's perspective for performing a 90-minute uncomplicated RD surgery with its associated perioperative work in the global period (Current Procedural Terminology code 67108) compared with managing 40 patients per 8-hour clinic day in the equivalent time period. The reimbursement rates were based on the 2019 values set by the US Centers for Medicare and Medicaid Services (CMS). Sensitivity analyses were performed varying the perioperative times, clinical productivity, and postoperative visits. Results: The CMS physician reimbursement rate for 67108 surgery was 17.13 work relative value units (wRVUs); meanwhile, the physician in the reference case could have generated 40.89 wRVUs in the office. CMS reimbursement therefore represented a 58% opportunity cost relative to lost office productivity for the physician. A significant disparity was still present even when modeling 30 patients per day. In sensitivity analyses, clinical productivity exceeded surgical compensation in 99% of modeled scenarios. In threshold analyses, the surgeon in the reference case would have to complete the surgery and all immediate perioperative care within 18 minutes to equal the total CMS valuation. Conclusions: CMS reimbursement for RD surgery resulted in a significant opportunity cost for the physician relative to office-based patient care, which was more pronounced for more efficient clinicians in the office. The sensitivity analyses supported the robustness of the model. Reductions in surgery reimbursements relative to office-based patient care might disincentivize busy clinicians.\"], ['Clinical efficacy of a new surgical technique of oral mucosal epithelial transplantation for severe ocular surface disorders.', 'BMC ophthalmology', '2023 Apr 7', '37029360', 'BACKGROUND: Severe ocular surface disorders are one of the major blinding diseases, and a paucity of original tissue obscures successful reconstruction. We developed a new surgical technique of direct oral mucosal epithelial transplantation (OMET) to reconstruct severely damaged ocular surfaces in 2011. This study elaborates on the clinical efficacy of OMET. METHODS: A retrospective review of patients with severe ocular surface disorders who underwent OMET from 2011 to 2021 at the Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine was conducted. Patients who were followed up for at least 3 months postoperatively and had sufficient pre or postoperative records were included. Surgical efficacy was evaluated by comparing the best-corrected visual acuity (BCVA), corneal transparency, neovascularization grade, and symblepharon grade. Additionally, postoperative ocular surface impression cytology was used to study the morphology of the newborn epithelial cells. RESULTS: Forty-eight patients (49 eyes; mean age: 42.55 +/- 12.40 years, range:12-66 years) were enrolled in the study. The etiology included chemical burns (30 eyes), thermal burns (16 eyes), explosive injuries (1 eye), Stevens-Johnson syndrome (1 eye), and multiple pterygiums (1 eye). The mean follow-up period was 25.97 +/- 22.99 months. Postoperatively, 29 eyes (59.18%) showed improved corneal transparency, 26 eyes (53.06%) had improved BCVA, 47 eyes (95.92%) had a stable epithelium until the final follow-up, 44 eyes (89.80%) had a reduced neovascularization grade. Of the 20 eyes with preoperative symblepharon, 15 (75%) were completely resolved, and five (25%) were partially resolved. Impression cytological studies showed no postoperative conjunctival invasion onto the corneal surface. CONCLUSIONS: OMET is a safe and effective surgical technique for reconstruction in severe ocular surface disorder by maintaining a stable epithelium and reducing the neovascularization and symblepharon grade.'], ['Management and Complications of Dexamethasone Intravitreal Implant Migration Into the Anterior Chamber.', 'Journal of vitreoretinal diseases', '2022 Nov-Dec', '37009539', 'PURPOSE: To report patient demographics, the clinical course, and visual outcomes across a case series of patients who experienced dexamethasone (DEX) intravitreal implant (Ozurdex, Allergan, Inc) migration into the anterior chamber (AC), with a focus on the corneal transplantation rate. METHODS: In this retrospective cross-sectional study, a chart review of all cases was performed. For numerical responses, means and SDs were calculated. Percentages and absolute numbers were used to report the proportion of patients who experienced various outcomes of interest. RESULTS: The study comprised 32 cases. All cases occurred in pseudophakic eyes; of those, 8 (25.0%) had posterior chamber intraocular lenses in the capsular bag with no known capsular or zonular issues. The mean duration from DEX implant injection to detection of migration was 19.4 +/- 14.5 days. The DEX implant was explanted in 21 patients (65.6%) and repositioned in the vitreous cavity or subconjunctival space in 6 patients (18.8%). Twelve patients (37.5%) ultimately required corneal transplantation. CONCLUSIONS: To our knowledge, this is the largest case series of DEX intravitreal implant migration into the AC compiled to date. Cases of migration occurred in individuals with no known history of significant prior zonule disruption. This potential complication should be discussed with all patients undergoing DEX implant injection, which may aid in earlier presentation and improved visual outcomes.'], ['Posterior Polar Hemispheric Choroidal Dystrophy: Case Report and Presentation of Genetic Screening.', 'Journal of vitreoretinal diseases', '2022 Nov-Dec', '37009538', 'PURPOSE: Posterior polar hemispheric choroidal dystrophy is a rare dystrophy affecting the choroid and retina with a characteristic clinical appearance that distinguishes it from a broad variety of other retinal diseases. The disease process has a morphology described in the literature that preferentially affects the outer macula and spares the fovea with no arteriolar attenuation or optic nerve pallor. METHODS: This case report illustrates the use of multimodal retinal imaging, visual field testing, electroretinogram, and genetic testing of a patient who we believe fits the clinical pattern established by previous studies describing this condition. RESULTS: Fundus imaging in addition to further imaging modalities such as fluorescein angiography helped further characterize this disease process and aided in the diagnosis. In addition, genetic testing revealed unique allele variants found in this patient. CONCLUSIONS: By taking a multifaceted approach to the diagnosis of retinal pathology, clinicians can make informed decisions regarding patient care.'], ['Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice.', 'International journal of retina and vitreous', '2023 Apr 4', '37016462', 'BACKGROUND: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are the standard of care for diabetic macular edema (DME), a common complication of diabetes. This study aimed to identify factors influencing DME intravitreal anti-VEGF treatment outcomes in real-world practice. METHODS: This was a multi-center retrospective observational study using medical chart review of participants receiving anti-VEGF injections for DME (N = 248). Demographic and clinical variables were assessed for association with best corrected visual acuity (BCVA) and central macular thickness (CMT) outcomes using regression models. RESULTS: There was a significant improvement in BCVA (p < 0.001) and CMT (p < 0.001) after 12 months of treatment, although 21% of participants had decreased BCVA, and 41% had a < 10% CMT reduction at 12 months. Higher baseline BCVA (p = 0.022, OR=-0.024, 95% CI=-0.046,-0.004) and longer duration of diabetic retinopathy (p = 0.048, OR=-0.064, 95% CI=-0.129,-0.001) were negative predictors for BCVA response, whereas Aflibercept treatment (p = 0.017, OR = 1.107, 95% CI = 0.220,2.051) compared with other drugs and a positive \"early functional response\" (p < 0.001, OR=-1.393, 95% CI=-1.946,-0.857) were positive predictors. A higher baseline CMT (p < 0.001, OR = 0.019, 95% CI = 0.012,0.0261) and an \"early anatomical response\", (p < 0.001, OR=-1.677, 95% CI=-2.456, -0.943) were predictors for greater reduction in CMT. Overall, the variables could predict only 23% of BCVA and 52% of CMT response. CONCLUSIONS: The study shows a significant proportion of DME patients do not respond to anti-VEGF therapy and identifies several clinical predictors for treatment outcomes. TRIAL REGISTRATION: The study was approved through the Human Research Ethics Committee, University of Tasmania (approval number H0012902), and the Southern Adelaide Clinical Human Research Ethics Committee (approval number 86 - 067).'], ['A Multicenter Analysis of Nucleic Acid Quantification Using Aqueous Humor Liquid Biopsy in Retinoblastoma: Implications for Clinical Testing.', 'Ophthalmology science', '2023 Sep', '37025945', 'PURPOSE: Retinoblastoma (RB) is most often diagnosed with clinical features and not diagnosed with tumor biopsy. This study describes tumor-derived analyte concentrations from aqueous humor (AH) liquid biopsy and its use in clinical assays. DESIGN: Case series study. PARTICIPANTS: Sixty-two RB eyes from 55 children and 14 control eyes from 12 children from 4 medical centers. METHODS: This study included 128 RB AH samples including: diagnostic (DX) samples, samples from eyes undergoing treatment (TX), samples after completing treatment (END), and during bevacizumab injection for radiation therapy after completing RB treatment (BEV). Fourteen-control AH were analyzed for unprocessed analytes (double-stranded DNA [dsDNA], single-stranded DNA [ssDNA], micro-RNA [miRNA], RNA, and protein) with Qubit fluorescence assays. Double-stranded DNA from 2 RB AH samples underwent low-pass whole-genome sequencing to detect somatic copy number alterations. Logistic regression was used to predict disease burden given analyte concentrations. MAIN OUTCOME MEASURES: Unprocessed analyte (dsDNA, ssDNA, miRNA, RNA and protein) concentrations. RESULTS: Results revealed dsDNA, ssDNA, miRNA, and proteins, but not RNA, were quantifiable in most samples (up to 98%) with Qubit fluorescence assays. Median dsDNA concentration was significantly higher in DX (3.08 ng/mul) compared to TX (0.18 ng/mul; P < 0.0001) at an order of 17 times greater and 20 times greater than END samples (0.15 ng/mul; P = 0.001). Using logistic regression, nucleic acid concentrations were useful in predicting higher versus lower RB disease burden. Retinoblastoma somatic copy number alterations were identified in a TX, but not in a BEV sample, indicating the correlation with RB activity. CONCLUSIONS: Aqueous humor liquid biopsy in RB is a high-yield source of dsDNA, ssDNA, miRNA, and protein. Diagnostic samples are most useful for RB 1 gene mutational analyses. Genomic analysis may be more informative of tumor activity status than quantification alone and can be performed even with smaller analyte concentrations obtained from TX samples. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.'], ['Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.', 'Scientific reports', '2023 Apr 7', '37029145', 'This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and safety of preservative-free and preserved brimonidine tartrate 0.15% in open-angle glaucoma and ocular hypertension. Sixty eyes of 60 patients with intraocular pressure (IOP) >/= 15 mmHg diagnosed with open-angle glaucoma or ocular hypertension were randomized to preserved (n = 31) and preservative-free (n = 29) brimonidine groups. The enrolled eyes received brimonidine monotherapy three times daily. Main outcome measures were corneal/conjunctival staining score, ocular surface disease index, patient satisfaction score, drug tolerance, and drug adherence rate 12 weeks post first administration. Secondary outcome measurements included visual acuity, IOP, drug tolerance, tear-film break-up time, hemodynamic changes including blood pressure and heart rates, and ocular adverse events. After 12 weeks, both preserved and preservative-free groups showed similar IOP reduction, corneal and conjunctival staining scores, drug tolerance, and adherence rates. The preservative-free group showed significantly better tear-film break-up time and higher patient satisfaction regarding drug use and management. Systolic and diastolic blood pressure reductions during the 12 weeks were significantly lower in the preserved group than in the preservative-free group. Preservative-free brimonidine tartrate showed comparable efficacy and safety, better corneal tear film stability, and patient satisfaction than preserved brimonidine.'], ['[A multicenter clinical trial of collar-button type keratoprosthesis implantation for the treatment of corneal blindness in high-risk transplantation].', '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', '2023 Apr 11', '37012589', 'Objective: To evaluate the efficiency and safety of collar-button type keratoprosthesis (c-bKPro) implantation for corneal blindness in high-risk transplantation in China. Methods: It was a case series study. High-risk corneal blind patients who planned to undergo c-bKPro implantation were prospectively and continuously enrolled in the Eye Hospital of Shandong First Medical University, Ophthalmology Division of Chinese PLA General Hospital, Zhongshan Ophthalmic Center, Department of Ophthalmology in Eye & ENT Hospital of Fudan University, and Eye Hospital of Wenzhou Medical University from July 2019 to January 2020. The cure for blindness and surgical success were assessed based on visual acuity (VA)>/=0.05. The complications and keratoprosthesis retention rate were recorded to determine the safety of the surgery. Results: Thirty-seven subjects (eyes) were included, of which 32 were male and 5 were female, aged 27 to 72 years old. The indications of c-bKPro implantation were corneal graft failure (21 eyes, 56.8%), chemical injury (8 eyes, 21.6%), thermal burn (5 eyes, 13.5%), unexplained corneal opacity (2 eyes, 5.4%), and corneal perforation (1 eye, 2.7%). Two patients withdrew from the clinical trial at 3 months postoperatively. Thirty-five patients were followed up for 6 months, and 31 were followed up for 12 months. The VA was >/=0.05 in 83.8% of eyes at 6 months and in 81.8% of eyes at 12 months. Among the 11 eyes diagnosed with concurrent glaucoma, 6 eyes achieved a VA of >/=0.05. At 12 months, the c-bKPro retention rate was 100%. The surgical complications included retroprosthetic membrane formation (5 eyes, 16.1%), persistent corneal epithelial defects (5 eyes, 16.1%), macular edema (4 eyes, 12.9%), new-onset glaucoma (4 eyes, 12.5%; including one eye withdrawn from the study at 3 months), sterile corneal melting (2 eyes, 6.5%), sterile vitritis (1 eye, 3.2%), and infectious keratitis (1 eye, 3.2%). Conclusions: C-bKPro implantation is an effective and safe option for treating corneal blindness in high-risk transplantation in China. Improved visual outcomes could be achieved in most cases, with a relatively low incidence of postoperative complications.'], ['How many children with large clear cornea do not have glaucoma?', 'European journal of ophthalmology', '2023 Apr 6', '37021409', 'PURPOSE: A horizontal corneal diameter greater than 2 standard deviations from the mean (9.8 mm) or greater than 11 mm in term infants defines megalocornea (herein referred to as a large clear cornea). The aim of the current study was to report on the incidence and clinical characteristics of children presenting with large clear cornea that do not suffer glaucoma. METHODS: A retrospective chart review of children presenting with large clear cornea to the pediatric ophthalmology unit of the ophthalmology department of Alexandria Main University Hospital in the period from March 2011 to December 2020 was conducted. A large clear cornea was defined as a horizontal white-to-white corneal diameter (as measured by calipers) greater than 12 mm. Glaucoma was diagnosed according to the childhood glaucoma research network (CGRN) criteria and the axial length was used to filter out eyes with large clear corneas due to congenital high myopia. RESULTS: Out of 120 eyes of 91 (58 males) children a total of 76 eyes of 67 (41 males) children were diagnosed with glaucoma and 44 eyes of 24 (17 males) children (36.7%) did not suffer glaucoma. Out of these, 30 eyes were classified as myopia and 14 eyes as congenital megalocornea. CONCLUSIONS: More than one third of eyes presenting with large clear corneas may not have glaucoma, and almost two thirds of these eyes (that are not suffering from glaucoma) demonstrate axial myopia.'], ['An update in the applications of exosomes in cancer theranostics: from research to clinical trials.', 'Journal of cancer research and clinical oncology', '2023 Apr 3', '37010586', 'Exosomes are nanosized extracellular vesicles secreted by nearly all viable cells following the fusing of multivesicular bodies and the plasma membrane and discharged into the encircling bodily fluids. Exosomes can transport cell-specific components from the source cell to the target cell. Given the enormous potential of exosomes as non-invasive diagnostic biomarkers and therapeutic nanovehicles. Lately, accumulated evidence has demonstrated that exosomes serve an important role in prognosis, diagnosis, and even treatment strategies. While several reviews have collective information on the biomedical application of exosomes, a comprehensive review incorporating updated and improved methodologies for beneficial applications of such vesicles in cancer theranostics is indispensable. In the current review, we first provided a comprehensive review of the introduction of exosomes, featuring their discovery, separation, characterization, function, biogenesis, secretion. The implications of exosomes as promising nanovehicles for drug and gene delivery, application of exosome inhibitors in the management of cancers, completed and ongoing clinical trials on the biological relevance of exosomes are then discussed in detail. As the field of exosome research grows, a better understanding of the subcellular parts and mechanisms involved in exosome secretion and targeting of specific cells will help figure out what their exact physiological functions are in the body.'], ['Clinical Outcomes of Combined Phacoemulsification With Intraocular Lens Placement and Microincision Vitrectomy in Adult Vitreoretinal Disease.', 'Journal of vitreoretinal diseases', '2023 Jan-Feb', '37008401', 'PURPOSE: To evaluate the safety and clinical outcomes of combined phacoemulsification with intraocular lens (IOL) placement and microincision vitrectomy surgery (MIVS) in adult patients with concomitant cataract and vitreoretinal disease. METHODS: A consecutive series of patients with comorbid vitreoretinal disease and cataract who had combined phacoemulsification with IOL placement and MIVS was retrospectively analyzed. The main outcome measures were visual acuity (VA) and intraoperative and postoperative complications. RESULTS: The analysis comprised 648 eyes of 611 patients. The median follow-up was 26.9 months (range, 12-60 months). The most common vitreoretinal pathology was intraocular tumor (53%). The best-corrected Snellen VA improved from 20/192 at baseline to 20/46 at the 12-month follow-up. The most frequent intraoperative complication was capsule tear (3.9%). The most common postoperative adverse events after 3 months of follow-up (mean, 24 months) were vitreous hemorrhage (3.2%) and retinal detachment (1.8%). No patient developed endophthalmitis. CONCLUSIONS: Combined phacoemulsification with IOL placement and MIVS is a safe, effective technique to manage a broad range of vitreoretinal diseases in patients with significant cataract.'], ['Paradoxical Exudative Retinopathy and Macular Star Formation After Treatment Initiation in Coats Disease.', 'Journal of vitreoretinal diseases', '2022 Nov-Dec', '37009530', 'Purpose: This work describes a unique clinical feature in Coats disease. Methods: A retrospective series of 2 cases is reported. Results: Two pediatric patients receiving treatment for Coats disease were included. In both cases, vision worsened secondary to paradoxically increased exudation and macular star formation following standard treatment with intravitreal bevacizumab, sub-Tenon triamcinolone acetonide, and laser photocoagulation. After serial treatments under general anesthesia, the exudates in both cases consolidated. Conclusions: A paradoxical exudative retinopathy can occur in some patients when initiating standard treatment of Coats disease. Longitudinal follow-up with continued intravitreal antivascular endothelial growth factor agents, laser photocoagulation, and corticosteroids might help control persistent exudation in these cases.'], ['Ankylosing spondylitis and glaucoma in European population: A Mendelian randomization study.', 'Frontiers in immunology', '2023', '37020551', \"BACKGROUND: The relationship between ankylosing spondylitis (AS) and glaucoma in the European population remains unclear. In the present study, we applied a two-sample Mendelian randomization (MR) method to investigate their causal relationship. METHODS: MR analysis was conducted to validate the causal associations between AS with glaucoma using summary statistics from the genome-wide association studies of AS (9,069 cases and 13,578 control subjects) and glaucoma (8,591 cases and 210,201 control subjects). The inverse variance weighting method was performed to evaluate the causal relationship. The MR-Egger regression approach was applied to assess pleiotropy, while Cochran's Q test was used to analyze heterogeneity. Subgroup analysis was performed according to primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). RESULTS: The results of the MR study reveal a risk-increasing causal relationship between AS and glaucoma among European populations (OR = 1.35, 95%CI = 1.16-1.57, P = 8.81 x 10(-5)). Pleiotropy and heterogeneity were not found in our study. In the subgroup analysis, AS was also causal with POAG (OR = 1.48, 95%CI = 1.17-1.86, P = 8.80 x 10(-4)) and PACG (OR = 1.91, 95%CI = 1.03-3.51, P = 3.88 x 10(-2)). CONCLUSION: The results of the MR analysis suggested a causal relationship between AS and glaucoma in the European population. Further studies are needed to identify the specific mechanism between these two diseases.\"], ['Metabolomic analysis of aqueous humor reveals potential metabolite biomarkers for differential detection of macular edema.', 'Eye and vision (London, England)', '2023 Apr 1', '37004107', 'BACKGROUND: Macular edema (ME) is a major complication of retinal disease with multiple mechanisms involved in its development. This study aimed to investigate the metabolite profile of aqueous humor (AH) in patients with ME of different etiologies and identify potential metabolite biomarkers for early diagnosis of ME. METHODS: Samples of AH were collected from 60 patients with ME and 20 age- and sex-matched controls and analyzed by liquid chromatography-mass spectrometry (LC/MS)-based metabolomics. A series of univariate and multivariate statistical analyses were performed to identify differential metabolites and enriched metabolite pathways. RESULTS: The metabolic profile of AH differed significantly between ME patients and healthy controls, and differentially expressed metabolites were identified. Pathway analysis revealed that these differentially expressed metabolites are mainly involved in lipid metabolism and amino acid metabolism. Moreover, significant differences were identified in the metabolic composition of AH from patients with ME due to different retinal diseases including age-related macular degeneration (AMD-ME), diabetic retinopathy (DME) and branch retinal vein occlusion (BRVO-ME). In total, 39 and 79 etiology-specific altered metabolites were identified for AMD-ME and DME, respectively. Finally, an AH-derived machine learning-based diagnostic model was developed and successfully validated in the test cohort with an area under the receiver operating characteristic (ROC) curve of 0.79 for AMD-ME, 0.94 for DME and 0.77 for BRVO-ME. CONCLUSIONS: Our study illustrates the potential underlying metabolic basis of AH of different etiologies across ME populations. We also identify AH-derived metabolite biomarkers that may improve the differential diagnosis and treatment stratification of ME patients with different etiologies.'], ['Correlation Between Lens Density Measured by Swept-Source Optical Coherence Tomography and Phacodynamic Parameters of Centurion Phacoemulsification.', 'Current eye research', '2023 Apr 3', '37009774', 'PURPOSE: To evaluate the correlation between lens density measured by IOL-Master 700 based on swept-source optical coherence tomography (SS-OCT) technology and the phacodynamic parameters of Centurion phacoemulsification in cataract surgery. METHODS: This prospective study included 66 patients (83 eyes) with age-related cataracts. Using the Lens Opacities Classification System III (LOCS III), the lens nuclear color (NC), lens nuclear opalescence (NO), cortical (C), and posterior subcapsular (P) opacities were obtained. Six meridian orientations of IOL-Master 700 images were captured, and the lens and nuclear regions were analyzed using ImageJ to generate the average lens nucleus density (AND) and average lens density (ALD). Phacodynamic parameters were recorded. The correlation between lens density and the phacodynamic parameters was analyzed. According to the AND, patients were divided into four groups (soft, medium-hard, hard, and extremely hard nucleus), and the phacodynamic parameters were compared among groups. RESULTS: The correlation between the AND obtained by LOCS III grading and SS-OCT-based cataract quantification system score (NC and NO) was statistically significant (r(NC) = 0.795, r(NO)=0.794, both p = .000). AND correlated significantly with cumulative dissipated energy (CDE, r = 0.545, p = .000), total ultrasound time (TUST, r = 0.354, p = .001), and total torsional ultrasound time (TTUT, r = 0.314, p = .004). Among the four groups divided by AND, the difference in CDE (P(13) = 0.002, P(14) < 0.001, P(24) = 0.002) was statistically significant. CONCLUSION: AND measured by IOL-Master 700, SS-OCT correlated significantly with LOCS III classification and phacodynamic parameters of the Centurion system, especially with CDE, TUST, and TTUT. AND can be used as an indicator for quantitative evaluation and help inform the surgical plan.'], ['Optical Coherence Tomography Angiography: Clinical Utility and Future Directions.', 'Journal of vitreoretinal diseases', '2022 May-Jun', '37008547', 'PURPOSE: This work aims to review the principles of optical coherence tomography angiography (OCTA), to survey its clinical utility, and to highlight the strengths of this technology as well as barriers to adoption. METHODS: A literature review with editorial discussion of the current applications for OCTA is presented. RESULTS: There have been recent advances in multiple domains in OCTA imaging, including devices, algorithms, and new observations pertaining to a range of pathologies. New devices have improved the scanning speed, signal-to-noise ratio, and spatial resolution and offer an increased field of view. New algorithms have been proposed to optimize image processing and reduce artifacts. Numerous studies employing OCTA have been published describing changes to the microvasculature in diabetic retinopathy, age-related macular degeneration, central serous chorioretinopathy, retinal vein occlusion, and uveitis. CONCLUSIONS: OCTA provides noninvasive, high-resolution volumetric scans of the retinal and choroidal vasculature. OCTA can provide valuable data to augment traditional dye-based angiography in a range of chorioretinal diseases.'], ['Expression of alpha-Synuclein in the mouse retina is confined to inhibitory presynaptic elements.', 'The Journal of comparative neurology', '2023 Mar 31', '37002599', \"alpha-Synuclein (alpha-Syn) is enriched in presynaptic terminals of the central nervous system including the retina and plays a role in the synaptic vesicle cycle and synaptic transmission. Abnormal aggregation of alpha-Syn is considered to be the main component of the Lewy bodies that are the pathological hallmarks of Parkinson's disease. Although expression pattern of alpha-Syn has been described in the retinas, its precise cellular and subcellular locations are poorly understood. We investigated the precise expression of alpha-Syn using light microscopy (LM) and electron microscopy (EM) with antibodies against alpha-Syn in the mouse retina. We found that the majority of alpha-Syn immunoreactivity (IR) is located in GABAergic, glycinergic, and dopaminergic amacrine cells, and their processes often make a direct synapse to other labeled or unlabeled amacrine profiles, bipolar cell terminals, or ganglion cell dendrites. Further, our LM and immuno-EM results confirm the absence of alpha-Syn in excitatory photoreceptors, bipolar cell bodies, and their ribbon synapses, providing evidence, for the first time, that ribbon synapses do not express alpha-Syn. Additionally, alpha-Syn IR is located in the ganglion cells, some of which are intrinsically photosensitive retinal ganglion cells. These results reveal a previously unappreciated inhibitory synapse-specific expression pattern of alpha-Syn in the retina, suggesting that alpha-Syn may play a distinct role in the modulation and integration of inhibitory synaptic transmission in the retina.\"], ['Benefits of a laser chorioretinal anastomosis plus ranibizumab vs ranibizumab alone for central retinal vein occlusion: 4-year results.', 'American journal of ophthalmology', '2023 Apr 6', '37030494', 'PURPOSE: Evaluate what clinical gains can be achieved over conventional treatment with ranibizumab alone for central retinal vein occlusion (CRVO) when causal pathology is additionally successfully addressed with a laser-induced chorio-retinal anastomosis (L-CRA). DESIGN: 2-year extension of prospective, randomized, controlled clinical trial. METHODS: 58 patients with macular edema secondary to CRVO randomized 1:1 to receive either an L-CRA (29) or sham procedure (29) at baseline and then monthly intravitreal ranibizumab 0.5mg Outcomes (best corrected visual acuity (BCVA), central subfield thickness (CST), injection requirements) were monitored in the monthly pro re nata (PRN) ranibizumab phase from months 7-48. RESULTS: Injection requirements for those with a functioning L-CRA (24 of 29) during the monthly PRN period from 7-24 months, were mean (95% confidence interval [CI]) of 2.18 [1.57, 2.78] injections compared to 7.07 [6.08, 8.06] (p<0.0001) for control (ranibizumab alone). These decreased further over the next 2 years to 0.29 (0.14, 0.61) compared to 2.20 (1.68, 2.88) (p<0.001) for the third year and 0.25 (0.11, 0.56) and 1.84 (1.34, 2.54) for the fourth year (p<0.001). Mean BCVA was statistically different at all follow-up time points from month 7 through to month 48 for the group with the functioning L-CRA compared to the control monotherapy group. This improved to 14.06 letters at month 48 (p=0.009). There was no difference in CST between any of the groups over the 48 months of follow-up. CONCLUSION: For CRVO patients, addressing causal pathology in addition to conventional therapy, improves BCVA and reduces injection requirements.'], ['[Chinese expert consensus on the diagnosis and treatment of drug-induced keratopathy (2023)].', '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', '2023 Apr 11', '37012587', 'Drug-induced keratopathy occurs when the use of certain drugs, particularly ophthalmic preparations, causes pathological changes in the cornea. These changes can be related to the toxic effects of the drugs themselves or drug preservatives. The disease is characterized by a range of clinical features and lacks specific diagnostic criteria, which can lead to misdiagnosis and inappropriate treatment. In order to address these challenges, the Cornea Group of the Ophthalmology Branch of the Chinese Medical Association has brought together leading experts in the field to review key techniques for the diagnosis and treatment of drug-induced keratopathy. As a result, they have developed this consensus to guide the prevention and treatment of this condition.'], ['[Research progress on the epidemiology and risk factors of dry eye in children].', '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', '2023 Apr 11', '37012598', \"The prevalence of dry eye in children is increasing with changes in the environment and the widespread use of electronic products. However, due to poor ability to express themselves and hidden symptoms of children, lack of understanding of dry eye in children, children with dry eye are likely to be misdiagnosed. Dry eye can seriously affect the quality of children's learning, life, vision and visual development. Therefore, it is urgent to raise awareness of clinical workers about dry eye in children, prevent the occurrence of related complications of dry eye, and avoid permanent visual damage to children. This review discusses and summarizes the epidemiology and common risk factors of children with dry eye, with the aim of improving doctors' understanding of dry eye in children.\"], ['No Strong Association between the Apolipoprotein E E4 Allele and Glaucoma: A Multicohort Study.', 'Ophthalmology science', '2023 Sep', '37007646', \"PURPOSE: To elucidate a potential association between the apolipoprotein E (APOE) E4 allele and glaucoma prevalence in large cohorts. DESIGN: A cross-sectional analysis of baseline and prospectively collected cohort data. PARTICIPANTS: UK Biobank (UKBB) participants of genetically determined European ancestry (n = 438 711). Replication analyses were performed using clinical and genotyping data collected from European participants recruited to the Canadian Longitudinal Study of Aging (CLSA; n = 18 199), the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG; n = 1970), and the Blue Mountains Eye Study (BMES; n = 2440). METHODS: Apolipoprotein E alleles and genotypes were determined, and their distributions were compared on the basis of glaucoma status. Similar analyses were performed using positive control outcomes associated with the APOE E4 allele (death, dementia, age-related macular degeneration) and negative control outcomes not associated with the APOE E4 allele (cataract, diabetic eye disease). Outcome phenotypes were also correlated with Alzheimer's dementia (AD), a clinical outcome highly associated with the APOE E4 allele. MAIN OUTCOME MEASURES: Results of APOE E4 genotype-phenotype comparisons were reported as odds ratios (ORs) with 95% confidence intervals (CIs). Replication analyses investigated APOE E4 associations in 2 replication cohorts (CLSA and ANZRAG/BMES). RESULTS: The APOE E4 allele was inversely associated with glaucoma (OR, 0.96; 95% CI, 0.93-0.99; P = 0.016) and both negative controls (cataract: OR, 0.98; 95% CI, 0.96-0.99; P = 0.015; diabetic eye disease: OR, 0.92; 95% CI, 0.87-0.97; P = 0.003) in the UKBB cohort. A paradoxical positive association was observed between AD and both glaucoma (OR, 1.30; 95% CI, 1.08-1.54; P < 0.01) and cataract (OR, 1.15; 1.04-1.28; P = 0.018). No association between the APOE E4 allele and glaucoma was observed in either replication cohort (CLSA: OR, 1.03; 95% CI, 0.89-1.19; P = 0.66; ANZRAG/BMES: OR, 0.97; 95% CI, 0.84-1.12; P = 0.65). CONCLUSIONS: A small negative association observed between APOE E4 and glaucoma within the UKBB was not evident in either replication cohort and may represent an artifact of glaucoma underdiagnosis in APOE E4 carriers. FINANCIAL DISCLOSURES: The author(s) have no proprietary or commercial interest in any materials discussed in this article.\"], ['Anti-vascular endothelial growth factor for neovascular glaucoma.', 'The Cochrane database of systematic reviews', '2023 Apr 3', '37010901', \"BACKGROUND: Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization. Studies have reported the effectiveness of anti-VEGF medications for the control of intraocular pressure (IOP) in NVG. OBJECTIVES: To assess the effectiveness of intraocular anti-VEGF medications, alone or with one or more types of conventional therapy, compared with no anti-VEGF medications for the treatment of NVG. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register); MEDLINE; Embase; PubMed; and LILACS to 19 October 2021; metaRegister of Controlled Trials to 19 October 2021; and two additional trial registers to 19 October 2021. We did not use any date or language restrictions in the electronic search for trials. SELECTION CRITERIA: We included randomized controlled trials (RCTs) of people treated with anti-VEGF medications for NVG. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed the search results for trials, extracted data, and assessed risk of bias, and the certainty of the evidence. We resolved discrepancies through discussion. MAIN RESULTS: We included five RCTs (356 eyes of 353 participants). Each trial was conducted in a different country: two in China, and one each in Brazil, Egypt, and Japan. All five RCTs included both men and women; the mean age of participants was 55 years or older. Two RCTs compared intravitreal bevacizumab combined with Ahmed valve implantation and panretinal photocoagulation (PRP) with Ahmed valve implantation and PRP alone. One RCT randomized participants to receive an injection of either intravitreal aflibercept or placebo at the first visit, followed by non-randomized treatment according to clinical findings after one week. The remaining two RCTs randomized participants to PRP with and without ranibizumab, one of which had insufficient details for further analysis. We assessed the RCTs to have an unclear risk of bias for most domains due to insufficient information to permit judgment.   Four RCTs examined achieving control of IOP, three of which reported our time points of interest. Only one RCT reported our critical time point at one month; it found that the anti-VEGF group had a 1.3-fold higher chance of achieving control of IOP at one month (RR 1.32, 95% 1.10 to 1.59; 93 participants) than the non-anti-VEGF group (low certainty of evidence). For other time points, one RCT found a three-fold greater achievement in control of IOP in the anti-VEGF group when compared with the non-anti-VEGF group at one year (RR 3.00; 95% CI:1.35 to 6.68; 40 participants). However, another RCT found an inconclusive result at the time period ranging from 1.5 years to three years (RR 1.08; 95% CI: 0.67 to 1.75; 40 participants).  All five RCTs examined mean IOP, but at different time points. Very-low-certainty evidence showed that anti-VEGFs were effective in reducing mean IOP by 6.37 mmHg (95% CI: -10.09 to -2.65; 3 RCTs; 173 participants) at four to six weeks when compared with no anti-VEGFs.  Anti-VEGFs may reduce mean IOP at three months (MD -4.25; 95% CI -12.05 to 3.54; 2 studies; 75 participants), six months (MD -5.93; 95% CI -18.13 to 6.26; 2 studies; 75 participants), one year (MD -5.36; 95% CI -18.50 to 7.77; 2 studies; 75 participants), and more than one year (MD -7.05; 95% CI -16.61 to 2.51; 2 studies; 75 participants) when compared with no anti-VEGFs, but such effects remain uncertain. Two RCTs reported the proportion of participants who achieved an improvement in visual acuity with specified time points. Participants receiving anti-VEGFs had a 2.6 times (95% CI 1.60 to 4.08; 1 study; 93 participants) higher chance of improving visual acuity when compared with those not receiving anti-VEGFs at one month (very low certainty of evidence). Likewise, another RCT found a similar result at 18 months (RR 4.00, 95% CI 1.33 to 12.05; 1 study; 40 participants).  Two RCTs reported the outcome, complete regression of new iris vessels, at our time points of interest. Low-certainty evidence showed that anti-VEGFs had a nearly three times higher chance of complete regression of new iris vessels when compared with no anti-VEGFs (RR 2.63, 95% CI 1.65 to 4.18; 1 study; 93 participants). A similar finding was observed at more than one year in another RCT (RR 3.20, 95% CI 1.45 to 7.05; 1 study; 40 participants).  Regarding adverse events, there was no evidence that the risks of hypotony and tractional retinal detachment were different between the two groups (RR 0.67; 95% CI: 0.12 to 3.57 and RR 0.33; 95% CI: 0.01 to 7.72, respectively; 1 study; 40 participants). No RCTs reported incidents of endophthalmitis, vitreous hemorrhage, no light perception, and serious adverse events. Evidence for the adverse events of anti-VEGFs was low due to limitations in the study design due to insufficient information to permit judgments and imprecision of results due to the small sample size. No trial reported the proportion of participants with relief of pain and resolution of redness at any time point. AUTHORS' CONCLUSIONS: Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short- and long-term effectiveness and safety of anti-VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.\"], ['Intraocular Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy: A Review.', 'Journal of vitreoretinal diseases', '2023 Mar-Apr', '37006665', 'PURPOSE: To review the current literature on the use of intravitreal methotrexate (IVT MTX) for the treatment and prevention of proliferative vitreoretinopathy (PVR). METHODS: All reports of IVT MTX to treat and prevent PVR published in PubMed, Google Scholar, and EBSCOhost were reviewed. The relevant current studies are included in this report. RESULTS: The literature search yielded 32 articles describing the use of MTX in PVR. These included preclinical studies, 1 case report, and several case series. Early studies found that IVT MTX is a promising medication for the treatment and prevention of PVR. MTX works as a potent anti-inflammatory agent through a new mechanism of action different from that of other medications for use in PVR. Few side effects have been reported and were mostly limited to mild reversible corneal keratopathy. There are 2 current ongoing randomized controlled clinical trials to further evaluate the efficacy of MTX for PVR. CONCLUSIONS: MTX is a safe and potentially efficacious medication for the treatment and prevention of PVR. Additional clinical trials are needed to further establish this effect.'], ['Risk factors for recurrences and visual impairment in patients with ocular toxoplasmosis: A systematic review and meta-analysis.', 'PloS one', '2023', '37011101', 'BACKGROUND: Ocular toxoplasmosis (OT) is caused by the parasite Toxoplasma gondii. OT is the leading cause of posterior uveitis globally; it is a recurrent disease that may result in visual impairment and blindness. This systematic review and meta-analysis aim to summarize and evaluate the risk factors for recurrences, visual impairment, and blindness described in the literature worldwide. METHODS AND FINDINGS: We performed a systematic literature search in PubMed, Embase, VHL, Cochrane Library, Scopus, and DANS EASY Archive. All studies reporting patients with clinically and serologically confirmed OT presenting any clinical or paraclinical factor influencing recurrences, visual impairment, and blindness were included. Studies presenting secondary data, case reports, and case series were excluded. An initial selection was made by title and abstract, and then the studies were reviewed by full text where the eligible studies were selected. Then, the risk of bias was assessed through validated tools. Data were extracted using a validated extraction format. Qualitative synthesis and quantitative analysis were done. This study was registered on PROSPERO (CRD42022327836). RESULTS: Seventy two studies met the inclusion criteria. Fifty-three were summarized in the qualitative synthesis in three sections: clinical and environmental factors, parasite and host factors, and treatment-related factors. Of the 72 articles, 39 were included in the meta-analysis, of which 14 were conducted in South America, 13 in Europe, four in Asia, three multinational, two in North America and Central America, respectively, and only one in Africa. A total of 4,200 patients with OT were analyzed, mean age ranged from 7.3 to 65.1 year of age, with similar distribution by sex. The frequency of recurrences in patients with OT was 49% (95% CI 40%-58%), being more frequent in the South American population than in Europeans. Additionally, visual impairment was presented in 35% (95% CI 25%-48%) and blindness in 20% (95% CI 13%-30%) of eyes, with a similar predominance in South Americans than in Europeans. On the other hand, having lesions near the macula or adjacent to the optic nerve had an OR of 4.83 (95% CI; 2.72-8.59) for blindness, similar to having more than one recurrence that had an OR of 3.18 (95% CI; 1.59-6.38). Finally, the prophylactic therapy with Trimethoprim/Sulfamethoxazole versus the placebo showed a protective factor of 83% during the first year and 87% in the second year after treatment. CONCLUSION: Our Systematic Review showed that clinical factors such as being older than 40 years, patients with de novo OT lesions or with less than one year after the first episode, macular area involvement, lesions greater than 1 disc diameter, congenital toxoplasmosis, and bilateral compromise had more risk of recurrences. Also, environmental and parasite factors such as precipitations, geographical region where the infection is acquired, and more virulent strains confer greater risk of recurrences. Therefore, patients with the above mentioned clinical, environmental, and parasite factors could benefit from using prophylactic therapy.'], ['The impact of the image conversion factor and image centration on retinal vessel geometric characteristics.', 'Frontiers in medicine', '2023', '37007779', 'BACKGROUND: This study aims to use fundus image material from a long-term retinopathy follow-up study to identify problems created by changing imaging modalities or imaging settings (e.g., image centering, resolution, viewing angle, illumination wavelength). Investigating the relationship of image conversion factor and imaging centering on retinal vessel geometric characteristics (RVGC), offers solutions for longitudinal retinal vessel analysis for data obtained in clinical routine. METHODS: Retinal vessel geometric characteristics were analyzed in scanned fundus photographs with Singapore-I-Vessel-Assessment using a constant image conversion factor (ICF) and an individual ICF, applying them to macula centered (MC) and optic disk centered (ODC) images. The ICF is used to convert pixel measurements into mum for vessel diameter measurements and to establish the size of the measuring zone. Calculating a constant ICF, the width of all analyzed optic disks is included, and it is used for all images of a cohort. An individual ICF, in turn, uses the optic disk diameter of the eye analyzed. To investigate agreement, Bland-Altman mean difference was calculated between ODC images analyzed with individual and constant ICF and between MC and ODC images. RESULTS: With constant ICF (n = 104 eyes of 52 patients) the mean central retinal equivalent was 160.9 +/- 17.08 mum for arteries (CRAE) and 208.7 +/- 14.7.4 mum for veins (CRVE). The individual ICFs resulted in a mean CRAE of 163.3 +/- 15.6 mum and a mean CRVE of 219.0 +/- 22.3 mum. On Bland-Altman analysis, the individual ICF RVGC are more positive, resulting in a positive mean difference for most investigated parameters. Arteriovenous ratio (p = 0.86), simple tortuosity (p = 0.08), and fractal dimension (p = 0.80) agreed well between MC and ODC images, while the vessel diameters were significantly smaller in MC images (p < 0.002). CONCLUSION: Scanned images can be analyzed using vessel assessment software. Investigations of individual ICF versus constant ICF point out the asset of utilizing an individual ICF. Image settings (ODC vs. MC) were shown to have good agreement.'], ['Sex-based electroclinical differences and prognostic factors in epilepsy with eyelid myoclonia.', 'Epilepsia', '2023 Apr 5', '37021337', 'Although a striking female preponderance has been consistently reported in epilepsy with eyelid myoclonia (EEM), no study has specifically explored the variability of clinical presentation according to sex in this syndrome. Here, we aimed to investigate sex-specific electroclinical differences and prognostic determinants in EEM. Data from 267 EEM patients were retrospectively analyzed by the EEM study group, and a dedicated multivariable logistic regression analysis was developed separately for each sex. We found that females with EEM showed a significantly higher rate of persistence of photosensitivity and eye closure sensitivity at the last visit, along with a higher prevalence of migraine with aura, whereas males with EEM presented a higher rate of borderline intellectual functioning/intellectual disability. In female patients, multivariable logistic regression analysis revealed age at epilepsy onset, eyelid myoclonia status epilepticus, psychiatric comorbidities and catamenial seizures as significant predictors of drug resistance. In male patients, a history of febrile seizures was the only predictor of drug resistance. Hence, our study reveals sex-specific differences both in terms of electroclinical features and prognostic factors. Our findings support the importance of a sex-based personalized approach in epilepsy care and research, especially in genetic generalized epilepsies.'], ['Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review.', 'Indian journal of ophthalmology', '2023 Apr', '37026263', 'This study reviewed the efficacy and safety of intense pulsed light (IPL) for the treatment of dry eye disease (DED). The PubMed database was used to conduct the literature search, which used the keywords \"intense pulsed light\" and \"dry eye disease\". After the authors evaluated the articles for relevancy, 49 articles were reviewed. In general, all treatment modalities were proven to be clinically effective in reducing dry eye (DE) signs and symptoms; however, the level of improvement and persistence of outcomes differed amongst them. Meta-analysis indicated significant improvement in the Ocular Surface Disease Index (OSDI) scores post-treatment with a standardized mean difference (SMD) = -1.63; confidence interval (CI): -2.42 to -0.84. Moreover, a meta-analysis indicated a significant improvement in tear break-up time (TBUT) test values with SMD = 1.77; CI: 0.49 to 3.05. Research suggests that additive therapies, such as meibomian gland expression (MGX), sodium hyaluronate eye drops, heated eye mask, warm compress, lid hygiene, lid margin scrub, eyelid massage, antibiotic drops, cyclosporine drops, omega-3 supplements, steroid drops, and warm compresses along with IPL, have been found to work in tandem for greater effectiveness; however, in clinical practice, its feasibility and cost-effectiveness have to be taken into consideration. Current findings suggest that IPL therapy is suitable when lifestyle modifications such as reducing or eliminating the use of contact lenses, lubricating eye drops/gels, and warm compresses/eye masks fail to improve signs and symptoms of DE. Moreover, patients with compliance issues have been shown to benefit well as the effects of IPL therapy is sustained for over several months. DED is a multifactorial disorder, and IPL therapy has been found to be safe and efficient in reducing its signs and symptoms of meibomian gland dysfunction (MGD)-related DE. Although the treatment protocol varies among authors, current findings suggest that IPL has a positive effect on the signs and symptoms of MGD-related DE. However, patients in the early stages can benefit more from IPL therapy. Moreover, IPL has a better maintenance impact when used in conjunction with other traditional therapies. Further research is needed to assess cost-utility analysis for IPL.'], ['Optic neuritis presented as the only manifestation of neurosyphilis.', 'Oman journal of ophthalmology', '2023 Jan-Apr', '37007240', 'Here, we report a case of syphilis presented with optic neuritis to consider neurosyphilis as one of the differential diagnoses of optic neuritis. A 25-year-old male attended at outpatient department of chittagong eye infirmary and training complex institute with a history of a sudden loss of vision in the left eye for 20 days. On eye examination, the patient had reduced visual acuity on the left eye (6/60), and the left pupil showed a relative afferent pupillary defect and swollen left optic disc. No other abnormalities were found in a routine blood test and magnetic resonance imaging of the brain. Intravenous corticosteroid was administered for 3 days followed by oral corticosteroid. His vision was gradually improving within a month and became 6/9 in the left eye, but after a month, the patient returned with the blurring of vision in the same eye for 3 days. An extensive serum biochemical and serological test and cerebrospinal fluid (CSF) analysis was done including syphilis serology and human immunodeficiency virus (HIV) serology. Venereal disease research laboratory (VDRL) test and Treponema pallidum hemagglutination assay (TPHA) were found positive with high titer (1:1280) and rapid plasma reagin (RPR) titer of 1:64 in blood. The CSF analysis showed leukocytosis, and VDRL and TPHA were also found positive with high RPR titer. The HIV serology test was negative. The patient was treated with injectable ceftriaxone 2 g intravenously for 14 days and also injectable corticosteroid. His vision was improved within this period. Unilateral optic neuritis due to syphilis without other ocular features is uncommon but should be considered if a patient presents with visual loss and optic disc swelling. Early diagnosis based on clinical suspicion and prompt management is important to prevent visual impairment and subsequent neurological complications.'], ['Five-Year Incidence of Proliferative Diabetic Retinopathy and Associated Risk Factors in a Nationwide Cohort of 201 945 Danish Patients with Diabetes.', 'Ophthalmology science', '2023 Sep', '37025947', 'PURPOSE: To evaluate the proliferative diabetic retinopathy (PDR) progression rates and identify the demographic and clinical characteristics of patients who later developed PDR compared with patients who did not progress to that state. DESIGN: A national 5-year register-based cohort study including 201 945 patients with diabetes. SUBJECTS: Patients with diabetes who had attended the Danish national screening program (2013-2018) for diabetic retinopathy (DR). METHODS: We used the first screening episode as the index date and included both eyes of patients with and without subsequent progression of PDR. Data were linked with various national health registries to investigate relevant clinical and demographic parameters. The International Clinical Retinopathy Disease Scale was used to classify DR, with no DR as level 0, mild DR as level 1, moderate DR as level 2, severe DR as level 3, and PDR as level 4. MAIN OUTCOME MEASURES: Hazard ratios (HRs) for incident PDR for all relevant demographic and clinical parameters and 1-, 3-, and 5-year incidence rates of PDR according to baseline DR level. RESULTS: Progression to PDR within 5 years was identified in 2384 eyes of 1780 patients. Proliferative diabetic retinopathy progression rates from baseline DR level 3 at 1, 3 and 5 years were 3.6%, 10.9%, and 14.7%, respectively. The median number of visits was 3 (interquartile range, 1-4). Progression to PDR was predicted in a multivariable model by duration of diabetes (HR, 4.66 per 10 years; 95% confidence interval [CI], 4.05-5.37), type 1 diabetes (HR, 9.61; 95% CI, 8.01-11.53), a Charlson Comorbidity Index score of > 0 (score 1: HR, 4.62; 95% CI, 4.14-5.15; score 2: HR, 2.28; 95% CI, 1.90-2.74; score >/= 3: HR, 4.28; 95% CI, 3.54-5.17), use of insulin (HR, 5.33; 95% CI, 4.49-6.33), and use of antihypertensive medications (HR, 2.23; 95% CI, 1.90-2.61). CONCLUSIONS: In a 5-year longitudinal study of an entire screening nation, we found increased risk of PDR with increasing baseline DR levels, longer duration of diabetes, type 1 diabetes, systemic comorbidity, use of insulin, and blood pressure-lowering medications. Most interestingly, we found lower risk of progression from DR level 3 to PDR compared with that in previous studies. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.'], ['14-Year Outcome of Angle-Closure Prevention with Laser Iridotomy in the Zhongshan Angle Closure Prevention Study: Extended Follow-Up of a Randomized Controlled Trial.', 'Ophthalmology', '2023 Apr 6', '37030454', 'PURPOSE: This study aimed to evaluate the efficacy of laser peripheral iridotomy (LPI) prophylaxis for primary angle closure suspects (PACS) after 14 years and to identify risk factors for the conversion from PACS to primary angle closure (PAC). DESIGN: An extended follow-up of Zhongshan Angle Closure Prevention (ZAP) study. PARTICIPANTS: A total of 889 Chinese patients aged 50 to 70 years with bilateral PACS. METHODS: Each patient received LPI in one randomly selected eye, with the fellow untreated eye serving as a control. Since the risk of glaucoma was low and acute angle closure (AAC) only occurred in rare cases, the follow-up was extended to 14 years despite substantial benefits of LPI reported after the 6-year visit. MAIN OUTCOME MEASURES: The primary outcome was incidence of PAC, a composite endpoint including peripheral anterior synechiae (PAS), intraocular pressure (IOP) > 24 mmHg, or AAC. RESULTS: During the 14 years, 390 LPI-treated eyes and 388 control eyes were lost to the follow-up. A total of 33 LPI-treated eyes and 105 control eyes reached primary endpoints (P <0.01). Within them, twelve eyes developed AAC or primary angle closure glaucoma (AAC: five control eyes and one LPI-treated eye; PACG: four control eyes and two LPI-treated eyes). The hazard ratio for progression to PAC was 0.31 (95% confidence interval, 0.21-0.46) in LPI-treated eyes compared with control eyes. At the 14-year visit, LPI-treated eyes had severer nuclear cataract, higher IOP, larger angle width and limbal anterior chamber depth (LACD) than control eyes. Higher IOP, shallower LACD, and central anterior chamber depth (CACD) were associated with an increased risk of developing endpoints in control eyes. In the treated group, eyes with higher IOP, shallower LACD, or less IOP elevation after dark room-prone provocative tests (DRPPT) were more likely to develop PAC after LPI. CONCLUSIONS: Despite a two-third decrease in PAC incidence after LPI, the cumulative risk of PAC was relatively low in the community-based PACS population over 14 years. Apart from IOP, IOP elevation after DRPPT, CACD, and LACD, more risk factors are needed to achieve precise prediction of PAC occurrence and guide clinical practice.'], ['Ectopic expression of a mechanosensitive channel confers spatiotemporal resolution to ultrasound stimulations of neurons for visual restoration.', 'Nature nanotechnology', '2023 Apr 3', '37012508', 'Remote and precisely controlled activation of the brain is a fundamental challenge in the development of brain-machine interfaces for neurological treatments. Low-frequency ultrasound stimulation can be used to modulate neuronal activity deep in the brain, especially after expressing ultrasound-sensitive proteins. But so far, no study has described an ultrasound-mediated activation strategy whose spatiotemporal resolution and acoustic intensity are compatible with the mandatory needs of brain-machine interfaces, particularly for visual restoration. Here we combined the expression of large-conductance mechanosensitive ion channels with uncustomary high-frequency ultrasonic stimulation to activate retinal or cortical neurons over millisecond durations at a spatiotemporal resolution and acoustic energy deposit compatible with vision restoration. The in vivo sonogenetic activation of the visual cortex generated a behaviour associated with light perception. Our findings demonstrate that sonogenetics can deliver millisecond pattern presentations via an approach less invasive than current brain-machine interfaces for visual restoration.'], ['Erdheim-Chester disease with chorioretinal and orbital involvement: a case report.', 'Arquivos brasileiros de oftalmologia', '2023 Apr 3', '37018824', 'A 42-year-old woman presented with bilateral proptosis, chemosis, leg pain, and vision loss. Orbital, chorioretinal, and multi-organ involvement of Erdheim-Chester disease, a rare non-Langerhans histiocytosis, with a negative BRAF mutation was diagnosed based on clinical, radiological, and pathological findings. Interferon-alpha-2a (IFNalpha-2a) was started, and her clinical condition improved. However, 4 months later, she had vision loss with a history of IFNalpha-2a cessation. The same therapy was administered, and her clinical condition improved. The Erdheim-Chester disease is a rare chronic histiocytic proliferative disease that requires a multidisciplinary approach and can be fatal if left untreated because of multisystemic involvements.'], ['Can precancerous stem cells be risk markers for malignant transformation in the oral mucosa?', 'Cellular & molecular biology letters', '2023 Apr 7', '37029348', 'Accurate assessment of the carcinogenic potential of oral mucosal diseases can significantly reduce the prevalence of oral cancer. We speculate that precancerous stem cells (pCSCs) arise during the evolution of carcinomas based on long-term experimental findings, published literature, and the cancer stem cell (CSC) theory, wherein pCSCs exist in precancerous lesions and have characteristics of both CSCs and normal stem cells. This apparently contradictory feature may be the foundation of the reversible transformation of precancerous lesions. Predicting malignant transformation in potentially malignant oral illnesses would allow for focused treatment, prognosis, and secondary prevention. Currently available clinical assays for chromosomal instability and DNA aneuploidy have several deficiencies. We hope that our study will increase attention to pCSC research and lead to the development of novel strategies for the prevention and treatment of oral cancer by identifying pCSC markers.'], ['[Chinese expert consensus on meibomian gland dysfunction: definition and classification (2023)].', '[Zhonghua yan ke za zhi] Chinese journal of ophthalmology', '2023 Apr 11', '37012588', 'Meibomian gland dysfunction (MGD) is a common clinical ocular surface disease. In recent years, great progress has been made in basic and clinical research on MGD, and new diagnostic and therapeutic methods have been continuously applied to clinical practice. To improve the understanding of MGD among Chinese ophthalmologists and standardize the diagnosis and treatment of MGD, the Chinese Branch of the Asia Dry Eye Society and relevant academic groups organized experts to discuss the definition and classification of MGD based on recent research progress and clinical experience at home and abroad, forming consensus opinions for the reference of clinicians.'], ['Congenital insensitivity to pain associated with PRDM12 mutation: Two case reports and a literature review.', 'Frontiers in genetics', '2023', '37021010', 'Background: PRDM12 is a newly discovered gene responsible for congenital insensitivity to pain (CIP). Its clinical manifestations are various and not widely known. Methods: The clinical data of two infants diagnosed with CIP associated with PRDM12 mutation were collected. A literature review was performed, and the clinical characteristics of 20 cases diagnosed with a mutation of PRDM12 were summarized and analyzed. Results: Two patients had pain insensitivity, tongue and lip defects, and corneal ulcers. The genomic analysis results showed that variants of PRDM12 were detected in the two families. The case 1 patient carried heterozygous variations of c.682+1G > A and c.502C > T (p.R168C), which were inherited from her father and mother, respectively. We enrolled 22 patients diagnosed with CIP through a literature review together with our cases. There were 16 male (72.7%) and 6 female (27.3%) patients. The age of onset ranged from 6 months to 57 years. The prevalence of clinic manifestation was 14 cases with insensitivity to pain (63.6%), 19 cases with self-mutilation behaviors (86.4%), 11 cases with tongue and lip defects (50%), 5 cases with mid-facial lesions (22.7%), 6 cases with distal phalanx injury (27.3%), 11 cases of recurrent infection (50%), 3 cases (13.6%) with anhidrosis, and 5 cases (22.7%) with global developmental delay. The prevalence of ocular symptoms was 11 cases (50%) with reduced tear secretion, 6 cases (27.3%) with decreased corneal sensitivity, 7 cases (31.8%) with disappeared corneal reflexes, 5.5 cases (25%, 0.5 indicated a single eye) with corneal opacity, 5 cases (22.7%) with corneal ulceration, and 1 case (4.5%) with a corneal scar. Conclusion: The syndrome caused by PRDM12 mutation is a clinically distinct and diagnosable disease that requires joint multidisciplinary management to control the development of the disease and minimize the occurrence of complications.'], ['Upregulation of C-X-C motif chemokine 12 in the spinal cord alleviated the symptoms of experimental autoimmune encephalomyelitis in Lewis rats.', 'Frontiers in neuroscience', '2023', '37008218', 'BACKGROUND: C-X-C motif chemokine 12 (CXCL12) is a chemokine that performs many functions. Studies have shown that CXCL12 can aggravate inflammatory symptoms in the central nervous system (CNS). Evidence also indicates that CXCL12 can promote the repair of myelin sheaths in the CNS in experimental autoimmune encephalomyelitis (EAE). Here, we investigated the function of CXCL12 in CNS inflammation by upregulating CXCL12 in the spinal cord and subsequently inducing EAE. MATERIALS AND METHODS: CXCL12 upregulation in the spinal cords of Lewis rats was induced by the injection of adeno-associated virus 9 (AAV9)/eGFP-P2A-CXCL12 after intrathecal catheter implantation. Twenty-one days after AAV injection, EAE was induced and clinical score was collected; Immunofluorescence staining, WB and LFB-PAS staining were used to evaluate the effect of CXCL12 upregulation. In the in vitro study, oligodendrocyte precursor cells (OPCs) were harvested, cultured with CXCL12 and AMD3100, and subjected to immunofluorescence staining for functional assessment. RESULTS: CXCL12 was upregulated in the lumbar enlargement of the spinal cord by AAV injection. In each stage of EAE, upregulation of CXCL12 significantly alleviated clinical scores by inhibiting leukocyte infiltration and promoting remyelination. In contrast, the addition of AMD3100, which is a CXCR4 antagonist, inhibited the effect of CXCL12. In vitro, 10 ng/ml CXCL12 promoted the differentiation of OPCs into oligodendrocytes. CONCLUSION: AAV-mediated upregulation of CXCL12 in the CNS can alleviate the clinical signs and symptoms of EAE and significantly decrease the infiltration of leukocytes in the peak stage of EAE. CXCL12 can promote the maturation and differentiation of OPCs into oligodendrocytes in vitro. These data indicate that CXCL12 effectively promotes remyelination in the spinal cord and decreases the signs and symptoms of EAE.'], ['Iron deficiency and overload in men and woman of reproductive age, and pregnant women.', 'Reproductive toxicology (Elmsford, N.Y.)', '2023 Apr 5', '37023911', 'Iron is an essential micronutrient for human biology and health, but high iron levels can be dangerous. Both iron deficiency and iron overload have been linked to reproductive health. This review summarizes the effects of iron deficiency and overload on omen of reproductive age (including pregnant women) and adult men. In addition, appropriate iron levels and the need for iron and nutritional supplements at different stages of life and pregnancy are discussed. In general, men should be aware of the risk of iron overload at any stage of life; women should take appropriate iron supplements before menopause; postmenopausal women should pay attention to the risk of iron overload; and pregnant women should receive reasonable iron supplementation in middle and late pregnancy. By summarizing evidence on the relationship between iron and reproductive health, this review aims to promote the development of strategies to optimize reproductive capacity from the perspective of nutrition. However, additional detailed experimental investigations and clinical studies are needed to assess the underlying causes and mechanisms of the observed associations between iron and reproductive health.'], ['Joint Multimodal Deep Learning-based Automatic Segmentation of Indocyanine Green Angiography and OCT Images for Assessment of Polypoidal Choroidal Vasculopathy Biomarkers.', 'Ophthalmology science', '2023 Sep', '37025946', \"PURPOSE: To develop a fully-automatic hybrid algorithm to jointly segment and quantify biomarkers of polypoidal choroidal vasculopathy (PCV) on indocyanine green angiography (ICGA) and spectral domain-OCT (SD-OCT) images. DESIGN: Evaluation of diagnostic test or technology. PARTICIPANTS: Seventy-two participants with PCV enrolled in clinical studies at Singapore National Eye Center. METHODS: The dataset consisted of 2-dimensional (2-D) ICGA and 3-dimensional (3-D) SD-OCT images which were spatially registered and manually segmented by clinicians. A deep learning-based hybrid algorithm called PCV-Net was developed for automatic joint segmentation of biomarkers. The PCV-Net consisted of a 2-D segmentation branch for ICGA and 3-D segmentation branch for SD-OCT. We developed fusion attention modules to connect the 2-D and 3-D branches for effective use of the spatial correspondence between the imaging modalities by sharing learned features. We also used self-supervised pretraining and ensembling to further enhance the performance of the algorithm without the need for additional datasets. We compared the proposed PCV-Net to several alternative model variants. MAIN OUTCOME MEASURES: The PCV-Net was evaluated based on the Dice similarity coefficient (DSC) of the segmentations and the Pearson's correlation and absolute difference of the clinical measurements obtained from the segmentations. Manual grading was used as the gold standard. RESULTS: The PCV-Net showed good performance compared to manual grading and alternative model variants based on both quantitative and qualitative analyses. Compared to the baseline variant, PCV-Net improved the DSC by 0.04 to 0.43 across the different biomarkers, increased the correlations, and decreased the absolute differences of clinical measurements of interest. Specifically, the largest average (mean +/- standard error) DSC improvement was for intraretinal fluid, from 0.02 +/- 0.00 (baseline variant) to 0.45 +/- 0.06 (PCV-Net). In general, improving trends were observed across the model variants as more technical specifications were added, demonstrating the importance of each aspect of the proposed method. CONCLUSION: The PCV-Net has the potential to aid clinicians in disease assessment and research to improve clinical understanding and management of PCV. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found after the references.\"], ['In-depth molecular profiling of an intronic GNAO1 mutant as the basis for personalized high-throughput drug screening.', 'Med (New York, N.Y.)', '2023 Mar 22', '37001522', 'BACKGROUND: The GNAO1 gene, encoding the major neuronal G protein Galphao, is mutated in a subset of pediatric encephalopathies. Most such mutations consist of missense variants. METHODS: In this study, we present a precision medicine workflow combining next-generation sequencing (NGS) diagnostics, molecular etiology analysis, and personalized drug discovery. FINDINGS: We describe a patient carrying a de novo intronic mutation (NM_020988.3:c.724-8G>A), leading to epilepsy-negative encephalopathy with motor dysfunction from the second decade. Our data show that this mutation creates a novel splice acceptor site that in turn causes an in-frame insertion of two amino acid residues, Pro-Gln, within the regulatory switch III region of Galphao. This insertion misconfigures the switch III loop and creates novel interactions with the catalytic switch II region, resulting in increased GTP uptake, defective GTP hydrolysis, and aberrant interactions with effector proteins. In contrast, intracellular localization, Gbetagamma interactions, and G protein-coupled receptor (GPCR) coupling of the Galphao[insPQ] mutant protein remain unchanged. CONCLUSIONS: This in-depth analysis characterizes the heterozygous c.724-8G>A mutation as partially dominant negative, providing clues to the molecular etiology of this specific pathology. Further, this analysis allows us to establish and validate a high-throughput screening platform aiming at identifying molecules that could correct the aberrant biochemical functions of the mutant Galphao. FUNDING: This work was supported by the Joint Seed Money Funding scheme between the University of Geneva and the Hebrew University of Jerusalem.'], ['PRPH2 mutation c.582-1G>A causing adult-onset macular dystrophy with a benign concentric annular macular dystrophy phenotype in a family.', 'Arquivos brasileiros de oftalmologia', '2023 Apr 3', '37018821', 'The peripherin gene (PRPH2) mutation is associated with photoreceptor cell dysfunction as well as in several inherited retinal dystrophies. The PRPH2 mutation c.582-1G>A is a rare variant reported in retinitis pigmentosa and pattern dystrophy. Here Case 1 was of a 54-year-old woman with bilateral atrophy of the perifoveal retinal pigmentary epithelium and choriocapillaris with central foveolar respect. Autofluorescence and fluorescein angiography revealed perifoveal atrophy of the retinal pigmentary epithelium with an annular window effect without the \"dark choroid\" sign. Case 2 (mother of Case 1) presented with extensive atrophy of the retinal pigmentary epithelium and choriocapillaris. PRPH2 was evaluated and the c.582-1G>A mutation was identified in heterozygosity. An advanced adult-onset benign concentric annular macular dystrophy diagnosis was thereby proposed. The c.582-1G>A mutation is poorly known and not present in all common genomic databases. This case report is the first one to report a c.582-1G>A mutation associated with benign concentric annular macular dystrophy.'], ['China Glaucoma Treatment Pattern Study I-Primary Angle-Closure Glaucoma: protocol for a multicentre, retrospective, observational study.', 'BMJ open', '2023 Apr 4', '37015785', 'INTRODUCTION: Primary angle-closure glaucoma (PACG) is a leading cause of irreversible blindness globally, and the number of patients with PACG rises every year. Yet, there is a lack of knowledge about the clinical characteristics, therapeutic options and profile of patients with PACG in China. Hence, we design the China Glaucoma Treatment Pattern Study -Primary Angle-Closure Glaucoma (Ch-GTP). The objective of this paper is to describe the design and methodology of Ch-GTP. The aim of this study is to characterise the profile and trend associated with initial PACG treatment for the last 10 years in China. METHODS: Ch-GTP is a national multicentre retrospective observational study that will randomly sample from 50 hospitals throughout China. Over 7000 patient records hospitalised for initial PACG treatment from 2011 to 2020 will be selected randomly. The data from electronic medical records will be uploaded to an encrypted online platform that will receive and collate data from all collaborating hospitals. Data abstraction and monitoring will be performed in a standardised manner by trained statisticians to ensure consistency. Systematic data cleaning will also be conducted by statisticians to ensure data integrity before final data storage. The outcomes will include four broad categories: (1) demographics, (2) clinical characteristics, (3) therapeutic strategies and procedures and (4) early outcomes at discharge. The demographic characteristics and early outcomes will be summarised using descriptive statistics. Comparative analyses of characteristics and treatment pattern changing trends for different regions and years will be used to test for significant differences (t-test or Mann-Whitney U test). ETHICS AND DISSEMINATION: The collaborating hospitals obtained local approval based on a standard ethics application from internal ethics committees or acknowledged an existent ethics approval of the leading institution with approval from internal ethics committees. Due to the retrospective nature, written informed consent from patients was waived by the ethics committee. The results will be published in academic journals and presented at national and international academic conferences. TRIAL REGISTRATION NUMBER: ChiCTR2100054643.'], ['Pediatric Rhegmatogenous Retinal Detachments: Etiologies, Clinical Course, and Surgical Outcomes.', 'Journal of vitreoretinal diseases', '2023 Mar-Apr', '37006670', 'Purpose: To describe the predisposing factors, clinical course, and surgical methods of pediatric rhegmatogenous retinal detachment (RRD) and determine which factors affect anatomic success. Methods: Data of patients 18 years or younger who had surgical repair for RRD from January 1, 2004, to June 31, 2020, with a minimum of 6 months of follow-up were retrospectively analyzed. Results: The study evaluated 101 eyes of 94 patients. Of the eyes, 90% had at least 1 predisposing factor to pediatric RRD, including trauma (46%), myopia (41%), prior intraocular surgery (26%), and congenital anomaly (23%); 81% had macula-off detachments and 34% had proliferative vitreoretinopathy (PVR) grade C or worse at presentation. The presence of PVR grade C or worse (P = .0002), total RRD (P = .014), and vitrectomy alone at first surgery (P = .0093) were associated with worse outcomes. Patients who had scleral buckle (SB) alone at the first surgery had statistically higher rates of anatomic success than those who had vitrectomy alone or combined with SB (P = .0002). After the final surgery, 74% of patients achieved anatomic success. Discussion: The majority of cases in this study were associated with 1 of the 4 risk factors predisposing to pediatric RRD. These patients often present late with macula-off detachments and PVR grade C or worse. The majority of patients achieved anatomic success after surgical repair using SB, vitrectomy, or a combination.'], ['Potential Protective Function of Adiponectin in Diabetic Retinopathy.', 'Ophthalmology and therapy', '2023 Mar 31', '37000404', 'Adiponectin, one of the most ubiquitous adipokines found in the blood, plays a major role in glucolipid metabolism and energy metabolism and regulation. In recent years, a growing body of research indicates that adiponectin also plays a significant role in diabetic retinopathy. In the present review, we specifically address the protective effects of adiponectin on the development and progression of diabetic retinopathy through improvement in insulin resistance, alleviation of oxidative stress, limiting of inflammation, and prevention of vascular remodeling, with the aim to explore new potential approaches and targets for the prevention and treatment of diabetic retinopathy.'], ['A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension.', 'Current medical research and opinion', '2023 Apr 4', '37013445', 'Objective: To compare the efficacy and safety of two fixed combination, preservative-free eye drops (bimatoprost 0.01% in combination with either timolol 0.1% or 0.5%) in a gel formulation, with bimatoprost 0.03%/timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).Methods: Phase II, randomized, investigator-masked, multicenter, 3-arm parallel group (Eudract No. 2017-002823-46). Eighty-six patients aged >/=18 years with OAG or OHT, with intraocular pressure (IOP) initially controlled for at least 6 months by a combination therapy of a dual prostaglandin and timolol or insufficiently controlled by first-line monotherapy were included. Patients were randomized to receive T4030a (bimatoprost 0.01%/timolol 0.1%; N = 29), T4030c (bimatoprost 0.01%/timolol 0.5%; N = 29) or bimatoprost 0.03%/timolol 0.5% (N = 28), administered once daily in the evening for 12 weeks. Primary endpoint was defined as change in IOP from day 1 to week 12 measured at 08:00 (+/-1 hour). Further efficacy, safety and pharmacokinetic endpoints were assessed as secondary outcomes.Results: The mean change in IOP from baseline to week 12 was -9.8 +/- 2.1 mmHg for T4030a, -10.1 +/- 2.5 mmHg for T4030c and -10.0 +/- 2.8 mmHg for bimatoprost 0.03%/timolol 0.5%. All treatments were well tolerated with no safety issues identified in any group. In patients treated with T4030a, the systemic concentration of timolol was significantly lower after 12 weeks than in patients treated with T4030c or bimatoprost 0.03%/timolol0.5%.Conclusions: These study results suggest that the preservative-free ophthalmic formulation of T4030a (bimatoprost 0.01%/timolol 0.1%) can be regarded as a useful tool in the therapeutic management of OAG and OHT.'], ['Sensory impairments and subjective well-being status in middle-aged and older Chinese population: Cross-sectional and longitudinal analyses of a nationally representative survey.', 'Frontiers in public health', '2023', '37006552', 'PURPOSE: To investigate the impacts of sensory impairments (SIs) including single vision impairment (SVI), single hearing impairment (SHI) and dual sensory impairment (DSI) on subjective wellbeing measurements including life expectancy (LE), life satisfaction (LS) and self-rated health (SRH) in middle-aged and older Chinese population. METHODS: We obtained data from the China Health and Retirement Longitudinal Survey (CHARLS). In total, 9,293 Chinese middle-aged and older adults aging over 45 were included at baseline 2011 in this study, and 3,932 participants who accomplished all 4 interviews from 2011 to 2018 were adapted for longitudinal analyses. Sensory status and subjective wellbeing measurements were collected. Other covariates included socio-demographic characteristics, medical condition and lifestyle-related factors. The impacts of baseline sensory status on LE, LS and SRH were assessed using univariate and multivariate logistic regression analyses. A linear regression analysis with generalized estimating equations (GEE) was used to assess the association between time-varying sensory statuses with LE, LS and SRH over 8 years after being adjusted with multi-confounding factors. RESULTS: Participants with SIs had significantly lower level of LE, LS, and SRH, compared to those who were free of SI. All kinds of SIs were significantly associated with LE, LS, and SRH according to cross-sectional data. The correlations between SIs and LE or SRH over 8 years were also noticed. However, only SHI and DSI were found to be significantly associated with LS according to longitudinal data (all p values < 0.05). CONCLUSION: Sensory impairments had explicitly detrimental effects on subjective wellbeing status over time among middle-aged and older Chinese population.'], ['Fibrosis in neovascular age-related macular degeneration: A review of definitions based on clinical imaging.', 'Survey of ophthalmology', '2023 Apr 4', '37023894', 'Despite the success of antiangiogenic therapy in controlling exudation in neovascular age-related macular degeneration (nAMD), the involvement of the outer retina in fibrosis results in gradual vision loss over time. The development of drugs that prevent or ameliorate fibrosis in nAMD requires that it is accurately detected and quantified with reliable endpoints and identification of robust biomarkers. Achievement of such an aim is currently challenging due to the lack of a consensus definition of fibrosis in nAMD. As a first step towards the establishment of a clear definition of fibrosis, we provide an extensive overview of the imaging modalities and criteria used to characterize fibrosis in nAMD. We observed variety in the selection of individual and combinations of imaging modalities, and criteria for detection. We also observed heterogeneity in classification systems and severity scales for fibrosis. The most commonly used imaging modalities were color fundus photography (CFP), fluorescence angiography (FA) and optical coherence tomography (OCT). A multimodal approach was frequently utilized. Our review suggests that OCT offers a more detailed, objective and sensitive characterization than CFP/FA. Thus, we recommend it as a primary modality for fibrosis evaluation. This review provides a basis for future discussions to reach a consensus definition using standardized terms based on a detailed characterization of fibrosis, its presence and evolution, and taking into consideration impact on visual function. Achieving this goal is of paramount importance for the development of antifibrotic therapies.'], ['Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients.', 'Frontiers in endocrinology', '2023', '37025403', \"OBJECTIVE: To analyze the efficacy of mycophenolate mofetil (MMF) and glucocorticoid administration in patients with thyroid-associated ophthalmopathy (TAO). METHODS: Sixty patients with moderate to severe TAO treated in Jingzhou Central Hospital from January 2022 to June 2022 were selected and enrtolled in this study. The subjects were divided into experimental group (n=30) and control group (n=30) based on the random number table method. Glucocorticoid pulse therapy was provided in the control group, while MMF was given in the experimental group on the basis of Control group. Clinical activity score (CAS), quality of life (QOL), visual acuity, eyelid fissure width, intraocular pressure, and degree of exophthalmos were observed at the time of admission and at the 12(th) week and 24(th) post-treatment weeks. We compared the immune function (TRAb, IL-6, and CD4+/CD8+) of the two groups pre-treatment and 24 weeks post-treatment, and evaluated the clinical therapeutic effect. RESULTS: The clinical effective rates at 12 and 24 weeks in the experimental group were higher (73.3% and 83.3%) than those in the control group (46.7% and 60.0%) (P <0.05). After 12 weeks of treatment, patients' CAS scores, and bilateral lid fissure width decreased and right eye visual acuity increased in the control group compared with those before treatment (P < 0.05); further, after 24 weeks of treatment, patients' QOL scores and bilateral visual acuity increased and CAS scores, bilateral lid fissure width and proptosis decreased compared with those before treatment, and patients' QOL scores, CAS scores and bilateral proptosis improved more than those at 12 weeks of treatment (P <0.05). Additionally, greater improvements were observed in the patients' QOL and CAS scores, and proptosis after 24-week treatment than after 12-week treatment (P<0.05). In the experimental group, the QOL score and binocular visual acuity increased, whereas the CAS score, intraocular pressure, lid width, and proptosis decreased after 12 weeks of treatment as compared to the values of these parameters in the pre-treatment period (P < 0.05); after 24 weeks of treatment, greater improvements were established in the ocular-related indexes improved compared to the pre-treatment period and after 12 weeks of treatment (P < 0.05). After 12 weeks of treatment, the patients in the experimental group had more considerable improvements in the right visual acuity, right intraocular pressure, and left lid fissure width than the control group (P < 0.05); at 24 weeks of treatment, patients in the experimental group had greater improvements in the QOL score, bilateral visual acuity, intraocular pressure, bilateral lid fissure width, and bilateral proptosis than the control group (P < 0.05). No significant differences were found in the values of TRAb, IL-6, and CD4+/CD8+ between the two groups before treatment (P>0.05); the values of TRAb, IL-6, and CD4+/CD8+ in the experimental group was significantly lower than those before treatment and in the control group after 24weeks of treatment. (P>0.05). No statistically significant difference was observed in the incidence of liver damage and menstrual disorders between the two groups during the 24 weeks of treatment (P>0.05). CONCLUSION: The combination of oral MMF and glucocorticoid shock therapy is an effective drug for the treatment of patients with moderately active TAO.\"]]\n"
     ]
    }
   ],
   "source": [
    "import csv\n",
    "import random\n",
    "from sklearn.model_selection import train_test_split\n",
    "\n",
    "# Load the data from CSV file into a list\n",
    "data = []\n",
    "with open(\"pubmed_abstracts.csv\", \"r\", newline='', encoding=\"utf-8\") as csvfile:\n",
    "    reader = csv.reader(csvfile)\n",
    "    next(reader)  # Skip the header row\n",
    "    for row in reader:\n",
    "        data.append(row)\n",
    "\n",
    "# Divide the data into training and test sets\n",
    "random.seed(0)  # Set a seed for reproducibility\n",
    "train_data, test_data = train_test_split(data, test_size=0.2)\n",
    "\n",
    "# Save the training and test sets to separate CSV files\n",
    "with open(\"train_data.csv\", \"w\", newline='', encoding=\"utf-8\") as train_file:\n",
    "    writer = csv.writer(train_file)\n",
    "    writer.writerow([\"Title\", \"Journal\", \"Publication Date\", \"PubMed ID\", \"Abstract\"])\n",
    "    for article in train_data:\n",
    "        writer.writerow(article)\n",
    "\n",
    "print(train_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "[E966] `nlp.add_pipe` now takes the string name of the registered component factory, not a callable component. Expected string, but got <spacy.pipeline.ner.EntityRecognizer object at 0x2840699a0> (name: 'None').\n\n- If you created your component with `nlp.create_pipe('name')`: remove nlp.create_pipe and call `nlp.add_pipe('name')` instead.\n\n- If you passed in a component like `TextCategorizer()`: call `nlp.add_pipe` with the string name instead, e.g. `nlp.add_pipe('textcat')`.\n\n- If you're using a custom component: Add the decorator `@Language.component` (for function components) or `@Language.factory` (for class components / factories) to your custom component and assign it a name, e.g. `@Language.component('your_name')`. You can then run `nlp.add_pipe('your_name')` to add it to the pipeline.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[11], line 20\u001b[0m\n\u001b[1;32m     18\u001b[0m \u001b[39mfor\u001b[39;00m label \u001b[39min\u001b[39;00m labels:\n\u001b[1;32m     19\u001b[0m     ner\u001b[39m.\u001b[39madd_label(label)\n\u001b[0;32m---> 20\u001b[0m nlp\u001b[39m.\u001b[39;49madd_pipe(ner, last\u001b[39m=\u001b[39;49m\u001b[39mTrue\u001b[39;49;00m)\n\u001b[1;32m     22\u001b[0m \u001b[39m# Update the model with the training data\u001b[39;00m\n\u001b[1;32m     23\u001b[0m other_pipes \u001b[39m=\u001b[39m [pipe \u001b[39mfor\u001b[39;00m pipe \u001b[39min\u001b[39;00m nlp\u001b[39m.\u001b[39mpipe_names \u001b[39mif\u001b[39;00m pipe \u001b[39m!=\u001b[39m \u001b[39m\"\u001b[39m\u001b[39mner\u001b[39m\u001b[39m\"\u001b[39m]\n",
      "File \u001b[0;32m/Library/Frameworks/Python.framework/Versions/3.10/lib/python3.10/site-packages/spacy/language.py:772\u001b[0m, in \u001b[0;36mLanguage.add_pipe\u001b[0;34m(self, factory_name, name, before, after, first, last, source, config, raw_config, validate)\u001b[0m\n\u001b[1;32m    770\u001b[0m     bad_val \u001b[39m=\u001b[39m \u001b[39mrepr\u001b[39m(factory_name)\n\u001b[1;32m    771\u001b[0m     err \u001b[39m=\u001b[39m Errors\u001b[39m.\u001b[39mE966\u001b[39m.\u001b[39mformat(component\u001b[39m=\u001b[39mbad_val, name\u001b[39m=\u001b[39mname)\n\u001b[0;32m--> 772\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mValueError\u001b[39;00m(err)\n\u001b[1;32m    773\u001b[0m name \u001b[39m=\u001b[39m name \u001b[39mif\u001b[39;00m name \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m \u001b[39melse\u001b[39;00m factory_name\n\u001b[1;32m    774\u001b[0m \u001b[39mif\u001b[39;00m name \u001b[39min\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mcomponent_names:\n",
      "\u001b[0;31mValueError\u001b[0m: [E966] `nlp.add_pipe` now takes the string name of the registered component factory, not a callable component. Expected string, but got <spacy.pipeline.ner.EntityRecognizer object at 0x2840699a0> (name: 'None').\n\n- If you created your component with `nlp.create_pipe('name')`: remove nlp.create_pipe and call `nlp.add_pipe('name')` instead.\n\n- If you passed in a component like `TextCategorizer()`: call `nlp.add_pipe` with the string name instead, e.g. `nlp.add_pipe('textcat')`.\n\n- If you're using a custom component: Add the decorator `@Language.component` (for function components) or `@Language.factory` (for class components / factories) to your custom component and assign it a name, e.g. `@Language.component('your_name')`. You can then run `nlp.add_pipe('your_name')` to add it to the pipeline."
     ]
    }
   ],
   "source": [
    "import csv\n",
    "import spacy\n",
    "\n",
    "# Load the training data from CSV file into a list\n",
    "train_data = []\n",
    "with open(\"train_data.csv\", \"r\", newline='', encoding=\"utf-8\") as train_file:\n",
    "    reader = csv.reader(train_file)\n",
    "    next(reader)  # Skip the header row\n",
    "    for row in reader:\n",
    "        train_data.append(row[4])  # Store only the abstract text\n",
    "\n",
    "# Load the default English model\n",
    "nlp = spacy.load(\"en_core_web_sm\")\n",
    "\n",
    "# Train the named entity recognizer\n",
    "ner = nlp.create_pipe(\"ner\")\n",
    "labels = [\"CLINICAL_TRIAL\", \"ORGANIZATION\", \"DURATION\", \"TOPIC\"]\n",
    "for label in labels:\n",
    "    ner.add_label(label)\n",
    "nlp.add_pipe(ner, last=True)\n",
    "\n",
    "# Update the model with the training data\n",
    "other_pipes = [pipe for pipe in nlp.pipe_names if pipe != \"ner\"]\n",
    "with nlp.disable_pipes(*other_pipes):\n",
    "    optimizer = nlp.begin_training()\n",
    "    for i in range(10):\n",
    "        random.shuffle(train_data)\n",
    "        losses = {}\n",
    "        for abstract in train_data:\n",
    "            doc = nlp(abstract)\n",
    "            gold = [(ent.text, ent.label_) for ent in doc.ents]\n",
    "            gold = [(text, label) for text, label in gold if label in labels]\n",
    "            nlp.update([abstract], [gold], sgd=optimizer, losses=losses)\n",
    "        print(f\"Loss after iteration {i}: {losses}\")\n",
    "\n",
    "# Save the trained model to disk\n",
    "nlp.to_disk(\"entity_recognition_model\")\n",
    "\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.7"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
